-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LrGAigYDnHI3xU0xlNqRhj+Kgo8Fer3hGvzDYCPBzl0YNvaNlj4qhZWh15GOzAl+
 kd2Hz9pv1fyBz59inAOf6w==

<SEC-DOCUMENT>0001193125-05-152582.txt : 20050729
<SEC-HEADER>0001193125-05-152582.hdr.sgml : 20050729
<ACCEPTANCE-DATETIME>20050729145337
ACCESSION NUMBER:		0001193125-05-152582
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20050630
FILED AS OF DATE:		20050729
DATE AS OF CHANGE:		20050729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PAIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		05984443

	BUSINESS ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE
		STREET 2:		SUITE 70
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6506248200

	MAIL ADDRESS:	
		STREET 1:		416 BROWNING WAY
		STREET 2:		NONE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d10q.htm
<DESCRIPTION>FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005
<TEXT>
<HTML><HEAD>
<TITLE>For the Quarterly Period Ended June 30, 2005</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 10-Q </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%"
SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3"><B><FONT FACE="WINGDINGS">&#120;</FONT><B></B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3"><B>Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT FACE="Times New Roman" SIZE="2"><B>For Quarterly Period Ended June 30, 2005 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3"><B></B></FONT><FONT FACE="WINGDINGS" SIZE="3" COLOR="#000000"><B>&#168;</B></FONT><FONT FACE="Times New Roman" SIZE="3"><B><B></B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3"><B>Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT FACE="Times New Roman" SIZE="2"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U></U>to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.<U></U> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Commission File Number 000-29959 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>Pain Therapeutics, Inc. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR
WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>91-1911336</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>416 Browning Way, South San Francisco,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CA 94080</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(650) 624-8200
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by
check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT FACE="WINGDINGS" SIZE="2"
COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate
by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Indicate the number of shares outstanding of each of issuer&#146;s classes of common stock, as of the latest practicable date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Common Stock, $0.001 par value</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">43,853,482 Shares</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Class</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Outstanding at July 18, 2005</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<A NAME="toc"></A>PAIN THERAPEUTICS, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><U>TABLE OF CONTENTS
</U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Page&nbsp;No.</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">PART&nbsp;I.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_1">FINANCIAL INFORMATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_2">Financial Statements</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_3">Condensed Balance Sheets &#150; June 30, 2005 and December 31, 2004</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_4">Condensed Statements of Operations &#150; Three &#151; and Six-Month Periods Ended June 30, 2005 and 2004 and the Period from May 4, 1998 (Inception) Through June 30, 2005</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_5">Condensed Statements of Cash Flows &#150; Six-Month Periods Ended June 30, 2005 and 2004 and the Period from May 4, 1998 (Inception) Through June 30, 2005</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_6">Notes to Condensed Financial Statements</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_8">Quantitative and Qualitative Disclosures About Market Risks </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_9">Controls and Procedures</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">PART&nbsp;II.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_10">OTHER INFORMATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_11">Legal Proceedings</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_12">Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_13">Defaults Upon Senior Securities</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_14">Submission of Matters to a Vote of Security Holders</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_15">Other Information</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx67358_16">Exhibits</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Signatures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">32</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_1"></A>PART I. FINANCIAL INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_2"></A>Item 1. </B><B><I>Financial Statements</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">
<A NAME="tx67358_3"></A>PAIN THERAPEUTICS, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(A Development Stage Enterprise) </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Condensed Balance Sheets </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Unaudited) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(in thousands) </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>June 30,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>2005</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>2004</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">79,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">98,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">81,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">99,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">83,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">101,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Liabilities and stockholders&#146; equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued compensation and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Additional paid-in-capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">206,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">205,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deficit accumulated during the development stage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(130,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(112,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">74,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">93,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">83,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">101,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE><HR WIDTH="8%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Derived from the Company&#146;s audited financial statements as of December 31, 2004, included in the Company&#146;s Annual Report on Form 10-K filed with the Securities and
Exchange Commission. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying notes to
condensed financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">PAIN THERAPEUTICS, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">(A Development Stage Enterprise) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">
<A NAME="tx67358_4"></A>Condensed Statements of Operations<B></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Unaudited)<B></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(in thousands except per share data) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>June 30,</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>May 4,1998<BR>(inception)<BR>through<BR>June 30,</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,518</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">111,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,657</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">140,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,657</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(140,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest and other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(18,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(130,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Return to series C preferred stockholders for beneficial conversion feature</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(14,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Loss available to common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(18,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(145,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic and diluted loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Weighted-average shares used in computing basic and diluted loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43,744</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Included in research and development
and general and administrative expenses are stock-based compensation expenses of $123 and $259 thousand for the three-month periods ended June 30, 2005 and 2004, respectively, and $90 and $312 thousand for the six-month periods ended June 30, 2005
and 2004, respectively, and $12,420 for the period from May 4, 1998 (inception) through June 30, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying notes to condensed financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<A NAME="tx67358_5"></A>PAIN THERAPEUTICS, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(A Development Stage Enterprise) </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Condensed Statements of Cash Flows </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Unaudited) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(in thousands) </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>May&nbsp;4,&nbsp;1998<BR>(inception)<BR>through<BR>June 30,</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(18,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(130,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-cash net interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">307</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Non-cash stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">561</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,356</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Accrued compensation and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(17,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(15,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(108,735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows provided by (used in) investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Purchase of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(23,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(30,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(206,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sales and maturities of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">42,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">37,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">126,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash provided by (used in) investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(82,502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash flows from financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from issuance of preferred stock, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Proceeds from issuance of common stock, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">166,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">193,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(8,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">See accompanying notes
to condensed financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<A NAME="tx67358_6"></A>PAIN THERAPEUTICS, INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(A Development Stage Enterprise) </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Notes to Condensed Financial Statements </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Unaudited) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Note 1. General </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pain
Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of innovative drugs. We specialize in developing safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers, which are
sometimes referred to as narcotic painkillers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We own
worldwide commercial rights to all of our drug candidates. We incorporated in Delaware in May 1998. Our clinical pipeline consists of three proprietary drug candidates. We are developing these three oral, small molecule drugs to treat patients who
suffer from severe chronic pain, such as pain associated with advanced osteoarthritis, low-back pain or irritable bowel syndrome, or IBS. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the course of our development activities, we have sustained operating losses. These losses may continue through the next several years. We expect our
current cash, cash equivalents and marketable securities will be sufficient to meet our planned working capital and capital expenditure requirements for at least the next twelve months. There are no assurances that additional financing will be
available on favorable terms, or at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our development
activities involve inherent risks. These risks include, among others, dependence on key personnel and determination of patentability and protection of our products and processes. In addition, we have drug candidates that have not yet obtained FDA
approval. Successful future operations depend on our ability to obtain approval for and commercialize these products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have prepared the accompanying unaudited condensed financial statements of Pain Therapeutics, Inc. in accordance with U.S. generally accepted
accounting principles for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In our opinion, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and
six months ended June 30, 2005 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires that
management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses incurred during the
reporting period. Actual results could differ from those estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 2. Loss per Share </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Basic loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted loss per
share is computed on the basis of the weighted-average number of common shares plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and outstanding
warrants. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In all periods presented we have reported a loss and
therefore all potential shares of common stock related to potentially dilutive securities have been excluded from the calculation of diluted loss per share because they are anti-dilutive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 3. Comprehensive Income (Loss) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Comprehensive income (loss) is the sum of net loss and other comprehensive income (loss), which consists of net unrealized holding gains and losses on
available-for-sale securities, as follows (in thousands): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>June 30,</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>May 4,1998</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(inception)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>through<BR>June 30,</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(18,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(130,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(317</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(18,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(131,267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 4. Stock-Based Compensation
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We use the intrinsic-value method of accounting for
stock-based awards granted to employees in accordance with Accounting Principles Board Opinion No. 25 and its related interpretations. Accordingly, we would recognize compensation expense in our financial statements in connection with stock options
granted to employees with exercise prices less than fair value at the time the stock option is granted. We record stock-based compensation expense for non-employees at the fair value of the options granted in accordance with Statement of Financial
Accounting Standards No. 123, or SFAS 123, and Emerging Issues Task Force No 96-18, or EITF 96-18. The fair value of options granted to non-employees is estimated using a Black-Scholes option valuation model, or Black-Scholes. The model considers a
number of factors, including the market price and volatility of our common stock at the date of measurement. We periodically re-measure the compensation expense for options granted to non-employees as the underlying options vest. The compensation
expense related to all grants is being amortized using the graded vesting method, in accordance with SFAS 123, EITF 96-18 and FASB Interpretation No. 28, over the vesting period of each respective stock option, generally four years. The graded
vesting method results in expensing approximately 57% of the total award in year one, 26% in year two, 13% in year three and 4% in year four. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If we had recorded compensation cost of our stock-based plans in a manner consistent with the fair value
approach of SFAS 123, our adjusted net loss and adjusted net loss per common share would have been increased as follows (in thousands, except per share data): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Pro forma net loss (in thousands except per share data): </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>June 30,</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss, as reported</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(9,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(18,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(19,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Deduct: Total stock based employee compensation expense determined under the fair value based method for all awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Add: Total stock based employee compensation expense </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adjusted net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(12,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(10,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(22,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(21,702</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss per common share basic and diluted as reported</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Adjusted net loss per common share basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="3" NOSHADE ALIGN="left" COLOR="#ffffff"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B></B>The weighted
average fair value of stock options granted to employees was $4.27 and $6.29 in the three months ended June 30, 2005 and 2004, respectively, and $4.13 and $6.42 in the six months ended June 30, 2005 and 2004, respectively. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For employee stock options, the weighted average fair value of each option
granted was estimated on the date of grant using Black-Scholes with the following assumptions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">82%&nbsp;to&nbsp;86%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">95%</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Risk-free interest rates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4%</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected life of option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5&nbsp;years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5&nbsp;years</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For the 2000 Employee
Stock Purchase Plan, the weighted average fair value of purchase rights granted were $4.43 per share and $1.66 per share for the six months ended June 30, 2005 and 2004, respectively, calculated using Black-Scholes with the following assumptions:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">55%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">94%</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Risk-free interest rates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3%&nbsp;to&nbsp;4%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3%</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Expected life of option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2&nbsp;years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2&nbsp;years</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Note 5. 1998 Stock Plan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In accordance with the provisions of the 1998 Stock Plan, effective January 1, 2005, the number of shares of common stock authorized for issuance under
the 1998 Stock Plan was increased form 10,100,000 shares to 10,600,000 shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Note 6. Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In
December 2004, the Financial Accounting Standards Board, or FASB, issued a revision of Financial Accounting Standards No. 123, or SFAS 123R, which requires all share-based payments to employees, including grants of employee stock options, to be
recognized in the income statement based on their values. We expect to calculate the value of share-based payments under SFAS 123R on a basis substantially consistent with the fair value approach of SFAS 123. We plan to adopt SFAS 123R in 2006. We
expect the adoption of SFAS 123R will have a material impact on our financial statements in 2006, but we cannot reasonably estimate the impact of adoption because we expect certain assumptions that can materially affect the calculation of the value
of share-based payments to employees to change in 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_7"></A>Item 2. </B><B><I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included elsewhere in this report.
Operating results are not necessarily indicative of results that may occur in future periods. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">This document contains forward-looking statements that are based upon current expectations that are within the meaning of the Private Securities Reform Act of 1995. It is our intent that such statements be protected
by the safe harbor created thereby. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such
forward-looking statements include, but are not limited to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the timing of expected announcements of our clinical trial results; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">future operating losses and anticipated operating and capital expenditures; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">expected uses of proceeds from our securities offerings; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the sufficiency of materials required for the clinical development of our drug candidates; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the size of the potential market for our products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the utility of protection of our intellectual property; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">expected future sources of revenue and capital or increasing cash needs; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">potential competitors or competitive products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">future market acceptance of our drug candidates; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">expenses increasing substantially or fluctuations in our operating results; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">future expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">anticipated hiring and development of our internal systems and infrastructure; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the sufficiency of our current resources to fund our operations over the next twelve months. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Such forward-looking statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">difficulties or delays in development, testing, clinical trials (including patient enrollment), regulatory approval, production and commercialization of our drug candidates;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates that could slow or prevent product approval (including the risk that current and past
results of clinical trials are not indicative of future results of clinical trials); </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the uncertainty of patent protection for our intellectual property or trade secrets; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">potential infringement of the intellectual property rights or trade secrets of third parties; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">pursuing in-license and acquisition opportunities; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">hiring and retaining personnel; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our financial position and our ability to obtain additional financing if necessary. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, such statements are subject to the risks and uncertainties discussed in the &#147;Risk Factors&#148; section
and elsewhere in this document. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We are a biopharmaceutical company dedicated to the development of
innovative drugs. We specialize in developing safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. U.S. sales of opioid painkillers exceeded $5.6 billion in 2003. We own worldwide commercial
rights to all of our drug candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our clinical pipeline
consists of three proprietary drug candidates. We are developing these three oral, small molecule drugs to treat patients who suffer from severe chronic pain, such as pain associated with advanced osteoarthritis, low-back pain or IBS. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our drug candidates are: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Oxytrex&#153;, a new oral opioid painkiller, currently in a Phase III clinical trial for the treatment of severe chronic pain; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">PTI-901, a drug candidate to treat men and women with IBS, currently in two Phase III clinical trials; and </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Remoxy&#153;, a long-acting formulation of oxycodone designed to deter abuse, currently in one Phase III clinical trial and non-clinical studies. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We expect to announce top-line data from Phase III clinical trials of Remoxy, Oxytrex and PTI-901 by the
end of 2005. In March 2005, we announced positive clinical results from the first of two Phase III clinical trials for Oxytrex. In this variable dose study of 719 patients with severe low-back pain, Oxytrex showed minimal physical dependence, better
overall safety, less drug use and similar pain relief to oxycodone. Specifically, Oxytrex patients reported 50% less symptoms of physical dependence and withdrawal (p&lt;0.01) after cessation of prolonged, high-dose opioid therapy and about 20% less
overall opioid-related side-effects during treatment, including less somnolence (p&lt;0.05), less uncontrollable itching (p&lt;0.05) and less moderate to severe constipation (p&lt;0.05). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have yet to generate any revenues from product sales. We have not been profitable and, since our inception on May 4, 1998
through June 30, 2005, we have recorded an accumulated deficit of approximately $130.8 million. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related
costs and general corporate expenses. Research and development activities include costs of preclinical and clinical trials as well as clinical supplies associated with our drug candidates. Salaries and other personnel-related costs include non-cash
stock-based compensation associated with options granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of the timing and enrollment rates of clinical trials for our drug
candidates and our need for clinical supplies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We expect to
incur significant additional operating losses. Our cash requirements for operating activities and capital expenditures will increase substantially in the future as we: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">continue to conduct preclinical and clinical trials for our drug candidates, including the clinical trials of Oxytrex, PTI-901 and Remoxy as well as formulation and development
activities for Remoxy; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">seek regulatory approvals for our drug candidates; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">develop, formulate, manufacture and commercialize our drug candidates; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">implement additional internal systems and develop new infrastructure; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">acquire or in-license additional products or technologies, or expand the use of our technology; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">maintain, defend and expand the scope of our intellectual property; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">hire additional personnel. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our drug candidates. If our development efforts
result in regulatory approval and successful commercialization of our drug candidates, we will generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties
from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, collaborators, contract research organizations and clinical
research sites for a significant portion of our product development efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Since our inception, we have focused all of our research and development efforts on the research and
development of opioid drugs for the treatment of pain. Research and development expenses related to this project for the period from inception through June 30, 2005 total $111.6 million. The following table summarizes expenses by category for
research and development efforts (in thousands): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months Ended<BR>June 30,</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>May&nbsp;4,&nbsp;1998<BR>(Inception)<BR>Through<BR>June 30,</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2004</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,133</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">978</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,192</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,943</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22,880</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Contractor Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,998</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,254</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,337</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,254</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">68,353</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">942</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">406</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,110</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,376</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13,231</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other Common Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">445</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">543</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,001</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,104</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,109</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,518</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,181</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,640</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17,677</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">111,573</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
</TABLE><HR WIDTH="8%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Contractor fees generally include expenses for preclinical studies and clinical trials. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Supplies generally include costs for formulation and manufacturing activities. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Other generally includes the allocation of common costs such as facilities. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our technology has been applied across our portfolio of drug candidates. Data, know-how, personnel, clinical results, research results and other matters
related to the research and development of any one of our drug candidates also relate to, and further the development of, our other drug candidates. As a result, costs allocated to a specific drug candidate may not necessarily reflect the actual
costs surrounding research and development of that drug candidate due to cross application of the foregoing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Estimating the dates of completion of clinical development, and the costs to complete development, of our drug candidates would be highly speculative,
subjective and potentially misleading. Pharmaceutical products take a significant amount of time to research, develop and commercialize. The clinical trial portion of the development of a new drug alone usually spans several years. We expect to
reassess our future research and development plans based on our review of data we receive from our current research and development activities. The cost and pace of our future research and development activities are linked and subject to change.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Critical Accounting Policies are described under Item 7.
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our Annual Report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. There have been no
changes to our Critical Accounting Policies for the period ended June 30, 2005.<B></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Three and Six Months Ended June 30, 2005 and 2004 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Research and Development </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Research and development expense consists primarily of costs of drug development work associated with our drug candidates, including: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">preclinical testing, </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">clinical trials, </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">clinical supplies and related formulation and design costs, and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">salaries and other personnel-related expenses. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The increase in research and development expense to $9.5 million from $8.2 million in the three months ended June 30, 2005 and 2004, respectively was
primarily due to the timing of the Phase III clinical trials and other activities for Oxytrex, Remoxy and PTI-901. The decrease in research and development expense to $17.6 million from $17.7 million for the six months ended June 30, 2005 and 2004
respectively was primarily due to timing of our clinical trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">We expect research and development expenses to increase over the next several years as we continue our development efforts. Our development efforts are designed to result in our drug candidates progressing through various stages of clinical
trials, including our Phase III trials of Oxytrex, PTI-901 and Remoxy. Also, we expect to continue other development efforts on our product candidates. The increase in research and development expenses may fluctuate from period to period due to the
timing and scope of our development activities and the results of clinical trials and studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><I>General and Administrative </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">General and administrative expense consists primarily of compensation and other general corporate expenses. General and administrative expense was approximately $1.1 million for both of the three months ended June 30, 2005 and 2004 and
increased to $2.2 million from $2.0 million for the six months ended June 30, 2005 and 2004. The increase was primarily due to an increase in personnel-related expenses. We expect general and administrative expenses to increase over the next several
years in connection with precommercialization and commercialization activities for our product candidates. The increase may fluctuate from period to period due to the timing and scope of these activities and the results of clinical trials and
studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Interest Income </I></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I></I>Interest income increased to $0.5 million from $0.2 million in the
three months ended June 30, 2005 and 2004, respectively, and to $1.0 from $0.5 million for the six months ended June 30, 2005 and 2004, respectively. These increases were primarily due to increases in average balances of marketable securities as
well as to increases in interest rates. We expect our interest income to decrease during 2005 as we use cash to fund our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Liquidity and Capital Resources </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Since inception, we have financed our operations primarily through public and private securities offerings. We intend to
continue to use the proceeds from these offerings to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of June 30, 2005, cash, cash equivalents and marketable
securities were $81.7 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Net cash used in operating
activities was $17.5 million for the six months ended June 30, 2005 compared to $16.0 million for the six months ended June 30, 2004. Cash used in operating activities in both periods related primarily to the funding of operating losses. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our investing activities to purchase property and equipment were $0.2
million for the six months ended June 30, 2005. Other investing activities for the six months ended June 30, 2005 consisted primarily of the purchase and sale of marketable securities. We expect to continue to invest in our infrastructure to support
our operations.<B> </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our financing activities provided $0.1
million in the year ended June 30, 2005, primarily from the exercise of stock options issued under our stock plans. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We lease approximately 10,500 square feet of general office space. In addition to office space, we also lease equipment pursuant to operating leases. Our
leases expire at various dates through 2010. Under the terms of our facility and equipment leases, annual minimum lease payments are as follows (in thousands): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2005</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2006</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2007</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2010 and</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Thereafter</B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Total</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Minimum lease payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">187</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">191</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">187</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">196</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">206</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">160</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,127</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have license
agreements that require us to make milestone payments upon the successful achievement of milestones, including clinical milestones. Our formulation agreement with Durect Corporation obligates us to make certain milestone payments upon achieving
clinical milestones and regulatory milestones. We believe the amount of each of these milestone payments will be immaterial within the period such milestone is achieved. Our license agreements also require us to pay certain royalties to our
licensors if we succeed in fully commercializing products under these license agreements and in some cases modest license maintenance payments. All of these potential future payments are cancelable as of June 30, 2005. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Since our inception we have used cash of $108.7 million in operating
activities and have an accumulated deficit of approximately $130.8 million. We expect to incur significant additional losses and expect our cash requirements to increase in the future. The amount and timing of our future cash requirements will
depend on regulatory and market acceptance of our drug candidates and the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products. We believe that our current resources should be
sufficient to fund our operations for at least the next twelve months. We may seek additional future funding through public or private financing within this timeframe, if such funding is available and on terms acceptable to us. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>RISK FACTORS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our future operating results may vary substantially from anticipated results due to a number of factors, many of which are
beyond our control. The following discussion highlights some of these factors and the possible impact of these factors on future results of operations. You should carefully consider these factors before making an investment decision. If any of the
following factors actually occur, our business, financial condition or results of operations could be harmed. In that case, the price of our common stock could decline, and you could experience losses on your investment. <I></I> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks Relating to our Financial Position and Need for Financing </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our operating history may make it difficult for you to evaluate our business to date and
to assess its future viability. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We were founded in May
1998 and are in the development stage. Our operations to date have been limited to organizing and staffing our company, acquiring, developing and securing our technology and undertaking preclinical studies and clinical trials of our drug candidates.
We have not yet demonstrated our ability to obtain regulatory approval, formulate and manufacture our drug candidates on a commercial scale or conduct sales and marketing activities. Consequently, any predictions you make about our future success or
viability may not be as accurate as they could be if we had a longer operating history. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>We have a history of losses and expect to incur substantial losses and negative operating cash flows for the foreseeable future. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have incurred net losses each year since our inception. As a result of ongoing operating losses, we had an accumulated deficit of $130.8 million as of
June 30, 2005. Even if we succeed in developing and commercializing one or more of our drug candidates, we expect to continue to incur substantial losses for the foreseeable future, and we may never become profitable. We anticipate that our expenses
will increase substantially in the foreseeable future as we: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">continue to conduct preclinical and clinical trials for our drug candidates, including the clinical trials of Oxytrex, PTI-901 and Remoxy as well as formulation and development
activities for Remoxy; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">seek regulatory approvals for our drug candidates; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">develop, formulate, manufacture and commercialize our drug candidates; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">implement additional internal systems and develop new infrastructure; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">acquire or in-license additional products or technologies, or expand the use of our technology; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">maintain, defend and expand the scope of our intellectual property; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">hire additional personnel. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We will need to generate significant revenues to achieve and maintain profitability. If we cannot successfully develop, obtain regulatory approval for and
commercialize our drug candidates, we will </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">not be able to generate such revenues or achieve profitability in the future. Our failure to achieve or maintain profitability would have a material adverse
impact on the market price of our common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we cannot raise
additional capital on acceptable terms, we may be unable to complete planned clinical trials of any or some of our drug candidates or to pursue attractive business opportunities. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have funded all of our operations and capital expenditures with the proceeds from public and private stock offerings. We
expect that our current cash, cash equivalents and marketable securities on hand will be sufficient to meet our working capital and capital expenditure needs for at least the next twelve months. However, we may need to raise additional funds within
such twelve-month period or thereafter and additional financing may not be available on favorable terms, if at all. Even if we succeed in selling additional securities to raise funds, our existing stockholders&#146; ownership percentage would be
reduced and new investors may demand rights, preferences or privileges senior to those of existing stockholders. If we raise additional capital through strategic alliance and license arrangements, we may have to trade our rights to our technology,
intellectual property or drug candidates to others in such arrangements on terms that may not be favorable to us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If we determine that we need to raise additional funds and we are not successful in doing so, we may be unable to complete the clinical development of
some or all of our drug candidates or to seek or obtain FDA approval of our drug candidates. We then could be forced to discontinue product development, enter into a relationship with a strategic partner earlier than currently intended, reduce sales
and marketing efforts or forego attractive business opportunities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Clinical and Regulatory Risks </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we fail to obtain
the necessary regulatory approvals, we will not be allowed to commercialize our drug candidates, and we will not generate product revenues. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Satisfaction of all regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the drug candidate, and
requires the expenditure of substantial resources for research and development and testing. Our research and clinical approaches may not lead to drugs that the FDA considers safe for humans and effective for indicated uses we are studying. The FDA
may require us to conduct additional clinical testing, in which case we would have to expend additional time and resources and would likely delay the date of potentially receiving regulatory approval. In particular, the FDA may require additional
toxicology studies for certain excipients used in Remoxy or any of our other drug candidates. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that
occur prior to or during our regulatory review. Delays in obtaining regulatory approvals will: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">delay commercialization of, and product revenues from, our drug candidates; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">diminish the competitive advantages that we may have otherwise enjoyed, which would have an adverse effect on our operating results and financial condition.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Even if we comply with all FDA regulatory requirements, we may never obtain regulatory approval for any
of our drug candidates. If we fail to obtain regulatory approval for any of our drug candidates we will have fewer saleable products, if any, and corresponding lower product revenues, if any. Even if we receive regulatory approval of our drug
candidates, such approval may involve limitations on the indications and conditions of use or marketing claims we may make for our products. Further, later discovery of previously unknown problems or adverse events could result in additional
regulatory restrictions, including withdrawal of products. The FDA may also require us to commit to perform lengthy Phase IV post-approval studies, for which we would have to expend additional resources, which could have an adverse effect on our
operating results and financial condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In jurisdictions
outside the United States, we must receive marketing authorizations from the appropriate regulatory authorities before we can commercialize our drugs. Regulatory approval processes outside the United States generally include all of the
aforementioned requirements and risks associated with FDA approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we
are unable to design, conduct and complete clinical trials successfully, we will not be able to obtain regulatory approval for our drug candidates. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In order to obtain FDA approval for any of our drug candidates, we must submit to the FDA a new drug application, or NDA, that demonstrates that the drug
candidate is safe and effective in humans for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials.
Oxytrex, PTI-901 and Remoxy are in Phase III clinical trials in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Our Phase III clinical trials may not demonstrate the safety or efficacy of our drug candidates. Success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful.
Results of later clinical trials may not replicate the results of prior clinical trials and pre-clinical testing. FDA guidelines recommend that the efficacy of new painkillers be demonstrated in more than one clinical model of pain. This means that
even if one of our Phase III clinical trials demonstrates positive results for our drug candidates, we are likely to have to demonstrate positive results in one or more additional Phase III clinical trials prior to receiving broad label FDA approval
for treatment of severe chronic pain. Even if the results of one or more of our Phase III clinical trials are positive, we may have to commit substantial time and additional resources to conducting further preclinical studies or clinical trials
before we can submit NDAs or obtain FDA approvals for our drug candidates, and positive results of a Phase III clinical trial may not be replicated in subsequent trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous
requirements. The clinical trial process is also time consuming. Furthermore, if participating patients in clinical studies suffer drug-related adverse reactions during the course of such trials, or if we or the FDA believe that participating
patients are being exposed to unacceptable health risks, we will have to suspend or terminate our clinical trials. Failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon clinical trials or to repeat
clinical studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, completion of clinical trials can be delayed by numerous factors, including: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">delays in identifying and agreeing on acceptable terms with prospective clinical trial sites; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">slower than expected rates of patient recruitment and enrollment; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">increases in time required to complete monitoring of patients during or after participation in a trial; and </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">unexpected need for additional patient-related data. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any of these delays, if significant, could impact the timing, approval and commercialization of our drug candidates and could significantly increase our
overall costs of drug development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Even if our clinical trials
are completed as planned, their results may not support our expectations or intended marketing claims. The clinical trials process may fail to demonstrate that our drug candidates are safe and effective for indicated uses. Such failure would cause
us to abandon a drug candidate and could delay development of other drug candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Clinical trial designs that were discussed with authorities prior to their commencement may subsequently be considered insufficient for approval at the time of application for regulatory approval. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We discuss with and obtain guidance from regulatory authorities on certain
of our clinical development activities. These discussions are not binding obligations on the part of regulatory authorities. Regulatory authorities may revise previous guidance or decide to ignore previous guidance at any time during the course of
our clinical activities or after the completion of our clinical trials. Even with successful clinical safety and efficacy data, we may be required to conduct additional, expensive trials to obtain regulatory approval. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Developments by competitors may establish standards of care that affect our ability to
conduct our clinical trials as planned. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have conducted
clinical trials of our drug candidates comparing our drug candidates to both placebo and other approved drugs. Changes in standards related to clinical trial design could affect our ability to design and conduct clinical trials as planned. For
example, regulatory authorities may not allow us to compare our drug candidates to placebo in a particular clinical indication where approved products are available. In that case, both the cost and the amount of time required to conduct a trial
could increase. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>The Drug Enforcement Administration, or DEA, limits the
availability of the active ingredients in certain of our current drug candidates and, as a result, our quota may not be sufficient to complete clinical trials or to meet commercial demand or may result in clinical delays. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The DEA regulates chemical compounds as Schedule I, II, III, IV or V
substances, with Schedule I substances considered to present the highest risk of substance abuse and Schedule V substances the lowest risk. Certain active ingredients in our current drug candidates, such as oxycodone, are listed by the DEA as
Schedule II under the Controlled Substances Act of 1970. Consequently, their </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">manufacture, research, shipment, storage, sale and use are subject to a high degree of oversight and regulation. For example, all Schedule II drug
prescriptions must be signed by a physician, physically presented to a pharmacist and may not be refilled without a new prescription. Furthermore, the amount of Schedule II substances we can obtain for clinical trials and commercial distribution is
limited by the DEA and our quota may not be sufficient to complete clinical trials or meet commercial demand. There is a risk that DEA regulations may interfere with the supply of the drugs used in our clinical trials, and, in the future, our
ability to produce and distribute our products in the volume needed to meet commercial demand. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Government agencies may establish and promulgate usage guidelines that directly apply to our drug candidates. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Government agencies, professional and medical societies, and other groups may establish usage guidelines that apply to our drug candidates. These
guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could limit the use of our drug candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Conducting clinical trials of our drug candidates or potential commercial sales of a drug candidate may expose us to expensive product liability claims and we may not
be able to maintain product liability insurance on reasonable terms or at all. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The risk of product liability is inherent in the testing of pharmaceutical products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to
limit or terminate testing of one or more of our products. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of
our products. We currently carry clinical trial insurance but do not carry product liability insurance. If we successfully commercialize one or more of our drug candidates, we may face product liability claims, regardless of FDA approval for
commercial manufacturing and sale. We may not be able to obtain such insurance at a reasonable cost, if at all. If our agreements with any future corporate collaborators entitle us to indemnification against product liability losses, such
indemnification may not be available or adequate should any claim arise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If
we receive regulatory approval for our drug candidates, we and our collaborators will also be subject to ongoing FDA obligations and continued regulatory review, such as continued safety reporting requirements, and we and our collaborators may also
be subject to additional FDA post-marketing obligations or new regulations, all of which may result in significant expense and limit our ability to commercialize our potential drugs. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the indicated uses
for which the drug may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition, if the FDA approves any of our drug candidates, the labeling, packaging, adverse event reporting, storage, advertising,
promotion and record keeping for the drug will be subject to extensive regulatory requirements. The subsequent discovery of previously unknown problems with the drug, including adverse events of unanticipated severity or frequency, may result in
restrictions on the marketing of the drug, and could include withdrawal of the drug from the market. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The FDA&#146;s policies may change and additional government regulations may be enacted that could
prevent or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Any of these events could
prevent us from marketing our drugs and our business could suffer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks
Relating to Commercialization </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If physicians and patients do not
accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Even if the FDA approves our drugs, physicians and patients may not accept and use them. Acceptance and use of our drugs will depend on a number of
factors including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our drugs; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">published studies demonstrating the cost-effectiveness of our drugs relative to competing products; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">availability of reimbursement for our products from government or healthcare payers; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">our ability to implement a risk management plan prior to the distribution of any Schedule II drug; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Because we expect to rely on sales generated by our current lead drug candidates for substantially all of our product
revenues for the foreseeable future, the failure of any of these drugs to find market acceptance would harm our business and could require us to seek additional financing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we are unable to develop our own sales, marketing and distribution capabilities, or if we are not successful in contracting with third
parties for these services on favorable terms, or at all, our product revenues could be disappointing. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We currently have no sales, marketing or distribution capabilities. In order to commercialize our products, if any are approved by the FDA, we will either
have to develop such capabilities internally or collaborate with third parties who can perform these services for us. If we decide to commercialize any of our drugs ourselves, we may not be able to hire the necessary experienced personnel and build
sales, marketing and distribution operations which are capable of successfully launching new drugs and generating sufficient product revenues. In addition, establishing such operations will take time and involve significant expense. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If we decide to enter into co-promotion or other licensing arrangements with third parties, we may be
unable to locate acceptable collaborators because the number of potential collaborators is limited and because of competition from others for similar alliances with potential collaborators. Even if we are able to identify one or more acceptable
collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, due to the nature of the market for pain management products, it may be necessary for us to license all or substantially all of our drug
candidates to a single collaborator, thereby eliminating our opportunity to commercialize other pain management products independently. If we enter into any collaborative arrangements, our revenues are likely to be lower than if we marketed and sold
our products ourselves. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, any revenues we receive
would depend upon our collaborators&#146; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, further business combinations or other factors outside of our control.
Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable
terms, or at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we cannot compete successfully for market share
against other drug companies, we may not achieve sufficient product revenues and our business will suffer. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The market for our drug candidates is characterized by intense competition and rapid technological advances. If our drug candidates receive FDA approval,
they will compete with a number of existing and future drugs and therapies developed, manufactured and marketed by others. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific
indication than our products, or may offer comparable performance at a lower cost. If our products are unable to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We will compete for market share against fully integrated pharmaceutical
companies or other companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors have opioid painkillers already
approved or in development. In addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well
as significantly greater experience in: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">developing drugs; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">conducting preclinical testing and human clinical trials; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">obtaining FDA and other regulatory approvals of drugs; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">formulating and manufacturing drugs; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">launching, marketing, distributing and selling drugs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our ability to generate product revenues will be diminished if we fail to obtain acceptable prices or an adequate
level of reimbursement for our products from healthcare payers. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Our ability to commercialize our drugs, alone or with collaborators, will depend in part on the extent to which reimbursement will be available from: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">government and health administration authorities; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">private health maintenance organizations and health insurers; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">other healthcare payers. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Healthcare payers, including Medicare, health
maintenance organizations and managed care organizations, are challenging the prices charged for medical products and services and/or are seeking pharmacoeconomic data to justify formulary acceptance and reimbursement practices. We currently have
not generated pharmacoeconomic data on any of our products. Government and other healthcare payers increasingly are attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for drugs, and by refusing, in some
cases, to provide coverage for uses of approved products for disease indications for which the FDA has or has not granted labeling approval. Adequate third-party insurance coverage may not be available to patients for any products we discover and
develop, alone or with collaborators. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for our products, market acceptance of our product candidates could be limited. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks Relating to our Intellectual Property </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we are unable to protect our intellectual property our competitors could develop and
market products with similar features that may reduce demand for our products. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Our success, competitive position and potential future revenues will depend in part on our ability to protect our intellectual property. If we, Albert Einstein College of Medicine or our other collaborators fail to
file, prosecute or maintain certain patents, our competitors could market products that contain features and clinical benefits similar to those of our products, and demand for our products could decline as a result. In January 2003, the U.S. Patent
and Trademark Office, or PTO, disclosed that a law firm for an unidentified third-party filed requests for an Ex Parte Reexamination related to certain claims on patents we exclusively licensed from Albert Einstein College of Medicine. As of June
2005, Reexamination Certificates have been issued resolving all but one of the proceedings. In addition, a Notice of Intent to Issue Reexamination Certificates has been issued in the remaining proceeding. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We may be involved in additional challenges to our intellectual property. An
adverse outcome of the reexamination process or any other challenges to our intellectual property could result in loss of claims of these patents that pertain to certain drugs we currently have under development and could have a material adverse
impact on our future revenues. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We intend to file additional patent applications relating to our technology, products and processes. We
may direct Albert Einstein College of Medicine or our collaborators to file additional patent applications relating to the licensed technology or we may do so ourselves. However, our competitors may challenge, invalidate or circumvent any of our
current or future patents. These patents may also fail to provide us with meaningful competitive advantages. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>We may become involved in expensive litigation or other legal proceedings related to our existing intellectual property rights, including patents. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We expect that we will rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities
to develop and maintain our competitive position. Others may independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our products or know-how or require us to license such information
and pay significant fees or royalties in order to produce our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Our technology could infringe upon claims of patents owned by others. If we were found to be infringing on a patent held by another, we might have to seek a license to use the patented technology. In that case, we might not be able to
obtain such a license on terms acceptable to us, or at all. If a legal action were to be brought against us or our licensors, we could incur substantial defense costs, and any such action might not be resolved in our favor. If such a dispute were to
be resolved against us, we could have to pay the other party large sums of money and our use of our technology and the testing, manufacture, marketing or sale of one or more of our proposed products could be restricted or prohibited. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks Relating to our Business and Strategy </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Competition for qualified personnel in the pharmaceutical industry is intense, and if we
are not successful in attracting and retaining qualified personnel, we could experience delays in completing necessary clinical trials, in the regulatory approval process or in formulating, manufacturing, marketing and selling our potential
products. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We will need to hire additional qualified
personnel with expertise in clinical research, preclinical testing, government regulation, formulation and manufacturing and sales and marketing. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other
research institutions. Competition for such individuals, particularly in the San Francisco Bay area, is intense, and our search for such personnel may not be successful. Attracting and retaining qualified personnel will be critical to our success.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If third-party manufacturers of our drug candidates fail to devote
sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed and our costs may be higher than expected. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have no manufacturing facilities and have limited experience in drug
product development and commercial manufacturing. We lack the resources and expertise to formulate, manufacture or test the technical performance of our drug candidates. We currently rely on a limited number of </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">experienced personnel and a small number of contract manufacturers and other vendors to formulate, test, supply, store and distribute drug supplies for our
clinical trials. Our reliance on a limited number of vendors exposes us to the following risks, any of which could delay our clinical trials, and, consequently, FDA approval of our drug candidates and commercialization of our products, result in
higher costs, or deprive us of potential product revenues: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Contract commercial manufacturers, their sub-contractors or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy
clinical needs or commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified
personnel to adequately staff production operations. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Our contract manufacturers could default on their agreements with us to provide clinical supplies or meet our requirements for commercialization of our products.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The use of alternate manufacturers may be difficult because the number of potential manufacturers that have the necessary governmental licenses to produce narcotic products is
limited. Additionally, the FDA and the DEA must approve any alternative manufacturer of our product before we may use the alternative manufacturer to produce our supplies. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">It may be difficult or impossible for us to find a replacement manufacturer on acceptable terms quickly, or at all. Our contract manufacturers and vendors may not perform as agreed
or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If any contract manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to such
innovation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our employees and consultants are generally
subject to confidentiality or other agreements with their former employers and they may inadvertently or otherwise violate those agreements. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Many of our employees and consultants were previously employed at universities or biotechnology or pharmaceutical companies. While we require our
employees and consultants to honor any agreements they may have entered into prior to working with us, we may be subject to claims that we inadvertently or otherwise used or disclosed trade secrets or other confidential information belonging to
former employers. Failure to defend such claims could result in loss of valuable rights or personnel, which in turn could harm or prevent commercialization of our drug candidates. Successful defense against such claims can be expensive and might
distract us from our execution of our strategies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Law enforcement concerns
over diversion of opioids and social issues around abuse of opioids may make the regulatory approval process very time consuming, difficult and expensive for our drug candidates. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Media stories regarding the diversion of opioids and other controlled substances are commonplace. Law enforcement agencies
or regulatory agencies may apply policies that seek to limit the availability of opioids. Such efforts may adversely affect the regulatory approval process for our drug candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Developments by competitors may render our products or technologies obsolete or non-competitive. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Alternative technologies and products are being developed to improve or
replace the use of opioids for pain management, several of which are in clinical trials or are awaiting approval from the FDA. In addition, the active ingredients in nearly all opioid drugs are available in generic form. Drug companies that sell
generic opioid drugs represent substantial competition. Many of these organizations competing with us have substantially greater capital resources, larger research and development staffs and facilities, greater experience in drug development and in
obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. Our competitors may market less expensive or more effective drugs that would compete with our product candidates or reach market with competing drugs
before we are able to reach market with our drug candidates. These organizations also compete with us to attract qualified personnel and partners for acquisitions, joint ventures or other collaborations. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Business interruptions could limit our ability to operate our business. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our operations as well as those of our collaborators on which we depend are
vulnerable to damage or interruption from computer viruses, human error, natural disasters, electrical and telecommunication failures, international acts of terror and similar events. We have not established a formal disaster recovery plan and our
back-up operations and our business interruption insurance may not be adequate to compensate us for losses we may suffer. A significant business interruption could result in losses or damages incurred by us and require us to cease or curtail our
operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks Relating to Manufacturing </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We rely on third-party commercial drug manufacturers for drug supply. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Approved third-party commercial drug manufacturers may subsequently be
stopped from producing, storing, shipping or testing our drug products due to their non-compliance with federal, state or local regulations. Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the DEA, and
corresponding state and foreign government agencies to ensure strict compliance with good manufacturing practice and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#146;
compliance with these regulations and standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition,
even if we enter into long-term supply arrangements with third-party suppliers, we cannot control changes in strategy by third-party suppliers that affect their ability or willingness to continue to supply our drug products on acceptable terms.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If our drug supply for one of our drug candidates was
interrupted, our operations could be negatively affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If we cannot formulate and scale-up a wide range of dosage forms of Remoxy, we might determine that the commercial
opportunity for Remoxy is too limited to warrant further investment in clinical testing and development. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We plan to formulate and scale-up a wide range of dosage forms of Remoxy. We may not be able to successfully complete our formulation or scale-up
activities or we may determine that the commercial opportunity for Remoxy in certain dosage forms is too limited to warrant further investment. If we are unsuccessful in our formulation or scale-up activities with Remoxy, our future sales may be
less than expected and our operations may suffer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks Relating to our
Collaboration Agreements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If outside collaborators fail to devote
sufficient time and resources to our drug development programs, or if their performance is substandard, our regulatory submissions and our product introductions may be delayed. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We depend on independent investigators and collaborators, such as universities and medical institutions, to conduct our
clinical trials under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority to our programs or
pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, the approval of our
regulatory submissions and our introductions of new drugs will be delayed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Our collaborators may also have relationships with other commercial entities, some of which may compete with us. If outside collaborators assist our competitors to our detriment, the approval of our regulatory
submissions will be delayed and the sales from our products will be less than expected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>We may not succeed at in-licensing drug candidates or technologies to expand our product pipeline. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We may not successfully in-license drug candidates or technologies to expand our product pipeline. The number of such candidates or technologies may be
limited. Competition among large pharmaceutical companies and biopharmaceutical companies for promising drug candidates or technologies is intense because such companies generally desire to expand their product pipelines through in-licensing.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our collaborative agreements may not succeed or may give rise to disputes
over intellectual property or other issues. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our strategy
to focus on development of novel drug candidates discovered by third parties requires us to enter into license agreements with such third parties. In addition, we may enter into collaborative agreements to commercialize our products. Such agreements
are generally complex and contain provisions that could give rise to legal disputes. Such disputes can delay the </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">development of potential new drug products, or can lead to lengthy, expensive litigation or arbitration. Other factors relating to collaborative agreements
may adversely affect the success of our drug candidates, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the development of parallel products by our collaborators or by a competitor; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">arrangements with collaborative partners that limit or preclude us from developing certain products or technologies; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">premature termination of a collaborative agreement; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">failure by a collaborative partner to devote sufficient resources to the development of our potential products. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Risks Relating to an Investment in our Common Stock </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our stock price has been volatile and could experience a sudden decline in value.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our common stock has experienced significant price and
volume fluctuations and may continue to experience volatility in the future. You may not be able to sell your shares quickly or at the latest market price if trading in our stock is not active or the volume is low. The following factors, in addition
to other risk factors described in this section, may have a significant impact on the market price of our common stock: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">results of or delays in our preclinical studies and clinical trials; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">publicity regarding actual or potential medical results relating to products under development by us or others; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">announcements of technological innovations or new commercial products by us or others; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">developments in patent or other proprietary rights by us or others; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">comments or opinions by securities analysts or major stockholders; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">future sales of our common stock by existing stockholders; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">regulatory developments or changes in regulatory guidance; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">litigation or threats of litigation including the risk of class action lawsuits related to opioid misuse or abuse; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">economic and other external factors or other disaster or crises; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the departure of any of our officers, directors or key employees; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">period-to-period fluctuations in financial results; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">limited daily trading volume. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The National Association of Securities Dealers, Inc., or NASD, and the Securities and Exchange Commission, or SEC, have adopted certain new rules. If we
were unable to continue to comply with the new rules, we could be delisted from trading on the NASDAQ National Market, or Nasdaq, and thereafter trading in our common stock, if any, would be conducted through the over-the-counter market or on the
Electronic Bulletin Board of the NASD. As a consequence of such delisting, an investor would likely find it more difficult to dispose of, or to obtain quotations as to the price of, our common stock. Delisting of our common stock could also result
in lower prices per share of our common stock than would otherwise prevail. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Anti-takeover provisions in our charter documents, our Stockholder Rights Plan and Delaware law may prevent or delay
removal of incumbent management or a change of control. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws, our Stockholder Rights Plan and Delaware law may have the effect of deterring or delaying attempts by our stockholders to
remove or replace management, engage in proxy contests and effect changes in control. The provisions of our charter documents include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">a classified board so that only one of the three classes of directors on our board of directors is elected each year; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">elimination of cumulative voting in the election of directors; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">procedures for advance notification of stockholder nominations and proposals; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the ability of our board of directors to amend our bylaws without stockholder approval; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the ability of our board of directors to issue up to 10,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges
and preferences as our board of directors may determine. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The rights issued pursuant to our Stockholder Rights Plan will become exercisable, subject to certain exceptions, the tenth day after a person or group announces acquisition of 15% or more of our common stock or announces commencement of a
tender or exchange offer the consummation of which would result in ownership by the person or group of 15% or more of our common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, as a Delaware corporation, we are subject to Delaware law, including Section 203 of the Delaware General Corporation Law. In general, Section
203 prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements
are met as set forth in Section 203. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">These provisions, alone
or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Volatility in the stock prices of other companies may contribute to volatility in our stock price. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The stock market in general, Nasdaq and the market for technology companies in particular, have experienced significant
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, there has been particular volatility in the market prices of securities of early stage and development stage
life sciences companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company&#146;s
securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of management&#146;s attention and resources. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our share ownership is concentrated, and our officers, directors and principal stockholders can exert significant
control over matters requiring stockholder approval. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Due
to their combined stock holdings, our officers, directors and principal stockholders (stockholders holding greater than 5% of our common stock) acting collectively may have the ability to exercise significant influence over matters requiring
stockholder approval including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control of the Company and may make some transactions more
difficult or impossible to complete without the support of these stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Publicly available information regarding stockholders&#146; ownership may not be comprehensive because the SEC does not require certain large stockholders to publicly disclose their stock ownership positions.<U></U> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Our operating results may fluctuate from quarter to quarter and this fluctuation may cause
our stock price to decline. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our quarterly operating
results have fluctuated in the past and are likely to fluctuate in the future. Factors contributing to these fluctuations include, among other items, the timing and enrollment rates of clinical trials for our drug candidates, our need for clinical
supplies and the re-measurement of certain deferred stock compensation. Thus, quarter-to-quarter comparisons of our operating results are not indicative of what we might expect in the future. As a result, in some future quarters our clinical,
financial or operating results may not meet the expectations of securities analysts and investors that could result in a decline in the price of our stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>There may not be an active, liquid trading market for our common stock. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">There is no guarantee that an active trading market for our common stock will be maintained on Nasdaq. Investors may not be able to sell their shares
quickly or at the latest market price if trading in our stock is not active. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>
<A NAME="tx67358_8"></A>Item 3. </B><B><I>Quantitative and Qualitative Disclosures About Market Risks</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The primary objective of our cash investment activities is to preserve principal while at the same time maximizing the income we receive from our
investments without significantly increasing risk. Some of the securities that we invest in may be subject to market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For
example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rates later rise, the fair value of our investment will probably decline. A hypothetical 50 basis point increase in
interest rates would not have a material effect on the fair value of our available-for-sale securities at June 30, 2005. To minimize this risk in the future, we intend to maintain our portfolio of cash equivalents and marketable securities in a
variety of securities, including commercial paper, government and non-government debt securities and/or money market funds that invest in such securities. We have no holdings of derivative financial or commodity instrument. As of June 30, 2005, our
investments consisted of short-term investments in corporate and government notes and obligations or in money market accounts and checking funds with variable, market rates of interest. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_9"></A>Item 4. </B><B><I>Controls and Procedures</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><I>Evaluation of disclosure controls and procedures.</I> Our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls
and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that the Company&#146;s disclosure controls and procedures
are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in SEC rules and
forms. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Changes in internal control over financial
reporting.</I> There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_10"></A>PART II &#150; OTHER INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_11"></A>Item 1. </B><B><I>Legal Proceedings</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">None. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_12"></A>Item 2. </B><B><I>Unregistered Sales of Equity Securities and Use of Proceeds</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>
<A NAME="tx67358_13"></A>Item 3. </B><B><I>Defaults Upon Senior Securities</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_14"></A>Item 4. </B><B><I>Submission of Matters to a Vote of Security Holders</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Annual Meeting of Stockholders was held on May 26, 2005 at the offices of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation located at
650 Page Mill Road, Palo Alto, California 94304 at 10:00 a.m. Of the 43,677,148 shares of our common stock entitled to vote at the meeting, 40,566,631 shares, representing 92.9% of the votes eligible to be cast, were represented at the meeting in
person or by proxy, constituting a quorum. The voting results are presented below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Proposal I &#150; Election of One Class II Director </I></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The stockholders elected one Class II director to serve until our Annual
Meeting in 2008. The votes regarding the election of the director were as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P><HR WIDTH="21" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Votes&nbsp;for&nbsp;Director</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Votes&nbsp;withheld</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Robert Z. Gussin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,515,075</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,051,556</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our other directors
with terms of office that continue after the Annual Meeting of Stockholders are Remi Barbier, Nadav Friedmann, Ph.D., M.D., Michael J. O&#146;Donnell, Esq., Vernon R. Loucks, Jr. and Sanford R. Robertson. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Proposal II &#150; Ratification of Appointment of Ernst &amp; Young LLP
as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2005. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The stockholders approved the ratification of Ernst &amp; Young LLP as Independent Registered Public Accounting Firm for the fiscal year ending December
31, 2005. There were 40,286,742 votes cast for the proposal, 276,089 against the proposal, 3,800 abstentions and no broker non-votes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_15"></A>Item 5. </B><B><I>Other Information</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">(a) Changes in Executive Compensation in effect on May 31, 2005 are described in Exhibit 10.1 of this Quarterly Report on Form&nbsp;10-Q and are hereby incorporated by reference. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx67358_16"></A>Item 6. </B><B><I>Exhibits</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The following exhibits have been filed with this report: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT></P><HR WIDTH="30"
SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P><HR WIDTH="94" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.2&nbsp;(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Bylaws.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Specimen Common Stock Certificate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.2&nbsp;(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Preferred Stock Rights Agreement, dated as of April 28, 2005, between the Company and Mellon Investor Services LLC, including the Certificate of Designation, the form of Rights Certificate
and the Summary of Rights attached thereto as Exhibits A, B and C, respectively.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Changes in Executive Officer Compensation Arrangements</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.</FONT></TD></TR>
</TABLE><HR WIDTH="8%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference from our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2005. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference from our Current Report on Form 8-K filed with the Securities and Exchange Commission in May 3, 2005. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">
<A NAME="tx67358_17"></A>SIGNATURES </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Pain Therapeutics, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date: July 29, 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ Remi Barbier</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Remi Barbier</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board of Directors,</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ Peter S. Roddy</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Peter S. Roddy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT></P><HR WIDTH="30"
SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P><HR WIDTH="95" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.2&nbsp;(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated Bylaws.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Specimen Common Stock Certificate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.2&nbsp;(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Preferred Stock Rights Agreement, dated as of April 28, 2005, between the Company and Mellon Investor Services LLC, including the Certificate of Designation, the form of Rights Certificate
and the Summary of Rights attached thereto as Exhibits A, B and C, respectively.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Changes in Executive Officer Compensation Arrangements</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.</FONT></TD></TR>
</TABLE><HR WIDTH="8%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference from our Quarterly Report on Form 10-Q for March 31, 2005. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference from our Current Report on Form 8-K filed with the Securities and Exchange Commission in May 3, 2005. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">33 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>dex31.htm
<DESCRIPTION>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
<TEXT>
<HTML><HEAD>
<TITLE>Amended and Restated Certificate of Incorporation</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 3.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PAIN THERAPEUTICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pain Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), hereby certifies that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A. The name of this Corporation is Pain Therapeutics, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">B. The date of filing of this Corporation&#146;s original Certificate of Incorporation with the Secretary of State of
Delaware was May 4, 1998. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">C. Pursuant to Sections 242 and 245
of the Delaware General Corporation law, this Restated Certificate of Incorporation restates, integrates and amends the provisions of the Corporation&#146;s Amended and Restated Certificate of Incorporation as follows: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FIRST: </B>The name of this Corporation is Pain Therapeutics, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>SECOND: </B>The address of the Corporation&#146;s
registered office in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THIRD: </B>The purpose of this Corporation is to engage in any lawful act
or activity for which corporations may be organized under the General Corporation Law of Delaware. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FOURTH: </B>This Corporation is authorized to issue two classes of shares to be designated, respectively, Common Stock and Preferred Stock. The total
number of shares of Common Stock which this corporation is authorized to issue is 120,000,000, with a par value of $0.001, and the total number of shares of Preferred Stock which this corporation is authorized to issue is 10,000,000, with a par
value of $0.001. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Preferred Stock may be issued from time
to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board). The Board of Directors is further authorized to
determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock and, to fix the number of shares of any such series of Preferred Stock and the designation of any such
series of Preferred Stock. The Board of Directors is authorized, within the limits and restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or
decrease (but not below the number of shares thereof then outstanding) the number of shares of any such series </FONT>
</P>



<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">subsequent to the issue of shares of that series, to determine the designation of any series, and to fix the number of shares of any series. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FIFTH: </B>The Corporation is to have perpetual existence. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>SIXTH: </B>Elections of directors need not be by written ballot unless a
stockholder demands election by written ballot at the meeting and before voting begins or unless the Bylaws of the Corporation shall so provide. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>SEVENTH: </B>The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of Directors. The number of
directors which shall constitute the whole Board of Directors shall be designated in the Bylaws of the Corporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board of Directors shall be divided into three classes designated as Class I, Class II, and Class III, respectively. Directors shall be assigned to
each class in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the date hereof, the term of office of the Class I directors shall expire, and Class I directors shall
be elected for a full term of three years. At the second annual meeting of stockholders following the date hereof, the term of office of the Class II directors shall expire, and Class II directors shall be elected for a full term of three years. At
the third annual meeting of stockholders following the date hereof, the term of office of the Class III directors shall expire, and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of
stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Notwithstanding the foregoing provisions of this Article, each director shall serve until his or her successor is duly elected and qualified or until his
or her death, resignation, or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal, or other causes shall
be filled by either (i) the affirmative vote of the holders of a majority of the voting power of the then-outstanding shares of voting stock of the Corporation entitled to vote generally in the election of directors (the &#147;Voting Stock&#148;)
voting together as a single class; or (ii) by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors. Newly created directorships resulting from any increase in the
number of directors shall, unless the Board of Directors determines by resolution that any such newly created directorship shall be filled by the stockholders, be filled only by the affirmative vote of the directors then in office, even though less
than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred
and until such director&#146;s successor shall have been elected and qualified. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The affirmative vote of sixty-six and two-thirds percent (66-2/3%) of the voting power of the then outstanding shares of Voting Stock, voting together as a single class, shall be required for the </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-2- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">adoption, amendment or repeal of the following sections of the Corporation&#146;s Bylaws by the stockholders of the Corporation: 1 (Annual Meeting) and 2
(Special Meeting). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No action shall be taken by the
stockholders of the Corporation except at an annual or special meeting of the stockholders called in accordance with the Bylaws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any director, or the entire Board of Directors, may be removed from office at any time (i) with cause by the affirmative vote of the holders of at least a
majority of the voting power of all of the then-outstanding shares of the Voting Stock, voting together as a single class; or (ii) without cause by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the
voting power of all of the then-outstanding shares of the Voting Stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><B>EIGHTH: </B>A. To the fullest extent permitted by the Delaware General Corporation Law as the same exists or as may hereafter be amended, a director of the Corporation or any subsidiary of the Corporation shall not be personally liable
to the Corporation or its stockholders and shall otherwise be indemnified by the Corporation for monetary damages for breach of fiduciary duty as a director of the Corporation, any predecessor of the Corporation or any subsidiary of the Corporation.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">B. The Corporation shall indemnify to the fullest extent
permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director or officer of the
Corporation, any predecessor of the Corporation or any subsidiary of the Corporation or serves or served at any other enterprise as a director or officer at the request of the Corporation, any predecessor to the Corporation or any subsidiary of the
Corporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">C. Neither any amendment nor repeal of this
Article EIGHTH, nor the adoption of any provision of the Corporation&#146;s Certificate of Incorporation inconsistent with this Article EIGHTH, shall eliminate or reduce the effect of this Article EIGHTH, in respect of any matter occurring, or any
action or proceeding accruing or arising or that, but for this Article EIGHTH, would accrue or arise, prior to such amendment, repeal, or adoption of an inconsistent provision. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>NINTH:</B> Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might
otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Voting Stock required by law, this Certificate of Incorporation or any rights of designation of Preferred
Stock conferred on the Board of Directors pursuant to Article FOURTH, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the Voting Stock, voting
together as a single class, shall be required to alter, amend or repeal Article SEVENTH or this Article NINTH. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>TENTH: </B>The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the
manner now or hereafter prescribed by statute, except as provided in Article NINTH of this Certificate, and all rights conferred upon the stockholders herein are granted subject to this right. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-3- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>ELEVENTH: </B>In furtherance and not in limitation of the powers conferred by statute, the Board of
Directors is expressly authorized to make, alter, amend or repeal the Bylaws of the Corporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>TWELFTH: </B>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation may
be kept (subject to any provision contained in the statutes) outside of the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THIRTEENTH: </B>Advance written notice of new business and stockholder
nominations for the election of directors shall be given in the manner and to the extent provided in the Bylaws of the Corporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FOURTEENTH: </B>Stockholders shall not be entitled to cumulative voting rights for the election of directors. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This Amended and Restated Certificate of Incorporation has been duly adopted
by the stockholders of the Corporation in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware, as amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">IN WITNESS WHEREOF, Pain Therapeutics, Inc. has caused this Amended and Restated Certificate of Incorporation to be signed
by Remi Barbier, its President, and attested by Michael O&#146;Donnell, its Secretary, this 19th day of July, 2000. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">PAIN THERAPEUTICS, INC.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Remi Barbier</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Remi Barbier, President</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Attested:</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Michael O&#146;Donnell</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael O&#146;Donnell, Secretary</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-4- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SERIES A PARTICIPATING PREFERRED STOCK OF PAIN THERAPEUTICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The undersigned, Remi Barbier, does hereby certify: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1. That he is duly elected and acting President, Chief Executive Officer, and Chairman of the Board of Pain Therapeutics, Inc., a Delaware corporation
(the<B><I> &#147;Corporation&#148;</I></B>). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2. That pursuant
to the authority conferred upon the Board of Directors by the Amended and Restated Certificate of Incorporation of the Corporation, the Board of Directors of the Corporation on April 28, 2005 adopted the following resolutions creating a series of
600,000 shares of Preferred Stock designated as Series A Participating Preferred Stock: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">&#147;RESOLVED, that pursuant to the authority vested in the Board of Directors of the corporation by the Amended and Restated Certificate of Incorporation, the Board of Directors does hereby provide for the issue of
a series of Preferred Stock of the Corporation and does hereby fix and herein state and express the designations, powers, preferences and relative and other special rights and the qualifications, limitations and restrictions of such series of
Preferred Stock as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1. <U>Designation and Amount</U>.
The shares of such series shall be designated as<B><I> &#147;Series A Participating Preferred Stock.&#148;</I></B> The Series A Participating Preferred Stock shall have a par value of $0.001 per share, and the number of shares constituting such
series shall be 600,000. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2. <U>Proportional Adjustment</U>. In
the event that the Corporation shall at any time after the issuance of any share or shares of Series A Participating Preferred Stock (i) declare any dividend on Common Stock of the Corporation (<B><I>&#147;Common Stock&#148;</I></B>) payable in
shares of Common Stock, (ii) subdivide the outstanding Common Stock or (iii) combine the outstanding Common Stock into a smaller number of shares, then in each such case the Corporation shall simultaneously effect a proportional adjustment to the
number of outstanding shares of Series A Participating Preferred Stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">3. <U>Dividends and Distributions</U>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(a) Subject to the prior and superior right of the holders of any shares of any series of Preferred Stock ranking prior and superior to the shares of Series A Participating Preferred Stock with respect to dividends, the holders of shares of
Series A Participating Preferred Stock shall be entitled to receive when, as and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash on the last day of January, April, July, and
October in each year (each such date being referred to herein as a<B><I> &#147;Quarterly Dividend Payment Date&#148;</I></B>), commencing on the first Quarterly Dividend Payment Date after the first issuance of a share or fraction of a share of
Series A Participating Preferred Stock, in an amount per share (rounded to the nearest cent) equal to 1,000 times the aggregate per share amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in kind) of all non-cash
dividends or other distributions other than a dividend payable in shares of Common Stock or a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise), declared on the Common </FONT>
</P>



<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">Stock since the immediately preceding Quarterly Dividend Payment Date, or, with respect to the first Quarterly Dividend Payment Date, since the first
issuance of any share or fraction of a share of Series A Participating Preferred Stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) The Corporation shall declare a dividend or distribution on the Series A Participating Preferred Stock as provided in paragraph (a)
above immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in shares of Common Stock). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) Dividends shall begin to accrue on outstanding shares of Series A Participating Preferred Stock from the Quarterly Dividend Payment
Date first following the date of issue of such shares of Series A Participating Preferred Stock, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends on such
shares shall begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of shares of Series A Participating Preferred
Stock entitled to receive a quarterly dividend and before such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall not bear
interest. Dividends paid on the shares of Series A Participating Preferred Stock in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a share-by-share basis among all
such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series A Participating Preferred Stock entitled to receive payment of a dividend or distribution declared thereon, which
record date shall be no more than 30 days prior to the date fixed for the payment thereof. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">4. <U>Voting Rights</U>. The holders of shares of Series A Participating Preferred Stock shall have the following voting rights: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Each share of Series A Participating Preferred Stock shall entitle the holder thereof to 1,000 votes on
all matters submitted to a vote of the stockholders of the Corporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b) Except as otherwise provided herein or by law, the holders of shares of Series A Participating Preferred Stock and the holders of shares of Common Stock shall vote together as one class on all matters submitted to
a vote of stockholders of the Corporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(c) Except as required by law, the holders of Series A Participating Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent that they are entitled to vote with holders of Common
Stock as set forth herein) for taking any corporate action. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.
<U>Certain Restrictions</U>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) The
Corporation shall not declare any dividend on, make any distribution on, or redeem or purchase or otherwise acquire for consideration any shares of Common Stock after the first issuance of a share or fraction of a share of Series A Participating
Preferred Stock unless </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-2- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">concurrently therewith it shall declare a dividend on the Series A Participating Preferred Stock as required by Section 3 hereof. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) Whenever quarterly dividends or other dividends or
distributions payable on the Series A Participating Preferred Stock as provided in Section 3 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on shares of Series A Participating
Preferred Stock outstanding shall have been paid in full, the Corporation shall not </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) declare or pay dividends on, make any other distributions on, or redeem or purchase or otherwise acquire for consideration any shares
of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Participating Preferred Stock; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) declare or pay dividends on, or make any other distributions on any shares of stock ranking on a parity (either as to dividends or
upon liquidation, dissolution or winding up) with the Series A Participating Preferred Stock, except dividends paid ratably on the Series A Participating Preferred Stock and all such parity stock on which dividends are payable or in arrears in
proportion to the total amounts to which the holders of all such shares are then entitled; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) redeem or purchase or otherwise acquire for consideration shares of any stock ranking on a parity (either as to dividends or upon
liquidation, dissolution or winding up) with the Series A Participating Preferred Stock, provided that the Corporation may at any time redeem, purchase or otherwise acquire shares of any such parity stock in exchange for shares of any stock of the
Corporation ranking junior (either as to dividends or upon dissolution, liquidation or winding up) to the Series A Participating Preferred Stock; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iv) purchase or otherwise acquire for consideration any shares of Series A Participating Preferred Stock, or any shares of stock ranking
on a parity with the Series A Participating Preferred Stock, except in accordance with a purchase offer made in writing or by publication (as determined by the Board of Directors) to all holders of such shares upon such terms as the Board of
Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, shall determine in good faith will result in fair and equitable treatment among the respective
series or classes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) The Corporation shall
not permit any subsidiary of the Corporation to purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under paragraph (a) of this Section 5, purchase or otherwise acquire such shares at
such time and in such manner. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6. <U>Reacquired Shares</U>. Any
shares of Series A Participating Preferred Stock purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares shall upon their cancellation become
authorized but unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock to be created by resolution or resolutions of the Board of Directors, subject to the conditions and restrictions on issuance set forth
herein and in the Amended and Restated Certificate of Incorporation, as then amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-3- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7. <U>Liquidation, Dissolution or Winding Up</U>. Upon any liquidation, dissolution or winding up of the
Corporation, the holders of shares of Series A Participating Preferred Stock shall be entitled to receive an aggregate amount per share equal to 1,000 times the aggregate amount to be distributed per share to holders of shares of Common Stock plus
an amount equal to any accrued and unpaid dividends on such shares of Series A Participating Preferred Stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8. <U>Consolidation, Merger, etc</U>. In case the Corporation shall enter into any consolidation, merger, combination or other transaction in which the
shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case the shares of Series A Participating Preferred Stock shall at the same time be similarly exchanged or changed
in an amount per share equal to 1,000 times the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, into which or for which each share of Common Stock is changed or exchanged. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9. <U>No Redemption</U>. The shares of Series A Participating Preferred Stock
shall not be redeemable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10. <U>Ranking</U>. The Series A
Participating Preferred Stock shall rank junior to all other series of the Corporation&#146;s Preferred Stock as to the payment of dividends and the distribution of assets, unless the terms of any such series shall provide otherwise. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">11. <U>Amendment</U>. The Amended and Restated Certificate of Incorporation
of the Corporation shall not be further amended in any manner which would materially alter or change the powers, preference or special rights of the Series A Participating Preferred Stock so as to affect them adversely without the affirmative vote
of the holders of a majority of the outstanding shares of Series A Participating Preferred Stock, voting separately as a series. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">12. <U>Fractional Shares</U>. Series A Participating Preferred Stock may be issued in fractions of a share which shall entitle the holder, in proportion
to such holder&#146;s fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of holders of Series A Participating Preferred Stock. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>RESOLVED FURTHER</B>, that the President, Chief Executive Officer or any
Vice President of the Corporation be, and they hereby is, authorized and directed to prepare and file a Certificate of Designation of Rights, Preferences and Privileges in accordance with the foregoing resolution and the provisions of Delaware law
and to take such actions as they may deem necessary or appropriate to carry out the intent of the foregoing resolution.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">[INTENTIONALLY LEFT BLANK] </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-4- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">I further declare under penalty of perjury that the matters set forth in the foregoing Certificate of
Designation are true and correct of my own knowledge. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Executed at South San
Francisco, California on April 28, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2"><B>/s/ R<SMALL>EMI</SMALL> B<SMALL>ARBIER</SMALL></B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Remi Barbier</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>President, Chief Executive Officer, and</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2"><B>Chairman of the Board</B></FONT></P></TD></TR>
</TABLE></DIV>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>dex41.htm
<DESCRIPTION>SPECIMEN COMMON STOCK CERTIFICATE
<TEXT>
<HTML><HEAD>
<TITLE>Specimen Common Stock Certificate</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 4.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Pain Therapeutics, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH STOCKHOLDER WHO SO REQUESTS, A COPY OF THE DESIGNATIONS, POWERS, PREFERENCES AND RELATIVE, PARTICIPATING,
OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND/OR RIGHTS. ANY SUCH REQUESTS MAY BE ADDRESSED TO THE SECRETARY OF THE CORPORATION. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following abbreviations, when used in the inscription on the face of this
certificate, shall be construed as though they were written out in full according to applicable laws or regulations: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">TEN&nbsp;COM</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#150;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">as tenants in common</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">UNIF GIFT MIN ACT&#150;<U></U>&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Custodian</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">TEN&nbsp;ENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#150;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">as tenants by the entireties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Cust)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Minor)</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">JT TEN</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&#150;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">as joint tenants with right of survivorship and not as tenants in common</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">under Uniform Gifts to Minors</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">Act&nbsp;____________________________</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(State)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Additional
abbreviations may also be used though not in the above list. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">For Value Received,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sell, assign and transfer unto </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP STYLE="padding-left:8px; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">PLEASE INSERT SOCIAL SECURITY OR OTHER</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">IDENTIFYING NUMBER OF ASSIGNEE</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT><FONT SIZE="">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"
ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP OR POSTAL CODE, OF ASSIGNEE) </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">_____________________________________________________________________________________________________ Shares </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">of the Common Stock represented by
the within certificate, and do hereby irrevocably constitute and appoint </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">___________________________________________________________________________________________________ Attorney </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">to transfer the said stock on the
books of the within named Corporation with full power of substitution in the premises. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Dated
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>NOTICE:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE
WHATEVER.</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Signature(s) Guaranteed:</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT><FONT SIZE="">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE
GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">THIS CERTIFICATE ALSO EVIDENCES AND
ENTITLES THE HOLDER HEREOF TO CERTAIN RIGHTS AS SET FORTH IN A RIGHTS AGREEMENT BETWEEN PAIN THERAPEUTICS, INC. AND MELLON INVESTOR SERVICES LLC, AS THE RIGHTS AGENT, DATED AS OF APRIL 28, 2005 (THE &#147;RIGHTS AGREEMENT&#148;), THE TERMS OF WHICH
ARE HEREBY INCORPORATED HEREIN BY REFERENCE AND A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF PAIN THERAPEUTICS INC. UNDER CERTAIN CIRCUMSTANCES, AS SET FORTH IN THE RIGHTS AGREEMENT, SUCH RIGHTS WILL BE EVIDENCED BY SEPARATE
CERTIFICATES AND WILL NO LONGER BE EVIDENCED BY THIS CERTIFICATE. THE COMPANY WILL MAIL TO THE HOLDER OF THIS CERTIFICATE A COPY OF THE RIGHTS AGREEMENT WITHOUT CHARGE AFTER RECEIPT OF A WRITTEN REQUEST THEREFOR. UNDER CERTAIN CIRCUMSTANCES SET
FORTH IN THE RIGHTS AGREEMENT, RIGHTS ISSUED TO, OR HELD BY, ANY PERSON WHO IS, WAS OR BECOMES AN ACQUIRING PERSON OR ANY AFFILIATE OR ASSOCIATE THEREOF (AS SUCH TERMS ARE DEFINED IN THE RIGHTS AGREEMENT), WHETHER CURRENTLY HELD BY OR ON BEHALF OF
SUCH PERSON OR BY ANY SUBSEQUENT HOLDER, MAY BECOME NULL AND VOID. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>KEEP
THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, MUTILATED OR DESTROYED, THE CORPORATION WILL REQUIRE A BOND OF INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT CERTIFICATE. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g67358img01.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Pain Therapeutics,
Inc. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">COMMON STOCK </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">SEE REVERSE FOR CERTAIN DEFINITIONS </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">CUSIP 69562k 10 0 </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">THIS CERTIFIES THAT </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">SPECIMEN is the owner of </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $0.001 EACH, OF
</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Pain Therapeutics, Inc. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">(hereinafter called the &#147;Corporation&#148;) transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon surrender of this certificate properly
endorsed. This certificate and the shares represented hereby are issued and shall be held subject to all of the provisions of the Certificate of Incorporation and the By-Laws, as from time to time amended, of the Corporation (copies of which are on
file at the office of the Transfer Agent), and the holder hereof, by acceptance of this certificate, consents to and agrees to be bound by all of said provisions. This certificate is not valid unless countersigned and registered by the Transfer
Agent and registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">Dated: </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">SECRETARY </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">COUNTERSIGNED AND REGISTERED: </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">CHASEMELLON SHAREHOLDER SERVICES, L.L.C. </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">TRANSFER AGENT AND REGISTRAR </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">BY </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">AUTHORIZED SIGNATURE </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>dex101.htm
<DESCRIPTION>CHANGES IN EXECUTIVE OFFICER COMPENSATION ARRANGEMENTS
<TEXT>
<HTML><HEAD>
<TITLE>Changes in Executive Officer Compensation Arrangements</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CHANGES IN EXECUTIVE OFFICER COMPENSATION ARRANGEMENTS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following is a summary of changes in compensation arrangements for our executive officers during the quarter ended June
30, 2005: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Effective May 31, 2005, we increased the base
salary of our executive officers by approximately 5% each. We also provided our executive officers bonuses ranging from approximately 20% to 44% of the executive officers&#146; annual base salary. In addition, we provided stock options to purchase
between 75,000 and 300,000 shares of Common Stock, on terms consistent with those options granted to our non-executive employees, pursuant to the 1998 Stock Plan. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>dex311.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302
<TEXT>
<HTML><HEAD>
<TITLE>Certification of Chief Executive Officer pursuant to Section 302</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 31.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">I, Remi Barbier, certify that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Pain Therapeutics, Inc.; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s
auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ REMI BARBIER</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Remi Barbier,</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board of Directors,</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman"
SIZE="2">Date: July 29, 2005 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>dex312.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302
<TEXT>
<HTML><HEAD>
<TITLE>Certification of Chief FInancial Officer pursuant to Section 302</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 31.2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">I, Peter S. Roddy, certify that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Pain Therapeutics, Inc.; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s
auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ PETER S. RODDY</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Peter S. Roddy,</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: July 29, 2005 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>dex321.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE AND FINANCIAL OFFICERS PURSUANT TO SECTION 906
<TEXT>
<HTML><HEAD>
<TITLE>Certification of Chief Executive and Financial Officers pursuant to Section 906</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 32.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND THE CHIEF FINANCIAL OFFICER </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">PURSUANT TO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(18 U.S.C. Section 1350) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Remi Barbier, Chairman of the Board of Directors, President and
Chief Executive Officer and Peter S. Roddy, Vice President and Chief Financial Officer of Pain Therapeutics, Inc. (the &#147;Company&#148;), hereby certify that to the best of our knowledge: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form 10-Q for the period ended June 30, 2005, and to which this certification is attached as Exhibit 32.1 (the &#147;Periodic Report&#148;),
fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934, and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Date: July 29, 2005</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ REMI BARBIER</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Remi Barbier,</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board of Directors,</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/ PETER S. RODDY</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Peter S. Roddy,</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g67358img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67358img01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"$@*H`P$1``(1`0,1`?_$`)(```$$`@,!`0``````
M```````%!@<(!`D"`PH!"P$!`````````````````````!```04!``$$`0,#
M`04%`@$=!`$"`P4&!P`1$A,(%"$5"3$B%D'P43(C%V%Q@3,DD<%""J&QX30E
M)AC14F*"<J*RPD-CHS7QXE-S1!ED)RD1`0````````````````````#_V@`,
M`P$``A$#$0`_`/?QX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!
MX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!
MX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!
MX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!
MX!X!X!X!X!X!X!X!X!X!X!X'%7(CD:JIZKZ^B>J>J^B?KZ)_5?3_`%\#EX!X
M!X!X!X!X!X!X!X!X!X!X!X!X'%KE57HK'-]KO:BN]OH]/:UWN9Z.5?:BN]/U
M]%]47_3]?`Y>`>`>`>`>`>`>`>`>`>`>`>`>`>!B!GA6,3IP#!3862R0NF#(
MA*B;-$OMEA=)`][$EC7]'-]?5J_U\#+\`\`\`\`\`\`\`\`\`\`\`\`\`\`\
M`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`5?1%7_=^OZ_HG_BO^G@?$5%3U
M145%_P!45%3_`,%3P/O@'@'@'@'@?/7_`&_]O_AX'WP#P#P#P#P#P#P#P#P/
MB^O^GI_X^!]\`\`\`\#BK6JJ*K45S?7VN5$56^Y/1?153]/5/Z^!R\`\`\`\
M`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\!)I:"CS@CP
M,_3UE(#(20;('5`C`#/,+?\`(44^$6.*-Q!#_P!7O5/<Y?U5?`5O`/`/`/`/
M`/`/`/`/`/`/`/`/`/`/`/`/`\JOV/\`YI_N_P`V[#TK!<RYO];M"#F>Q[[G
M>5H[3.=8M]?<5V2ZCJ.=UK?_`)P:V-MA=6D.?@G<Z,2"%#"WP*UD8TDZ!&7%
M/YQ?Y).I&;"MT'#_`*N8^>@Y?T?HF=DJ:?IVV*V]QSVGGT<G-<X#5=)A')UM
MU25YKQUF)'&1P[/61WS>U@-RU_\`BA[[FP5X6ES''_J5O,<[VQ6=MFC.SSVM
M+:PMA:;G]-GHCC+2A/@L"&!/*@CLJYI"3.CGEAA=*H(8W_Q13]^;VF(N,G];
M?J);UX/O(LKI^M[7'25M;+-/($98E)7HT"108T62&1_RND<B0I+[D1`D!W\_
M/W9(XZWJU+QKZQV\9O>#.)XX8C-_8JHINFP5E*'I;7<Y73Q$75325==7V`H3
MJ^Y>%9NL2?C=%&Z)8W@UG?\`Q0Q]^JTW_P"B/ZK?7"I`<815#HZ]Z?-,6?%/
M.+,0"4`?:`V=?63(Q"?@<LS7Q31M8JI&]P-_6_\`Q2-]S\IHK*DN/KQ]7Z`*
MM&-+GNC;?L%PHX\'>*WA8KC:2KF@LQIRCK-EDL?]WLB:Z!'.D]'J'<S_`.*&
M?Y!@AI2KOAOTI'6#204L@\%SWM6L#*K#"1S3)U;)/4EOLZZ83X2(/A^9&L6=
MKO?[`D$G^?+[PCSTP!?+_I766=Y7#V<8DU_U\Y`@9I19929"ZZR(!^6OK'33
M%#%2AD#M2)SF>QZJP'AT7^='[M\ZW5CSFUY+]45LI8,W:XW9#2]:(PNOS>Z#
M`,PEHRRET(BU5CIAKH*1@GN*A@>^8>8ED\3&3!&H7\S_`/+5!J;JGM^3?410
M<^J(<?#A^Q@T\D<P@A<)<-\=TI*QP\K"'(-(DJPDR1^U'(WU>@.?FG\T_P#(
M'U6XWTM`-]37X+EO-M3T+9Z\#G711'V,E))FAJ2DPK-CV+/4]I%H+71+7J64
M7#[9Q9)H(B!T]5"/H/YT?Y%R:UUI7+]"+L:J1I]^'7UG5(KP6BFG$>TU!S-\
M/7&D"5ME#,0P"4S\9GM?.D22*D8<(_YX_OD33Y^SG?\`4JHDL)SDO6+SGH<P
M]-7UKZV>>T$D/Z_7ON19ZRTCE:^!'1,1R*UTWI(C0;=!_/#_`",W\.C)_`^M
M`4><S'/]82X;CV^NZV>MZ'SX7:@"#VE?V!SOW&M+)8._Y(8X)A)4G:]KF/C0
M'%3?S9?R12595K?7_P!.XQ!X(P*R4;E6VK@];H8A0);T"DLK7M;ZSXJN<Z."
M*5\S!G3RHQ\J_HY0>/1/YL/O7RFDXQ9VLO"M)4=LRNA93;>DXO>S8_-]<S>R
MBR]I@;62J[A8P_X=3U4T5B;H%,1S&D,;$-*C7M0&&)_-?_*<6,1"!G/KYI[6
MT"CL\DS*_7/JY@1HDLD4\#GEKV><.P!EK7NE>3%-&R""-TS_`.UKD0)*YA_,
M?_(?O>G8/BI1GUREZ'O>G9W"QA9/CNNLQLK27,ZV-M=Z6V.["/2+I*'&RK9-
MJ199FO:`1^00/'*++*&3:_RZ?R!IKK[.93??7O3"UNPN:0*)_$R*W<V%:-/:
M.JRH\5!V^U>(PRNKI)9)"B86C.'?&_W.<UR!:GZ#?R3?;'O_`-E>0X7HV[Y;
MI,%NM%N\Q>TF?Y)/C[@9*7DFMWU'=5]Y)OKPJ)TUOF_B6&4+V/&]Z>Y'HU[@
M]'_]4_5/_!?U_P#D^!UPPQCQ,AA8D<43&LC8GK[6-;^B(GKZK^B>!V^`>`>`
M>`>`>`>`>!UR?+Z-^)8T=\D?N^1'*BQ>Y/E1OM5%^3X_7V_Z>O\`7]/`XS00
MDQ/@GC;-%(B-DCD;ZL>GZ+Z*U?T]/5/`[O`/`/`/`/`/`/`Z1_R/C_\`4_#\
MOOD_\CWI'\?R/^'_`,S^[WI#[?=_I[O7T_3T\#N\`\`\`\`\`\`\`\`\`\`\
M`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\
M`\`\`\#Q$_?GZT]P/ZE9?:[DG-KSH%.-U'[V\:U#:4<E;*AW`/V7[I58&VO3
M<[9RGBYXUNMA9726`CZQA`K'3?!*YKI@T:\.U.QS&NH-YQFRL&[+F>IS%I*E
MGMR,4/=D!D@T7^)O)==>P^BM-'82Y\JI?I?VR>M#BC-/CFDCC>$W_:WG[^([
MBGZIQ1EF3D.D50W<74>?%M^;Z?C-'=:?5R3<;U<E=*@VYJQ>D_\`T-&S^X=U
M7;5L*R1,%</+.$.`F=?[=L:S%$[2>YM@;6NSUUH+W).S]3!O#[4/-!N@YU3B
MU<6IOK?K&0L[("*2(=?V<M(TD&!4@B()N^R'0B(7U7*<=>Q4_P!<.%86#+YF
M=C:_%UW1M777ZU/;_L/CN;BZ-2M<W:]7U,=>ZX;*.^,"N%A129A(U4.OZ_<*
MZG]@A<A)SFLM<WR'.;O5'](ZEM;*MJ^+<VQ-057F75IL-!KKJCJV4UA9TA20
M_BR`J>4QH$-<YCV3>!`^D<TJ/0V"T^<ZQG:O(=#L$(I':,;-[&N&_D'S+FVH
MJQS5.DJ*(\:8<N"=/:<B.1ZJL;'?(&R*TY']=NKU.^QO+/M`7F.Z3AY:XI\?
MV+)S<DQ-AU.GU>LNK6#G?=C;06E+>*+9$5KXM857(DJK*TN=&10PA1SIV3[!
MRKIM#B]]CF<PTO23<]HPKZ]@2+"S86V>50I=<^N**(^JU5,/8$GI$'66!8Q/
MY35<@\J.(4+-W_/R^C?72^VL>D(+3A6@&YOR:W=!%E<UG^;[R\T4E53=9SX-
M'9U[2.5]5MCF_`IRQ!#W()@\I,+92!@I6W*:[0Z`3FCLF;7#45U<U8-[8:NP
ML<ME,K44]94O?9B(^9T=#D<[F*351/;^5`1+O25C?*^1SD"\&LS--5\MXI@J
MZUVE)S?M^\#ZUO>@]"_;1]3N-@+2W5#R:GY1RE\]-6(&)7VY&\+!+,($SZZ.
MLA**F)?^*\*W8K([+K`VZ.Q>SXAZ9:O/SQ_3^H;8#`<J"EW$90-85_U3TM!`
MRY@EIS+(^`2F!,L*F&9&+7.8R,F8+5D,^J?.+X?(8LOJGV3Z#Q[E=/'#TO8@
M@5_UYRG5PR+\S4ZRIQMK2C]&ZI2Z'1I*TI;B8:)C$'D"%'BB@]X5?^G%@%M.
M]/PVCN,QG:KK>6^M.<L-?L[I,?F*T[1?6^S%"O[VQ-H[*"BK,[:/$)185E;*
MJ_&Q1_>LD88/V!XUVKZR9S!"]\JC+`!MUJ\W4["O*RFNRVSLK48&]K!Z;>51
MT=#?%BY6W)9&.V<4QK(WPO$(+BB2,)PXQS&RU.:ZKQ:^O+.\YV=CJSM6<-YA
M759?0\QWX;$W]V;4U#M32(DF"ZQRV(K/P'#P#@E7-55CK&`0[\N0*<MN]/A;
M-E!G])JKB*[.;L,P!EMU&HG0!9I_RJRR0(9I%F-8C4N8J\C8!!L(C%LM;9"-
M]B(CE"RF*I"N>\'ZG>XJX?9W<]78<-M(<YIQLWQG`<?L2KI.J:A-RC;F&UZ3
MBL,E3DIC)BW26%O=J""Z6<;\]P9.*SMB)VO.<XS.3%TUS0VPES140^<H[::D
MR68Q[M899Z)^G<-59(`@(@B,\*RA)='*8H,%DB3K%*&Z_P#CKPM3S;[0_0O/
M0]7PVQZM?]&[CT[LM7RB==AS=,_K/KMUH#FU:-T^K`@S-A?4\`[B9:H"<@,5
M)Y&HC)H'*X/7UX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X$*]A^Q
MO"OK_'E7=GZKC.=3;K34F,Q5?H[B`:YU^KT=A%5TF?S%%%\US?6EB?,V-D0L
M$KO7U5?1$54""KW[*[W@V\,I/LWDJNHY#>79%;S7[`XG]XN:0ZQL3A&YS%]'
MQPU:9<8356/[A^&&1&\ZJL91E=^0/+(@S0N-0:*@U-9%<YJYK+ZJGDGACL*@
MX:Q$4@69XQ8SIQ)98VE!DQNBFC54?%(U6.1'(J($'_96[Z?C\;G^A<TT]540
MX#=9;0]&S-QGQKD;HG+9+%E/M<H%8O(&-R>AAK+-;*LL8/E1#@(X)HI()Y?0
M+$^`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`
M>`>`>`>`>`>`>`>`>`>!X%?N)8]+H?LK]J`^-=!Z!S/IU7]QNW]/PMW@M=>Y
M$F73U'3M0+(%>"@V00]N#I*&^)%JDF6*MCMAUF*=*LC8O`H'4=)X9U+]_P"Q
M;SF26^B`B-I.DW?`Z_.Y@/=<WTQ3R]>9N^8Y\RFPNNMLM=9>4RQ(S#Z*XI3Q
M0[:<BR@0J7P+4=G_`,,^R'+:'.?5K3V_3Z[ZJ9\'3X?[&6XE5E.EWF%ZS8#3
M:;C7V1Y7N5K+D;K.0Z,%#7VEX++/675!8A0?\N55D@"H_P!*PM?#TC*]]TG)
M;/J&0^O)M7KJ7EMT74\JYYKMK;U%EC<"5H;+3TE77Y#.YVWLPR+DF=DQ\M&'
M^WA1OD:L2!*G>ZSZYW1G0(A]3LNWV-3J(M=N.@2X.3@G%9MB7.8!S?EE1E+4
M\7=]*Y;6.`E2MK(6Y>GMIVNM"G-"2")H5XDDT>M4JZV]_8-J*W(3X;DU`-^W
M5>'R(BE"9S87'/,=165?B8:(>I^($28`<:YBOG&3-'*>^1S@:]$6(%=+`354
M@DQ_$MV/>?-#:`V<S2_NYG/S8HHI(@P`*B0ZN_(D^<.$^)S8X/[T:J-"RYA5
ME8E@[4_.4^G`<3:X'KF?OBP64@)1@*TM4/:Y\UPM@0[I_/?>6;^X_AI!8QSL
M'^?YV0N!O9_13X>>YXKI9ZK3\ILQ;<NMPG3`IK+B@Y]_6A-QG0-Q8QA8,K'"
M5)PT,-B!BK`>[B)&1O\`R9&1^X+^<^^T^(U-#%]=Z7F&?YIN.BQR<_\`LO#K
MMD[K',>V\<GJ"9N?="I=4%^'?XWJ/';8RFN,U<O$L)='3J218DR>Y2&!0^MY
M@=9W&-30=%;-Q3;[,>DP?3!]D-E^6:JZ,T%Y7>^KV!AKJU#H+=AHMDV%[RJV
M$.=[XV00R1J%NNT_8K$=>FR]=K.4\OW7?(LV[!`:6PT&QYU]5.3<+QDL]#S?
MG69J3SUV/1;2XJHQY;G2/+S9%T59K4CCM$>0CPJ9HG1]5UCB#J4JDYOS?]JM
MV\L6H;5@9,.T'%IZ["Y#,$K;8`_#:*T`D6V)H;,0X3/?^GFA%]8W2`AU24M$
MMSJ#+)UIH>IE&UV6MRB"RJR;*TC7W&IV-V<KK:PJ8[76BOKPT:*(`HT$_P`,
M[AF)[0BO`U<!%M<TU6P:.O@Q?T[EM!YVV#4!<GU_$)T0X-@;^?6F0"V@C8G$
M/FDA_'B8UJRK)\CPE^[N-7R30Z&]P1Y5'S3KAZVFKYIF0(--C[S<%F#7FKH3
M><6>:WV9N)](.;/9C&V48I`?SDQPN8P85K`M%R7['<NY1<P2Y?CP>-[[E*2T
MN/J5V_GVZ=J."W$4<EG9B\6[)SW2Z`'I=ESZ]C/DK+BCB-L8,L1<3J!`H[AQ
MFA6_[!8<\#JV[(YK#A*K":0BBM^BT6*TY-_@^4II*$#17X>ON'5])+EH*;//
M3\82Q_!E+$&G%G>^:)R."W`F_P"2<1XSF_K[T/,B]$RG/+J;H7%<CSWH%+;7
M76.V[JJFN+3JGV4Z0566_,$KN=4%B+6YG)U84T4$M.0\PZ9%GAD"!M-HW:_1
MV?(N9T0N+H]$1"1<X[%6EZ0+H"DL$TG0^AKI>A9RUK^R1XV^KD.0ZY=".I*R
M.188%^-P;-_XL!4%^_/UA&SCJJKPU%==2RHF>8?!!(`X+@'1YJ,"&K(E*L6'
MCC0DEO@CD<+'$8KD?(]/=X'M1\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\
M#H>1%'-!`[W_`"D)*L2)'(YJ_"U'/]\C6K%%_:Y/3W*GN_T]?`[_``&?ON@8
MGEF1NM[T744V-QN=':5=:*_,C`K*^&2:,>%9IY%_64@F9D<4;4=)+(]K&-5R
MHBA0;ZK09C[4=DZA]S=9PC0YV.IL:?E'UAT_9<W7BZQW-<U6ML]+T+G]`?'-
M:X>EWVQNB&L(E2"P-AKVJOM@]B.#8I>4=-IJ:TSVBJP+NBNP2:RWJ+06$VNL
MJXR)T!81HA#)(2!B(7JU[7(J*B^!IIJL,'_&#]L<3#@XKFO^E7W.W@F%TN:G
M.&(QW"OL7=QS#\ZN\N`KQ",]4=.*B2GMGHPK\TV08PN9LD#Y)0W,6]96W%8;
M5VX\9-6;`^$X>5SXXI!U]%>U[XWQN8W^WU54<GI_7P%!9&(SY%>U(_;[UD5R
M>Q&>GN]_O_X?:B?KZ^OIZ>!6[9?:+%4-9='X;(]2[V50P.E,J^$XJ;;K+(Q[
MXW`A:,LVBPQ=HU\:HHK;;\A$3U5B)^O@6)`*4X$,U12@E,$&*4,Z-L)PBD0L
MF44R)DDK(BQ_?[)&H]R->BHBK_7P,OP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#
MP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P.#7LD158]CT:]S'*QR.1'
ML56O8OHJ^CF.145%_5%3P/`_]VRIS/NOV-]18C26>9[UW&*5+(V(E1K@_N/0
M6TTH+4_'@K8ZZKG&@<KX(OCC<ON,D]$C4-3]!6#0]%M6\JN&"TU#N]9>T-FG
MNJLV)A4LRX;9]YF9(<Z1EJB2JD<%&;8@]*&(:U8X#`&N_P"6'=EN=T6TYEVO
M0<VY9T/8Y*K*8/HRJ>&PCM!G":X_,<T@%O8KO\7G)E-MK>KE`N2#AU@8_P#)
ME>2JRPR!RX]E_L-#1[G3=KT4W3.K9N\RU[?]<RBQVW+;3G4=)<!X8?(V]31Y
MN@H+JJZ!+=.T#?Q*Z[O""VEQ368\O_-!C"ZTJ[R-!<YS3LG?5GZP"RDAL[,"
M#&:NQFN:@2N.OTL_\=LLC-525\->(4#>T)'J2)#3M6(E\@.<@JC=S?'VM(5!
M!5MIW#SCN@!(JOW>KU9`^N6F_9P*2JJ)5)])(QJX4"MA'>K_`,=K$:+$#:,O
M23^KVK%LC9):WE_2:E3:ZS@BC<,/]IZFU$LX#9Q\]5E'R@M54D1PXBQK\3V-
M:OHX+2C22U>2LJZ.>J02VT)K<G;AM>->608-:>#=U\-2]RD``W"'C#$5T`(V
M<(0GTAB*;\OJ#&ZE_P#11H<(-4`5^AO*+".Q!,C:<JZAJKF^O935QQ9PT&MH
MLO<Y:D*A+,`.QF@SH\;62"S5"2+(@2%B,X-O]=2U>9.S6K@RQ535Z'=:2ZCE
MYG0;QV@TEO#&S6+8B4X=Y1O$-%#9`Z"2441RBP1!NA@:%>^8<+O=O]KI.C5>
MJPUG/O\`<;(&?B`%PVKP/"+S9`YB,KJN`TFK(HL9?[?0#@P#:DEM9G6%NT)C
M`B4E%F=`#EUU7JJ/9ZGAY]+!5']EIZ>TY4W1&YRNP/8:P1]]GZO$55CK*(["
M7D=4AKW@!6H%X*.8/.$HL14PI#07,.5&52=!ST@UP791VN6U&:IJ]=E25[/\
M4*@RFLR]7)K;MUZPG'&NB_-KP*;-",8+$HU,*WVD>`^1QXM`RCL_QIY*\0^P
MJ;B#2555(%GMP3;?Y,$786-G:2CN;;U+(4C,TLGO1\:M$L6SL>B!$_#EKZO4
M]%W$\Y5C):\L^L6.!LI+;1VM!8`F_5+3Q0C#!*!+/6MLG2*QDZ2DNG][UD8W
MVM]P._>&"4F%$FH7R9_\CH-98F3TL5K:35V9R[&65Y=ES8G98J_&S=Q97T`G
MY0YLB3SM;$6+9/>@2AT4XM97P4/'&UE$7MKBWMKD7'@CTEM893(:RL(N='^R
MI7\[R%1EV7U/6P$DP,S^<*B'#B2SB))^+X0;7V#XCN,WUG'Q%CT%/!C,WC\]
MK.)T&G*NZ'[<9JGO:K?"Y;KFFRM_/F\9F^<3G#568BMHK]RW0Y0YGX4$,BL"
M0.S\Z$X'O\Y/T>D97X^^(,JA.F6H;=)79+8VN0@GC)TVDH+ZV"@MIZ_0_D2/
M%L91BJ<]XPT[($<B`R^";C*A]),XD^"[Q.TGS6DJJWGL^;=F&U&F:V6W;J#Z
MVGI&<.RDO1Z2:%079JH$MKRNG;$0:;',YKPWI_Q+6X]]]NOKZU\S)B6]UZ=J
M"&R6H]HLY%E]3^D4T%M\TKYXR32&5LRR2@$G/C=*]A<B.5G@>T3P#P#P#P#P
M#P#P#P."O1'-8JHCGHY6I^OJJ,]ON7_N17)_[?`Y^`>`>`>`>!U2?-ZQ?%\7
MM^5/G^17(J0^Q_JL7M3T63Y/;_7]/;Z_Z^G@=O@'@'@'@?/Z?[?[?Z>!JY;T
MOG?WF^WJ<IH"[G3<:^FA,^SZ;!$PH3$[;[`SV:4W-Z&Z<QZ0:K/\^@`M[6,2
M7T&GN(!YWQR1BP.D#:/X!_7P*M?=CD(W<OJMW#G3UCAL[#!75OE[%PHA4]-L
M<N,[29.X!_,'*C'/`OJN!\<S6?)$O]S%1R(J!E\:[F+TKE_U?TL7Y%P=W3F]
M'MISQ6ABBP`LPM=>WEJ:,]I#4#GNK441L,2M<DA;/1WHU6N!P:+F5[U:WL!>
MG'_C\K'E_&K.6T9<PX^PB9&L<IW3[<5\1%Q5$2*JPT0[XJYT7I^=^8J_%$$V
M5U;75``=54@!UE9701"`5U>+"$"$+`U&0CB"#QQ0#P1,3T:QC4:B?T3P,[P#
MP.+O?^GL]OK[F^ON]?3V>J>_T]/U]WM]?3_3U\#EX!X!X!X!X!X!X!X!X!X!
MX!X!X!X!X!X!X!X!X!X'3%/',Z=K/=[AY?@E1T;V(DGQ13>C%>UJ2-^.9O\`
M<WU;Z^J>OJBH@=W@'@'@'@'@'@'@'@'@'@'@'@=44$,#7M@BCA2262>1(V-8
MCYIGK)-,Y&HB.EE>Y7.<OZN<OJO@>`S[:\TZ_N?MU]W(.4\GV^WU1WVGZI0Y
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M?=`P+'_</HOUPN>FV$'6OKWSGG]B823DNB].^J6=M,QE];)KW0!<G[P5RT,Y
MW/.P5,&CDKRK\`RNSEU1:("!PID!,DX<05HY)]>NK762M>DYFB*^R7('4&OT
M==UGAD1^GN,=H:!TM2;8;#GT=-)U#"&ZU:U]$10RTP@1LJ0GD%E0PL(<%;9K
M2J6[S]W)67K'%\X[`4$MZ\S]V;;S?9;),J(+(NOB!(LY75B,='%$D7X[9OA:
MU7^DRAL!X_R'J/7]7I0>)<[O.A+SO+76K:PR:L`HI='F(KLRSAZ=U#;W^0S^
M&S]UL&"H888>QT=81[(V_P#HFS2`R@<!9<CWF7RMN-S_`.S7<NA5=YFK2OJB
M&;3C];2]&K2K<TW=[K/,J]+U+H@&%B-LI!JL@3.0R1CCNL[%I2P."X(_=\_T
M/ZK;2LFP8&NZ1RV/,<]^JF#&YWE,GG/K_ONV6-M8Z3I]]EJV`"DI.W:;FU+9
MEJ98B,DPV=#E;,T4:=CB0U6X$?*KI!:#'["9_4[JRJF63K2!I7/MSIF:2^0J
MJC!.,J-,$'<*1=_AVY;?7]KJF)*,*(5$]H;W>R=6KX^"\'Y7P?+Y"/G'0LF?
MT6R^JNJYSB=+C*#M5Y879&WUN6I-D9LQ0.+]$VX^DK;[/B3B/Q5LV,H6`&<L
M2:4-8E1R?.]HGT73^<[?.?5+NE1O,WL[S/\`9]$)8_7?3W&A>_,6X`?6<+7G
M=&Y:%B)!)5N*>[KR:\X5WS*7`^9ZL"3-5]</LUQWJNQPW4^&[C/\ITB";;']
M.SD]A:\U*">61;Y?5!="PP90<\]@,LPX_P"XWK7SO-;&1&-&QZ^!3'FF5M-I
MM(.98FGL=/?V4_TLA%HZ4&:PT!IP'U]5!:(>JH66%MH301YY7.#!>XB:)WJQ
M$15>H6NZ-PC=\7ZU/I>Z4@&`$S^N*ILOQ>BT/,-WUIU3GWV$U>/^XU=Z6G*\
M)>UUA#?6_P"]6*645M.@M:)-)(U[0M#]2^H81EKK.)_83F_+>9\$WZ;W3_8Z
MDHZUE1HNLV'+F672]#BM#O"S`.H0<VI#Z`>;5:$FU+#N($/"5B,L*^M<&KG;
M+7:'IFVTVAMC^>7FTEK][C<`&"&%2<OSE(':6=3D-=2!W?[GE*]D-O#"765T
M!IPC9V$'-9*Y(E#<5]?N@4'-?J#TJW!Q]?DNP:K4TG._LGB=)3"[2H[-DLMD
M1]'DMIB0-5/I,!5=CRN&T)LZO?6L'U.;K86NE(<"Z)X4C+YOSCK]QI@[=*7Z
MM]OR&9ARM/>9_-4T/ULZ!38PM-/DM)EA3JW8[?E.^M\0</9!/,CMJ&%[(@AQ
MAP0HG,#;A]!.5]/YG]Z_I#I=UAQA:GI1_0$$Z!C+#/\`2.<7>HJ?K3U6'758
MG6L;H+3-65^)H`B%G8P8.=9/GA=#"P=&>!["?`/`/`/`/`/`/`/`/`/`/`/`
M/`/`/`/`/`/`/`0].VS?F]`VD5$N74=LVH58VS(EHX`A`%6)TD3940I6?VJY
MJ._IZI_7P*_?36CR5)]9>*MR3*B6&?G.7;;6U76UE;)<:`8!(M"591U;I85L
MTT*EH0UTDKXR%D:YRN]RJ%G?`/`QC$%40K\Y8FA?C3H8XA[8QVBK$[\A9WO5
MK60I%ZJY55$1/7U7P/.WQ[[&GUFDQ>+^J^6-^P59SSG2<6^D?.#[),`SM(60
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M)&(B<CXIQYXVRPS1N3]'1R1O16K_`*HO@=_@'@'@'@'@'@'@'@'@'@'@'@'@
M'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@>''^1WM71S>T:?Z^
MX>SOLSDP?M#]KM/L,:'?D9W/]<W.MW%O%@X=`TZ\K8S6"2YT9\/_`#&C,CE)
M<,R,R=LC@T6X6D^QO4]-D^>\HRFAK-1VJIS^)&2W&3F.;SPKI"CZ/:2ZC4H"
M36$T,)(UD8@]S)8#RCV$#72JW^X)#[MT3_KWT0KD'%Q0K+@/))XL7AK'*)'S
M\RUP?-QC9:2]ZQ=W2P278=GIQK?6#MA_"%6QU$1I\1$T4DS0B_+![+F<H/0L
MWF<EH<T-I:67=:/G)W^54[KU[8'YW([O%4]DVU=CJ_HN@MM%.:-#&T",4%[3
M&&,8U`E[L=OHNO4`OVPY[0GPX'K=Q;TO=QLS*/;X^M^Q5=7,M=Q&'7;"&R-R
M?-NT4K:+4B)702TI-R^1II4KQ9'($8<QOM9PJKI.N9ZRU/+MEC.BR7'-75)!
MB:F7.T@$%/I9!=#6VH=PRNJ;5A$;YXIHP["K?/%&!%-$_P!H.O3::_'ZRS8;
M`BYZL?;"]RVUFMD2!F-QNB)OL;G-3^,D)U.\C,2J$8-"AK8WC0HUOI\CO;-X
M%ONO_93[$;SG-WSB]UY(N*_*I:$3GF!T953C,K25&R*TI-6N&FB+K]M8D?G1
M0,MCI9CY7-(A*(/@_P#,"I)U=I':#1]`S4582'8@5459;YJVI*>VI[LD*LBK
MZ*OIK!@5BPZD%"A+BE$I7D_E5ZMAGFCGF8P)]Z=7[_D&4H/HMB]00!;5S3^N
M?9R[SCQN?\^LNV=6G%N[:"UN9VA:P,GE6=.S5$<P_P#ON3VG+$,1$3[&!#D?
M'<=KQSX*3O?-K>V)2WJUS$6`TP&"@"UQ0PV@HXM2Y9[&V_:<557U'7(,(*X9
M=%<2%/B2.!LH3YA#]?V_FQF7VFCN*'J7`L_#M.-$;,N"YG+YIOK.S`Z/S2"U
MJXB;C_$BS2*8J*UK!WPJ;GB&&K\$7O@"-:CFUM4_E37I&)IP3\9>9N@9'O:>
MPT=K?65L(X<BE"I(+HIC,_)7?DN+CG!KTF9-'(L_Y<C_``+#9_H/>G4N*I@-
M+LC><66;_9+["Z?9F:#.FUV.NM'1`+9XZQ'MZX6(K,7\L4JQQ0S,)9^8CGS?
M"5X$%_6'4MXGU$'J>>=$/:4&'^O%AAB?<.!JLY:[/Z<:=E,1,-`&EH"72_O4
M<@\<LSY7.#6!GQ*^15!O7&2W6MPF*FQ]E6Z<*(W73:]E5;-`N!M->LSTR[%U
MU<'!1C#FBDK*\CYB:\@6!T1,+"")'($IY[2;'ZR<K;T".ZSEW]C?M/,/R/F4
M67(S_2[GF/U[PI-JFNSUXNB$*<0=V+IT8=,A0`]ZL594JY\D12JWP(9_Z>,2
M6SOMEO,K0$EG,L9L_95DN^OI=!=ZFX.KZCL.K@B'!9?Z"O+@KRWUSIT$_3U2
M7TA=*$F\6N;^$BK^IVTU;L?CNU?XK1<[W<I$NIY(O7X/B.YUN:'730%6M3B<
MUUJR_P`>B(FC2PCH[0V>,-\T:-B#!(R/4(.H"3DC4Z3Q:C/V>UTD>LQM@U;G
M"I9KN*MUC812GRG'4U+802S^T*ZB*/`C9')&UL"!N3_BKTEU9?9[ZO9`0XX+
MG.5^P75M'G:%#4&I&DZSZS=QC;",-6R+%:W8[X'$33%^[YHI9"O?+,1)(X/9
M?X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X$%Z#Z_Y&Q"MX<A?;WD=C
M=:<O:%W/*M<=FWKJ+`91[.VDSIC+C#GK;/\`2<R`NJ)&++3\B6-\SG2*%9M_
MI?MC]=\_8:+>_9?Z@V/.`1E9%T+O^5T''KD2S>>D=;76Q.3V3L9=S%5W_'**
M-6R3&)_RA&L<C6!+7U([L3]E<!#UZ@Z?QKJ/-;,N^SM+H.046XK:TO2Y#0&Y
MK4^XK;FJ;,(%<59$$7L&;',UK98Y98G,>X*P_?'<7/:NI<L_CPYYK3\M_P!6
M**TZ]]N-MF;=]3H.8?4+%6(L%Y61VT$4KZ"V[_HF_P"*!S>K)FUJVD\?Z0.<
M@7HY=P[A7.;:[Z#R3GF*R]OT++<[HK739>M&&FO,3SG-QY_F5!`5#[FCY3*9
MV18ZT$;X@X/GEE;'\DTKWA-/JG^W_?Z)_P"U?`/`P+6R"IJRQN+&7X*^J!,L
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M5#T^DY#J,AP;4KF^V]%,Y-E;&^V-)4/RG1P0?W23%]7A'K;2''Z`VL=\P,84
MUS`:D4J1S>K8_E!:S?\`)'DK.]X[EK[E>IHM7W_6]+Q7)<FS5XC_`"?27/(C
M-@)NIIZ35VV*,KJ6%,.<^O/5)!#6_$U7PR3PL>$E<[_D1^J/2*Q]K7;^PS@X
MAE4!=/VV0U&7$RY&@L)JK._Y7=GU?^.9R#2V4"Q5LI9L45@KXW#ND9+$YX71
MKK*NN``[6I/#LZRP&B,`L0"82PC1)V))"2*4.^2&>"5CD5KVN5JHOZ+X&;X!
MX!X!X!X!X!X!X'Q?`_/3_DGDI-7]N?MG0.U4>,W6>^R?31#;.[J;309VPRA1
M-9J\X?/=UH5^W+E57X,T"P2Q5;HH`OR(2%F;&K@COZ>TN'P'/_L[]L=;+TOI
M5']=>"V-5F<39X]*C"Z/OGV.K[GF67HB;F<J[T5>3[K&U-:1`^IC4@J)P9#'
MHZ*0-?%G'1VN-Q64'&SO(,'D;>%TT$HQ,5II)*41,P2YT5B3L=CUO0%@`P3&
M&%1/'GK!BW1/A<D<#`PL4+;4]X+89?J4U=?Z5QLTHLTZ55^V"Q9"9?EDN.*+
M@B70U%8VK,'4N20F=T,",5[W(H6F^NFQY]N^:=Y^N=OQ6_S^UZ@@72L35\T'
M=?;`[O/)\GNJF?`AXV]DO\[SZBN.9W=O&0-1@TT;A@XGDM$1DS&AA@_6KHZM
M@#T.'UKJ@401PPJ<]L1K3V4DPI]$LEA&19X^J(EKTF%%L%L7504BI,<J33R2
MP@LIPOLVQNPM#'QRW"2"K[$-^$;85%@GS:?>YV]SF:O"C+9AX\UG4A2F-,D;
M/`CH96S2.]$]X2S3YGH%2%;9/?<HW]CE[6W&.??45749FXSNAS@E\H-E77.B
ML;$F:C.G>-"6/+^LCI6.$:Y1(7N"1=-P;Z@<#7G_`%;J_P!GK"^S!/7>$9KL
M7"B';#ZI_8+G/+^BWL%6=U/FU834V.W[/B`H;02VD-IR00GP1FQ(J,24>,,R
MT^U7&J7JOV<KPN(__3]X?1W/2,CG25^NEJ;)\FCT_12,;TYO8^MSY/KM)LLO
MSY^6JR2AP[F"VDJ2((2VJ^$F,)DZU]^-A<W7;Y!?J/\`8S\/I?TPS_U4KL?!
M<Y"IYISG>U4-R59_83'#8BCH"JC6V+[<=9Y*Z2O)A?#$HYZ0LC2(&=O?MM]?
M9L[VVUZ5]3.X<\TO9KCC8G*^AOYAR[H,?%L-CLW0X[LM;)T;FM/==)J;?IE1
M7%J5%'0V$UI7$*Z>Q<=(ID(<N(\Q^G7VPH\)D*S[(84+N&K(^R6WZ9F^;-Z+
M96^#YYRK-,M^0TF?XEU>Z_ZDVV^T@HR$35BVQ`!X["(EFG/;\)`5<H-):;[-
M<HT7/Z>EBR=%6!I%<OUF:S["9C)9S+N'8U&K+RNQBUTA94EB6#8@2)"?#%\#
MVI"C6!AYO`;22^L=R;EX[$&3.<8J='6IVGB[M=9$YSD+\QHBQ;"VW#J93!;(
MM9?EG8A!;E65',C<BH"NSD>8<7(#$5I[J2NE"&RN<7;_`%MRZP5K31S(G$Z!
MG4#FR?$'%ZCMA$&?"1`DL:HQZ1L"5?M=O+@/4\US7/>3"XC'\9X.S)4.SZ`0
M-;ZW&X#;$":@P'_K-'HM:.+A-MHW?NM>\2Q*AC&,:&,UCX)1WAKV/)K3-:P\
M[5:#0D>K(:FYPX@0.:IK"SF_:ZVU%&U!`9=PT,*KD!GL#A626=W6Q2)&K)6M
M0'YG[W3AY*(FE@S6IQU=KLW<PI8TA,E/EM[S^P@GQ/0(\'=P'TE6ZOG@]X<W
MPC(`\QCE63YEB>&P?[S"4.LTO/OL'F:[48>/[@\:RGV0N;.NOV:&D+UUA5)5
M[RIL,CH9WRA6$FXB(LF@#%*5\1$B_!#!'\"A*O\`$]O&"?>+Z<9>BL"'9[8=
M0WAQLI9*-FOK$#ZQ]QL:YT#6R2^ZK"BF+EA&5\C%^5I**R1RL4/=/X!X!X!X
M!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X$#_8KNU9]?N>MUDF;NMWKM'HJ;G_
M`"SFN;<'#H>E]0U;IX<KC*PVSF%IZ:,QPTQ)UD=-"#558I)A$C88'^!J8L/X
MQ_L-]Y-#6]3_`)+>U(VFCT0.JQ7T]XP99@<RX^(`P,FGIS>@UMK576SW85A$
MZ<^_%099"&Q,%<V"%OR!MT^O/U_YG]7>09+B'(:>6DP>-9:K6C%E26%D6;?7
M5AHKRVM[*?TGLK>XN[4@DB>3^Z221?\`3T1`U`6D6A@YI_(M]OZTR>G[A]E]
M7TW"\9L*\9"98_KI]/FF<_SN4&,="4M3+NVY_6:596(LS$O$>QOR#(U0V,_Q
MU=ELOL!]'?K#UN[_`&/]_P!7R?.LT<>:0EM&-H\\R;+Z`2NC-9$;#`'<4D\7
MQS,9*QS%:YK7(J(%RIQ1RF,C)ACG9%..3&V5J/:P@69A`TS47U])()XVO:O]
M6N1%3P.USFM:KG*C6M3W*YRHB(C?U555?T1$1/5?`U$TO1ONK]Z+6TP__0W)
M_7OZ4Z>YLFV'>R^KU^MZGV[D(5Y+$)2<SP%``U<6/UF@%1AUO<$P3U=:9*@<
M!!'Q3M#;@((*`*,""/"($$/"(&(-&R$<44:-L(X\$,:-CBAAB8C6M:B(UJ(B
M>!D>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>!HUZ)_+'L^>:$VK)YB;HHQ&U
M$\PV'Y9LM@@<>AJ8KRI&70#[JM%.F04A@SY5"%C>8CD:B1-^3P&J+_,OH;02
MS*K?K[W5?VNU,HB4,^JW0@HX[02+Y'#K-8=1KXGK(J/]C47U>V&14_HGJ"15
M_P`T>GCJFV6EXOT("*=L;Q"?_I>-O4BDQN)LH)7Q2WG5X`G(*\'XI/\`U**^
M942'YD>U4"H?V"_DX^RFN&O-=]8>4%%=`GTV*)N:WH/+*S!<_P!QE<@'8S@2
M1W.Y"ZKH*NU1]J^*9DJ4LCZMD[P)&E+[W!2PGJ/W)W$X5WJOL5#S".@EZC94
MN=^MO-.88N7G]AVV\?LNF55;NM.)L=M4YK4WC7O^&"R<XD<:)B,](U5`;L#^
MCU"&"P_8[[24PMR3#>M$K?L'U#,LTM@;,.A.\:S*E46?MMB<T:&%373,G1D3
M&2.5K&*@)E,-]F`!ZL+G7W9^SE*1DUVQE)8=,T>5Z"77Z+7!CKI2:R\T5%M[
M\1FN`>_]T#(F96%2*]7,;(Y%>&%QKK'V-^M,0U.%F>+_`&/Y)K*C)5G7>939
MFJYC%V?*9=]J`%S_`'E;;879XJ_C@ICHY*W01T8>@KG`Q@Q*T!D430V7?4K^
M4GI7#./P8S7<OZ38Z'3;_HNZI,0%S6QZ#G.0T6ZW6DT5/R/,;F;HF'MM#E,7
M5R,8#+8AQFP-G:.J-@:/&T+09/\`F<W=RTF2PX;L4'8R(B(R/C5S3#Q@HICS
M#)FVO9YIY4"'$5TD36L(3T56QN8J/\"8\O\`RC[;1]0Y?BA^6:$VGVNVQN6T
M-D+QS35\>5AUI,;1YKF^N.H#4E4C@W?)',QM@UWO:C(Y55$<&ZOP#P#P#P#P
M#P#P/SD_Y%^@5@?WB^\^<-S<#Y@_L_T98]%`)#96H)Y>1SMA3$"T/[^YY*D!
MUIX<3BQH7$D2HT6%\/S&,"O>BV&ZP_`L3S;%Z&VA9JM1I=;VJAN+"VJQM5HI
M8JTW`76DKXLUIZL=^:J8()0!4"%&:<(3[%>K%D\"&=.-14Q5=I>B;^E@B`L0
M;:[*L5)OK2MCILU'<_BVD$!EBN4I*^K<.XLVTDK7U["'@CHZ2QC%<$112Y#0
MV`UC^'*VVJ1Q[K9U&DJB*BTR;M+!57V0*OCA+PD;(VM\DJ65"[]QADT<D(SF
ML"FDE&:%COKF'I&]BSM8I.JOJ6^Y1WBQ(**%#/FLZHWZM?8V^N39[VN8F=L<
MFQFE'@AL`"TC*);"]\?K+')($^<PX3]<KSDW*S;GDO,9K#1<\QY=S5/X_G91
M933\Q3J:@9A1T1+QYY7N1LTDC'3(YJHBN]?`F$7Z_?5,\ED`?)N;2H^1)'B5
M''<@!7?DEQ.1I!+Y7_$PE%@3WN=)_?\`&C?U9X"B%P_ZUPCN?'SCF9+6U[8U
M:O&,68D0[97"0!.:5(D3#)'B>CD^)S$:K47VHGN<&1!S'@0EY<;@/%A/O38X
M5L[PG#CV0SX861P23_B65G:1QPL%F=&K1QV>C/<QB,]45`E+]SK&UCK2*ZU+
MZ]&0_&0)GXW,E;^@HP\,;KECX&R1,1%C_P#3.5C?:OZIZ>!@PV&1K1WSP6=I
M3LMDA:;`^EKULGO29P[5)&AN'D"S1*JM=$YR2MC5'*KE5/<"F;>TU6$ZH_>-
M"$ARMF:7!3UP4<[&@,8V`DPRQ9$H4`\Z.5CT5C5]7)_7^X(?Z'R+C'3:6&7?
MYJ"P(=%+$%92!UE/9C!EP!2GG#:"G.$LJXB!P<4L:.6:%CV(J*QS5\#KJN0<
M*SV*J:>@P67N:(:&)P`]QB,[;FE-1GSC'EV1U$687^1(SV12(1\J>UK%2-/T
M0.H;C_)(13[*PXC@JVF;&KXRF9+`FOFG_N;%6$#$9\&(9!HYO1TCWS>B/]BL
M]?3U#E+R[DI-@!7B\<YS9K:!,:+,9A\8/$L(\9Y4*/G*RD,D#IB'L;.Z97*R
M&-K6-143U!A=JNJ6HSV;R<<(>.RV"PG$`:LZRC``QV?MK6ATTQ]3%65$LRLH
MZ^.9I"EPA0Q0C5;/6:/T9Z!00[2\NHP#0FQ7AV7H:>MN]=I/V]`-!4YK8"#Y
M_!WU'F0;"YDV]%TBXCAL8P`S6FY@!R6YD;6.=%"$BC6M3#`&.+LY*[;\[&O&
M[/&;#]BL3\<H@M!&(+?V&)K79F71`I?-="E02I!M7^/.QOQH:H86..VNAM^$
MY7!ZW:-GN:+J-YTZMIQJDD:G!S\.)@S5I^<;8:>[MOV0V<0(J=(E8V>4&*8B
M&-S6^P+=?Q`:';%?R8_4BI8X^+#TT?1@I@R:NR=2@3&<@[G'FZL1]V%5V-9=
M`9VO%7W/F,*;#.H\XH\+1BR0]]7@'@'@'@'@'@'@'@'@'@'@'@'@<7/:ST]R
M^GN<UB?U7^YZ^UJ?HG^J^!R\`\`\`\`\`\"D6MS8.R^_G*Y-?%7V%7R7Z[[/
M>\JK;"M650NE:_9B8;7ZZI.)K7"_O-+@61US?@*0D<6ZG]T:1D>Y0NYZ>!%?
M;^JT'$.4;?K&K85_C&&IW76B($)`"?6TL9$$-G<S&VA`M>$#2"3/+)FFD:R(
M>%[U_IZ*%7/LGSRH`^F4[>948UC4<]QC]154-I-/9,O,5:YJUJ>@!V-@BOL2
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MU3U>_P!7+^J^`[_`/`/`/`/`/`PY3AX2Q`9%>A)T94H[$AF?&YH:0K.LD[(W
M0PJWYV^B/<U7^O\`;Z^B^@9G^W^W_L\`\`\`\`\`\`\`\`\`\`\#Q==DC)%Z
M1K7US[,(Q2N2A%&6&ENA+#+H-RJK*F)S]?5`7(]Q46XI:1O9)$UD9([E;,B/
MDC4(=F;KP*H'16`QQ3:JT+AGD$LRT$AGB881"V4FFK:<^6R-14D=*UGJL:,:
MJHYR>`IBZO9467@J$S^6L858V"J$N-@[0$@.F:^PCL:ZN?GXX*]T/R-:D+S)
MH7.B<QT3'+[W`GV+[P?.2335H9CI!00="+_F%UG71R0-LB('3%OJ;*D-`B$+
M2=K(@VSJZ61(HHD5GJ#3H9]%73@7(]14NJ)H&G4ULZY/.@AE$,_*'5(G9VEB
MFKU$<]K828Y&I[E?\2(B)X'5:/V!]@(Z<,.TMW?D0U$$FH-L9/V..<6>$(`(
MS/&H#5!F%N5D*S),CFJ]BM:Y/<'2,#L8XY)!P:-)EGE()J1]:;6A$I`]"7EE
M''@F-+*<1/Z(.L4?N]TC_1ZL7U#$=!J"EG6"HH((:P>*(>U0XQM;&R3WJ<U9
M:FIIB4E'1/2+YO>U?5$_N]RN\![5B7]0,3=#5U2V^&0*`)K[2N-99#,_$$;;
M$OBRY$]+9"%1?V1S1R-G9*Z5I"2,1C@YTE/?WI=2#`8Z2P_<8ODIQM&3-81!
MGF-=^$,EN-%`U].ULCU5\T$14G_(:O\`<C7!8CZO0[&/[+<5;&8$33U/9L,U
MMF3;V81I%"S4`T_Y%?!'0QRMG%&^)D@39GQMB]S/5S6JJ![)?`/`/`/`/`/`
M/`\`?W4N,U']\/M]^X+D=%5P?:+45>T?;9Z@/,KJZU/RD#_FB_("M;Z#+UH<
MR(Y\[2QY'L;`U8XXT<&JVZFW5QI-1#G,E:4/Y]Q#4W->)<WC\K>4"V`<'[<3
MJ[.*&RL*R&$R2\E():CYA`YHT=\UPQ8`CJZP65HPOWGIO7@+`\1@+K&&A''O
MC=%79VW&_P`,R72);$<;)]'`S/[O+J-4)4RDQV5C"00YQ%75C,:"77\WY!IQ
M!Z0;8],9-F]$6%;TF^%SEK1[K5%EK:KH^CV]?9T=GJ&9_15MP54@PR?@99N;
MLRV3K!"^&R":?KUD^A4W7J,JPOJ_6UNWYGW&\T_4J@ID)]I9Z;ZI]3O<W7UV
M3L+`<[$TNN!"AMS(QPQWP7H[V1BABFPCP`U.X=/BP9WT_H+WL':.(8NS^MNH
MOY+SA\%K<W]CO*8+!!X@ZUIZS/Z`DNK&E-GB3Y8&HQ7,1TS55'*#_P`^WLNR
MWGT[CZ;]@OL]C=-V+E>IV?1\=4ZG-9W/@;C!UF->!7@U#:6:6J"UDSB"KH%[
MY'M(+DCB2)K/10F+@_5]$+]03^N:"\DTNWK*SO&[>^U.LY(RI,GNNBBTM?9"
M5I(LQ8HX5*,)'$J>UD">UB)[G>`[>6:GH.*V?,JNSZ;;=!?W?C.AVU_4:VHQ
MXLF?T](%C-%"5E8:"CK_`,;*Z/\`S28*.G+E(:*@L3XYG/<YKPBOEG;23[/Z
M^T]_U(3::3K1_0ANJ\C.93.;S4JCS]_KH4I<G#6#7F*MLL?5QT\HEK,4VWB5
MQ2)^0WY/`Q\=U^XL^KXC+6'0M5:]4L^L[7%].XLV$9F"Q7(\S4Z^UK2,5)!G
M1&P7.?`DI3F6H=G.?<+821%P1MC1HX?-;V"XK]-%;V_0M8N]RGV:J^:LXM;7
M95AS43DEYO:/&"Z$KG<=-</6&UY_<BW#=8IT<\MJ6D397(B!J%]WFRL$FEC+
MCEJ4:2TOWPPQ>D(I36$3(@SU<,YT#/=ZK%'(J>WU]&^J("@H\G]L0,4ZO&6&
M0P1ZH',`DS6/C=.\NP*L'ANC)63VQM:CG?VN8YR_J&!$1`)#<2"2P/F?$6PN
M=%F^:6`:1)$&4:<6"S_!'>GN;+$QJJQ43U545&A]$)9.%"8Z6-1WD#S1L3\B
M1"7.:]6L'>L9<`\2$R/D=^0L3U^/W_VH]J>!43[`<WRY_3L_=:_14F4G_P"C
MO*[@SX&S[.3>8@JM.,TW.]'RN9X]!;T>CTPU2RXN%L8IR*D1*E(E@)F(C"FL
M]SQ>F?26#8]=>VN?U>OM8+FQU-I!=8JRW$YLG5]_1@KE+):>UOJ.HL0+`$R>
MTKJZ05M>$D1#FFJ&;E<'RX=,D%SO6M`#R`A]GD<'OV+8\\99LO;FJQM[L=9"
M/^_::?,:\30,JH+$00<_)55N+[QL^4A#@M)PK+:'F[QY]S'5NS0H&5O;^"QL
ML]=U-]>5NLS.U*GHX![$#2!V@!5E;54,Y:1ED4(->?.V`J"Q&0-FO\4%G:WG
MWZ^IPYY4"?C;C?7+OR8[2'YFP?7ON(S*JOF<D].7:"+:M,F1K(Y/PYXW-F<B
MR,:'N>\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\##EKP)S`["<(28^
MO85&`=*/#(6%&<V)IL8A+F+,.PML#$E1BHDB,;[O7T3T#,\"CG\F5V1G/X]?
MNE>"TM=HIJWZU]=(_9+>3X:NRB_PVU80-8RJQZ,"6![EE7T5/8B^!9[$55-<
M\FR-&6(#:9VUYW051($T+)ZVQI3LR(),)(.[W1R@EA2JQ6+ZHZ-RI_1?`I%)
M]$/H;!]C9NB<UYCE\+]Q<'S<>TK-KA=3OL7JZS-Z-TF=HK+9-RMZ'4:>OOR\
M;^&1^[C6$QHH4D4C9(O<U0J9H?X_/Y./LB&'RW[?_P`D&?A^M9-HCNDX'ZT\
M7KN==-[-DQS&S_X'I^PD$#%Y3*Z$)\@=S%4UK93Q4^/Y&,DD:H;5=[V[Z]_5
M^FQV9Z%M<QR3,Q9V4/)1W2%UF;K\SBQZBKEB_=U%DJ*FOI!SPH?_`%,\2(DL
M:)Z^O@3E5V0%S6U]Q5&#V-5;`B6=98"2-F%.KSX(R@S!I6*K)1R1Y6O8Y%]'
M-<B^!G>`>`>`>`>`>`>`>`>`>`>`>`>!U0QOB8C'32SN]\CODF2-'^CY'/1G
M_)CBC]L:.]K?T]?:B>JJOJJAV^`>`>`>!X]]R0:SJO<P*RQRDL9M5R:Y,HM2
MRLO3R1[+E-910.S`$D$I(DV?FI9'J=^.DM?,:UR2-]T3/`I%U+B&&Z?L,EK;
M""\IK;G!8IF:V6>V-C31$VL!@]VL!@,)0>6ESXEE&UTC#1/RBQU8B(K?7V!9
M*R97OKI*T2ECT9MWHH[:A.J)R0R\_3R`S"6!`G^1V!8X4WYX'S$?-'#'(&UO
M_P"2;"Y`CFL4FN(G-2RAFKY";*M;665:58PD02K^VDA!"T#QDADGAFDDCE<R
M>"*2*27W-?['*"+^W68T-BI$U@KIC!((&U]/7'@-#C6=))W6%R0"4'$$R*"-
M6QQ(Z5KE>YRM_1P99/[J1'//$VO"@J+`2-T\+M++&^<$4:56`EGURP,4\J/W
M>Z,A71HJM<UC%1$#(JD(CD(/"'&5@MT^PC!N1_P(O;$R*4.=DV=L%B>*]KTE
M5LPY4GK'ZJJL<Y/`3&5&H0V5(XU$DMH(4`&@$@>"2^P+<-&.(IS8")A(H(U<
MSX86R>QJM:J>Q44%,ZFNGH0/72UQ19MW7AW"SCWA9R$!+*M=7AS&$6$?OL8H
MEE=\LON:[U:J>U8_0,83_*:AY[)7%5\89AM3,=.A=()#:16?XTP7Y@5A)^4:
M*Z5J3?D!OD=(]K6*KGH]@63^O<MWGOL#Q`FST,AEC7=5P54%!+4,<P29^EKW
M%V8#Y636$XKXB986.;(QJ%SO][D5JIX'L6\`\`\`\`\`\#XO@?G:_P`B72N2
M8W[H?>@*UGZ09J9/M-HE$H9:IV>Y\RTJ9.9ZXRZ!V-20=,0P5L049GY;`TE)
M,8'+*D4D#H0UF])U17:[#09/':/HN1VLUC%-7NCM-%<T%_6$N]ET#H*(DZVU
M&#FA,CK3@;9JW0,,]:Q\D#(GRN:#/K8,GA&OQE",5N]=2QLHJ)_2OW3.@U@Q
M==6Q9_+P9A2*&WL0I#+"UJSS+I8J@T"B)-9%$#$LK@ZZC3"6]K--4<^PE[D#
MJI&0.HZ&PYUJF51PA9LE<!HZL>"&PL-/@@:*I,@L`S7GW]K=`I`BRPN>$U?5
MG!ZEW=LCL8K\HT#IV7[9H'_OPF@IKV"NW/'-CI(HX)UHHLUO<:>=/5M9;AD5
MKK`VO:6/"UJ+!X%LN)X88BH^LO5[#37%5>X#ZZ#8>.MK(:T>KF$Z75XJUM2O
MW(L,[ULHR<N/'$K9)U9&KT?ZJG@3%?\`/H=%T'EG5BKS026/+V[IE,KFTTE3
M<$[ROJJNY=:M]92SVQ,IX?A;`QKU<U5?Z>J+X#)H..4.+XWH.#4>HNXLQH*;
MI=0-860M*)<AOZ9;Z:ZL2!Y5J@"KX6OLM.5^(KYD5D21QND]&*]`2^7Y7N#=
MKR:]WS<'4)Q3FV@P-03AKJ[V;]H3:PY>C+O[,:^QP5-SL*OHL6*^(>4RR-_,
M+EC?*D#8UD!2KZCMMST'&Z?H-GRK,MYK?:[23;3$E3&W?4[BPJKG$Y=MJ#+2
MCP9BEH\<:3(5"IUM(IC&)`]@[%50CO,<XZV'!S;G\Q&6"Y+RGNND[3G][+:V
M@6_U'Y=QH-!F,T3F[#*5W[-93V6V+%N;E;0YEF"+&L$#73+\82-T2M[9K3V9
M/0[[FX?$H]WD]RTX?]\"Z3#68/2TNSIN<#YX*&?+DPV&LH62?O4QC25%:Z+\
M-)O0A`L9-H[MM6A0=R<T*)A!,T\-@F;0R5JN(>Z`03VDSQ)$C8W?I(KG^J.:
MO_"H-XF\.=,X8RZN'R_BCSO._P`C;:ASBER1DQBONR9RR9%5RL;\*JGX\LBL
M8U',<J!QIIXZ<&YBHB+4"*Q:&;;GU]G:4M/8R!22,''.N/R$GE4+T>QL43E;
M.YZ,5CO<OH&)%+7WI/L*"L2V2SCJ+`A%A!^X3?-%^.HXD$CF1R3+\<OK.B1L
M;"J>GK^B!7CO..-FZ7E>BDU^DO,C5?6/G@E]ELE72I>6F9!T.RH>@:3:ZFJM
M3KW-Y\#+H,VMC"JB2S[2L06(@1"%(\"I(G6.J43BLWSS0Y_!_AWA@]H)S;*U
M`&6I+\.V93"6]Q8+8&%7@M5J<Z?=DI:2D&6P./O02)E?[V/`N*,K9R%RC`9C
M)QU4LUF1?T65HL[3TU(359+,6%!V,(DZBYR%8A\BM:BL%-I"1[,U]B\L<4R`
M@Q\8=0`H?#-"#I,CS^PWF]DA0HW4[C/C&[Q,U9)+>LKJ@4YUOS1M'`38SUZE
M*R[LBOA'D<;\[!Q90W3_`,3%OHK+[U?4"\ON-$\ODO;^Y#B*40`,2WD%^O/=
MBQX1Z:*O9#6*'G)Q)WE!$O224V2*=K7/6.,/=-X!X!X!X!X!X!X!X&)$"+`6
M6=%$C"CF#,+E]TBK,T-LK1D5JO6-GQ-F=_PHGKZ_KZ_IX&7X!X!X!_V>`>`>
M`>`>`>`>`>!\]4_W^!]\"#OLWR;_`*\_7+N_$OF@'7K?(>B<Y9.5"R<>*38Y
M.UH(Y)HI)8(W1M><BKZO:B)^OJGIX%,OX]^F_:W1_5FJY/V[B5]R#[$\;P8>
M`J-?T.O0WEO5DR+2\;0=$!+REF01%%8Q4D!EA5_/',YI#919Y8)4EC"S/UH^
MMA/"5Z?K=ETW1]K[1V_8Q[+J74=*!7T3"XZH%*;%X3%Y*J=+68OFO/J%%&JJ
MUDI,WRD%%$$3DES2J%I?`CKI').9]?I9\YU'#9O>4)()U614::MAM*\BOLI0
M)[`*88AKHY!C)JL=TC%14<L+?7^G@/FO!"JP0JRM&A"KZX08``,9B1#B!!PL
M'%&@B;Z-CA@@C:UC4_1&HB>!F>`>`>`>`>`>`>`>`>`>`>`>!URND9&]\4?R
MR-:Y61*](TD=Z?HU9%1R,15_U]%]/`[/`/`/`X1QI$WVHY[D]TC_`%DD?*[U
MD>Z14]TCG.]K5=Z-3U]&M1$3]$\#GX'DOUOU0Z79]/M>DYSFFRWF>DPO.H0-
M3SLL;\DO1_X.96T0K*:Q.FDNR:FSK2I9XDC185CCC?)`DJ(X*\5_#-5:Y!0`
ML!M!)P](76LS=I6ZNDL*8)RC2"W*4?K9PE(5<'J/)"Z1C)9/1K7Q-:Y_@+&E
M^OO1*=8K,OA_1*JQLY"1*9N._P`VN@!Y:J>P"@FDF-,*&C>1:U;GMAFGE]D:
M2-160OA>T&A9<9WUA.VY3BF@JP8&3Q%&T%)J4%"B'&'_`'H*KH2Y29X#((GJ
M]OR3.<Z95^)_]ZQJ#4;QG9C0135W/-[(PTQ8U"ML=N!8#V.;$7`X0F-#95^9
M)6/6)4B<K)/U]6M<U`[;OA^]##KDO>,=%'`L8OFC8-EM*4(1/)#Z2"*D)<,<
M<R1L^16/3WM:B>OJQ47P,P7Z[=(L86F-Y%MBAF#_`)+0Z6GWLY`Z3/C_`!I$
MI[@(&![Y$]_HZ'Y'JBM<[U5C44$MG#=E`\4LCDFJJ5(+B$D+.SNO&B!.F=%*
MR?\`=@RCB8_VU9'/>JP1NC]B+_Q>K5!ZP?5O:ASD,L>4;<TF61!PZ>LI-/IW
M%&(R>![CG68].`^/U6*1OQDHJ0O<J/5WN;X'9F_KO;6\*TLO(=DMC!-!9UE7
M+G=5`7?VDD?H:!,-(DN>=:PL';"'[IVCO9[7R.65K'1A:;A/U9B"^PO/#S,=
MK<+4T^TY_JB969G8->XT.T@6URH%V>88MX?67<BQR3$#Q#QC#2?\Y[4;),'J
M]\`\`\`\`\`\#XO]/`\"WW]/U`'WI^W5/4YJDV=9??8NUI:"@TM?%=UXFMOZ
M?',6USF?JBC-/7W;9K>=KIX6U\QQ+F(PQL<J00!JFUVDY;F:JVQR=)KL[G5N
MC['1P#X,V@Q-@1D+3)5%J%HM'$?>V.FFR%Y;@NL";IDLC;!PL`3WMEC^4$L^
M;8U=%;066'/Z-R`D5T^2T1H))DF0I]#E?\*?59CH>5F6\K2,3@Y0Z9M<.?-7
M'6.HO%8.Z85?4,:N/K3+6U;D^64M?8,LR2J_;&6!F^_932R:R]G.%RU6%$]Q
MD!5$+;5P)@EI&MADH1H6-D)B24)-PNXON+]CI^R;_08VBU>:#V6H)Y_K6&]*
M_>\I:CED:.C/R==HHKZ;%`@VEJ6+ZV50E76'1-B9[Q)(5"=9OLMI'T#JKD/$
MOJ+28O(1K79<<OCG38:2NJ,M1U8Q-#:65W]EY::HM0-`>/40NF/?$,^1?E>B
MQO1`RR?N_J'5U962<#^KC=`8SK!D9MAC>GQJ,WG&4@T@=.RDKOL*?2MFLTN8
M6J:I[H6*BN]B^Y5:'0#]PN@.T(=*)S;ZQC#/CL9K6YTO+.HPZ/,6U8.;;AU\
MV9BZA`)?6EF*^".&<<N`=A#IG2?%\;XF@JZO[@[6C(K*\_Z]?7F4_4B55G4O
M'YWJ3I:+.7K`",]7:6$_NPU<3;1S3+/9%NC"KJX8RO>:Z*"66>(&=_\`3R]<
MU&5IX.8<E^C>U]ASOS0]7S[J>0OIQSB;&@JKRHP-OWT*4G\'7"2BGC!EEI!"
M&3%/-$>L8CPSB_N/]G3`:Z>#Z6_6LB)TA;702\2[[_D]<-)<B)5V4=+/V2"F
MGE!S5A%))^/)*PBQ@G!C]"8VQO#B1]_^H5!'LVW,OIC6!MO*NKH\G0\:T^OW
M!Y%R774U,;H`9_LS!EL1$9N&V`#"[.QB'BA^:5T<\U<:,@=E+]PND7].^_J>
M/_7BAEQT,1FYQ][PV]F(;67TW[36%9VPG[`#"_V7DC5?&UQ4A`9`9+/2`CV(
M#FS/W`[7^RVT!/-OJ)/^W7:RAP9[ZZ["JJ;*KG_/%B96MWW4L\8!.#'$A'QS
M!&*]"EC<6S]71AQJ?MWTMY=Z1=8SZ="9"NS'*=`(Z?@@P3:N[Z'DEL[.TU-#
M#O(-)^W5)I436,B48YT3'^WYD9(K`D2O^T^M+I9B-O2_7>O#FNZVJHYZ#ZLL
M'LB1#GL&M+*"CT_5+-XP\(1DKPQY24F.-C95I+$7/%(X*][#7VW5NM5O2,?U
MW"4.M9G,1CJ3G(>6?Q$O`$8C-V&MYFRP>.2?@+FSL;:W)VA(::@:T,2G6J46
M8Y+(80(E.M^F6-?/(O%8R_S)'PXC>Z''VIA)\$(+`LQ%IK#"$UL5S?EMM1X;
M@B>0Q\QFDTI#Y/=$ON!GW-#87!@,?7#@N6!4@4)`^=T@513:QV=NJ.0JMKLS
MF<&T6R_=(1"K7]Q6&L:DM=65TLAB@PS3M"9N<[G,6(]=C<9::X"NM;&MU62.
MV8E7`!;V=I)8W4`)U.577<5&&%37WY$44L\LXEZUH<CI+)TBP!M<_BVTE_??
MR"_6XVXOVVK[/?:0V"PMQ[BMN=3(G`^SQFR,C-KW41T=-&U95<$5*]?R&?HG
ML>Y0]Q7@'@'@'@'@'@'@'@'@'@'@'@<)%<C'>Q&J_P!J^Q'+Z-]Z)_;[E1%5
M$]?3U_[/`^L]_L;\GM23VM]Z,559[_3^[V^OZ^WU_I_KZ>!R\"MWVT^PTOU4
MX/O._P`_,]3U/-<OI+?8;NCQEQD:G0U6'SM':WF@T@#-I>9ZLN'UD5<QGX41
M*%SK,BQ-=[53P&%P[[B#=0Z0+QSH7'^@\&Z=H><,['SVEV9^-TM%TKEZ$TP%
MIH,EK<)H-!5?O&5L]`%!<4YR!V`?YD$K&3#RI*@6+W_05P4^`@3#]#VO^>]"
MI>?+-@,VW108I+FNNK'_`#C?R.."_P`=Y[4_LWP&V2).L!)8S/B=\OJT)#\"
MC/VA^T?<N(:J6IY1]4+3O67SO'MAU[I&Y=UG-\LI,4)FIY$K<P,FAS]U)JM)
MI`@#IXX!%;^*P9JS^QL\;_`K*O\`)5]@<]QF]^P71/H/K*?ECOK*-]D<!:8?
MN6)WUAK`II<28;DM$*7F\;!@;2DRFT2V(?/*:\D>O+B!A,(C9#(&W2O,0\`$
MY&>Q#0QBT8CG.1B$P,F1J.?'"]R-]_IZJQJ_[T3^G@9?^R?I_P#L_P!/`/Z_
M[_\`7]?]W_9_W^`?^U?Z^!]_V_V_T\!#NM+G\XM0V_NZNE=H+L'-T3;,X8)U
MQH+)L\E?25C)Y&..M"XQ97QP1>Z1S(GN1/:URH#+YSL]UJ2>F1[OE=CRP7']
M*O<IB#K35YG2Q=/P5;549M7U2OCSY,TF6K;TZP,%;5V*1V`ZU[I)&HV5G@22
MI([5@:Z>%KBE5HK5EC127)&Z96CHKO\`G*D+%?Z-]?[45?Z>!](^?X)_Q5A0
MKX9/QE(1ZP)/['?"LZ1JV184D]/<C51WM]?3]?`HU])?L+VSODOV<A[+FN99
M=>#?9;>_7FD=SV;631Z>/G]5FK0S9GKJE8ZO'N6:F)D(D;9/@4>1RSS->Q4"
MZ$.ESI%03?CWU+/1!M,>7=PV@,M0*RN=(RP>39,G<%`T!\+TF5[T2)6*CO3T
M7P%$$X*S#%L:TP6PKSAX2P3P2(BPS!2(TE@)$*@?)`0/-$Y',>QSFN:OJB^G
M@97@'@'@'@'@'@'@'@'@'@'@'@'@0I)];N`2EV)S^,\T_,MK`NVLB&XZC8\Z
MS/>V4T\KV!M28LN1J.ED7^Y[D]555\#%=]8?KJ\O\]_$N9.-3T]"EQU(I'Z*
MBI_S?Q/?^BI_O\#*(^MW`2X"1BN.<X)',A>.7#/DJ>6(B"1GQOBE8\5S7L?&
MB-5%_143T_IX'0%]9?KS6L?%7\5YH%%)\?R1BX^E@9)\2>V/Y&QB-:_XV_HW
MU1?3_3P.F7ZN_7*<J(Z;A_+Y3()HR("GXRC<1"1"B-BGCE4/WLFC1/[7(J.3
M_?X&;/\`6[@)3)8R>.<Y(CGBE@F;/DZB9)(9_;\T3_D&=ZLE]B>Y/]?3P"#Z
MW\#%BC@%X]SL>")J-CAARM3'$QJ>JHUD;!FL:B*O^[P$^Q^K/UNMYHR;3A?*
MK$B)OL9.;AZ`F1C/T_M:^8)[FI^B?Z^`L0_7GA8\;(H>1<\CCC:C&1LRE.D;
M&)^B,9'^+[6M1/\`1/T\#%_^EL^OZ%3&MXSS5I9,CY9R6X^D;--+)&D4DDDC
M1$<Y\D2(URJOZM3T\!4'X-Q064:<;E.`@F"+$.$FBRM.R48T">,D(J"1HB/B
M(%(A8^-Z*CFN:BI^J>!+/@'@'@'@'@'@?%_V_P#E_P"[P/SZOY%-E49'^1K[
MGW,U-9N*YS]E\MMS9Y[PJHKM,TWDW.Y:JGB$BII)R@*PFO\`G*2%9)7^B/A)
MBF1D7@:AK7`WI&4@U.P0&HR>E(MC<UE:/XKT/2'Y6"F70!154^@&_,YY3NO2
M!#PPYGMFE,G%:]K(8T$!KU^*Z#EC8[K"ZO:6B3QD[BWWE:MNS:WE^JT=>'0U
MV6ABE)AR>NJ)&5^OL%CC4@E0M$*4Y6*'.#F,M/LCIJPB<7_J38Q$QI>68]Q9
M65KE\I,+3O\`P?K_`-,F.29G0N:9>45AUST!LA,VF@9#6-(?(V6,8,3.8J@!
M'?5_OIM>1%;FZ&.&H*K=23SS;&Q6EA;V`FMLK:AK=A7W=[-^X7$".+;&4VH&
MBFFAK1)"`6Q3=)B@K7G&AH48N0VCZVPILJ^N.D==#50F3LWV9PA)-C/GH*RC
M1S6SL@69)G.ED6!SS7`V]?J<_<IE"Z6MAB@L\?\`=8\K.27-O.@\M9PZA"4$
MP^1<\:L9]XU8V(QD317O1@I#HD83($M:SI>CLS]?E*`.NI;+\_4Y7/9]YMR^
M8$3/QS65C8GD;BNJ775I<2$,%^8<JRKV1S(L1WS?"-("R&'K^JT6DU=T`"-E
M\P9EL+M(:>[H_P`K-!2X&[YYFL5GF6IMO-1QZ3&0E"%FSC/<8`;)!)&UY"1,
M"-=#Q(:X?76V:N4E.@I:RM*9J248%0T1JBT)&,Q<@KZO]KTFKIA!%(L#R:V<
M.[#!N62OGDM2F@V*C&=0L*ZRSE>W=IFXFS#FAR;.K$2?%QMO&#=3KMDRQ!S5
M3]S;$,>8,P]Y?[#^&CS&3K&OQ-#$=SZOKC[VMU4-+L;L6K@S.AHJ&D'`SVCQ
MVD:^L`AT*2$7%??6&(_`3-LM`6$SP@0E$.+60E)VA)=H?I,!GS=+55N=FK]W
MFJ2UFJM):SFI;T%CL=5.);::M%&KR<[;5FGQ'P!E5ZP)9.7]8GS3?'""ECNE
MRLTE)C*W/4-J:)L::A-SDHNMT1L><TB&3937!V<.D**B*KRP):WWEMI,](*-
M&]AA:-59@01MH;73Z.U-R5>=3OY5]+;&+-O.C+<9^0*`(V&*ZIDN+8A@\A*?
M&J&6L4KF+$B$HGOE!XP@W6ZN8N-9M0RPP3-C,8R"<2"CO<M6AV=]I_EK;^Y>
M-%%GLY2S-`#%+:R2(584_,G);*,'?N<5SZ_&,MX+>['./GL-378S:W4K\OJ+
M_2W@QHVVT!]'2);66@`U2#6]<L`D,%;<N5CODK[:V24(P;S/M8I@8-*))JVV
MC[R\EN13(R>?['=#".6VRFKRU+9%&Y'Z:Z`620XJI2,:QK+GWQ0#-&EB>.#M
MK>!DPVM25TP^_E=!))<CYD:VAU'8<GK+"U/GLK0C=!6-H+-@=C^V?%)GRW+/
M796M'`DAC)G.F)"=LSE+/`5(V_P`3LQGZBYK,PE28:+!IR=I4ZZQZS5N_;3J
MBJIRJ-JWILOQ$#>L1[#W12.CGF5`V._Q-6EX1]\_J<.+E*8#*LZ=T<V2P&&F
M)*K;P'DG8\P55!6A5G&&(-+76(<DD8H2$31_'[O@&;$V8/>-X!X!X!X!X!X!
MX!X!X!X!X!X!X!X!X&OC^5ZS"K_XW/NR,2Z>0O0_6SKF4H*T)"7VM_I]+BKB
MHSV=I8`QC#";J[LRHQQHX8997RO3VM5?T\"M\_/N=X#ZKW?WY([-WSH>[S/T
MP"QN8W^8K\AI]5S#FH,.?T._S?&,#38S*T`FGTMWF(8;2SLABK9CJ^)7D1M%
M]O@5-YWW[6@\QN@]#VGJ-))B_P"7;B)F7JQMUV;:L(^K73[GD^HK,B[>:RC$
MU?0^-?LE]=DSS%.DJDA"(:YR!PLC0%K4]0U>$ZCJ>EA]K^Q5IH:+^8CF''1*
M^UWG1-/@ZOZO]#SG/6=#SX_/118,"1RX>>PNWH?+7%S4)@".B.A>.YRAN9^Y
M5S7TGU/^QL]B0<,VQXMTK/`.K!+`ZRGNM-D+:@H0:T6K$/.DL#[BQ@A@]D3_
M`$E>U5_3U\#77=:0.V_@I)KZ`7;FW5;]$J+E+L_#C]='TB'H-;RBFQD^4@R2
M4\FH?L1=%_Z9K(AI7(4GO8KFI[O`KET0SIF%J_NERGZ]7GVFL\4VN_CX[!:5
M.;AZ?T3HU9SS;Z18/MX=PJPV[9K"_P!18\ZKZT^[SM?9H9\A1GXL,!Q#F*#H
MBY[S+6U/TPY_+UW[C]#X3O?LCWT>Q68+O/#:+0<^Z!RZ[FKLP?28>MR>EHN(
MYOK,M>'027Y%>0"5-+`+(^M<_P!`6Z.YT1GWQ-KAL_\`8[/8D^[^Z7U\Z1MK
MFE[8/;6)UK2<\U7&C6=!H*4/G^,Y33T@-O%@#0I)2JX2O<:591&ERQ2!63A&
M8[5K_JKB=O\`1W6]WT?2"OXP^TY+L>GN-7TB6PZ5]@/V["_]`CZ#4=HD2O,[
M>TH73OK]#!'[&!F#OGD_$>*Q`F_&9$:FY7ANU<OK/O%=YWGGVV^J_6^F9SKO
M+-9A=)A*&ISY_-NN5.(Y9093-[C=&4=5:A%[QP=99UU\8(IP\AQ$4SD!IZGB
MW_43BO"3^D?63MM_E>,_RX=TT6BS5]S+JA&HJOK/TO<?86TRFKS>4'FFU%Y@
M_P#Z,\C&KZZ,O]M&B6)T<4(T[6!-NM$ZKF=!]I+C%\4[?T'D#OY!>(]'Z=SY
M^0Z,;<=(^LR?7S`X3H0O'\[JPDDW=7B.VTD5J?FZ>:0:QK*XR`49[2&0D`X-
MWQ,T#=_5ZV^KW'=[0\YPUS'%5<;[#RGHY.,FI;C[(U6OU6HQ.QGU-?OOJIT;
M(O+,O*>6VB94V>;B2F=7QBLB%0-HO$.\"=J;V2)N`WG/[+BO:=KQ>\K-J#5L
MDT)F4KZ&]K]CD3*"UNZVZR6LS>G!+#D;,TF&2208B&$B&2-`TJZ?EO1NA_5S
M^0_)7'UH[X?;=-_D*J^\\KS<^&+S-UL,&7LN&-#TU;''H:V5!Q@^=7#CAC91
M2T"6-9Q_:3&CP>VHXAV#GNH^S</$OKAKO^@6?^[?U=[E)P.BS60RF4[5Q:EY
M9G\OW0'C&5?<4^=/T(?1*L?4EU=I^V1Z&>F;"Q)7E-5P;.>%6P.*CYIROG'U
M4W_'.3:3.=/W<!AD.+H\YS2T7:`6HV4T>3!UME=9^]Z43KC[<`(2"48"$6:$
ME`Y?8.@6U\`\`\`\`\`\`\`\`\`\`\`\`\#K26-9%B1[/E:QKW1>YJR-8]7(
MQZL]?<UCE:OHJI^OI_V>!V>!%_5NQ83BU+3Z#H%B=6UE]J*K(5LM?26][++=
M7#"IA8I1Z8(V8>!!PII'2O1K$1GM172.8QP17C/N1P;?7@V>S&ELC;(C,:+8
M_')F[H1D.=R\UB/;6!"DB1OC^*>IG8V+VK,KVHU6HYS44&AE_O[];]B8,+0W
MVF)'?706ME<2XZ]&H\]7EW$-($7H+289HX`I1A,:I,GR0Q1N]971JCD0$P;^
M0WZ[DPA%+)T$8$_=%<]&-+P-U"R2^"E:*0J">CK/\9MA-".QOP*3++.Q(X7M
M1[F`Y,1]X^%[^#6349.KB7#\U.ZOJ1[+.O$*JLF`5:B/>^!ID[RCYI*:=61P
M)(ST:B/>QWJU`:]Y_(9P7/9F+76(70V414T(=>='F07C65FVG#TEO4@&+>L`
MG/SN<L1S3$^9(_CG;'`^>=KX6!=RLL1;BMK[8%[I`K0$2Q#D<Q\3WBFCQDCO
M?%*UDD3G12HJM<B.3^BIZ^!G>`>`>`>`>`>`>`>`>!^?9_)X)87_`-]?N6%0
M<\_<+6L[C%;2W%F,2[,'#U7->713DFV0R4M2&;&&<\1HDYTYLORI+\?Q/:QP
M5*Y-ER>B_57[$Y^RR>LM])]3DT7<.2+DK^P!J+7DFYT%+C^T%TW2W-KZH/#X
M=Q45RT9UC8FQ.E*A5C8F0,4*C1*>=1F56)UCM'5"EL;9X:_L*G!Z6@B%.6PB
MAS5N(^AH.BBCU9S)Y9D?6%.LQA)F+*D/OD#"?_GDM%2P7`Z\WQL,<L5A!T$*
MJHJBLK4+<=)!0T33+4TPBL(+2U06H&*G'0N1C6+$.V1@61^HG,<'UCJE?GZZ
MPZ!>47,L!T?J^STT-6V6IL:GB=?<ZPDBNSA=;=5-@'K]/F`JDN:RAM+`H^R^
M5*V"$CX?`KU;7/4]GT+5=$U?.HI+GJ%H9ULBN_\`.)&<7(0>!GO\*E&JGF5H
MX#!JL'\05OR-)(9"R-T+H_`8F@L6;\#%"ATM?15962^Z59\$R34N9SK4X]0$
ME,GK3Z<*6LG+B?["/D:L4?L>R6*3T8_P)THBM`JV&?S&?JSLO42W153G!):4
M.HK*9Q]JEU:V.PO2R*8"DLI=9&1):'E"3+^Y)`V!'JWYPLY](:"UUW9])Q:T
M@HK;E'V:L,_RKIEC57.<945?3Q?W77<?CT,AUY67U'&[H%+&).?`V`MT13PU
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M9<566$`H418^T_-SLNCF#U5B?5R&BQ@22F$Q2FMC1&R.>Y@2U]ON?\^X+]EN
MGXJCQ=IS_"29'+Z_C'2H;<J[T-SQ?84=?K<1L]!7F7=KGSI0I;J8*Q6$49T$
M@<D;"8?A]&A`L]9K=B8^>O+Y]>P9<X<N'2@;H?+"45]>A,K:G6OSFFN1+84(
M-H$9E8BNM(08RQXH9O2:610:4QF7K[*8?7:>VVNPJXB:BPSPVNO"`*O]OBF;
M73:FZST/Y^M(&)H'P6(-8^OE<ZN>CRIHY'1J&SOM>$FY#SO@_)!N2YG+BV?-
MN:?8&^I^G6->1G<)UCHU!FZVX3G4VHM6VZ:"NR"#E&UKP'6`%;:MFFB:I$;V
MA</^)Z>[A^X/UI9.:AM+<=$+L&V5:'3FYG]XFX]W@Q:PJ8.1L=5H(P$>@T:I
M(1,*Y"VO?"Z-\@>WWP#P#P#P#P#P#P#P#P#P#P#P#P#P#P/CFM=Z>Y$7VJCD
M]R(OHYOZHY/7^BHO^O@"-:B>U$1&_K^B(GI^O]?T_I^OKX`B(GZ)Z?I^GZ?Z
M?]G_`&>!]\`\`\`\`\!(T`!MK0W576V3::QLJFP`!MW`P6:599@DPX]A^VDO
MC&/_``I9$D^&14CD]OM=^BKX$+?5GA2?6/Z^\KX##M;7H('*,J%CJ?67E33T
MMO94E4LD50RQ`HHAZEI05?[(5?!%$V1(T<K$55\"P'@'Z?U_V_W^`>`>`VLG
MCLOA:A:'(45=GJAUG=74@-9`D$,UOH[8V^OK2?\`XGD6%Q<V$Y)$KU<^6:5S
MG*JKX#E\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\#J2&%LSR$BC2>1C(GS(QJ2
MOCC5SHXW2(GO<QCGJJ(J^B*J^!]<Q'/C?ZR(Z/W^B-D>V-?>B(OR,:OLD]/3
M]/<B^W_3P-8'V,[UA]ILSN,;[F.=U%%1]7I\9#!-UK49?4A338XF[M=5LLME
M*!A==S^X"/0&M6<\@>VD5SWQQ_&U6!5S(]/R7/$(Z-G/J1KQ@*+-[7#_`+&_
MM?V'M]QJZRU9GFYK+YGGUU66%7HZ/2%=13]N**:YM>,.82"UK(6>@/P+HOU]
MTI'=:*G^J!K*&PX]T.:NM)]+KP.:=?PG/,_EJJ6FO*L!&U]38#Q6P+9XY1I3
M60R.*ADED4A4!-"WN%TVOMJ>C^KF<U5SM+T84N%=OOM+D=%8]$T6EGW/0>8T
MUY/74U9B;&;!LM&&@A5<A,1$)#G-?_:\&%E.HTE'H=:9RSZ.#YG5WW/>FTNE
MTNTVO3R\;NL!06EQ:^A<+`K&35W6EM@[0:2<D9]J&]($65XI,2($A:3JV=$Z
M=H[XSZ?9/=])')=C=-3YHG9V&E_Q[&J3DSNG4U!94T>9@R&@SLI-37.C0:RN
M2:W\$F=61CI$%[/J#WR_[,%MZ6ZP-?SX?G+\I44=15.M"18*DZM-04"8T^$?
MVG5P];&D@LT`)XJ2(R<1C/AG("Y?@'@'@'@'@'@'@'@?%_I_O\#P5_S"55\=
M]I^VYJBK'B2:S[$:S0,EL:JTL:':W%%ROBN>F'<F1,;I";.GI[D(9T(;76GX
MLC6C^[WRCH&MOZV]\Y=]<OMC@;$SIFUJN(6FKW%!TFT#J*L/.:'D_8V$9;1%
M=#Y!^&126&:@K2Y+:8=@QTC9?B<YKYI$<T*MZO%4%'U.QX=V:JJL%O>>[708
MV?L$U4`)E-/1YRQ@?66AV?YUZTN7TFX,LJ&2M_QX=L1><L)AY1II9%DB#+V&
M%R^5LKRQW>FY_I@0\]9$CXJAO"-'I;&0.MLK>VF?3-SI<-!$=7UAC9#"Y6/=
M"3*$YJ$0MC\"QG/.P=$YG]2>T:S0397F5S]D-'F>'\JHL\..)I#>8\ZT%?JN
MM=%PDP5L"7?4NJMK7%TEY#IKF!LMHDB1JZ":6*,*D9AV5O-"XH*MT;9*.Z*&
MMK&TK0:RPMS2:6W<RX+E^,^H(SM_?#$17(T[HD%@G2/^SX7M<$J],M[037C6
M)M#H[?1UU/\`8V_'`,SAPEVMN;]=<FW1UPALD5J<=!=-21@DOQ-<>WX)D']?
M:QP8^M*</E>ISC"QBVS+VFN!(`80JYN>@E.NXQF+JHY1A3Z^2,.,B`1&OM0B
M(HIOP_1\4JA@D1<^S4]6,M'L5V^2@KSGVV3O/\8MJZW?4#7KJVC?FQ-%$%?0
MP6(J@Q2$A6B3.^9L0S9DFB"9/M[T2@VW;:WNGR?]2^2?9"DR'4<R=9/_`&7I
M/.NQ3V.9Q79<F17"#T=>"_+]#IK&Y*"<=:LOH"AC2'1Q&R3RA#H8_+RK*700
M]3H!.?S3&WAEJW'Z?0=1M06-_P`O@#BJ+$L>LHI:P2T=:052F2O6O*_(D>V*
M2%C0MQ]+>FF\9M.Q?84G1OXKR#E_+=]S'G%?A29[_0]`^Q'7ZBZQF0M;L5$@
M_`UHU"'?7CM!*>!-E/:T:.%HSX$F"G@`7)]9%8"VE9U(2X_'-U-7^;HH=)(L
MB9:2TD"OE6BS$&3*HP#+(4@UITA\IE>04L4T:-B<#OQE#<WMOR(&CS.WUG1=
MA57LF7S.=LR[>PW]K9Z)];*W]UNJ8R3VPW-*7+"YL+CV$2.<^.(?UD\!RY8Q
MV?Z2?6'9Z-NEBX1]>1'0Q6M!:GEZ$F[L*R:NC=7CJZP($U0T$C"7QM@>4BI$
MD:.5/`:(=?C++EDEKJ,[>:6RT5Q:09<Z,<&6B-SN6!/*FT!)91#+O]XKCS:]
M8I6!RTU>.OP2F^DZ)&%G]IU/1=)^HW&=7G;>0BOX'I3^1=,Y3UBV@M<7:<HZ
MYJM+KN'=1IT.J87:#/C16NBSE=;S&TC<<DM:C8&_E#0RA6EE%@M)21C9?I?/
M^0V`L57I=#3["HUM@3DK0BNKKFKBJ;>J85_EL=517@[;>8F.`:4H@89Z.F]Z
MM!;XD')?]CY7S'CN@&$Q%ALJ_6]J[P54U^.O!>3<VJS;+HEG5TE@%=S0U])C
ML?9?O`L#93-&%;QL,D:PN$50GOHO;,C]A^K="ZGJAM[H3.L]=M9,]:P.HPXZ
M2C+*>G/!*S*3@W=YEOQ<RA0\`Z$AUU;'FXZ^26-CV0J&R[^(X?20_:?A(ED%
M;5O[#]ISLS\]L-2$PV<U5]>OL(CFJ3/!.4-83TD,L\88Q\[JUS28E=(B*C0]
MRG@'@'@'@'@'@'@'@'@'@'@'@'@'@:NNA_R(6F'W6IP+^<T`Q,&UM,5C-5?:
M\NOR=@;2$=)KM)/J38J*9<W'CI,E66A_JY['TAQ,T;T<$]K@0M=_(1N\S7F-
M"S'&-;=CWEOS0:OQW0K[1G6V]IL`;OINA4^=!SR7=QP^:(%:[\H3YS8[%WQ>
MK_8[P$FG_D'[=:V)@$W$J"E`!MZ7GVCVF@DV6?PG,MO;;5</!HNBW]Y6U@H&
M?)LV.]<]&YNDKGK&PWX62?,T$ZP_DZV51`583<6CMPB,E:19-M"[7'`;;J@F
M;PEG1Y/$Z@;/F";-FSM]A(@0=>')9Q5$+;!\;XW.8T',7]ZNNC7U$Y*SCY6-
MV?1GYS)V-4'KS+=*!G,.7=.9!H1[W1Y$.MT,T/4H*][XGS,@)$<Y1Y/E2.('
M5S_[X:.UYW%M]I5\M@`$WG/*73Z[.Z6QBP&2H>DY/1W@U7?6]LZ2('=8J\JP
MJRVA<1\'R60[T2%TJ0M"+`/Y)>CDU@XVGPO.^4VEG?[5:'7[X[2_].KC'9FS
MTU)7'1D1R55@+HC]7E9:*8&21)8RR@RX63C$M:@)-9_(EWS59_47F6YGEI;C
M+[#I8%UA(\[9W-YEZ3FTAKI0M)/!T>NLA#[(,-WY!DU6$X65$_'!-C7WH%I>
MC_8SNO/]_H_VO!T_4,)#79`S.97"52C[Z5-=S;J6OEL#]%K]SF<>34YFUYA_
MSUC;`20%8?\`+B4B.**8&QRK[J7VKQ/4MUK)L'7P\ZWN'S=Y2BQ_B)CZ+0=1
MCQ=S<Z`J/87EXQM?F_<?[K"KIO8]/=[)(/5S0BK>_P`B_4:'3[=,KQE;W`U&
M\6'"ZA]%M)8N@<DS50W2=`W=`:&.ZMMU"I.<[Q:]XCGP$31TT?HZ0IS)`<&4
M^ZW9;6D^PY-AG<P5I.:\RS6YH**@S-[8BT(]]%2RK:Z\F"^EN$)KJ>[6T+HY
MP*\R4,)\E?.;!(LD02I]?^U]]Z_O;*M<^KL^79ZB.`"Z[0X$.MRG1;-Y>PKZ
M7<`0W_2!M()4'OJ17Q"U5?;@321S?^OCAEBD0*UZ;[@?=/"<KO;>?F]3OKP;
M)#:6;;U6$L<M2Y(TVK[(L.<-Q)6GN]!>%RV?/Z]6&0.009AJ?E_$CV+X$QVG
MV/[Q+1?4>*IGJA2NW'6=3M;>+*C[2SKC)M*#2`%54.:-9@[("FKC9BCFC6K2
MX(AT+2`@6$N-H1G%W3[PSQC9%JVTBD<YK27=E'^O@PP(O9(#!];>X>;'%;8H
MI:8CFMU#$*4HL<,5H!,UQ4LK_P`9`?F$[M]CKC`_8U=1?*'H>=]X%YP-J:S`
M?G&8SFHW0#<O>]'%P#,U!)8SP90/]V9#(7>Q(UWY"^HZ?`X,;F7;ON=I\E]B
M-EILG:5M/AN6V\_(3B.=%4-KM-*)1PV%%J/^E!M67M2#=$#%^X.`99*P:<G\
M!14EC]RA%D7V1^Y<6JN+!!M*=SO-8,/2Y*T+Y+>UE]UBN<;>*;<3<W#Y?;WC
M[YU<*K6!P7-'+"\:"9`)XS4C:$C;W[#?=:XO=E:\:Y+J2\!;:ZN"Y#8W7.8Q
MG6&2J*DB7875_669PVOI)2+O$60U>RW!JY24O@'0QR,]DB@A#]A_D-UX5L!4
M\NO\W86%3E#,78Z&@H\B!)?93!:&TZQ1Z&QCI^C&T<=GN#P`*J0NH@AL?VM\
M84SHRE+8%K/J'N.R;6#I$O:(-S7W]?J)X`JK5\_M\-55U?)9W7X@V9>;C:6L
MO`(JZ(=/R`KB_:Y/:Z2:-[O:H7-3_P!O@'@'@'@'@'@'@'@'@'@'@'@)9%+3
ME2D3E5-83.2@OY,I``LTI"`ND>%\[Y(G/F_#=(Y8O<J_&KE]OIZKX&<@\".1
MS884<U6N:Y(F>K7-3V-5%1/5%:W]$_W)^G@?&CCM8L38(6QN:YJL;$Q&*UZ>
MCFJQ$]OM>GZ>GIZ*G@?&"C1O;)&,.R2.%H['LBC8]@[/_+@:YK?5L+/7]&I^
MB?[O`[E_T_HOZ^J>J?T5$]/5$_KZ_P!?`/1$7W>B(O\`3U_3^GJJ^GK_`%_[
M?`^HB)Z^B)ZJOJY41$55]$3U=Z?U7VHG_AX!ZI_O3P/O@'@'@'@'@'@'@)-J
MZ[:M8E+#5RM?;"MN76<Q4:P4?QSN-EKF"PR_DVBR-C9$R18XD1[G.<OM1C@\
M6/\`('T;@-]]EOMOSGL9'5.1]*XY]ULOM>5_8+`8*#I.==4=4Y)]?LQ+A-IG
M*'4YW<U%8ZS%24ZP#&)"2O3_`-0LA#H(Y`T43?6FBY;T:OS&LCH^Q<+U%AMZ
M_$=KX[=S!\IZ3LKLB.ZY5DMM9/$D7A^IF.JQ80@[:GJR([Z6'\J,F.65/`GK
MM?-K5?K)]<OL+;Y"TGGS>ED^NW2.NMR3:_IW[_R*IJK#A>.^Q^:E<*8/GL7C
M*PS.6RUM?&3;ATE?;@LD?/8!^!0%0L[%I`*&VKI]'N![8&EYU@\IKJ(G0]8U
MMY:U!-9&A^3*CL`N>-UNNO;@V69@4YM;;_A1"P&+\X86#^W5=A\5T[1<9/R%
MK;U_`:N'Z^TG-N/6@HF=Y-OWD&6<\*/%GV=[N>U=$[9H[#06U12^X&FJHWBN
MG+96$21AT\XQW'OW6FQOV<N-R]NEVN===\<X=E.?WU[+7AUA;8<[T#J.IT59
M@^;Y.6XFNI[`J,C1V5/$C2IX(7R.C>$=]EZ)5]7V'_4+#\M;Q"BMJ?[IU.8Y
M]2[!^N!S4M-];<;4T[(=_9C5)%GH[6<%I39EC&8XF=41&LCC:T-A]1]@>2][
MUMQS'["_7+.[UVJYQ:8NN[UQ4[5X;[-0T=H25HVWY^<T5]I^6=(TVJD%#F>'
M.+326$U6./(;[620QA3;2\JK-`W-]#^H]W<?8/$20XB[Z#R#1YW,<L^U60`H
MQ*P"WR3N2P6!!V]9)BH@()3<W=W4,)KV#.%&E1/0+5\\X#-MOK?]K*`;*7%J
M'C:C-_8NCJ6-LB[&TP5B0-E>A1_7^ZN8B='0&6..OH+*^&4DH_)75!!(^9T;
M3*\0*0Q9_)Q_EVI%M#?5;'VQ-R*HM#6ZHM[HXS<_ES#JRI?<U9#,%'7UTL]C
M/'5_@5PY,$I(92#H&P+M_(-=E<']1<#T[EH-+4Z7F<WVFON-\PR0]@`0?UI[
M:8.S[('`RIW>WNO\`*!RE$))9/M[BV_+E,GDDLH8_`JAD:7$Y"*\/[#EM]3%
M2-O\?F?K3S6]IY^_6Y]T2V]J:+=ZS15EYD^3'5U<#^#7N(;;VI-K(CB:E\:H
M5(%O+3O\M+H==S3C/$^/?7?C\G,Z'`#38G##[SM.ZRU#.)GI3]IWFSIJ/?Z0
M4*^(')<HC:@499E^(6.&&61H4VX`=F<KTS+Z#5Y9-96X?#_50.XS,=[!EF:B
M@%VETCJ6FV?Q3I1RCSU3Y89Q6.F$DD9(KV-:QR!(G6.2<%Z3OK3*_5#9:_!:
MRCN(-;4\!^TMOE\[46V>TV)$NBHN$_9-D]K@]%EJLZUKI@&Z.+/'Z-8Y?9,]
M9)H?`FSZ?XTZ/O?%X-CQJPY[7].@)^O'5:+IK'LP^FGUT5/$?0=]HKT.TSU>
M];6OJ=ISO3#D,!*DB`9!"6YQTH@:]MUB-#S;?Z_"ZFOHL!L<EK],)K\;T&S(
MJJ\314VCMZ>VO\4@F?U5M48;:EF0VH]+&]]I7/";7P1O%(%)\"['&>>W]9],
MNR])I,3:"8[?=<P'"X-6%GZ"I[9UK>:T5.A=*S'-Y)A2(Z47=3SUP-NT<V86
MGS=62/.R>W-<V(.&0P-(/N[.QO:-O).54EI3V`TY5W97>GWE=C*<6'6Z'C60
MVEA)-8TFSNH)P@[B[*%HTFADL&%1-(&1H;H_X^.UY0#M'T@XMAN.ORF8VWV1
MO^OW6NZ/K9MWUJ\U)7`.\T-%H!SJO*9/$Y;)V.?B?%7UM</.U@<S?<7++[UD
M#V'>`>`>`>`>`>`>`>`>`>`>`>`>`>`A%9?-'1EPFYVB,A/<4XZ$JHKR(C'&
MCF"&.*9*.]A"EBV)$<JO1RR1SR-=ZH]R*&*)B<:`6*>#DLR$>#109<(T2AJA
MBQ,R+(DPN=%(A%9*/1#RM1S!&*@[')ZHQ%\#-(S6=+"LZPJ@I2:V[?.^YKR*
ML&8&W>3(Z4EUF))`Z`]Q$KW.>LK7J]RJJ^JKX&1%34\#!(X:JMAC`?#(#'$`
M+&P)XXS0X'B-9$UHSX!&)$Q6>BMC3VIZ-_3P,<K-YXYD,1M#2F1#$(6-&75`
MD,'+:R-C28&2P.;$0UD+$1[?1R(U$]?T3T#DF>H&UY-2VDIVU1DKYRJQM8$E
M>3/)(V:28@)(?QIY7RL:]7.:JJY$5?U1/`R"JJK-A:.96UY8[96SM@)#'GA;
M.UZ2-F;'+&^-)6R(CD=Z>J.3U_KX!'5UD$Q1$-<#$0<Y7FS1!CLF,>K?8KRI
M61>\ARL7T57JOZ?IX&6D42>B?'&GHC6I_8W]$:CFM:GZ?HC6O5$3_1%]/]?`
MP91*@.,XF8:M%A(8LED1+`-!%.QJ*U7GRN:ULC&M7]5D5?T\#.;%%&C&QQ1L
M;&Q(XVL8UJ1QHGHC&(B)[6(GZ(B?IX`V&)KWR-C8V27V)+(C&HZ5(T5K/D<B
M(Y_L:OHGK_1/Z?IX'-$]$1$1$1/Z(C?T1/\`<GHOHB?[O`/U_P#C?[?IZ_ZK
MX'W_`&_^K_X>!]_\?`^?^/@??]O]OZ^!\\#[X'ST_P!O_J_[_`%3U\#[X!X!
MX!X!X!X!X!X!X&)8&,K@#;"2$HB,$0DR2`(>0LV=@T+YG0B"PHLI)4C6>V.-
MJ*Y[U1$_5?`H7E_LEV<WE_(>DW51R\EO=C=W=YBHHET2QX[&UG#.E=3R%7>6
M<MD6NEUCK7&""VLH\(<#&3D-BA1\;7*"=A^U_9?>]8N<81=<1PM3K.&U6[XT
M*=DMI>6=Q<VN!R)EE=SW3-575=G+@>B7!,-WF%@"/90&51D13EGF5@0)G?M?
M]N[;G7T^T<3\II=;V#'6/2]W08?Z[=,TPU\#_D>1K0<,`73;BR'Y`,*!>SNF
MTU[,2#[HT58F^QS7!L%^U75[OA_!MWU+/QAR6>47,2QH=4V5_`T2TV6>H[25
ME'3306]N7%5V<SAQAE=/,0C&L8]RHQP5OZ#]CNT6^WXYN^&"5%S]8;K:Y;G/
M2+RZS,55JJG<F=Z!Y!K\]>4FVU.)W&9EI89I8QVB45F2MG$K9HVQ>BN"+)ON
MMTKG]WLY^IGDLJ:3[-TV06EI^'V]P6SB5T+V0FCM.?&\]W'0;;I9M['@PYI[
M*6OJUK1F$R2A(WT<P%NY^X>XT77=78<,TL71>3T''S=U=9^TY[09P#.2%<,L
M.JXHZGVUKT.MVVKOM18D5$4E4W--$%%.F60J-XKT4+5?3OL>B[]P[/\`6M5;
MX8JYUYAIQ.6PBV<D'+E;$)"[E^I*NX@+DOH&2FC>R[<0!6JRPEDBC&9!'$^0
M*R=Y^UFHX_JOM3@8^T8V?6UO'0.J\=`(Q=63-RP,(MU#MG:AH=\V+2BT*V(%
MI&ZU6M1R2+'ZR1H[T"T?U.Z#INA<SNYM;MZ/I=UCNJ=4YR_H6?"IJP+8@8C:
MVM-4W4U9G9R*.OL9:R*&,F,5WP_-&YR-9[O8T(KX7V;::S[(]%P-WUW'[:J'
MJ^I6K>;U-1G`=)R5V([=9\\S8-L346!-X3#H,V,TA[[6*)\T[??![6>K$"^'
M@'@'@'@'@'@'@>#G^1Q[*_\`D!^Z))43[JJUO2I\QJJ2Q$1P,F3@X3R:ON:,
MX".NB@M`B(+@>R:]2"7OAE8QP\KFJSP-6&<TNMX+M^ST0^VFRM_;9VKRUQL>
M>Y+/Z1U7DG1$KD>D:;DE9G2*0[E5A3Z!8-*EZ]C9!9R)*Z=Y44"1!;0K[A=9
M[61LPOLZI.!WP?%KOFNPHN$4HU/0_9,KG4%9I^&6Y/-[?7$T=GNL?H2C:8/2
MB6,$MU16+6QCSSQCP,"@_P!?='R7F_4[+K&5ZW.+I,WAK3?\]T7'N?YO4[#D
MMSFRQ",>=OACK$2NR'11-%6JLPEP.^VD+JK!\=5.W\9TH65N/M?T>QLH*.GS
MV)^ON"QH5ICXCLI!H6]R^RO6S`*2GT71OL/WK/Y&ZZU9)>`(/):W`2)&?:,6
MJ<+)7PE.&"OO-H?QL[?;\<_/DF60FAQE5958N4JZVUQX$`5W<7M;J\1.ZENH
M=#K?Q)'0QOF(D(J_QT&'(5WH#=U,3*BV%H3K4PVWTE+]Q-''>VTD;"1P[7ZE
M9N`6L#2%SO;:1%2M@B)5S"(4A265C)%:G@.:HBAI<W!HSM':DVV3T$69KSFU
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M%1!$-!&>0JNE"L%4/9:6ZV&ST!-5GCL0W]M`-$J=&E!2;?=FUCJ2L-HM@1=2
MXEV,I:9RQV`5Y/`I\$<LLXQ$$'@.C"?#D)FEB@I05_0M9:W!H)1C["=*&G)+
MGKJO1-L:2U9:166OFE-BE%!)@@AG@:Y&3QR3Q@G\Y(FLNJ&505*<Z[*Y+];J
MRJE>#!,,/`N^/JR*<"@KI_VF`:3VM@E=Z1PR0JY\T\L+/5H)6VQ=/=45;J;J
MA?9.PE[E,28;7#:0%A&;M1YDSIECF.<9.\V9=+06];#`'5U[)1_B*^-9D&^5
M8@M!FOM[]A\+D^TU@-Q/T/CW4:&KY;]D/KMU&>HW&6,;MC-,_676".M=)J+_
M`)U8:B`0\P&CH;U@N<N`U)G&'B(@]H5M[5MN+O+RM\?N^A8J'48#-YN^Z%J&
MVVZVG=-QAQA:>[R>-U5`&3I*?K-SFBZ20,<\40.V8;"1$>2."SP+8Y/O'1>1
MQ5]?]<H=+R#:YWEEKR^Z-UM@+O0OKH)K+6MW_;:WAN%1=/D*JQUA4PT&AT#2
M['1/:`.HYC")"F,"-JRQLNC]=RM&^WU(]:EM8%BVMAK-HG09:0"K2WZCI[*]
M?H=UC=H_7Z`$USOSBJNQKZF+X!!R8X&E.#97_'Y6PZ/[D?3OH,T,,$N/^Q>:
MH81J-@M7F`2M;QSN59$&!"PB>8\:KHFQ#P#S?^H@9(CF+\,7L8'NF\`\`\`\
M`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\"/>M2[2#EO2)N<-5_08<+K),0QL0
M\TC]8RB/=0-@A,]0YB76B1)&V;_DN?Z(_P#M]W@:<H]-070'.QXMC]W3_K9/
M<9B'[9:;16W>PK('H1',=/#6T5=H!$$[3G:<O;LA3="T,@=!6V:5,,*#1$G1
MR`P]'HOMTW,=.&Q=_P#:D>AZ9R6'F/,+^Q#V2Z+GF5H==V_H>(ZV1^=2D6M!
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M8CVDLED\!\Q<EQTEA"%3<,^Q9/\`'4R\%MM)QD_+]Q,V5OV<G+G3PZ<7G-J;
M/V2RYQ77TD++2!T*U[M<D5FD;V#D&-"0N%\Y[F#W/#:W=XGL!7!P]#S86GYG
MN='<;/IW,.DS\(SU=F^J]2VD%P?7],H\R-#)0G"1?(E%=6"V94ADD;B!0W/>
M`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>!5$SZ-_4BQS.UQ9G!L)+E.A]&?UO
M89U!#(JFVZ--`6+/JFA0FQPUIQ0M@3%,P1(()HB9F/8YLTB.!S3?4KZTS[?1
M](DXGS]=SK<43SG0Z9M%!'966(,SU/D3,Y(^-61P5Y>6SX%=*D36/D"#AA<Y
M8XF-0'!QKZZ<+^O&8KL9P_E>+Y?E:B:]GJ:+(4HU77U;M,:-8WT==#&B_@BV
MAH4,DL,2LB5T351J>U/0)`VN)R'1\I?X7?9JDV6,U5:13Z3+:2M%MZ*\JRFH
MT@&SK38IA2QI41/5KVJGJB*GZHB^`@97C_*\/BJ'F^0YWC<Y@<M9B7><QU3G
M:L3.TMT!H?\`+@[FNJHAD$&MQM6G[FPEK?G:?_ZA'?+_`'>`VT^MOU[2IU="
MG#^3I2;NT9=[2I3G^62NU=S%"6/%::$-*OX+8^(>P(C;+.U[T9/(U%]'N]0R
MPOKWP>MT\&VKN,<L!V`N5$PH^H#P67&OX,57U;Z,')16T-8PUF<#I9'"1!(_
M\>,95B:Q&?V^!)E71TM(AJ4U165/[D:EC8_MH`H/[A8($'6H>;^+%%^48E?7
M#P?*_P!S_A@C9Z^UC40&L_E7,);G0Z*7G.$ET&NKR*C5WLF1H)+C35)<4$!5
M7H+)]>XRXK2818V20$/DB>V-J*U41/`<U'0468JQ:3-4M3G:4%)&A4]%7!U-
M6(V61\TC1:\"$<0=))I'/=[&)ZN<JK^JKX&#68S'TMY=Z>FRF:J=+I?A71Z&
MLHJL"\OU'3T'6[MA!83[58$_X/GDD]O^GIX#E\`\`\`\`\`\#XO]%_V_\/\`
MQ\#P6_R:76I__N'_`&LSF3.#L6#=N$LMG3W:B5PPK+3Z\<#0&,2Z/C&KX@Y\
MV(V>1CRGE2R0^R..-GM?X&JC:ZP'=[3<;)YRV7/H;X,\0UL9EQ8,@HZZ:@Q>
M?J>0[.N,-SO6NBVE<P4>[RP@Q<9$D!#;B1D<S6!,M/S#?9*PL];VBY&^LUZ?
MP^P[IA\7TOGYNJZ*/E(!::/#;'3X49[;+/BKMH65(MGJK48>Z%HCC1XR?9.U
M`J=];>;\UFB[//7Z";"84[*774=,9LK*YV6CZ%T+FLD9XW5<SM,SE1Y</_U.
M"MKX(^N4.RH7RL'@1('.82@*FSY9]I.:%0#_`&6XQ>XH#=7V<Z']<N@:#/5V
MSX7W$2RI*JP=G.8=1HKF/GK=Y;Y8C\W*+*0,.03/(-.Y2'PJ@,G,Z\JYR$]?
M2+>3UF5T1K:JP-$I])"5E=FZO:!I[6PC@S$H-K2:%7LL)XB93X8522(HE@[O
M>"KT37,MM#EEI,Q#6LOJ+[3T9)4T%87.<74?67%Q/=)<VP.841MW8FS$2H/!
M6N-;$DA3W.:U'!(U;&V633,>/!6R:'0@%U,8UE)J911LXR8'.V0="&#*T(Z<
MRY<KG/AT-D+/7S(CHU<V=`RM,;=Z6\Q>=SUG5_#DZ[5Y:7]ZGMA[3-V)U[+8
M=$V^$MHH[_$:^IMF32A.JKVN)B;81ODC-9/.U$"5L;P'H)=IA^@]EQ6RY%]6
M;SH)6#Q9%J!<V':>C28$6ZTFSW.4XQG5SUU64H61#DL+6S.6HHLW&Y@TI\;&
MR"2!!//:;CVL[UG]187I^(L]CM;;.]-[%;*W2['H_,[*S!J;G)D8BKMZ?F+N
M8CT@8@U$#6!5!@!=2(6PU[Y_[`D*]^F/>QP[GL];C-EU7Z?:?=V7+]OT7G^<
MK[K><#V_/[0NNTS>D_7ZT5_2+^G!HA(;:RH;"D)CN\W83$*A#?B(0(FR.FNT
ML>H\=V7[H1H")\U35U.!>6OX_P#FF1@)N*JMSEW6NI,ACJCJ6'5MD#GJUM=3
M*DT#5'=*@S)`Q,W'>K)5R0EG1V>4%NJ_2#%G34^@!KM]:)=U3Z"OMSGBDSUM
MJR>8DLIE&IJ6$<,GXTORSN![X&PDS_566U(!^91"<NX[:R!UP!6;NI"F=ICK
MI)2+BL+?1H8PB9ILXW[M(R>)C(5>Z!S)%!1U9A@68EP;(:V^_?(AK2N')!U5
MK$30<^-@C`J=B%DF9O88G3[.V:&X`FM'7\8\$GT%+:^5S0<XGU^^PNXRNI)R
MN2T^?Q7/PH^C?8#N^J."RW-LS4YB$W0)D:+46N;SC]B/30MD+$AIQSKJ[L&H
M*H<SQE9X##^S^-Y-_G'/,-HH>EVM5E^=T]S(;K(+[D=G]<N@Z5HFAO.@Y'F-
M#(5T&QZK8VX->C%OHSUKJRLD_)#&85!%&%SQ>`]"[FW,R_6B0;HO0.><FY[]
MANDX>\L&\DM-A0.0ZIZ%L.>W9,BY[H`59;+'-<QC$))`)=5Y#0@)?@24(BU.
M=M.&])Q]C>4NEK\6?6W5P>+K,)M:C2COL%/H]7E7<EH,ED<>)9US)/SI=?>P
M75A8@%H7`3+&4CE#85_'\%)CONI]4,P-^Z:.FUGV.YQ;5FD$DKR:0Z.HY9UV
MS;<RW8-@0VXB)$D1@'I)8QM%8J1$01._%8'N_BC?&\ASIY)FRR))%&](D:,Q
M(8X_AB5C&O<QSXU?ZO5SO<]?U]/1$#O\`\`\`\`\`\`\`\`\`\`\`\`\#&&G
M?.V99!2!%B(G@:A/X_K.R%ZL87%^//.GXY")[F>_V2>W_B8U?T\#)\`\`\`\
M`\`\`\`\`\`\`\`]?_J^`>!\3V^KO3T]?5%=Z>GKZ^B(BN_U]?1/_C>!]\`\
M`\`\`\`\`\`\`\`\`\`\`\`\#B]OO1$]7)Z.:[^URM7U8Y'>BJU47VJJ>BI_
MJGJG@<O`/`ZHXHXG2NC8UCIY/EF5/ZOE^../WN_5?[OCC:G_`')X';X!X!X!
MX!Z_[?\`=_7P#P#P#P#P#P#P#P#P#P#P#P#_`+O`\-G\DGUW$U?W,^_W4^F=
MSR7#^;[SM_,^(C5$66T/2.L]7C%^O7U^N]GF,QSX>:@RE3F+/&D2"V>DM;B`
M0(:=WK&K_3W!J%P_5J7D_3-5E>`RW^!YK-26XTFYZA/$O7^[YNNK(Q0:GI;6
M6-9'FZJTL7RW\@N>$1+,`!U6RP/G.9#(%I?LM]@MOM?I#S:EZ!;=%M:[NG3+
M#MNAZ<V-Y73NR8'#5I>.Y%C\_@C`G-(S=WIXK9<9G#@0Z\$0>306;HBSHP/`
MU.<^M&<TVF"M\/22<IU//K'+3\Z;==(M[7.:V^DU]$329:PL=".?F*(O3ESG
M$0DN)AJ7J'(.>(+\<)0X;$?M/VG5V/9>@9/C^T@Y1RRI#%[%9_7$F>S(XSG(
M-"78Z#393E^4NP8*%>9=@L(8Z>TYZL?MH+RBEG@$]\(]A*%8N(G\+Z!8%W&P
M35?3S896YEQ,A_+,6[J_UYV%5L9"#2&Q\HOM'67?/JRTM+(R+4%9^ZM`8P:^
M%E:*KX?1H,GJ?.M/S3I%YD-+L\KT^^H1?LR3%TOC9MWKJ8RUB^HV7]YV-O+Z
MNHM'57]@-)$A`\H0)0MJ/^.L,<D;44+GU/U[6IOG;3IGV#Y7]?\`&Y\6SML.
M++:R;/[#V]"H#L]5R<RX;D+V'7HM,7/^<61J3J&M=9SPD%E(+(YD85ZJ-GAN
M;;2LK^-[#HU():.;9:/[!["*JMN^2:S8Q#UUO<8ZAP]?9Y+D.<@HYFBRP5(Q
M-E)/:3QMMG1-?X%H^/=OVE']<?N1TR#H@E7#T&DR/U;K>DRVMBRCRG-[+6A[
M3IU1P6F,L:31ZN&EPH4-:<>P%#+VRMAH7QCLA-**"E.;I<G1:D1EERMV<HX+
MPZ8S8WC;"SVE.%6Q::TLK>[$KCU@=<`UP,=D=3,JF0%AZJBA$G@6%A,X;*_L
M+V_2=)Y?]6&[3;7E'8'<J%Y#N-[@MK?T^=TCLD;(3A];U.V6<VYQW8<EB81M
M/D+Z5C2Y2Z^SK;&4>>LCFE#7=D.NY_JEO:XW[456JZ&;GH[.SYO]F.,RU?(>
MX:!_/S`*^76[?02UUWG-1)I\VLI-*3H\U'9#()&^,V.!\7H%C&\#PLN^7<<9
M^U>?Z16=#H]5MPN#[_,;/F_<<S#J%')=GF"PLM<-U(LBR^6-;-FD$FF*JW31
M!M:C7H$4\;Q5EU;J&/QP.JJ\P?TCG7UUS<%G%:WU-G\O9'?:T6*&X/2KK=`0
M1564@4#396ND(D8,]D;/1LJH#M[C1\.Y.7MC^5:ZW[=L2]8%BA]OM<8'G/K3
MFA<^`U8:[G7*YM!8].Z/G(#\]#'1':*X8+'66!94]-.B-1@.[ZO6EMMOM'P:
M\WG4;;O+>9!N^R:4'0].3FN<9N?`YX/4:FTZW<;<7(Y#XLZ?)44&/RT:1!A?
M..PN6`6<H4L*]Z_6W&CZ!UWK&I_;.IZ+;[+3]!VNL)M=&?E+35/O+HZRR60L
M$TD;][FJ&=\&7(L8&2ON[.['G''8,P1LP;`>/]O;DOJE]@.2%_Y;29#E>MYY
MW>I,DN!-#VO!:W.S_P#T>CXBBCMZNHU^$Q<`E6=9#M''%O<>$64CPBP(W*$1
M_P#6\H34461NR,-W_BUR0*5+D-F20G_3.A*BL*G8U7-^ADF#=/S%<#I-4I00
MH\5U4"A*H/[;\,$B,#:!]+<+P2'L?T7U/(>H]#I[/._<K.9>YXGVR:GTVOLZ
MV?(]<NP[?G&QS$6:I3.<92RULXH==)5MFK1H?=[(U7]`]M2?T_V_^7X&*=+)
M`$9/"C5FA%(EB1R>K5DCB>]B.1%15:KD3U\#3/']XNVQ6[H#KZ@<,DDK81P\
M=2,81+*^6-!7GEZI)890E8JM8@[WS>C4]5]WZAUP?=;OD4$+S-1C&I+*]A$,
M=!G;&Z`B6%LL13Q`[X,&2%\KUC^/WI.BQO\`5C?1%4'%1?<#LUM915\._P`I
M"4;,=*!%ILYDJ"-M2'`^>0LL0+1W%O*:/&-+,^$=LC7C(GQN=-ZQ("-<_=?N
M<2&S"Z/,"NB(:'$,_-Y>&M^6,H<1)UN+C6`E(RR8]98F.#1\:O:UZ)[7^!R/
M^ZO<HUD@#U&7C<%7!2V,A&1HS2VGO&BD/$%$'TX,;Y0R7_#ZO<R.5RH]O_*<
MCD#($^ZO;Y*VQ>^ZSL4@EHR*OL["ARZM/A2*624`RJ!T;)ZPA(Y1YD>CY?[%
M<B>Y?;ZACN^['9&P32NV-`\N%$5@K<OBZJO-264D6-XLUMLGVKF-F9&J*L"*
MY7K^GZ(U0^0?=CM_HTPK29V&(=&2FU\>6R;H4C6)5A]]\5LP!6LGDC<DKVQ_
M\E?1&I)Z^O@8Y7W;[[)$/^VWN/3T%EGLYR,QGB6UBQR2,<LLT6U$#FACB^-Z
MJU4E59%3XT1/`Z*[[Q=]CC-0RZQ%H8BCM@'BJ\N`V%BM<TF=!XM8<2]4G7VL
M21[&/:WU1R.]S4#Y9?>;MX94T,VER`KIDD(`@DILG4M49%09&_)>ZEI)$T9S
M7M5WPQHOL_1KFJCO`R!ON[W4VU'$(T.4J@)I(!G'@93.7<<,ONEC(D*))VM2
M(.L;HT25%]49(Y$1%]'(@9\GW/[<'(1&NFI#2(W2LC67/X..N]89B%ED>ZOV
M!1;F-"BCD9ZK&LCG/;_;[6^X$Y?NE]@98H"VZ3.P"E&+!#(5E<A41?\`FO:P
M=C3=A86$L[VL]&K^.BR._HU$_7P,F+[M]X((!:RQI((D.;`5$_)YTEY#I3U9
M`*XU->&,%'*.J-25C2'-]JO<UJ^K4!9?]Q>U-(LUL]-24S66<[8@JZFQ-_)7
M!K!&:)!+,+>SQNE+'E5D7OD5WR(Q9/:Q[G-!'%^Y?>;8-SP]13UQOXD[A(K3
M(8(`8TN,F5R)+,9T!'LB8)Z-7V,]?<UBKZ(YZM!(@^ZW=IRYF";[*&APV#H?
MRH\WC+"*4<>.5[F(ZLOF_CD'/:C(E>O]51416^YR!B&?=OOHQ"M,Z+C@A$F>
MOY4&$Q_PR0+ZNB=#/:]#$^)JHGM:LT;7.?\`HJ(JHG@*0OW6[;-5*L6ZHY[I
M98T8],Y@"Z\<6:`9Q#CQ`M5`2TP52/?"QDGH]B?\WV.5K5#(,^Y_;0H8V.Z/
MB9YIYZDM$*I\!2&#@%ARK*.P1=A:L+?(:J,?[5^<9T3_`'-]JQJ\/LOW.[E,
MS\0+>9>$EDCU,-ER>/)$AACA'G1@Q9>QJ(8C9'/DB>V>-&(]&.8JL57>`@%_
M<G[`PC_DITK+DI^4X.6.$'EX<PSI()GQ/FA32&L=(]1)U:V*656_$OO1&^CG
M@1_=3[`&1J^/?4(4*QRO&5N.P1;9FL]9OGDLYM[".^"8:)SHE:QKW(]&HQ7H
MB*&-']S.Y3PSD-ZKG'3162"PC?C<ZBB)C_"?-(R.2"Q(8I3#&(QL:RM<^.1C
MD;Z>]4!0-^X?>_\`U#(.ABQ,18XXIP<1DC8W.C<QI)$)5AI`VOA6"%R^QT;7
MH^5%1%_X$!5$^RW?"A;.UDW=E&-'\(2'5(?*SFBVH[_C(??5U>MO;#U,GS-0
M3T:V2=R2(Q[E8[V@BO\`M3W]CH4CZK:J^1&/C"9SK-%3SR.5\#@8YYI@XGRN
M?(CD<U'-18T1%57>WP,<?[4=S=%\]YV*QI`V&$@GDNH<*PT`@=[O222J$J[:
M:$=WHL2JY5:LS?:CO5?3P.3/M=W=HRL9TG4%RRA+(+,S(X6%T!'MD1C3?SXA
MV%?*QK9&_CM_O5S6IZ+[FH"^+W[[!:`&(FCZQ=37$H%A8OS;!L/^X!#U)4$)
M[[`(/%618B.@F64='.19D8OM16(Y[02QOL_]AU_"@DW6G)')?`.,?79S'O(G
MF*8'.]I"&4L3V3"L?)$J(*U&RHJ_WM3]0PP_LG]AI6-IUZQ?2W+R_>TLNJRL
M`TL$:/CD^"2GYY:0-%9[V*Y9'HY7HY?<UK51059OL+]D89F"-WVN@&E%:C[<
MB@S$@@9$H:.CDF)*Q@,\2&V$;_Q_E':C8D1'([]7(!)]DOL*X<W\3H-F4P2J
MED+<\$!#!5&$((5%D9S@,#]XD+E47VHY(I70Q.C:B.<[P%BF^Q/?+:,`LOI-
MR"A!B,F8^FSM:"-6QK!*0;"R3&6!US9`^]4F!BDCD=`J2-<B.:[P'J3V;M`6
M9_>A-_MI)I%#97)85=8TC35PU@>48515Y_+JUC[4Y@3PW1M>Y!871RN1RN;[
M@;-[V?NH;9(ANFZZQ(&066WE$M<8)!52G)`L=1$T#D-NAYHCB'LD5KFJYPSG
MHU&.]K09=GWO[$L$>76[/JGL:1)$Y[:H>=HU8^28D4N4NQY$$%*9*SVPO<D"
M,;Z*YGKZ^C0PY/L5]@OQZ]D_0=S'/\[H+95EI1Y/Q1GI_P`\:`7DDKXYY(U]
MSY/<Z-Z*B-:ST5?`^3]R^QX=1'8KT;J;R))VUKX4S+H*YKGR,G#D%MKOEH\9
M!98S9'.3XU]&IZ-]?5'('6!WGNUM.$POL&TJT_(5EPGSC3RC"S$L@AL!AJKE
M"M6.'W>U8%F;(Z1S5]S6._0'H/V;M\&9LY6;7J5L?5J$Z<V*&<5BCW4I0*.#
M(MN<P0%S`.=$OO='[82%2-\2^OJH,^;NW6Q9'"V?7.FCFS4Y3QAB=)3CE,OF
M2*&&/+757,%FD@D,1))T29C(QO>Y'JYGL<#?$[OWF>8Z43JFZF'$BE')(#(T
M=I#,LC9(7.$)M,955L"J^2-(YOC<L3E]_P"B)Z*'8_OO8(&SS&=FZ$XEL[5#
M&?I:$`4A\X\:1LFC_P`;#(&KX)7/?(JN?.K8E5J/3U5`R`.Z]V/'CD;UG3*`
M"%(618Y@RUTTGY1*010PS$FL'J7-AEFB:0Q\DGX?N61$<U51`RBNU=92RF%,
MZCTJN_\`0$FC1F]!H`_9*(,)*Z`V(>Q"(>(H\KYW3PK\CE1C6P>CE5H85-V[
MJX;PI[+J&TNWAF+/(ZNVNF_;BVQN<&L,I!UT"&Z&PEC^>%',>C&JB.8B*O@(
MUGW+L`QC1Y>K[D5TTD$\K;;JU:$4K'33^\D,.FNFM'!>C6HZ-5?[/^%B*J>O
M@*1_=NF++,W)]8V!H)XI,J30[*^ND&F$<6AGXEU>;^N'BC^'TE@5!GJ^+T?[
M$5$:@-63O/4QT+#E[=KYAXU!F+GLNN5=:0V)8W#+)%)6;YIE?%&85')[8I)U
MG:U$>B(OJT',!VCHTM,QW_6'9SV),[9*LFMWN@)"96CN:(8TR2TZW&^8U)WQ
MHCW1NC<U4E1%17HT$XCJNW&=$#-W[<-N"IF20-L.UV/QP!2PRD(ZP@S?3WQK
M8O%A9*T<994:DZ(Y45GM0)8R':>MWE7'$%OKI`/S:=)[U-3.6?'^.\<QM55-
MTG3_`'V;ST5S9226PC*V1S'SN1D37ANCA5SH8G/_`.-T;%?_`,'_`!*U%=_Y
M;GL_K_N54_W*O@=G@'@'@'@'@'_?X'A:_E\VQ>7^[_7Z:.PK*[-YK[&UG4G_
M`+E'54XL^ML_K7]9J,^4BZUJDTA)`-.`+*/+(D0@\BM8J1?\TA`TD9;@\G;N
MR<PXSG>FC_M'3>F#XC-?XAD+]W0*VHTE^4><NSNKW0T&>#/BJ@1;613/WI1"
MZUY$Y2O)9"@9?8R*C>=7V?1]=9Z?@7&J'\+(<LQ!WH'MZ+CWU_MJ[+\I4K/V
MM[8NIZBMSM`ZK*4D<`.P)MI'C23*Y$8$6=&S/&+RKHER,&NXU;RBI09AFFT=
M#9M=IK840+*2:V0&UJ[&2FH7:E+:1*!\CFE$0O)?(V.2/P'?2\UL]MPC?6_0
M:2_R6\^EIH?:,G9XVML=#2[_`(5VGHA&>W05U:VMP+7V8V*UES178TE*<3/2
M5FE-D*;"]A#6A`H,`;L=?$Y>V@N;;=[+&6X=6@\]6]U=A8K(T!8+&RLDLK;6
M6L^B^=`Z\29J!N^(J8M%%:X)FW::&]EYGK@[)*O0LH/LF94V4`15524[8?JW
MCTIO@SKVD,TY(`6>:4I5JP=Y9,DCY&M;,J>!RU!VH@J^A5`@.<FDW>BK!])2
MKK,]H[6X%6WM+("30:&6<VR/&TAE=("V"-\+5DCC$2$GXVS/!GZ>RP;,V9IJ
MW;:#&V/[#`98X&DI*S2ZB'HD.57+Z^2MB'MJYXS[F<KYJC\RM(LU/1X)BH*Q
M6R!,_P!D\43RS0\=X;:2U>$P/UDY5G;S8G:BM:S>[?M_V4KL5U;KE]AR:YU1
M.E76NU\N,_;R8*NJSS\\D9S996I`H,"'6\>AJ:D4;*=>Z%D?Q--9%Z4K>L#V
MKY?S,OC:M^0A=2QYI\LK.:U<!Z3RC2?MM:Q8"6K&ORA93ZY<;.[9K>J?6LRD
M&VF<[5GR^F46UY544ZZK)=\YS@-;U+CJ=!JC[>8"@MKT2QM,>T2"O,;JP[9(
M12U:C(W!4RCDK1(V[>WN+REZ"#C=)&-F8:H!EIF]3T@4;%:BC/?H6$?MF@M,
MYI;0:RJ&#2O.G1\14"R1*YX.S(:786-KS>L=)#$#8T][6#5$8:Q"TV7R[`1*
M1ID=6/:'6ILQ4MB,QK"I%E>C7,B8V)88PE;ENSOI.[9:^^31UO58^$\</*'N
M"J343UIK/MR7,G[W8&##RW1[I[6:;U581&0RR,2%SF)X$0"LYA1(^AN3ME0V
M^#+T0]1*355&O$N)MG8@Z2QSUR&5!21U-U_D=0PQLD4;Z4E6P_EQD/A5'A-N
MIYJWG_U@J<YB.6/UU3]O>A0YK8[_`*O>5S<U2?7SZS759M9?2:TEJ%K,[V7H
M=B4ZM/D*LY;&/("CP23/A9!"$1<ZO.2XR>,2TKKCM>NJ*5P(I%ANK6H"#B2"
MLN*P47/#0R%2NL#L/5$S6%H4KFW4`['LC0IR-"0\_9%9R^Y+O.09J?K^1PFC
MGK=M];MP5'T;?VG.M!&71]KIZRWSX>;$UPNI'W)H8C&(R0:"'VDCF1Q/\"V_
M=.0XCA7;]AR2=-\F)`MJ0O"D2YO&7UYL>=S`!6^!LC[!@M%F+^3_`!B2-?W:
M4=CAK68>46>(H"2.0+A_QZ7EI;?<?Z^OB.FKZG5?;K#:_1-1\K:S:::'G_47
M"R>QY,D=>=2*=,Y60HO[E(J3S(B_\SP/=ZGJJ(JHJ+Z)ZHOIZHOI_1?17)ZI
M_P!Z^!C'*J!%JCTC5!2%2155$8J1/5'JJ*U41J_KZ^J>!YFNB=&W59F-EH,U
MJ6!V^=`O[BI4O+QW&?)BHXSS2%(2+IE);2SS-$9&TAA?K&BKZ1O>UK'!#I7>
MMSFH2LX9H(3[X$OA(R;C)YPE,"`5UO2/#UCK&,OJMV=2($+;0O#B:.1-+,0L
MLWIZ^Q0^XW[`;_12X>]VQ%6%SG3E\WH@;,:@FU%,NRT',AN@%9.[V=-U"!G/
M=P39.D<#4WM</7&T;8C("I2"H4\!W;?N.LIZ[MVOT&DS]`/B-%T;#YRBNW,-
M,O\`2X7!D:(&^_R(3I,ME8Z/0FUCBPZ2`6,23/N_)6=DKOG:#,WO>>P9A,*9
M8Q;*4CHN7VVD#BK.)TVAW5A4XO-8VYKS7<KS/V%L!<CEIEMR&$7++*.:1J,:
MD2*]ZJ#VI^Y:K0F9Z]EZWS\6B_PWAVN/R!>;':;6,[9T!^8/ITMYNA0VNC%R
M],')/5O-&5ZK-[B$8^%L2@Q8_L#TZ;-R:R\MBJ">9==%E8URG/<WF32\SS;L
M^]#M:*U"Z_86EZP$W`A1JI[0"I(9GLD2.1S6L!7-Z/VBGY]6$V^GL?W^P*UF
MHMR@:3EECO*_*4>5I+.O,?SIO<K`7;YBKNR"I;Q]=8.OQPG1_BC*^1)%!Y6_
M0=D=N^&A93HM02+T"6T;<)-74NVJKJM@P%KO&7F8=>;*FMZAEE^V_JPL'\H6
M)WM=ZRH_P*W\_P#L=U'187/;394A='HMG]<Y]=CGS4N=TU;JNOZ+?Y7`<W=5
M8_F6OONCV61K9MFMJ74RBPF$5\$GM5G_`#W,"6L5UW:]%U61*MME?9G+W'(Q
M>A:')%\YQ-;;5FKIML/S?79VSMM;KQ-5FX`-'7DNA@)@=8".18R6L:WWN"QY
MEH^&=)<S8PE#6@T:L!B>/J#8YE6>"9\;H]9",KV.8R217,:QK7,]'2>J^T.]
MRD%#-2YUB,-JV#JR`VVHJEY'R3.8XFNAK](>8T:*)&M]C6HY\CW>UJ?U0%28
M^Q+`6W9>6V?9*2LZV\$N:8UL,4;AGCL+LMPA;HAI?220E6MGE>Z3WL9[&M\!
M(!V#RWM#9:FW1$@Y(T-B\RET,$AJS#L'0FP_ST3\*L*J55\:_$V0::&-ON2.
M61Z`K5NM*AL8BCM3#9#"US;5:RHMJBLJWJ@#0*R&S#K]>0P<MGL])B845DJR
MR(Z1R.<G@-\?2VSC:D0`V7\J1@YJ/6'YQ[=ZLC4J"+YM\QX\$C(OA2!BR?W>
MLD:JDGIX'>/=A6%1+$_?WREEDG32Q":J!1/0>5&!36-97]!+5A%>Z1\:HY$<
M^-5<CD<OM\#BR\TLIJP4&KE$C&%@@_*ECKJZ4V;Y'M)<\BQZL`/^<*.J_)&C
MFIZM]?5SG*U`[+_2R$D4\(F_L$E%C(CN)KO4RFD.*":BDUYPH_2;"98K$H".
M&/V2K%!(2Q'-1OO<P,,?:FD2VHI?0+'/J,Y'M@%6"DCDFB'*A0$:P*ZDA<TA
M+H?:C6-2+W>CY_1OHO@9S+>PA+/2(NUF1@D2BD7QQ=ND<<?Q2H87,)U045C2
M(7MC9[_2-KGQ>B,]SO`4++0Q!?,B:O1WEA,.$6)5SZN*N$J&E(L;97N%Z22X
MEPH4BD0*Q\@SXG*QBJKG(@-V(NV"N/PA;FV@_+=8,"&'>PD=HQ,#HY"`RK#I
MX-E`3%!%[F*2C5AC:Y[/[G*YH*KC"BD*KC=T=?D"E*1-[-LV.`&%!VDP?C4\
M/0B"B4(@>JS?&USHDC1&JUOZO#%FN[&0\<EYL\(T/OGD!FE($`(]R#RRL_+C
MZ76J(QS!X_\`F-]K?1CG>Y?=(JAP_P`PM&!QL@UE@R(DD81K1=:^(*QL6OD=
M.+[*_H5F3(-^WS(^(4=6_C$)[VJB.3T!=<19_@LD@BU,]>-\?YTNGLB(ZNJM
M@9Y"4'%M3MQ2/A<<Q[EA%?(^:=/=[D>K&HP,&OUUE90UU)'H;J9PY,A),-(4
M;#>D".>ULT`Y@%W=$O,01GL9^:^8=OP,]&M5S_>"=,1`BD).MF8Z5QC$_?CS
M2&$5SX(`6#%2FV-*\DF"*572LA9$ON8Y_J]/`7:+0BU==744-OH02(;?VC4^
M7.O(@R!9`@@GQFAUQEL\P4V61_N9',U5G549[?ZH"):9C--%MG'926XL&%!0
M3W-BV\)KOV9R.G4*(2TM0Y!Y;>`9(7+*LDS71R(QR.<U4!-)J![`:4))U=60
M'RGUM5G`B!(`9KILD<KEM*6CL;`F1M2"L;(I2'>UL;72>WU<KP>EAS?&6],#
M<:7(22QP&G_A%W\11)$MM+$'9F6SQH60*##<5M:JN&D:[V6B(R+V?*T=02GX
MK+6N7>1!ESM&V2R%J@KP$(T,\4NHCDGAG"I(J"J+&"CKP6/F0DB2"18)&,7W
M)\:@+SCF94JD0XNG,U`P5EH+_3W=:(7/-8.,/(,*BJ),W/8UT_L>CGQR*Y8W
M>Q416,<B@JZ_#XBRKJK.6.')LIZFO?-5''.D$C!++DK35CM+6;.U5451,B9'
M"^!@T1;2F-:Z?^YT;P1R\9S*R*I(X,G"!&(KHA!0,:/='4->(^"6:P2)_--`
M2;*Z;Y)&/BG@;&L:-1??ZN0&@7R'G?[.':ORM9:J;^["QP6L,D[G0?'*2PE!
MS\A'[(8H"T6!7PR-<6US6-5J>QH='_3C(U*-#FYG04GMDD<5`!ST%;6+W,2&
M>!TD?()VQ_.Z5%5B2(KT=[4=[5]/`6:3'TC#76,.5S:SY\*PJ!Q+Y02"/BN@
MCV:FJCJ;#F<)3::9]L0V3T57R*]4]6K[FJ&954X*S"_AY4=PA0IC(0\UA@1I
M(J^8,FN7V0+Q![RATBBDC=[WNE0='(Q/[O=X"Z'59T#.D5LV`@)'LH@C[XXW
M+5JP164%3")2,2O+YO#^231,]60D3)"CQT_X&.]50.DS_P"=TU%8A$"UJ"I.
MU1*OGM7&+."(5&+7-%UG_1HZS)LW.BEBC8Y6,:L;%;ZM5OH'0<41>1V%M:?M
M9!40KO6#]B@A:2UJ(PR:.$O)CN0D5SEGEE6+W/(>US&^KO[0<^1LR008W`U)
M%J4VR&=)$;SJ"?,?@P+%62DRH+SD*.T>YY4;43WL8KBY55?153P%W&ML*C]Q
MO]`+4%2*QE'\L^;_``;,@>;]VE!HLZ0E2YU0385\C_D^.!/2*15<]6JY$#%L
M+XZ>6TM:&FHJR%]DKQ705<YA51$".HX1#9H<Y"TA&M`=),UWQHYKE<KF.>BJ
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M7VHH/H#HEVXF.*JU%A1Q_A"UDS2SB37_`(-9(RQ>&39@Z0PMS$B7TD5?5SOB
M9`USVHU4#>Y6.5];7O5ZO5X(CE>ON57JZ"-5>JN5SE5WKZ_JJKX&=X!X!X!X
M!X'Q?`\%7\O*W-9][OO;&3.>1D+K=<1*=)JJ%=5BJJXJOKOQ<DU^>@KU83G9
MFB*(ZP2>5/W%S/BCC7WO50UZ?77N4>(PG<^KY>QK\!8OX;TGA_'*T2OH6-(Z
MMUQ0*'\NPL"+88BYTM+RHJYB;+.>Z<-MZZ2:&+T8C@I)N3^<8^40+5U)NDZ-
M5YL,^N!K[8U>9?Y-7J0/!4VU6)*!J]?KZ11&W;2PC:VO=7!SC16QCI&12@A:
M#<T4E>_.]"X5E)R!LYC(8IJ4<W/6QUI#)8V6AH`:V.[V,[=(2.&Z"0LX.80=
M#7^[^V'YFA:[Z;;FOY3]D\5;Z?;,@XWT$GH&/[(1'I:LRSS?%>L8NVQ^ES5A
MGK/3AU-G9ATCJ-!ESY%DS]T%@6>6+\=C/`J_6"0`:K7Y?092E-V>4LBLO-H+
M/,P8X910$CJ*:XOLG6VF9S%Y;Z6JH!2Y6"-@_.B-C('C(0261X/()MO5VF'I
M;EDUEH+"X^X=DC`W2QMT:W7U.H;&J+%@0:LCSAU:A$3?3Y6#-*E>D'O8GR>`
MXY+70A6AMMS*JS9M%NTU63L[!*W$:G.>HQ*BV5'>&0GW49I`ILT$LJ2*-(]X
M,<DL$+I9GS@X/KOTZDINF5=MT#*5U5SSENQH-UU++Y>*MKZ_7T5380SD9JPN
MQJC2WAM=IK2I$+LPS2X8)7Q_"[TG=$UX0/O>CY*'J&RW/0]F7V#H/3NJ;;8$
M9RD..=!8&W6KG)FZ)/;OI`&EVWY6B"E)I!V%V%=`U[&35Z#RJP')F-=;59!.
M9BHL?.)79NXN:W.5O-%I`<]!(V1M8(KH_P`O27MKMK0,AK3CK#Y6^D3'*S\V
M/V@XL18P9K:Y7HF(UIO*=[4:?#:&D+TEXI-70:?*)7W-5I7WC(KG]CAFKH@2
M;(&=_P"8=[96-DDDD2/P)2^X72<YH/M5I-?E:D#5X#LVFGZEDKVXP]=2FA%6
M4/[=U>9)\]'548V:`V\9)$8R$DL8*,OK$@Q4T481-E+BS/U5>67$=49Y]F!6
M61I28XVA2&C'@BC!Q@L+<Q=U-P5-=N?&#5S.A(?#'&R-?E^1@<.4ZRV_=H(P
M4)O+L_B''+M\?YUG+K8P1ONR.11:L+1UOY\QM"+$8/#.P=9YWM'D8^3V.]5"
M1=;MR;';Q219O,MN>A?CU`MMGLK3DWUCL+\BHAR\X8`H<E6'IY[*="GS,`>4
M.R"-L2K[$<X).^X/6LMU7H]1#_U9IS\-RGB_'.&Y?.B5U'+L-.'C,_.'N10<
M4;64-+E2M;UPBZ+*T!TH`\[K9C/:6QJ).%,J#L&8UES6S9?GW.G5=P+72V+B
M:^MV6F.-975E1^U:;6=!!2'-RN`!4B2T!96HKV!11)[OCEF"6J.T_P`NN1I*
M`L7$R56F:"3;UH4&=QMI0?L$P=A'79H$>U.HXM7GK=U_).[]S2$V[1KH/:WY
M$#8=]A^M,W7U@^LO01)*2XT?+*^;ZN=[*TMYEMHV2LH]UHK+ZH&U^H)_8K0R
MX;3H4"2XJP?"UL$\+VM]J.:$K_0!US9_<3Z+VA=;3*HGVUS<9\N2J)(:@6WG
MP/3:XN$F(:1@W[U".-*XTOXO^2UK1GRSM@A<T/T#?`P;1KWUEBR-7-D<"6UB
ML]/<CW#R(U6^Y\;?<CE_3U<U/7_5/Z^!YH+&QIODGBT[K0O\@@Z#]DMZL<EL
MOSH2R:CE,L>\OS]J`1*1)$Z&4::)[4<J-D_M50[*5E(18R.N*2V>";'4OEB)
M6HT$=D5EHXURC;N:H[1!)[*8UC4KT]6O`9$OPK$Y&*@(C0<P':B:RHQ,1&BS
ML8.<GTV0"Y95;',9R8.7,`56=2U[(ZU@@K,VKX&`I.V*".-(V,1J-10=IH64
MC+LM5H<E66&ILL0?C@;VYP7.8[NQQ%H]J2U>HU^A[*478,G'F@B5B^LL44[Q
MW(C%6-01L_GN>@%1D4&=K<HPN820UN9QN8AJX2+$(:&U'"?DNO4>;B$CA#A;
M.Z5'-E9"B>US/1R@M5\62"EUD!U37D)/15^6!>@V1L87_LQ2'99D&9@ZR78U
M(^;:]\X,2?"T<B6-/5$=(B`U].)D(FCC19RE/IQD/0(-@%5GZ_\`)("+J[6:
MH#V'9IQF/F&M"(IT;'$V*(B5/:C)'>H*E'E\0[GYF&K^88C_`!DN^K[%:"UY
M_AV@PW"@/%'L:^6TZN10+>_CPQLALA1XR86C^K9$;)^H2JRV!NS(6R5I-3/3
MDB1QAB0_NC!'QUSP+HBH.J.OUM/0"6$19,$[!YHD8^>1/3\=&*X&5GX*@"U`
MCISJR1F:E*DS9P(X6CI:E8@3JCYJ8&;HII=-7#`FM8V!JQ-]TL2>Q5;^@<DL
MZF`N:Y/L)XK*,@RM.M'P)'<6\!\DIEG,>9<=CE.L[*S)F62:(898Y94:_P!_
MN=ZH#LFT%=11AVT)EU.DD<5HYUX*9'(57/!*A>%#=C]1^6J*N7RN]K8(VK$-
M(QR+'(Q/:'RDTV<+NR;`DR[IQWS--AJJN(;43B>KI1T&DBDZ1,'9U8LDZ?D.
MGD4Q)%;ZHK6N]`Q8S:]QLKHA;VUA!<V::"S)BS[!U.)G%"BG-?UN>PB&/FF_
MMACD='*0JL5B-]'>`E4UTRM"(*.8=HX%:(V9\]05!$(Z22(J61YA_4)Z]QXP
MHRCL?%&D36-6-7N:Y/`RJF]@:C*NKVMO"4Z&(<2O!.?)++$02EBC#H<YU*O=
M/9.57Q3-((2"-)O[7^J-5`6;$\'/F5)=>VSRQQ\S(_RY[,I69ZRK;,FN=^,L
MW5+(N,.85[?C:B/1S?E14]&QJ\&Z%JC!3]-13W%M5'%L@D@G`/%NPKV2PAAT
M$,@_^+]T&94/CDD2#X9X1W-B<J^WXXV>T$0JVC&/LEASEM;EP,_(;;'7V<IZ
MT2=[QVGFNEU'=T>>0V1?8B.B<]Z(KO:JL1W@<I=F5:BAVHS;RQ*&E@6T#^7/
MV\`UT4U7H\6WB^P$-/:QMD':LBNC?`L\+_Z0JQ7!FKLHA[&REEI#JP""1A4#
MG;+/1#E3DCM:RH#"KNWQVZFL5$BE]4;`1(V1S9)&?&_P.RIU,\+IIGYG5ZM]
MC50UMC:-LL=3!#"F/A+!M'VEMWD68HZLNQ1_FF6-T4D<;D5SV>SW!@W%]<#W
M&@BT*74@XM.%7#+6;/('UCT`"5PLB`B]JJO4!\A+8W),Y7NB1CF(C/1R`G!;
M(V8P%E?A-<)(.%8Q079>RPE=,?-*%+-6!O2/MUU-$(3,LL3Y&I[XXI&JKT1B
M*@88VTTQ*RN.S-HT8,6",>I'Z#E;@Y&J^0KU2=.OUJ&,F]SWO_(F69%>YGM^
M*)$:'18Z79_-501<TNXVCQ3**I>LP+)182Y)$FC62/>710\+28W2L0I%DBB:
MU[6L]Z.\#[6[W6,-BCFKK99C6S#MI8]ME-8\D4@::)EBX=^KJ7`)&'/)+&P9
MSYIXW>]47V,]`^6UMI_QG()C+XEDQ`AEBV6^S=4+[F_'-`7`9^<;:H5&U\L2
M*KW*]JJOJ^/WHX'!G[ZZC@EF)I8IOW.>.`"`;7R7%PXSX%K86A1?M\-.^O88
M>.I<+G,EECA^,=[95]5#H9/I)&6-U/EQ+"PLU<%,:-:X)DTFD;/(Z\99B4-,
M=9A#ACRI$U\+HD<2UZQR/:BL0'!#^Y@AS5EJ^E$^<,:Q;+`5=:"]I3B'RP(,
M9&_&/"!G!E$7\P(M\!"QKZ#Q^_VKX'&`=:\M[1Z,.:>5C9Q-"1#250IZME<Z
M`UL7_3JW.A:/$_W_`(\R(2,WY%>J.]40'%42V,LKQAK/+4YQJD1$6\@6AU-B
M3.8=*9(4`XCG,=/&-!'#$.UKXT8U'O\`[O56H@./*9L(G\B$6$HW\;5#0L/0
M`?+13V9SH?CJ["5W)#8@3C1:TE\39D<KWQ^U&JC7HH=M[B=`7:2%'BE6-\)9
M&U+``\1:S6=HRJ;)6$_ERG\FDCI"*^7U&='`')&[T1/D3^[U!2&KQAJ'.W@5
MG0E6T-J986&.?4EP0CP40PX^981+0\Z'*+L2*X=OY$+QO26*1Z,]%_5`PY>;
MD^R.YNLA3+97M]:0OGBR<X@Z."EC.+:&+:<GD,!1S)?2265Y+)8$>K5:Z)Z^
M!TUN8NS:2Q#L:7-"@!7T#2(866;44B6O<,A'[7_TG6-9WR!S.65B,AD-C2)&
M(J_J#-I,`99SD!U08MVKX+-TE8#EX*2(,NMKS+B<(R9_&IRYR(Z\))?B<R%Q
M3/<B-;[?503DP5T+;29YM"ZKOQ9`14JC,=I3+"*T]J&OE#"EX@1'/\H4<LB-
M8]'>OL>Z1$]$<&4RA`"%(;,A15C8#A$2L%RWXPA;&OL!C$LVUO'`CO\`D%L^
M3XG2>U4E5G_P4<H.$;&:'074\NDML]7F%55?!#+89RQD%9(8!"(/#-<&\F>&
M!9#OF'<R)?D=+*]8W>U'>Y040A;2BC=;P:*>&:MKB1(Q#Z*<>?\`;:]'4\T=
M?)%RZE*IVU[RHVSM^.98H5:K4_O]?`0;#-:H6N^:]GS<1\,E8,@%KB]=H[4B
MH$KZ]U>Y").=6".$B#>.D+(V)&T>?T>]KE]J`T@:P$=8U6\KY(2$EDB5,X/3
MQEOD:^$0MY+<##,`&&.2JS?\J65S6JW^UKE]`5:NK=#))6EGY^SKP'03_G`Y
M;274!LQ(L@(THU:91CCS2QR2,CFD1C(XHU3VN=[&^@.S/V?IE&4XG0*8`N+\
M^^!?.IF66FG"'(K2:BB?59F0Z*TMY7(L(KHHOR?:J/FC1/1P)A`=W<!-=66@
M(Z%ES5A(K*V[M[6\%?7C?/\`FMF'C`%S\$T+&-C)CB9"2C7-A=[/?X#<6.N@
M:@\-O.>"XW\B"MKI!J2&,0@?WP02DBG"%%S0E)(J*UL7]L7N_JYR("I94-:"
M0DDQM2/%-5,.E/0>UTCPF*CH8H9#K;1Q5XKD(D=_Z=R,^21[5]RJGN\#F#GQ
M-#)*3_DA\X(P`9$BD1CT]=^>2V`4W_FY_7.GA`B.BD'$D^%ZO;Z),V']54&J
M30N@D)^%\E&W]ICLI9OVRSLR!@I`@YW3(?/UH`=9)9)W^YK$^1CD<B?V^US@
M=U;(/>R2$AQP6<X=:<@\D8&6B0AK1IQ)Z<=@^^(2=J_EP2O<5(V:.1S7(Y7P
ML?X"A#0I1.<*8?\`AF068%=_CZPH'(:0L)"QK)>7/;!&!1D$L9&\@-S)F*U[
ME9[O9Z@FY.P/_?"K)9+/22#>DLI5G>LT<5=*=(1",0ZKKNM03$#RSE1/C65L
MB_WL?[48DDC`]"X"2("&DJM65!!TD5C(XV+)\+/>K&1/DB8U7>OHC7.:B?T5
M4_7P,OP#P#P#P#P#P/`I_,;B-_;?R2?9PP;1#CXFZW/&QZ<2WT-6/`W3UW!N
M0"6U.,R(4*VIWG1'"EPLF*G80@TDD+@YHV*0&J/4B:6PK1N9&V]IB*VCV\^X
MK(K26<DRJW<5#783?T37Y>IH].W07U/GAW"#^P<(D^=T,7M?,%'.%>Z^/DV+
MB8X>!-^RR/$LL_M]!$('GQ-"'KR:6GH&XX;X+R#:]$TGSTM"^4TUK1P2KJ9L
ME6+)[P5R-M3V=-6_GU&<GMX=<^D90Y[.'1[4KK0B-.M>#<UNRH4KK@%\4K4S
MVVLIC);B]BE&1KW/KYV!DRUF*=-;D92Z4*TH`8KC_":F>QJZ&I9<R6D#`@M)
MF:^(C8:/1VH,L18LPEH3$756H#YYR@I)9`;]W9;N[Z_;:F/*#UF(T:4@MZLM
MF/52Y2L_`EKJ:P<2JGM34#5-"7&H0#(HXV>\E9163L^8%W.,;B[7G@PUA6VD
MH6R^V%HX>G-E=24Q%W]7!CR*R[KB:FMK+.VE>U_PI'#&*(Z5SV>YDB/\"4XN
M?:VFE*LBMOGM%716W0(H:\WH%;>VE?F-17L.#.!.T@I.BG:)=$-GFK7!YV)G
MS+'""=#^O@,.X."S4]ME;=XXB;"IEL"98[IUK7'TD]L7<`7!"?C!6]@&+L1&
MCSP!HI4<I,C&I*D/R-!)MK#G&>J"KX:!FBLY"UEL+&]<1/G,9FSZ\6__`,L(
MIC5F(VV`SU401IK&1;%LCA#*4>)H[K;Y(0;.BZP^=UE96SZD&IE30'W1$O-Z
MR7,Y_E-O+,?6W>6`<`$?;?9.T,KX2+7`$O\`VJJK/CACA@EA+F%!YVVFQ]U/
MA6:[/MY^?1(9>%QC[JWLX:++9JIJK</4[S2/FS$^??>T@4=Y2-$+BGDH9Y??
M`U!5BD!O=!N]%NY\MFL=4&GX/!Y;;9O.5&@%BS<,M37U9'4=)J-&4)&1I!:9
M]<2TJMK)#'K(]H\T$CY"(H9`=//JG72V5&:'1Y_'A/MJ[3W.FETD<#XRLU46
M*9_(6,.:2VM)X+E'RSP0%5UO2EM>WX(AFM58PX97,W*'"YW-Z]H#]#P#F.6J
MY#*J+'40Q-%]L(1F7EM:09VASM'5R-'>$*.X`&1K7^KV"^]CXP<)-5H<X5?[
MD?*VS+7+Z2&;*%5!]AML\%<!V46F#SP0E?HB606%@+5FQBEH00R5S2AWDND1
MSW`ADTG(!B,9J77NDV^?%SEL7A<UHGWM31CN@K6PZ//["\M")U_RNOSNC'DB
M8`@<<MI:5#!R4FM1Y&!AIO[YZ'CY;(8W')6VEEB@\HP$*MGQG5"V_OMCANTV
M"P_&WA.(+:DNOWH\XLKM5-^-^7`)%.R0%:ATV"@DDMKJBDCI12KO-U.D6GK*
MK8;;>?N(U9K\O2X1@%.%`-AC"A5O+>-HDAF6L([>*6(E2!8@M-8(,W,6O.<X
M^.ZDUFYIZV^4ZLAL[JJM\,/HZEE:*CR]&TTO$V3;`,U*U"!XI0Y1)&%OC5SP
MN+_'KSBT"^^'TFT6@VE::)C_`++0UT-.-.^TFO-?<Y_HU2BS6`N='%AEK:*+
M\Q\KY@II'PMB]I`SHFQA^A#X'04B.%)1?7T6"9%]OI[O18W(OIZ_IZ^G^_P/
M-U+<T8%F>+%:U'S26ET^0E;0,DVMD^2>K@%G#EZE*Q/21DC'-_%5ZRR>^)?T
M8J!E"O"*GBE=:D&E,4R2"RO=.!-\$447R00BC6?6::O)BEDF^7XG^YS_`.]O
MM_3P/KC9R)5ECL[6TC*@`D]@!=;65ZQ-;[)5=&'T^*>."/XGHY89E>_VO?([
MV^YR@[*_0C2FEUKKD!)JAA<B$$FT]B9"22/&*M_<VK.CWK3088Y6%3I&R9Y2
MM]8&2SMC]P=!F=`@@(4?4$Z$8-7UC'EZ1\&8NBX?G),*%&L.D4V@2&%DT<"/
MDA'_`!W>U96>V3U>'>@-E:AP/L(/C@*L)JNPM2#G0/KRF6$!#*JV*_SL"PF)
M@K"FOE;$\B>:&=?7W.A16`GZ(";VSW#$8'55:DT\#<==UIM#'(+&\1@Q7IU@
M]QYKJMDGOEE^4J=Z-?(YSE3T!I15@]=)*4=9@-@40`^MK$(%/LX?DGBC%B1U
M=U6P_#B9!(Y[DF@A6-D*-1'2>UK@7E*&EEB`ENI(I2QCJT6QT>@:;#\ER#!%
M$`^&?JT4D<:51SFL<D'YJRO3^YJQN]@?8!HJXJ&G#NCCDCC`B_+9<OKP6*3`
M'+&E;:6^_I2XG06<S62R2)&R2<=DKE<QL<O@)T9PA,D*AEJ>7,=^Y3'9Z1T:
MN&A%>C83(1.A&CH,.])'RSP3*V69K51KOT]`<=272RM-BN+:".U:;7UC:J]-
MG)MFFRN>*V\GE,Z&<@E>UQCIOC%A1\K8?3V.B]/`4XQX"Q(OR;:<@`*KT(,U
M>7=)748EG!8CI&8Z>;H5(V1TGY"S?^:DDT+5:S]$1/`XA&@1$"2ADV\@]H%4
M`"BYV#,6,Q=BL#"*\5X4_27S_/!"V&:,I[I)2"))&R2.D<[U#JSA?Y1%X=9Z
M5!(K\&;VR.)I#;%QER2*+#3@!F=:+8"2D\2*-.^$5\;6_'-+$U6.\!1D!(?G
MR*V[N*ZJDL)76PNBLCUKS9!*QJNNE+;%T"NF)#C%+C^.*;T9,YS59[E3WM".
MW6P:G,>&4R64\5J^E39T]U`+$7'^,1)+/+U.U-25(B%EAF(=\_\`PN:K5:BH
M"],6-7?N%<+J8ZD:XL@H5$TYXQ,Y,<<?_IB'I2=8@D#C9,;\"H.ON?',OS,>
MQJN:&&L)]:I;R0PCB1!VB,(KYYE8L4\[18[`""/HDL$TQH[/5/?,^095<U7,
MG:K4#J0VEG'KY]':P!54AL8\$][>'K8A/K_1UK7SU$W7EL(OSBO5ORN"8QKH
MT^-7M57*"L25)&:V.6$FLA1\\Y,5//.&\B-I#0X3*^!>D5*V@XXC8G,CB]?2
M-TLKXT?\CD!U<JI^<:.^'#UNC*'834'S"24%Q$^6,D8>PD9"=%8=+O0X*^$(
M?Y6,D]L_R0?HU?5&^`PM)-,\A0'#&#,+D/6IAUED6D<42JD(I3QV=>:.U1U_
M1R0M:V2)R-;[6^GJ#3GF@J(JM1HAY"BF_(:^@T\"2AK`A7L.#@+Z8KUK_P`=
ML;E^%9%CD>CG+^GJT%EL*_(8/;W9D[('$#PU]KHF3NEMD<.^.*!PO4',=(HA
M3V?*YOQ^Q[D]SG_IX'.S]H<WQ1K+^_K+-7E24%E"XFK_`!XD@.:285HX6$3"
MOD8GK&4Y6L5%=ZIZ.0,4N$D&4<>SNK$>4>Q87\VAD?\`-'%-!!!`'#*F\<*@
M:O1TR+%!\['.]'.1GM10=\U)<4PIMV1$^IJC3(1:X7/BGF)8Z!@<AM<!(Y\%
M@R1(H?=-#&5,]6I%(C9/>U5:'91CQ11RR$S%`PCMGNH0KL<\]DZAP-E24>&#
M02DUI7Y4,<"S$J^*-TRS.;_:KD!PV48<YP\L=;(>0<(+%6W=1G#3"65%53P6
M+PO\@S]:%0V]C^4A$%@Y$DAA]DGO1DC7*P,.O9^+6,9&98P6-A7W4ASKH:)H
MQ([:Z*6<D/\`=X[&8H@P%KX&2L<^.2617>ST_M\#X,`.2T*OBJ76($0D^A_'
MJ<R^U2M&K&,K92ICJS'2JX4XUT1$[Y&QCRO]%B?$B-]`2!:%]^"I=J\2LCI8
MRW/_`'*&C"89#&^86(5U610V,+K6`UR,CC<UJQQ?JYCE1'("C2!6M>,1-G,_
M[7V1T-*\*+*L862$0JG1_G496"I[#\":&>(EY+)G_%[V(R15>GJ"U`-?6=W:
M#6&=89^(]*W2K/+7RGA/>!)76%Q8FCXFX(D6%D4B,]B01Q.9Z2*Y_J[P,UQ4
MK;0JN-S;KRGJ23!AA4I1L_;L:'%8%5<YEI/CY(P1I+2VA()]XOO)AAC1JHQW
MO>"[#FL^E85>YZCK[0S.U*D&GPA)`QQ=\!`TVODKXL8081?@&K,L*BE>XF&*
M5/@]9&I&#2?G;@6T:ZLJY@[&.-I<\KQ0C";0K\5H[`RXC,&YHRRGPO<"#"R*
M<AT#D29?D5&`D`TQ]L@M4H%U):?@G"4-?GZ85JU0,UG)82F6$XG,HUBJ;,@\
MIKH?E<L<Q'OE>Y/<Q0;?[,2YJ`SY,7+Q!0BMEAO(P*XRQ9`+/*.0^2UYQ9$I
M-8QM]C'L8U9)5C8GZ>O@+166KVHL4%7<G/8M9/.1EQA;$>(0])XJ-)B0N3U$
M4CVMB?&K$F5&N7U]K$3^X&>+5BS3^ZTIRXAI%EG8816YUTT\CUB$@";.5@3D
M`!51OD^1@TJPN8]$3]?5`E0.TT=6.YN8CC#JP;49T1%?7RS+6S$B_ES4DY\7
M.*,`@"U#"<^&.%J(0Y'M?)Z*BH"7JJ^SI3?VM"A3@M#3BV0<39!*:&.L(MBY
MFC6=-)D;8FM*2*,MK!/G(@B?$U?>Y8F,4(X@:1.^&10QZ_V@RSN0_,6T9ZI(
M!^-)`-()@:P.:>R&G6)D3)$:^!WM17M1?4$QH5HT4U1*R"LN8Q#&/4IE857A
MPR,2$:68'0@JU_QI)&BQQPPN8KD_O^-R>H3%S^OL64FNI1+Z,DG]J>9-72Y"
ML$2_0<>`HJNK1*QXE9:H^'\E9)4?%-&@C/6/W2HC0:K0F"R0CG4"V%!%(UH1
MA9M8V:05C$"B;+5E16LGY$,A:JZ-ZJC71RHQSOT5P?/VBM-FL@(IDEB#9'/5
M5]4&=#^7":^.*8.`XC]AK&EA1N>Z=[W0MD3WHU5=[6.!'#E@(<57S!MJHH7`
MQVLQ$^;_`"@4KD49HP,#")YK+Y@?9,LA$S6J0BK[T]%]X*O[].(.\J4ZU_;7
M1C5B?MD9[)V$O8LQ`<\$VLJ0YP'PHKR',:Y29%_YB^J^[P&@):K-(56A$%2&
MF-"':!'LZ9"ORXUF)'=%$ZW9*V25DOH]\\K/>B,61R._7P)1`N9(54T"TN8[
M<.QK@J."NM#:T=+&*K9,203#-T+\:<D4B!9&S_![24<J/3Y$;ZA@RR`5R'G6
M582-);P(/Z6&J(N2$.:?#9'&J,S5SOGD.D5@Q!4[XB'C->J-<]TL?@+V726,
MX8IEQ9CQI((RCE_:XB0]`8:/,OXS)K'>/J61B)&QB_DHC6#RI"QGJKHVAOLI
M%1::H5/3T6L`5/1B1IZ?BQ?TC3](T_\`L?\`3^G@*?@'@'@'@'@'@>`[^8IF
MBN_Y%?MU7T4""-`T&'C:E6566=M:.3ZZ<0+N;(O*G4-D(X^NJIWH`^8J":>&
M"16120-E1X:B>U$C?YIMMETG32<ZETAZWMAEL]S\NSOEM=$//9)9X6[-.%C*
MLJBX@8=6S2-5*RRDC8CO2"OC0(>KMJ-:65--QCF2:/2V\QI-ZVW>S;I>SDFU
M7+Z.]M,N^LFS]=F,Y7#@(U6!K855+/'*QX[2B)U"8#M;VH&LI([OEU61F[.I
M_P#GG:4W-N?'"<VSYE2196=K9V/-HQ-5B<?EXAK68.IRTXT`:TB)!^*ZPF*\
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M/^.^>"=0Z67\!GS+CLC+U':U,E75A2:,(`K3VQ]AOS+ZP%RU-0NMJ[\&3<``
MCANE`L@F%&TDC6158+8U"8LJ_P"V-)39<D?]GO+0&:RG=^UVO.76O^<UD[C[
M"UM<R_2-LX9K.JT-64V2*L_,%NK2X$GFACKZU@P0ST"#,0Z=.>;O,5?*-1,?
M4:8TS''KD=KI*?*="^/26W1\]I%FK`L9C^DVMS(.SX(72UM2:8]I4Y:.0))Y
M-!9ZK/;':\K+VNF:=5[W%9O8@XE,OFZ.?HPQ-;+6T4QUO/3:.:FH!!:$$!29
M'5K(58]I4@PJ1A$U9#346WLL#;4_1#CBX;*BF9%;W&@JZ73X25@]B+;4VMOQ
MG:RT>$80=.)#!"T9HKY(8XF#.;X#TI`P,]72TM+9V=)^3]=N4'#6>D-EC`KR
M:;[C7]:.'8Q-9:V<`(T=XBA#1I/\Q#?E5L<RLD<'S7XR[V-,5FM#,6'G;61=
M.559MUC:@RDYBI/RYCZR2ALJ8JSKH9[:U^6`F8ZQ1@S$5/<LOR@@!;KG.)(H
MPW1&=FC)L,JKCM!-4X/##;3,UNQDSGPXF$LK76N[LM!43RF3-)$AET5@`6<U
MP:UXXP2!A]%]@K.GCT];SU,X"'A*<.C!LM#FN.`UV7*DK!Q*7)4VCT+]-;Y7
M0Y.QJ;@:*R?-/&TR_;(LA<`,L(//2V-M^]9<SH?/GD+IY'5,.JTE2)-N@AW4
M.H`H-`!K*.HESMB)$`3JY)F"S&#UN?ID?''%,>U?`X<R!Y)L-EELS1E=/<%A
M(<Y5Q\Z2M,GM:2$3/V1#C.I=3SY0E=7VMC%IW1W)\LD;IUHPHH'+*/\`DR!M
MG_CX")S'W@^L(70ZNW!LM']@J>QI8VV5\Q_[\A/0'#$0M/),H;F@5)C?D>!&
M,:OR(\J9\?H.@>]3P.J=WM@F<B(JMBD<B.5K6K[6*OHKGJUC47_>JHB?Z^!Y
MQ;O1V1<UQ'#H[5:P<XM6.9O;0J.413Y&%0(/0]&'4KU]CEB5Q?QI\?HST7U;
MX&)6WG[*BR#7I!PXXQ8J5(&M0=LBB_NA4$!-B5UJX.9(,2>CI'2^CI&(B.5(
MH8VM#.*<XD:K@L-_;CPF.@4RZM-3J&U,$0`["@(G'S=CK+*`@$R::`F$6'\.
M=GHJ-D9)Z*"\3H;HP1C8=!>M%%`KBW`5.PM;1MU^0&"U"2:YO4:80<&!6O<X
M%LTT;)FJV!BL:CO`6\IHM(%2R0P;161&U1]$.%6Z"`$RG&";)87%G8BR=5N+
M`W07=<!-!$9*]MBLL+7->BHR1`YUV\N+ROOS"=.8'^78Q0U()^BN9S!]!"T$
MQ+\MTG5#4L3_`((X)")VPNF(59%>LC?D10YZ&VFNJ*$)AQW_`*:.IM:Z2XT]
MZPXRX$E>$M\?"+TFBSLRG#CK&P#YWCR/C6=8_?+)Z@R1+G4RSVE5!J#K8*%L
M]C[1],2%'8#"B"V=Q7.$H^C(,3`!+\T3AI"WM?*Q4C;Z?\08X=B?8%6)0-];
MN%(>/$>'6W"58H,!DT:%K/!'T&[>K6GSHU/B]DSHG(BM]%=Z`O&W]Q61Q2$F
MFRWTQU>Q+:VT<M^Y*^N%<V?/R5UOTNS'=-**7#*B-B5$9&QB>OHOQ!CZ/>$V
M(U3$9?VS;A<XVI1H]S>5(?K"Y`V1$+1]!RPYAON,@DFE1)'%.8[YE_\`A*&1
M1ZRR_=*N*/;W%=^/#`229":ID)UF5'\)`MD4'N[BV%K_`/G+^/.Z>9SQFJBM
M:YK6J"Q7ZF9U6=70$-@,,8.3%>6EW8/8097O)8/*M99='LV-E:',@8[%'CC]
M6+,YR21^U`Z+G7Z",C-N"VUX@()<22:BW6Z#>RSF>I3G"VL72J28H>I%;\L;
M4;+&.]/6+U1$7P%3,6YUVFG8IAI39RQ[$AE7KSTL#9!B''2J`#!JZL*K6.4>
M'U&'(1K'_&QJ.9[WH"H;HRV3:%]U^<*?3'P@.I=%?SEV`RF1F/J:L,YW1=(7
M.XZ(Q\DCU<.*.-#$T:1[$1K`;&@/-D)FGN+4TH-:22H*C$U%L@F=E)8P4=8)
M!ND43;0N$1\35*9$^3U7Y$E16(YH,;++4`)8&MUEB-8#M!*I?P])?GJ21.Y@
MLDQ<S^MZ9!AX:B15<CFN57_W1^Z141H=*_/?.EB/L],VMA#9`447N^AEA!QS
MRR6!!+V0=[KR*\+]QD^29P\#6CR/5D:_WKZABUU;)%6S?@J46R3Y"HX@-UMK
M:SE/FA";,0PD[K$UX;-^0U)7Q(9(R"-GJBJB_J&00%`84PHVVN2JNZ;(U\UE
MOM4-<(RNBC&M0@IYNWER!M,D;*V%PGX7S+[?5%D]50,BY/%-?-7,0]E1\3/Q
MEK]GOZ\<66O'>$#&IE3W/+>Q!@8T4AB-]DLB^YSGR?KX"6S)UX]K$QK3+LRE
M44:>6UZAI"OPR+-&*R(.%_=[I9`I?;[6S*0K6^BHJL5J^`B7=/6V<=>':M("
MG#-+@<9;]%W7NE"_)8,D#0'?8EM4$LTLRCM7XXW.BB]7?V_WJ'0#A\K$6DT6
M5J9&"N:Y+(GI&GE:V)S49#/'(+V%_L1'/?)"Z!RND<Q41SE3T\#O,ST5NI+I
MD)F<XMTOX=AL-P=7"USYV#`O*-*[ZP(8:)TL;&NF52'.5OR^GKZ^`OMP>;@&
M5QE/6Y^YKU7/S%5>FTI)A1HPK(WM=*O1-$P:1:_UDD9'/[&_$YOM1/8B@NNK
M,V)DY18\YHBI"U8TB\D,U9XU<QTQ$=G*ZXM.D!!3CV]N,TH%48LXS97C*[W(
MK/`01P:D%$IPQ:>$4F454FA"%LR$@G()KY)7`D)H;**22#Y$A8^5CW2+)^B+
MZ.\!6>V)=%6PCT!*3@E#P4Y)598N".9).CX'?M4VK&(C&A9$^)'.#66:5_\`
M=Z^OHX,UT=;+^[U@T>2O(!I#)"8K+"5`D6ALI)QP$'JDCR4UT,<<A;WL&:8I
M;&1._P!$>Y@.ZF2KO+ZSGM\O8?XS54\5C9)/D*2RLFB5HC&3C64T5(8.D;7B
M0Q?V!1M55<J(Y?=(X&_$5$=3YFJ2HQ[:H=AUH00O.*2=9KD@LE\A+A1,"P,X
MQ1!(X(X!Y87M5$=,LGJGJ&<A9HT)FIU-!7JM?ZU<%0O*:N>IB;/`QU63='_X
MR^W946"G3(Z"".&9D8ZN161N;Z!U#I&98J1+GZHYX@Y=@/85>(JY4*G^3]"X
MI(\!3AM!0:1WQQSO,6,AJ+*YR?HX'GH(G4Y`EO89H`ZHT$5A+5(9@*:F$CM"
MZZ-MA$;)!S^SL2+B2BGA*8D4L;9HI(_[/:U[%#&M)B`ZL$TVG!VJF`QV8YU;
M@*ED=&4X$-X"N/L\`)7EO"FC:R=D;6/@FAC8]J*R3W@5R11ZAMG;VU%:R6<K
M)";2XPE#)+HK2V@*F+#-SF>Y[!;%P$2LDKRV1V$#XI5;*KD21D:@UQ1CIKV^
M99P4%7`QK(IG"8>FL`YDC(>HE=.RTP%<36!4[I7>XI4FBA<CDD214\!/L1!E
M+KA'U=98U%C[6V"#8JH<3*D,9(QXM,\/C5H`<\4-7_$8Y5AB=+\?L5S%]X%U
M-8/1Y+\NL@;SD597\_S]2HXWPRQA!DV.@Y@8TADS6HJO=`U[EC]45$]6H'P8
MB`8JS`BK\XX8X8?VB2\ZKSK*O&BCK;-AA*4G+`81)82G/]DR.D1&IZ>GZ^Y`
M<`XH]B3.,8V_A$),JYJFS?R/-D/N`ORV`V#IH;?!CN&AB<6YT4C))?<^)&*C
M6R>Y@-G66XX10XDSZF:?/SJ`+*;F<U)8&5T:/'B<8)G^-E3@31CRI[!T):@\
M*_$WY6HZ10Z_W><P)8R$1B5X4D-<LN(R/L=/&:TR5DQ.@YH7)+(HL\K?C<D3
M41[$_16*J@@F6I`\T]7"?72>DU;+^3%FJ)M63(Z-J%5:I1<I!EA/>1&U[HI?
M8Z-K$:U[V>CW`\F/MXJ\.U'L%&FLK!:])JS&X,<R4>N$!)D(AM+[(26#F$2%
ML;*V67_F/;$YJI_1`Q2[9L3`3I]-E1/A_+4J8E*.QL!+0<&1?Q;&LIL6'5LL
MYW*]LKUFE29LJN]'>OL<'3+?7TT5DP:0F+YPAAB0Z:@QF0J?QX+)BMCLQ3\V
MT965QOP/@A:Q41)D551T?@8==LBHD^%U[5>\429QB%'TMPK$AE_MDE&KJ<6I
MB'*)^*/\=)/[G>U'IZ^K?`ZHM'<R1U[)=%J%`1[_`(!U$P.<%@?^4V"6,-IT
M(J>V2%D;?:B1/]Z>U55$]W@)QW0#GL]JZ$`!Y4I3VPC:$"U?\4WL:@PPU+>5
MD+'O^9GL7W?W*/Z^B+X&:)L[=SX;$+2V0Q19`T<5NIF6H*0(FP]\'NBGGN[,
MACU)D1T3EG]_N]BL:U[O5P=]CT6U^4_]SZ(1&6__`)SXJRWK]`YY8GK&1(2G
M^>"U7NB8YY"*@RHJK&KT58T7P'1%MM56QT\16HT,X$<0[X0['J-%B:R!9(YP
MX31(L[LTD0R,WXBG/]62RR)_>J-=[E#T`4,B2T=+*TG\U)*FND0SY73_`):.
M#A=^3\SGR.F^?U]WN5SE=Z^OJO\`7P%;P#P#P#P#P!?_`!_\/]OU\#\_3^9Z
M7[#6'\C'VTK.)D<IOH?\GPU7:Y4L*K"[+0`W'UU^O*66GI-185]):?XQ,]8$
MG@K;.P(%%B+?^&Y)$:\-%5$-U]].`!T2XRT&+>&3<W55I.>,O/\`+]A77L%8
M)+C,,6>),.76:8^M4&S@GKY()SW2I-\;OQ)`?\^'Z+MLG:5?/[K#@<SL(,?9
MV^-IAKP+H`NHM!=#CG2=`R$99EOTF3%<^5FFLSQCI<VM?4"/%C$FB(B\"*L'
M4]177Y+0T51NQM0%GP]!>T&)RMU!82VMO<U.WM)H&JW]SH[-C*7%U98,T[Q:
MXH&]@>Y\9$['@HE3Y^%E\!T<KF'4NL6Y!4EUTJX;>ZW`_P":!WI)=$9N[,(A
M*.QU^F_>Z2P;;#Y^QSM>%!`+9.+D9-+`#:@;]S1MS-JG;DS-G!:B("H30L<'
M19ZCCAT-GF+(O0UL0V.T5+--'*UH=&9""**QLA`CJ]8T8#Z:#I<[04EUK-9B
MM@:)MOMAH=;<<US!-#F-#'H?JJ(8[4T8*Y>A'F'((%)@EF@A$8;.YTK$?'Z.
M8"OG<]]A"OP:T7I7(WE9PVA@YG#=4M1;&ZW&[$H&U:EAM+&JL:O.:FAF?\K0
MR;@=2"&K[VP2-AD8#8'Q'>J[I.CBLNDUW']NV>H?H=Y>B`RRY^HM3`!:C+V-
MM7-TMETZM/E,<V2HD;:B1I+^(Z:8=%F@"4,T9?34=S5\C&K**8VAN\1%1U-+
M1\PT&Z%L*^AJSR<U:"7FEH0<Z-?-J*$?(06D$E)83J;`P^`5(8`0SN':62^K
M:8ZEO#;4&VT#6U=;R\:.T+BHMLF@&L2%_*CJR,U+T/I]_L:[VN65]3G[VOG>
MQC`T0$PN:G#N8Z_N3Q>AW%<UF8Y1R;29JUV>QPV6LZ2WPE[F$V%A=B5AS:1,
MW%36V3&)E4P^WC,->,>2K?`C[<T/V'W^HY\0%U_+0XB1H296WQ0N&H<AG,W7
M6MN851"T]D7D[;C,E5%8P5[1'5X_Y4A_J\B05(BG`]0\EV8V\`#U'=0[B(3]
MP2SQ=%F%!JH75%#)86%)0Z\<U-%87]/D8H&US#8!`[%Q2Q!3R(L+90=_.S7$
MZ<%^>TN<S36\!QIM;;Z/'GZK'U3*7^03]LKK*^$&`TQB5ID(GJ^M4":222:1
M%262%&^`T==A_M>#;Q6TTE)MK6UUDLU05CK.B=SK'!C@I8PZ!MF:=45N.JJH
M4-8$&^*KM997DNGA>V6-\@/MK;.<.*YTF^P$'60[K\P7NA>.`_Q<B[<?D@,Q
MB[TFM?;V@.LU=U8TM6'TLVK6R!("=)/!\4<!K`;FCP76$ZQ>PZ*MNAXMJ5I_
MP>H4<1^Y#.=H]!IA:K9LOL<=K:B&NRHO0=/<PE%G>W\$8P.!'HP5T(/%<_J,
MQ2.JME9VF6R5I7C3$<7VE=9V.DV,]AG&5E=266,F*KA*G0YR#FXV.CUAA$!$
M)0\Y`<,]C9.8@/$.NU?2LK^X\OMIJSEO[K.4?05F0H*;2T70Y)*\@;5DYLHS
M]NZ"S41G$E2:9'7,\X4C8Y@PX(Y6(&S#^-++[#GWVH^D55I_L/4[\J+[!8".
M3"TD8TM>^:]#V0UIHB]28CA[VT=8#.]C:MJ$D0N1")61"*(@?H-SK*D,OX[8
MWD)%(L#)G.9$Z;V.^)LSV->]L3G^B.5$543^B*O@8RH1)6N:;!%(2\)4*&&<
MZ6!\[H/2<<=\S8'20ND56L5Z,5R?JJ)X'F;@E#=_D`Z0:.I'9?6H8=?7Q5#C
MX/4X_P!8X;2@^P0==%$,]6M5D[6D#I*U4:QWKZ`[LP1;+3'1MM[L4.8%K)HB
M]37VDK'PDB5\`WPU_;(EG).&G=Z-EG56QM>V5['2-1X<C#ZR)PDPX^QI:F<T
M4`R1MSGJH&&T>D+["6`:S[I;Z"2(ATD$<?PM5RQHJO\`54<J`N0G@5CIJBIE
ML[JRA<2-^XB44(,PC1R/S9!6F:+LP(95A5-D>---/"KFJ]48GQ^U5#/K='0"
MM)%E?IKBQLQ([4DQ2:?12K#'85<M+0V8E1V"*RH!QX8"I'3!>BOEA:Q'O'5\
M;P<6)`M9+(\XVTL"VARUDT,%+H,G46#I[-+;Y$I:,SKRC&>K1U#D9(GS122^
M\97(GS,!B:8_]O(#ECL+UWRN@@D,G$G=7PV`I2S35A%EK^ZS0PL80L#O58W.
M1CG))ZHYS?`51!)DL9`YK%HI9>R*DC(@CJK,:*QCJPY);FRNJ+M5?2T]?$!:
M^B#M<DJ)$Y?QD]/<X%JG"S5ZJHAEQ=Q5GQC*.5?S'@6ZE_N!K]!&$#V"!\'[
M=(,R.(1JM<1&L:NC<Y95:#,BCFF+$@JIM%'&?(0V44@S,9=SB9)_R97)5B=Q
ML"*Y(ZM\TDTL+(Y)(W.A]?:K8U!*LIHZN0@*G9<TT,AIE?)%,'63*9*.IC28
M7ZTKN)=4.37CO5K9!VQP^]K9&JYS/5`SJ77(41(%\)YC96H*ZVG(791%0&NC
M8VO)CKNQ0*8+51QO2)\[?B&5KI6KZHBH&5<7R@%E5:+ISCQ8@:NH#)N<I6B2
MR"EDA'%R`-[,0%.,UMB]\D'ND1&.1T;7O5/4'W?7A;\Z(%)>68SJ:GK&5-''
M4U0B$S_/"*X4Z_GZS)5(>;45[R5FD^-7Q03,D_X_A>#7Q00UUH7V%*%,(:MC
M%9UXIY2:,MJ"-?'`*-:U78)JII%Y/*]OQR/]ZI`ON1K'-10?%:1.1;RV%[8E
MZH2H+I@R9_S*%*XZI?&^J9*!1-Z=&:8)4N,FB(1T+WL2!C6^](_1H,`EE<U*
MBNH_W<N6*/1$VUE2!5=7;R*8ID+Z99[[L]0`!"T,-TZS)&Y&OD_Y*,:UJ>`V
M0?R;2KBDGS=S:@AL/0?]KU&6,/,LWUP1T<!/X_:AB!VQH3'[YB$8,]BN^.1T
MCF*H=$5W%416A8E/?`M<H-7;$%WF%"KJY[F!R3I[[3O'Y9T+BV*^1(&R1^C6
M^B^OZJ'.E,,M!*N[=2Z2<V"TL(7_`"[FGM2"5?")(^2MEJ>ZP,$K2/RVM1\D
M\4Z>V:61RP-8JA\OMC<VPTHD>.L!JZIEA'FCKMSS^ECFE%E%FD-=7R][+FE*
M'C#^5K/B8-)(Q\G_`)S_`'N#-K87'U="=7TAXQMC9V0-A+;Z3(LAAE)$68`F
M6(ONM9#6&D@_*GR?\P?U]CE]/8Y_@))NHDN'"C6F?TCQ*6(4"FJH^@X2U_#&
M#(*4NONG4?77SE$2?"Q()6%O=(LGJK_T]4!IV=W.R,QX^3T%&0^:-:V:VO,8
MX9LI+'SM'(2?["%6"HZ6%OM(="V&%$<LKU;Z*H(%;HK&UMY6V.-(0JW+A$,C
MH^N9.:>24225T1`M/:=4>Z0$=)E3TE+]T39%5J>Q6JT)&L]/=!0P@!XB>O;5
MR-DCCCL^<S/&*<]_SB36I73[U]BP:1J1M?[B8'JJ+&KW>KO`PY+:^-$%J+*O
MMGAUB/+F";T;,GI1!6$?H.79@@:UDCRH(%?'.GJCH%8V-\37/>[P'#6#W%LH
M]'4Y2VHH0)UMZXF.XP]VEDP1X+YP["5NFM8W/-CF]\7QK`D"J]'M262/T!3,
MAN89FV]]1**7_D4`W^+_`.:BAJ7%*LI;:8C\5J>W\9S9(G(28C&Q?VMDB<OK
MX"T*E"=85,J5B4#8[(TBNJXRJBVL(;/\<>6RKIZ@@:SNQX8BVQ,!DB?[(E8Z
M-SIW/15!1E"SR?DV]+:5E=_]!DM64AHVG2:S:EF=>5A$3JW`MIX36?%(UQJL
M^-6N]J-;ZJYP-8',B#5'[@N7'H4.E*>VVUUL%+--8"N'E2MK@&XPTJ218S&L
MD<L<\4SU]6(GM5/`6='G*^SBJ8:P2A+G80<P*')26J4<Y<;$+GK*XROY''7O
M,KB)FPJUA#G(XI)7L_JBATA)1@0CSQ4^>#$+MT8,[4.=H;.`;W?*?#``SF8$
MDU:4),U%D58W?(CXV/\`7]/`7+.IS4A,CZ\<"XST=^)^TUKJ*\'!_8YI9?RH
M)C7\Q97QRSE$L^:!%E621[W-5J)[/`=XU3C:ZEO1B69=;928)YY/V$UNNI+R
MQ$GI0*.OL(^>G_D-,69DY3OPF/8L4L2(C(7/\#I;D*,:-K;H*I+.8(?5(/ML
MV=<5\PLR))#:I[L'GXZ.*HE(=!%<.9-#$QKIGQ*YOL\!LAYP.G<!(!7B`!G0
M-#*.$R]B7/=.)/8VDBA$#Y!''91N^!SI'QD1_G2)$^)T36.1X-JXI*0Z>E&6
MK>/^.L`DYFE&/8)$LI:L>V/\GDPC:VG`(]Z2I)%-&CGJ]Z>B*BAW6-`,.E9\
M%BV*&OEE/LDKL6:?6`1&%2^D,4F>XPV,LAD0Z$)*\B'WR+['1-:ULBADD8_/
MQH\5K<N@HI265>^TR9\%O<59<+994E),Q*K/-"D;F1P-B<B%NE1LC7>J^!B0
M9G+?N3(!"!+=Z/,FBA*YC:/'(C#/C6!L;:;E0PI!$@,J/=%&1[(UC]&OD:KG
MM#M)'(9'+##1A2J7Z>MC9Y*^)NR(G2U\2$RF6.+]PN<1X3/;"Z.2`=62?\7R
MN1`SM4%E2'5$M.7F(;<4`EVCBIN<W`8T%H.BO?-&[/8`V9D`Z*Y$(18$E>B>
MK&_T:"3/75I%T.08!0VA]D/733E*!I:^G#.FB%GGG;3F9V."=K1WI%,R5D<C
M9(U<JJKO1`R:^*KJP;!M>S.$*/9M`/=/GM:8=91@OA>$-0-`R$2P1"FQ?,45
M%,LI(TB12JUKG)X"I3!BF:"NJKLXK.CV*NL%0:ITGN6WM*T2,0NJJ;T@6OA`
MM2BA_D9+/&HD$J)$V5T2,0.9=0'EY`*(RQM21[$V:U>E91[*!(V0._92'`2U
MT=2,V(^6J?'"LRQ>J(YS4_N_4$6R`5UH]AAR1R#&M%2:P-ORX!/W,4;W#VDM
MQ?RGS%%_&])H4A>QOL]&HJ(KD#"D;7P3((+9Z$2+\EX[(`JK6VTPSD8CDA4^
M+4@,F^0Q/;(I1+WPQN1OHU6M3P,A2QJZ<F5;>:P-FA)IG`V8\#[<"F9$Q[5C
M=>=*)(JG.4J;X9P96S-5JJBM5WIX")/9CPV*/!O=,@LH3GUQ4&?N/P@W0$##
MBO:\7J5.3+8N@CEF<^1OP>V2-??[FJSP.^1*+YFM--O38:\(DVPE..H<U,R4
M8V/UBC,([;,=$(79*D!$D#FD1N>KFHB>JM#+J]6,*17W45R4&^5TDR4.<JS=
M(VIC>][6UQE@9VIM&:XD6?V#HU#/E8W]?[_;ZAC2[0:HLYHSZK\8(MA@B6-O
M>T,B4)B`D?MULM-:=F;IR&R+!&R2&:))D697JU'-]Z!Z#</)')B\?)$Y7PR9
M?/OB>[U1SF/JA%8Y4<06OJYJ^O\`YTO_`-V[_B4'5X!X!X!X!X!X'@%_F7K3
M]/\`R>_8C/5EO.07/TOZXT%9#9)1#Y^HMM=POF+YJP">4!E\3H[06B'^%K"7
MM8Z9/CC61[4\#2EO-W1YV_T6-R]+.N/PNBVV%S>+T=Q"9L[4ZLTBX<0"2WR!
M1<%;:3W5<.Z&J(;\-94OBM&RFR?FMB!MW)V0.M=I/EHM)A1Z:*JU%A:WY23\
MUS@&K,M,_G*&UZS`86=DDBUH[\)8#.J61#@PV5&KC#373N"5-)<76BM(['8?
M;*FMLA$Z`FJ.75;E\UOJ+AIM8]MO058E"/4:ZWN)FF"TULVO4HFZ-C"ED"^"
M>,(V2#E?.3BL97YC1[_16V@_Z5:\_>T7[,W$WUA^Z#"O3G]3`7:W.&J]*HV=
M"MY+M[HRV/19/QP!IGAAG//K:A=.!'_AF3I-%CLHD_,))J&H+,U&/NM5()5V
M.EJ=.607:UUP4+/7L`69$?*]SXR%G9$"]5DSUBYXF,=^>8[1?9T#21DNJ448
MF#Z@U!<DU)4TE77UD;G#DQD.C1T4J-@]7S333/50=E_GB&_N%_+FQ%EM'E&5
M-](I,53K*Z*."T_=79\UE[9069%N,J.@!FDE5"'0PS.:LJQA%>XN-'34&4I<
M*-D23]MQGG^GU>HV-<=<9.W)Z!`TJ#,27!&D&@P-/69:`2#XY%)LSK(R"(U\
M-:0/(P$V'59S3T5!C]-@G932D#V%[5.PP<NK!H<>6,43-6W]8;'G;+*96]P!
MQ5PU)9"S9VCRPM2&6L@B("3<Q=4I-0/5`=\RMUG<U366FH[(FQZU=@V&&GL8
MY`R#,Q=4$3'<ZSS`R@;:U%C6KBK-#<-L"()658_@-<[8<ZQXML#DX2-]J(*2
MDU/.[#0R74&6T&4$C#F/AK8Z6SEV5G;18NI9;6L!A-=)8N@$EF!`N#XQW`J0
M@6_40HGG9C(UK\_2G]#QD.2SCZ&&2SJ[#/@5M3^'GS`F,`3+Z41I[PB"FPFU
MA#!4>/#.]0X8*BO]!<TMD!S4HZ"HN199C3[;3:N&I&#K"+6NEJ1;3.X@_P#.
MMID*&</9'3#`L;)ZD>K9O4'MF[V]GMKJM@+GHIK#D&8$M'RCT9+Q;\S[]EQR
MO(I(Z<$#]R&9/,XMPT/XSY"&_"C9$=ZAB:.I@R6*T6CAPZ2G#=3I>8K,3(5I
M[2H2CHY"]S85>:NB<R!<'@NKZTE'2CBUT3V-<6Y[)X7($?4?6,&9E[)^^YU7
MQ@V%^E5%J,8'>D_N^LJ26V5L#'AKDR4:\7+"V$.F#B(CC)1L3_5SC:Q]>\)$
MC"S>;T5G59[[&5]74P::$+5Y'H6>T><+J+.*O>F7P^@L\`W395+3I(""M%&"
MOR'6P%I<S@#SFSI"(#MMKCC=%K&;FSN]/ULG)6BY#57Y4]Y32935H*`0Z#N9
MUS4P=$TI^:8#5GE)5UT,A/09V-9/)9&R5K`=&&W.UMM+B<Q>9;$YF)EP557N
M9AK:@)N>!!.AQUAIZ;J1UV89>I'5P5C@IYOAC^%Q\LLC0X:N.<-D?TGS9V9^
MY/U%KY:Z8I]1]T^>!6Y\+KZ*BKR)BMK%\Z0V,3PF%BV4[@AFQ%O&:MB](Q_D
MD690_0,_3P.+V^]CV>KF^]KF^YBJUR>Y/3W-<U45KD_T5/U3P/-9H39H[Z^&
M,OH)_P`>QT4T-G^YK6G%2B&S-*@4JVZT3%&]TT4"$.2)DDJ-<B1^C6^!(-!=
M715*&0!<4E73UUZ$80Z5T=G,4^V'9523SDS=7:(6+*&`]ZN8DD,+H'22,80C
M6^!TW.J'*`'8I-946++H^,:RK=I->E'D#9]LT@A=56=('GC#(M'0SI,_VE(U
M48GHSYFL!<ETF<_>Z&RTNT&N\V,1#^^RY6^+I7WEH<"Y+PF$O2=(=;_CR,?`
M,8T?V#H1"U\#I57Y&AA\TMARM+:J;>1@HP(V5`JG1@!!6!C:LIE0EE>7/:$I
MW#D3?`Q7L3\F-&R-1&JB^`DOVU34V3U719<P8,(FEKJK-6MVRR'?%%+(-;5Y
MH&_II)G)>2OGCE5[2TC:V)SFQ>B>`J:6TG$KZ$.QU-#[;!![>$I=5%3K=6%M
M!"*Z5X`70B!Q;,&(%(")EF2-\J*Z2596RKX#<ANJ$@@UE?JFK43:X>-0':V$
M&Q;$."WX29HK[IQ^2NIIY)O@(?(L*/:OJU)(FHO@+H-M56<D[O\`/6U)/I$P
M"<.U$)JI9@:Z,YS"'E=%%'"8*.C6?EP#MCGD=[D>])&JX&_`7*Q]M%5:06-2
M)1X1B+#7T=\]PB3D3F"S,I^CL0?V?MJ/:JSI[FM]'N]CD1X8=K?GI4P36&L_
M&':CVUH5GJJ_/QV8#IHED40(?HMG$UX$TJ.62:2.1BROC8YZ.D8T')G]7<6L
MEH>EM72EUU<`]*X.\K<U3%UY22!7@IM@5TR,.0$]D;U9"()(K4>O]/=)Z`EA
M:F6O_"]+(,@0V6:NLJVPT$%T#9F69,ZS.H9*GH-=64D`HK(XO<(Y)%8UCGM]
M$8Y`=5_:C-$2>CUX-+76'X(UJRUU(;9)"A#WQN#&!(Z*1H?=9B?-.ELQ[9HX
M7+"DKD<C%#`K+"S=H)E#V59!,*?!9L%H["'*#'-@>IA9,=OH>DUKHVQM&:R3
MVQPDPSSM1K?21RH&;*,_7S-LAKR`I@BP?EU.?O9K,++,$<23.RG:O0:NH+.>
MD*3/;*Y!)"IU<Y5<OJH)DSDJK*K@@V!T4.@HVL>X'4UU;^W.L72N46:*NW<Q
MA9TQ#'?^G;\TD4#DC=[7L<QH8N?UMA?YB,0O158KKN]JOFL`;.`C0L_`$EK)
M0YCYNGCL$K7^^!SQ9)!Q$F_YLD;GQ-<P$)LTHK"W$2PO@G?"/&61NJ.L,&E<
MYKS/PPANDM_)@GCAD;%&YJ-C:YO]'2?J"\-9H?6&C4V@^6,&P`C!)JBRA[&M
MAL`GC!$7.CM^B0@QPV@;W?(Q\T4$'L](FHST]P+4=O+51GGWNA$KH@I:0<Q!
MME56`I\TT#72&OKJ;H;?E),''1C6@^Z6.>57$>D3%<@80-_*E7"*'=QD-MHK
M!UT(0VDS<49%1#.GY$-]8;1Y#`9(;&:&*.&?\ILD;?D1(_A\!G6+KR-]:41:
MQD!W([ARYI;2>Q/$C]1Y!AWPNZ/7C$-?&YCDF&8C7JUS8U^3]/`^QGGR@0@A
MCK&;%9M(FMCM7+63%"R?(#^S0@.Z02U1I)28IVN8KWPO_17*QGH@=-O7VHC*
M];*UI2(W$,C)?#<7VAG!D=!"Z19XX-VL7YC$3T^-5B6:-&N_1BM\#Z!'?$LD
M+4V0)[X3W0K8Z&*AAB;!!-(LU8(W5'R?\V222/T$<D_O<UK$]R-3P%:RJB!X
MS)3B@73HM.(/^1I+K3$26Q,+)S4A>1>_B1B?//`PAQ+'HLZOA3VR(C?`DRAJ
M=+G+2:MTL9PD0%;=-<JRC\W=*#:UI-?8S0:*QF2N<;3I7R#P/>UTK[.5C(W.
M>S]09<]+<`)`2%<U$=5:R1&NJKZ^LM%>-HK58X@I+2GDJU,_(BED<]'Q_B_E
M2QND8Y&^K?`Z5:9:04#UG+&M)`Y1%_!DL4C`:POW2Z7Y:L,5(I!/F)5[B87.
M:,GHYWSL25P9LS(:PV[BJ[HNOO`+*1P8AAMO?5R54@+IZ><JR-RCZ8J1%'>@
MT34<DTCWK[T148@*(NIL8JRK_<#Y3"(*VR*>Z.N)]]:]9)95HR22J`^,<4R3
MTG;,H<I+)?5['NA5D30X78=N1:4MZRUJJ6*V='!8LKHK36:'.1ODE8D#\K/@
MQ(VS,JDA<U9OQG&2Q*Q'-]KO`Z<GF-/,8;44SFPOM5L!FFWE8/EJDVI-@)BT
M$[QA>;J^FM_PAX_QV+,LCR9FHGJO_&#-N9Z6OF*E-FH\H@A\<@<>@"!KT%K6
MSPH`1--N,0.^*QFF^)[YI'.']RM1K6^J.4'*)IK@['9^QK!W70C]#!:P:PPJ
MSM`CIBW*?35N;L:#FLU38$6T"./>Z,@Z(CUC="K(XW(\%QA7XR10BADRK6VM
ME;VC9,Y#K1)1I@@W//*LR.=4<S#5E14D<Q?9$]GIZ.]/8H1%S;N_`>LK;\TX
MMV2DZ9=I`7?ZC+Y+5)LA,O)50OHV37EG7<>92F10%V*`%Q-D;\\9$;D?'[T1
M0=[@X:TJIELH@'`,JZ$ZQB&QT1,E2<,R5T(8+Y^9$&(,X:1&EL]B3?.LD;41
M$]_@*MOE9":<,^GJ&263K/\`;S8K&N)L/G516D.F&@7ET04DY9CWK(WT5D7L
M1J*]?54!+'K0Z\8L2VF9)(5*"\9V3R@(@[ZTF29R'B6,',BYB1H7QPN2)\,+
M7^Y469C4<O@=L]?,#:F)5LE<#-*KQYKP0PC]Z*B:L0LA`2X((:(`J%[I)!4;
M,WW,:Q%5OJY`2OB#0N``-*9!!`XA;):BDS!,5Y8`?D/6PDD_P.,YP\\\SE'B
M2)'"JK6_KZ.>H*15:;4YT>7\REGJ]375I0X$D<QK<I.A;ROP;:(;&9\2MU`8
MX+HU:BR,9$JHKW(]Z*#9I!(''5\13\\8];$598O\6S)`TM>L!+BW&*^KE+<R
M)K(_9Z1^JR2M]4]%:J`YBZP<&F,%L+&L>IPM,)`#:-&B)@+/4>T&/A^"KS8R
MN'AAD@EG2>.6))TB:KFR*C04Q`UHQ*F[6/-#E7DI(;:EN2R1U6VN'C('/MCX
M");PB-'VLR-ACD7T;&WU_1Z-1P)1L0UN%(`W465I54M9-=7-;HRG!3#PTZ(/
M%<P5TFHI85BLPIFQ"RL=&DWQ*^3V1(KU#,9/3U)-:ZN*9(&RX%GC952MS`UQ
M7/@;&TQ][46)1M?'`,U8)IH$5\OSO]%>W]7`CW:4E?<6$3;/\Z"&<V5D=G=.
M,J4_-(A)E>(^\WE%:3#R$L<J$.@@GFF5RJKE140%:IUF?"DFEANK!P4KB3`X
M,V'7-*%(G]R05!]W6:^*8NMD1_\`RWMF(_'3^YG_`#F>]X,J>P@L)FL*OAY1
MXGM>^*]N(#+<8-DBI+&R0CL(/OBAA:U&,?'[$6+U=Z>KG('=)=B25EE#1Z&;
M2V212D0U5-:TP:A_@",D:J/?T5`ZXZ<%)6+%^0Y)7L]Z>YZL]0=,(%9#6`Z>
M?=UC+$`M9#!+"PLK8Y&25;YZ@M9`NJ,'`)<7#()!\DL<D<L'N1&QHV?P$DLB
M8P>R8'L9[!\+HC)267;:ZR)_-:]C"I3+/HXQA3/:K72N>5*Y[I/D55]5<H>A
M?%N]V.R;OE^?W9FB7Y_D;*DWK5BJLGRMG*;)\G]?<DDB+Z^ON=_50<W@'@'@
M'@'@?%_V_P!?_C?Z^!X#/YL:_;$_R1?:XJ`W49JEK(_K];Y`_+))4EW>D!Y;
MRU]A*';*)-6SW-6(Q\:2D/FG&B>U(151TA8P:D@N5C4O$(OM#FZFJO*O4=HN
M?K]T&;01A/\`\;WT.)I;6&SCI]19'Q4FIV!,]A!'?."9<N'`FF8D,CYY9`B*
M(WE-W#03DYB"=<]7_P"65V7]TEKAB'::.;-VTG3JFKD)TNY#V,5<!%([]S*G
M<:^NFBCA_'-E(#"PN1I\Y'HR=+W*G-J;,XPG9.0(W<:3=/;FYK(7J^WK7DY\
M/'=)Y4*<M-CRE>6/5D-D+*B:1"0,4#2`UU!S`+*X_/RTYI+:L*JK;G54V?Z)
MJP*ZR@!0"JO)+N:DRU:#F\M+&)`U12TIY"[:-7),Y8G@F:""3C_1V\BIM/;4
M#\^:"FFSUPKSH"$*FS,=?F+*U2SACN3L\'LI)HHY!XS!I4E;(Y&&$FR!*!EU
MIJM<8)T+X[6WS^K^R$$1-G=!!W-?6@?4R$+)O581*^U<L@[)/>K(IEB1K'O)
MG1(YW@D4VDZ=I@G$3&]4_=RZ8JH@LXH]M;CP9S)4R%7,CR+.CPVF`OOW1\L#
M76,);C70O'@NFC-BAD!CX"EDOQ_L1T^UN(9K[DN)PO0ES]S%(>4XZ[-I\6W6
MMK[&TG:X3'5IYB'QRAHU\DHL#V*L31U#'K]51Z:\W(O0<_:C$64U!::>US1\
M/[G9I2W-?+37!>@17NL;2'05I%TV*$BK+?[99IH9&ER+X#@Q68SUQ9WE?_FE
M_EVKZ;>HT]?E;$2ZAJG?M1I&'P6>=+<YBFX5=F(/97N=,O'MGEB&$$F8/(LQ
M0=K+NHYY\A&%DK#KTN:ULP];I0";W\S9@H3>7UIBZ:R9HZT&OU]M$RPL:^&*
MT)`*K!!FE.C"#20%KHX=T!DN7:H?4,H9^]Y(W17<0S(KN6JMS[J]H(;<"GJ0
MA;C,F:6GQ?M61!?S_BCF]PT?NA=*"WE[33T"@V4Y/["57V^&*:=#=W0["K8.
M-PO4Y:S296GV70X@KA]Z20<VBHU(-_2-;I(T0>,.O/;.SELFF4]>;87IO!46
MBMJF"T+M5E3^0FV.K`/VB^L'Z.2PF;5B2?,>026Q&I&Z!SI/;X#^H.36^_[3
ME,#H[[444&PV-%C5B**<ZCRDMU:9ZWFEJ8"9A9'BESPJ+8GTT0EA"83'^7\,
M39:YP9^BWU21J+X?4BC0'U]=;U^;-!SM9D;;(3YVS#(=+G+@6LC'6SH+$V%@
MKG+9213%$,1J2SE,F!M!8?EUD3GB\O;5=;B<W7D9]*4J!]Q54V;NQ+*\-TA>
MBREEHAMKM.8W4A*XH@I:MF4NI4K8H3*X0="0=@[>1<WLL(5;W^AUUYG8!,R'
ML]?3SRCTF1FEL8\94=`&EE'CU]]5W=^MD?=EBB,-,K9XIQG_`+?4I&%I2^<Z
M+3<DU_2OQUN=+D=ODN15>3'S%853%8/H=5K;IUK=UIZ9XZ?*8TC.TOXCHZAS
M(#4=#!(I#&I`$_?Q\XG?4GW&^CNE*OY[&E%^UO-Z>\A+NKM'6`MK1Z-F=%'H
MFVOXR+FB"9%E@*4H<:21\L0;2/DLY0_1%\#B[U]KO;_Q>U?;_I^OI^GZ_P"G
MZ^!YC[:KY]^[7T4IAEE>2["W)0@;J6P-E^".63WBNHX.VR0POCM&.>C_`$]7
MO?Z>R)G]B`I25M.LD5A<Z2Y+%KX1P*D"RZ9J(`QSA6R_CL8+#V=W[G+^21$^
M:`F-["7M15]S99?<#O"JX0Q!((Q]`L$5F*19T9.[L**M/##3\T4M;RO[1!9U
M\43C9'?.PF(:21[8G*K6I[`Y5>8P92S"#Z"Z,%KB[$G-7=/OKXDJDNRYHY')
MI[`_K:%2UY0X_P`R2)^3\<T21-:U)')("(?D<S+)&XBUTVA._<VUU1*SI6LM
M(3)(%-@0SX%[*U\0QD@WNDC-&AEC^=5BC]J+Z`XH,>V6H2\H#+=*DBLF#+JI
MNJ:&J<UL7I7N_!#L>SUQS8"XV,C@F&28OY6/>Y/U5Z@V3J&:&"3X2]0-IFG4
MV;/@AW]U'7#P52>@M,ZQ_P"JI`BSH:JL)6*/VDKZNDD>]RN4.(#*2BMK7-W\
M5FZ6]B!'?7UG43;LC\T=)G5T`MG+UTBPSSJYIZDMC#D9#*Z)(C$6./VM!Q_,
M`#,9<R:J]L+2","`.%FNM=!'%.^>44P$NHN^F3/($J?[E'4<1[9?:Q[D;[$1
M@<DA"<(11R;*YASU8,RS&M3NC:FL@-G/$$;85X?MUXEU+ZED2#M&(<D4,;'M
M:[U]?<""L0U%8S97,:N\*&KCB_GDK^BZXVNKB910WG$QO-Z-+&X,U(%9(K9H
MG1O:OQ1*YR^X%@&];0%6`]A<6=;/="2MD,=N(=<7:J'+$3*((W8=#E2F@"%<
MYR2PH/.4V1GM15=[4!*L[^O,IV!FR:BRS<)JQ5\ESU.\HRS(9IXHQWG?%U*&
M0I[JZL9&QON2&!'.5BHYOK(&=77-974E9F:"_P!!H$<:P@Z`'9V4HU3%$79/
MGIZ[5%="2ZE?(A#IY&NFF@561L3_`);6L8"01'0A:2OL+,_1W4T*NGB6FZON
MK2,B1DI,LA'XQ'4(B&V+9XF(^!XZ1^Y/61GQJGJ#QO26ZQER`1'NZ7]]-%)&
M^/JVUR85.*:1)(\.<"GZB.^>*5CV_!+[%?)&U&^B)Z^@88T\C-144.<U6C2S
MA$=701D[6\)K/S"/A$GDG/*Z#`H<,19!$LTSHO8(2]OQJ[^WP&9()FY0[2RO
M++44([I&1W=O8]DU=>J5D\+#HP`QC>RI#8$2D!,>I*M:X2-OK)*R&9[7!%)'
M?OKED$FJM7W#'UT#RVC@SV'V,.;/*YCAK`V8$]>^U4TLUDV=T21R>U\#O186
MM:Y/>'PW[=_4NKP6BKQ?M)S&C!AD$NY(T^T$%M92UA!8+X"2YO\`K.=<++,Q
M/G?%^3[(HX/;#ZI*]J@A<Q^S?U#ZY:*+SGMM3V2U-IK60+(YKNN['+8=7K-^
M>44!7=N0J,(0`:5\TB,5/[4]6+[O7P)7D6EA@@%-MM&+`*QDTZB=EW=I*@H%
M<Z.4F8(?MM2/7ACH,DLKTD8K?3]5]J>J!K(ZA_+;].L6?8TO.INF]U-++DS/
M[M0[CI`V8?*V<:9P]3IS>H:O]WK[!AT,+YH1)X&R22,C(]OO]@(O,/Y4/J]L
M]&/G]\WKO'F(YM:RPOMYT':\^@@DFM6AV5_L<YV.HBQ@A<H\08:FU\<<JOB;
MZI[T=X&S:*NSU_)6W+*%98KQP`M/JUW.F!"/BL08)P91[R+J\@<+)1IFRQO6
M5/:WV/\`7]$<H44N/O!D!/MM4_48GFVN*LC.GNYPW5)VC=:!89K#'NW<NDK,
MJ+I9FDUKGCN$59KE6>KEF:O]O]X9_P!Z_MWG_I)RC/\`3!.<U-\5J]?-E*VR
ML=/O*BNJMN%3':;.0RA5NVV)%\8;-5N&'A(EA2.7TD5'N5/:&9]`/O'G_N>)
ML+>]I`<CHZ`*I+@#H=1N=V/;8[1.M1'$-K-!?BI%:(8/)':3OAE^*P=(R-[U
M8KG!LCR3SZVX#%HLM''+.RV&6,Z,<6)'J!(/)&V>].L9?DA&E1$5RLE;)[?8
MC'>WP-,_WD^X77>*=-QG&?KP%E:\X[.0;?=6&WSYVS@:V6PL:')T((9Q8$>8
M)M8:J=ZR>Z1CV$1S?CR)[YVA<?\`C=Z9T[O/U;PV_P"F6=!J=I:ZSJ=.FDK.
M:92@`$FH=(6.!2V(@.80N>T;5PCM>US(6Q*SWJCV-25X>97GOV9_F2^R&\U7
M)/JSV#N>SWG,M;JM!=@T=UR_!&YK&56LLJIX=+5Z"MH86@!6CI'.-;+*4;)Z
MK-[(F1.E"<,?]/OYL[&[DNNO:'[CDV][=W+ZZ#0?<BDQF7`$)RUH556I45!U
M:5U81%J%;!+71@K7R5DKEC_']'-<$P\4^A7\L53MN-Z+<Z?8Y*JQO3\%M-D'
M>_:*[ZL#?9JMT%(;LH["F$O]/'->2-AD_!%4=HA$+6(K4(<^5`5/_B@O&.UN
M\^I%=95SQP]$/U6IISP*I<Y:/L2;S+GSV]725E-EJLG\AL;6O_(G0L(.2=88
MU5OL0+$?P2?>6SL\%IOX_-U8T-G:X)3=IQ&S'P^=FL[;GM%:D?Y3S,^R;G+<
M2ML^2Z<1;<<,@%QS*HE48_\`'@8YH>AP*30-NJ+3UE7$?\HI^Q@,T6:#KV+>
M/,44U9ZZ#G8ZFOG?)%(Z9)&+Z/27V>B>UP>4;^&"&RS7W>^P>3DRYN9&LN-=
M56FJS82+%=`9G?L..+J-`@FTS>KKPZNVD='&)"%7!--=$DJJUD36J'J@/IE$
MM:ZV"P\TSBXQ"I'V^4IZF>6OM8K!E0I4(O.Y([.LA."EA>3ZPHC4D]D7K*B-
M!<L0C0`:=\6;]US:6AKY8ZC$UY:'MAEGEIGU%V?RL=9B2P898Y)70NCC):KF
MHYL?M<"?&9/9U-F"1ALU2?LM1^UR$.JZTZ<8PPS\D.*PKJ[F<32S#Y`B$=(W
MT1)9GR-C=^K/`:,+;/YH)K$"J+<;(\BO,J<1F:ZQ:H:_A+,IEQR2$N$2(B%K
MUF]6*J^OM>BO;X#XK:/8OI:JUI6!&UUJ@M>E6P#-.D,D:9*XD!T8G/Z@*"6<
M7WM9#))(OND5LCW)(Y[0Q;-NDMLE0&.-S=8&-,=`U`\I0VUPVQ)O[**M(<#8
M\SKJBE`.`AE1R02S-FDC?,]8UE7T!N"2'5+WC6'Y%O/["?CM1QL5`&-(:KX7
MH"'75-+-%7SC%JB/>KI(T_L5)?55\##))NDHD082"K'6.-ML4VK$M'%$B3_"
M%1!LF$9`M97"^R9?1S4DAE1RL8K53P%Z.XOF5AMJ8RTTMO8S6$<=U:RY;]EE
M<*94PDSQ25KY9X[.GA]8D>BHD3G*GRN5B)X&+(1I#)0K`NP%C$I!P@7Q5`-*
MQQ5:+$>#6PSD65J/-*-'7@M3V>L/O9^DD;F_IX&9+IG3"AQ6I-O>I""L9,9V
MBK898)9$E&;!$+6F.'JX:\)D<@<4<DD<CD;[W1*K_:&';VA4VDFJJ'93MIKR
M9TF6*L+)\=T(D!;WB?O$U_O(HYB15GD22)J2BN4ATD?]S5=X#=M+JWEEC>/-
M8CJV*+YH9M8L`L\T;)6)+`VJU<+1DD?.DC4:[VL1JM1RH_U\!#AM+%J5THUF
M^BL(H9X#"`KBZF-5/R99V$LG*Z_"&KITG0?VQMD5T+'*[VH[VJ'*<VZ+5S#]
M>?I:4PM)SAINAVE7(&T02",1UBX'8>I[%?\`,Q585[QUB]J>]$1Z`VR72?&Z
M6&X/$@;`!43%TFQW2B$5[29):\\Q:WOX<4[1OR6,:85"UR+[??-_<K5!7MZD
MDAI-G>V5UI12`3_Q&G]*TJOL!U?'5Q-1E'VBO<)**\-%^52X8WHQ/[D3V^X/
M1?S5BQ\ZP3%;[%9C,PSV(0\M&>VE"3V_E2G6<A/IZ>GO<20K_P"JR/\`^)0>
MW@'@'@'@'@'@>%#^9ZJLR/NI]M=!:]-'S^;J=GRBKK**PJY[&_8>9]8>?*1!
MDIHWT]%7Y:QE.B;:$6![R8)Y_2*"2&16J%'?I+:Y7JHG9^%`=UI#.B_8[G&Q
MJ,13;'*7?.^I4??.74T&VY9H,[<6)8O.KR^Z+)4V-8`V:P>;'.4'&T61LRR>
M!J_TQF/)L1Z+MV'NL_=V;G6`A=;:146BE=4U(5C>MUU9;UA%9I8@!E8_XRRA
MII7RQN;9._X8`>9&=YK3UW^7V?0=!T46\BO3S0>?X&US^FMQ0KB:-"=_I=2=
M=Y6IQ]G+;BJT8$:\1XYAK914=^L068^GF.J=MU2'37^'K<MP#G6=[9WOKUKI
M,].+#:YS$8N:W&QUA<$6=5_E]A8;W0#05[9#YVNF)B1GLEB,$8%/7Q!:^V%D
M-Z*4?M+NV$UQO[;2VF^S>8(#OG1:2<1;.;,Z31Y]HL+T%E"K"7P5PKU6=S15
M]X%3A386XN"U)]]K?](^P=D,54?/?5=L#H?JP%936<=R:/4)&':1%1CQ1SPC
ML<JRPQ_W,]R@[<*TG526<=A8P<OS<-/9D2:RD_>XQ10:U@<8`B9ZN;[I#7Z(
MN&K`KGSAQ$K*Q)9/QAFM:#K^ENCX)R+[?X+HFUMB=SF:[3UG-.CX/<<Q$*SW
M2^;;DUE=NCV7=+=?L1$W-:>.0X:OM"A:O]W'>_\`)FD@D;(&?W;E6^^N74NS
M<8Z?7W>\Y#G^B:O.Y/;QVPEG-H,CH6!FX"PYGL:%U_-34-CA5"2J&57UT8EJ
MP>$8U4DDE"%@LWQ]*S1$LZGM""6PDYAV!;A\:^T<</:3Y:`9FJEW-?A!7&@B
M0B6;H11IFNKF(V!94?$@6&^K/--WWOH?..4\1AM.54^PZCD\\=UJ^L#W68UG
MGM$61LMI>Z2SKJ\K5UN,)IBC[C/!B,HAJJ:<D@0`9TI"AB?>NTX5M._]DL\=
MI&S\W3<7<V2.Y1GJ^AS,6"K"/V,/H!JV.DFHZ>ZB-M#2"!J0-W_HB)#_`)O1
M_J@0GAJXW([KDEY)^=US+:.NLYL]?,RAV>U-+,/JYZF59X[2R,$GTN9/5EC[
M0$.AM0[H:,7WK%(CP6^749TVN-R^%L(1J^RY_3)6>V66JK<I93_R'7512LE`
M`CM(A!$$%G>XV(@J:.+WM]C7-]R@_.O5W*Q;2J+L]?HYG<[M`P/\RAP5>51U
MUL1I7:%MM1YC-VW[]K*B:1H\\4XMNER(;)%(4C6MCC<%AOM._9:0[Z^]\YQ3
M5.XY;VKZWYRVT&8IBP-+S#+?8K`B5N`[?A;+`QEDW(5X'HJ8;1E/&!G*";?#
MER0B,&6><*H!$\&+MCMOF;OIN-KZ@$G=$.JLWFM?0H=90Z%MNVG0_3TFB=?V
M0V1CNZ^J>7="#E'UKXR?8Y[F`^>0V]%8:\UG'*8V24C.5MK8]'ZQ<Y?0ZG/4
M.O@CA+L#J"="^<<TA>`:0*AT)Q)#+99X'6$,[E@4-K'VCSG,N5XKZU?7W8=:
MTA70J'D4]UU0?.`7-WNA]]O#+#H?^"%S7%W1@#2T&0NV!SD6H$Y0;H'HV)K3
M&,0.KZ%9@`;[,?48O(ZF\(6H^W7$8M+4ZT(6PT-F#H['660^IJ=A(Y@\D3!:
M@:KL1YXA3E;Z_@?*'*ORA^@#X!X'G2_R.UCVMP&506UW,[8Z4.IFM-#S82IA
M%+M#XK25LHW9BRB!X`F(C(XW031_&]B,C]RM\#.@UAHK,P#59!;!X=?-8:8*
MDT^1>?<`W"K!*.6')]A'6HI]-^Y,AEEJ8/F&?$R0=6M3W>`\B]15@8L^Y-8!
M;:$LBGR>5B=<.==V"6%,RHL2RH;3K]3E#J^O_$B>^`F1)Y2I87,9)'\RH'5G
MX)"*R_#>^.V(J!:BW(FLKW/#@Q%A/+J;BA:>[L(,9[`C+!L9:13_``_D!,?`
MYZ(^1P<@=T?6I=Q5DIU?)4F!DRR33X?]AGCF#FR=:#('1].-..T<==;SV!"S
M(X0M@D+T24MS'*&5;Z>J(G&(,&H!IJ\:EI!4<VN`.CD4P!TNJCC#ZV/,ZO=!
M?J2U&Q*8Z(-K(F.E<L4H8.EUF?**GL*:KU+P:HAJ6%9<ZD,FDM9*>%%"NPY[
MOL%9?_CW2R23OBEG:4K8V.5C$]&J#(K3([BLMI;5VNS[%*)FS`3[W-'"FO(9
M*1=/E07LI]O''ZDMC:TDL9TL4RM1SHTD3P%&"28*WKIVMM(B3)J=$+H]/F(H
MCA+613`;.`>N[;8&T_XM<;^1*V9HDWQ0(WV+(GQJ&$>2"S3PNOM/>QFV)C$M
MK&X/I"_V^TC1RS-G</V&662L`,=\\<08$[WPO14;[7>!T]4.S//A;*ZT&L*S
M=375;K&VLKY*:\2D6L$FN'Z>,P3K8]:^J!$F_)2$='CD121_/$L_Z-#RK=&_
MD"^\WW&[!<<H^C#^DV^8('I](C.&4FB789:NC993SW/1=CN]&/15\.PLQ!`W
ML;+4U]=[IAF?E_C2/D!#VW7?YK_J;55UAVC3=%?G@;L"BEU6CFR/3>95;)OP
M1K(S3%U.]?<4A,ED7-$H3RA%?9RL?$:UJJWP/0=]+/N1E?NIQDG<QTNGRNOQ
M98M/O<*:7:BUC;K\4!1+2K;>]=RXS\UM6QD.%D#A1P9T<X\R^R#WN#2?_(!V
MC[.@_?K2<BXSWKL(K>@P<WH^3\HKNG7>%YU5V74L4&!I[766`W1#\W445)HW
M>Z6U/FE:18R21Q2111-F0'"!_&/_`"0;[050]Y%F@J*66NJ-<S8??8JJK[.M
M"I1:Z"%SLA=:+0D/!,"G'G$8!&DADK?;\T<CYF!')S_NO_'/U/)A:?2;5T.J
M9>6U*56==L.H<9^PE/25];:K679M_IZF2BV1M2/\;)$@K+6JA]A/[>21,YD0
M;>/L%V7/=Z_B]^PW0,TX\$36<%GV64L([<5+BA$006_LR+P:+LED55STIN=9
M7G-+:$1)$2^-T7Q(]C`\Z_TA^G(_W\YOT<X+JX>%H<QIZ?(CU&?YGB--)5L+
MH!=&MFNIONW<Z!HY+;2#S%AUZ#DB?LS(D5[?U9$&P^T_@!RNJJ+3+:W[J[DP
M/--2=N?"XER:>4LTCX*<RXG%I^]PCRGL$D4H!]E(Q`1(4@9[GN<QX7%^K?\`
M&'S7Z@=0"^PV:[7U/635N8N,-#S':P\0R<FQH]/!5A6]W+95'9;2,*?.0,1!
M6V$L+Y%(;[EE>.UG@1K_`##?9NTP?+*?DG+[ZI&*Z/$27O:4;0131G8K\HV"
MMRT<O^27=78`:6Q':2^,MLT\D`[1TC>U[VJ#E^G'T&Y#D>44)/>^94G6^@7&
M:AG)S=U<\JJ^:4,5D4)>A9UO/UV<X1FEK:Z",DLT\16Q$QS-%:R&.&60.[[C
M_P`>/+.C8J\O_KSS"[XYT7+Y$F;'19#2<5I\7?Q9\%)#<#?8<7I0-`7)IH((
MX1RXJJ0@`F"!Z,,]CH_`@3^&;[,ZW;X"W^K6K&&--Y?1A:?(REVV<>^#)1#P
M"VN4($+L0B8M727LHY$T<2-'&_<G1M^,>%BJ%:]692U7\W&8)K?R<[T-O9.,
MW5Q3EUPN@F'JR>9\V%GD'U`EM)4%K^PW,A4QBS_'*)"-`J>CG-<%_?YAJ`#=
M_6W&@:B@/$$K^PD%5UF+IL$VQTUA!SC1M'$8>(0:%GZN]E<D'YQ,<Q0,DXTD
M;9)$:JAKN_C3NZSZZ?8+ZY+9*E>7U/E//+6;*T^@ST9$^'Z5DZ6RAGMKFZJ1
M7UD.5[;GBPYVR.B666P+),^96,>H>K0%]5%:S%W,.1!&L"&2BN(E#L923(QY
MW`L!?6Y:R(((,NY(8RQE<\A%])&I&U6M<'F!^U^6L/L-]OOMCT+,WY^>-X9S
MS12B:$2$"J`J[W(,H>8(4!;P9L"TDCUU_;V9`C0ZX]M>V%I<BL5R1/#:7_#6
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M:XZ`FN223_UMD:.JN8Q7>!Z_N/\`;^7?8+D>3[;EI(*[&=+RE%L:P(VHO+%N
M7OS6K!<9\O0!<V;7ATN.ODG`?%$A3Q602P.DF^=)8P\U_P#'2#29_P#E`ZO2
MCW]@5ISI/N33/&N,Y=B!GC`=+$>([+(3@]HM7FV`4#BFQ-:+*3*3)$R-KH'H
M@>EB"GK[".%Q=B=<5;*\F)I?^*Z9XX%PH36OE`_/Y:*$2P-&HU%=$GN:UCU1
MB>K4!5K@`S:\EX=TDHM1+^;/2UV=/?-G1T>9*:>`VHXXDIR@UX$L_O9\:(4U
M'J_TD:B`L9VD2SGMX!OW,JO,%G+^9<'JP_VT![GRG!DRV?.T`?77#259.K85
M5SW_`"I'[XT:H-HP#.0W.J`&KJ4N>-?QQ8QLYIC7`%N+A_;9AQJGB<,LP!+W
M_C3,6955)/D3_A1'!(V/Q>%LP5N8[JES-E^SV(2$ZG%Z,``NV$FCCA%H"=#D
MX)A3*V*&09ZL&=)\"Q/]/^8K(@;EKF**@RI`5F;E&$MBABJVATN@*@:-$Y$M
M+:U.$Y_-95IMH1&%'7Q+`5&:UDOOEA<]OJ$:PU5#\$ZJ.4>Z6K!'&;'F^@5\
M8-FMBXA3T?-5UJ$#%MA)>T=T4;8)"G.55:UOO!UWD&55TP9I[<M:"Q_N1\Q<
MEBOPER#U@HU.AS`9UCJR!6^Z%?BA^-6>R+]'*K@S,['1W='/6M)VR/8D[B("
M';P8"84N,B.'.U]0?<T]64$62Y)"YW(YZ1QO]B.>K4<"$;'G&.G*F,/IX`[N
M6(&EJHKL,YILXI$4=6J9RV-.*8`^='0O(>V:5S4]&KZKZ`HV3J>P9.-7+;2V
M4<;SCW$`Z:Y$C4&2R4,RHFTV[J(9ZJ8<N*.5LOME<^)7L;ZN56AC31ADSSM)
MM`M&;;P2_&/2UNAK&CDR.B9!8*'G=!"$PSY'*D8ZE2M]6^C_`-$8K@0?Q1M.
M5*1%86DYT5=52A*[.V<0[/8R,1Z6-CH^TU<ZL&'&8U&0Q22-^-?T5JHO@9WO
MJ:*=9Y=]%8K\49\T%>^S)*B&_-1WYHT@&X">!+*L"^CVSI[8T>B_V*JJ&'^[
M0%R-A!DT-L..\EKD/SQ,T_[0:DL+BX'W7<R%0L:*PED<P>!T<B(LCHU5OO0$
M`I0FUXU<'H[FNC2&<*NL*VS2SGM:R(F"2NM/P&=@="B5\'R2P1D0_D2K!(UZ
M*Y(O<&'2:V"?1+G6XC2R4H^9M#"]V>=3@T%B:4<1)'G5CL.[&R4MH$$C9QO1
M/0^4A5_Y;XV^X/0_S&;\CG.#G_5?ER&=>BJ[WK[750GM]7*4:KO[?]\TJ_\`
MV3E_7P'SX!X!X!X!X!X'A3_F_P`B19_<;J19$5`[.6_V`YY06Q!8ND#(I2['
MZR<=A&OB],@X]3,1%7?FM%KZR4P\=L3BIAU]L"*&A+.=UT&2Z_F.K4^#PN:O
ML#UVFTU-D+,2US!Z%\PNJTR8E;NTO1[VXL+BM`6_)<8XMDQ$\#_G9(L@J!G]
MMR^=X=T6TNL'0:#:?4?[%K4?8+D^<F"6$5^-Z8X^_P#^C^<ZRBS!46ZHN]WK
M,A8(OQVDH57!,6(V!L<#P3]2G+\F)?(W([O_`#)K;:GH8=CJ:0/!Y\RJN;>M
M6PA?GHJ$K=5EI?1%!!C%3+'81$1321Q_DPK&&?\`YIN>%<!Z?INP?N(?V,^^
MFPJ*`G%WQ]QC@<EP;DUT'>E56US&I0`DW,[CINLKAZ,2*"MBKPZ><YS?1DTJ
M!%PVUSM_C-#:S`\ZJ8Z$7-STL^9$T89I@>A6/\JHL29=;84M\`KK55)C;8O,
M$:V:5L$,4L*RA(ROL66'+JPAU4^T*.[0<1I883Z*G#,M_J#-IZ@T:KLS3`B:
MHDTJ<>2<B8[^T#Y!")$1KW@^KWD>AHL7I*#<XFPS":[FN9Z%4V)],;M::_(J
M;<$B]N<E9N'AQEEGB@=6CUF=;,>+82,"]D)KO`B_JUZ)'2YJGBRF-@H`\#F3
MM23>A7A=N#'O1X37'6-V=/%%FKG*"W)%7"!ZASO6N^$4>=9Y7R!*W9K'4=8!
MP?V,X](M-K`.?Y3ZQ_<''8+(W^KYV%><DI:*@X[VS95U[=BV%12ZWC@[A84G
M/-'S5UG99(9(3&NGA"+::;FUAIS+.?F6R_R:^#R5AF<G6]E:#RXDZTJ-3?YU
MCWUP!NVNQK0*E4L@00R,9DMU6LC^3\U?:$R<+O=!RZ/0?</;9+:Q4W*L;'P?
MZ@U4YL^5Q6CWWV,H]?C#MCS"WK'`6LE1S/C=I?G6)0$8,AMVT-#B%3]8P@K(
MG?YT1-0:/"8"WK[.XLXS)`LVM-K\389O)6;CI@]B&3?60)E&11",B;(:Z22)
M2`1A272SN4)>^OGUJ[5U?-8Z]YMS3?W_`#7*6VJZWJ=H%E[:DY)RZA@T5'D#
MQ;7I-@0+CJV_HX@66+UIG%VE(&WUBB_&FE^(,KZT8^"@Z/28V/<AZ>[`YXS%
MB6K*[]PIN@L,_D-UM>FFI@85?=ED%L,647^^1)6.21&M5$?X$;:_>?\`36GV
M.4%%`J]<#UFQS.FBT5#3::UP^6HXK)9V-$)EO\W!%J-,2<%\[:VVD?\`A(KQ
MQ8U?-X$H8"6MZ]R\KZLD9G2L[IG;+4_9/Z:6_*TH\YI'7,]319[[)<"SD[K5
M:32:+09>@*T@9520,3&;F_ACE8B#RR!'E3<U^O=<?]1^6;W7;?-MT$FPM*'1
MD<WV2;`K.V6I=C=1C`@UH1+^KH`*VE@F8"Z=UU9C"^]D*1I,#KYWR++?8F]S
M6&EH?^E_TXY82-T#LD^>(!?F`<!C<^5U.PL-]L[\FRN=+HKSGKBR:<,@N>2`
MVUC]@0DRH]0G[0]RTOV#W.^[+G\:W%6O2"2K(C+V6:SW2*L"C)NLU^UY.32;
MDAVHJ*&(.D?75A4WX@UFH,(<9$$,DTS`V6?0#G,3/M/@MG158Y.0Y=]H_KOC
M;(<*K=9UF7TN^Z$*^H:#<(5+/1PN`1OXL4WN<@[WM>BK+&1,'NX_V_W^`>!Y
MT3[=MD=8UMJ44ROCM]3&#<F6-E=@`GRWUE.3`Z"OWHC'F*]\,DK2!IY'HY(O
M5C&L:T'A36EU2R9=]ZV;!G,J9I(;TL[84<)8Q)A+8(BA<ML1KJ?1$CUSDCB:
MDB$`R?(OO=_<T)FNHH(JBN--'I([F_T%9<$1T1)-3$V:["+'#>A\&T6!N@IP
M/BFB@J)$`]'M25BDKZ>!T;"HKEK3=;>3D5U196U';#@&3#V5S74UG-"=^8P$
MO9I1RW%G..Y?4%J!BH0YBM3_`($")U(*L1K&$EA<&=?2!%!YRSOSG6-A?6%V
MV&I"KJG/]#^%TU0YJ*I,[O1@D3QEE21D4;043()Q)UKUA?"+6E14LJ,GO\O9
M122QRMF`"M3ME&<637,@_+^4LF4;VRL@B>ON9$H(I8E9`+=P0Z4*8T2"I(*N
M1M&5/&/;BN^,'/O++Z`8'8RT<`SOR'@M?&YLZ-8Y(F^G@)T96DO]-H76][$+
M=UP]?,P+4REW)(Y+G!_A#3Y8?8Q4M7-9+)$QT4T4<7]K47T:]ZJ#HK#ZUHEE
M6`"6(=F:LI]AIY]-9`5(/Y-D`Q99:&@W0\24`TZ'C/=&QR3'E1"BJ]C(FM!%
M^2:*PNJVYL99K:FL#Q22!+=M$.*4&B#6DA45/NRPH!!Z^!K89")D3Y%CC7V?
M\+@U_?RU="E;]"/L6?5!+11EX.IJ'WP#:N>&HHS"L=G;2::V.VE@XVA?6$V,
MZP_C3AHUR,]J0.5_@4M_^)[[[.G?4JTT>';E:[I%KW/:6'3;0HH>DL_E?3U#
M\]'H,K%N:"IGI;#)?`L$TT,@9SIW_&QS55K0W8:FFK+;#B51^1@*S^EL+FBL
M["QU(`YE\&55DAZ6GN*/_J=8*`PN,M\WX\WQHJ^WV>U4<WP-2_\`&K]#.\_2
M#N72NB;7:\[O?KAH75E-3Y%G0]C=:`!^?U7[ID5T:729S-1&WF&6.)HS2BT@
MB3U571NF?$&J/^4RSLZK^9'F5_DJJR$`M,K]2]M<".T4GP5E7#UW5TNH+N&'
MWAU/<"@5=9-/,YS"V03-551KU<BA[+MJ%1":&6IG,'-KC$!?8PMTPD5?(#5&
M?/<WM#)%N/R'V]N/^+/'"'+*YT9B0JWW*K?`T(_S<14%1]7^/$.GJG'V'V4S
M1N<RHB6J7[RZ5NV$OJRUG,W5I^X16E$V*<X6&&:)P:HV5(WO=$H/GE]=<]&_
MB2W7.K3-T]>FG^O?9;*ZS!95U0UT]:V/0I10%4(6C'GAJ9;>M:^(5!_B62>-
M7Q>U_M4-87\&W>N*?7;.?:47HO3\!RV@;=<QES,>RV-355A$E?F=##J118"M
M95`0CAWQ1#/QF0/]L3??ZK\G]X;[++^23Z0W),,T?VUX%=WMK;VHXPM3UC<*
M"8%#GH]/!61#T^IB(1#H8)FQ$%/="\>5?^8K8V*@+O*?N1]?^S;ZUS7'NFYK
MJG0LO51:*PSM!/MZ)B@W/X]:2>>/_D064%'@O)H'L%F1OK.0QL<*^GM:'G,^
MZ.?/ZG_,!S+F6DMF"9;_`*K<6HGAFW]C^]2T=>?@2])`$!;2S6"Z$`Z&9LE9
M$:+Z#*Z9ST?ZL8'K%`L*_P#,V@\D&BO3+>AN@Z*K6QC$8+\`,9Q!3*JQM3'@
M.E"'5!)`/QBVQ>]CE6.1R/!#%`J&+6M,S5W&1%^40Z6,S2B6A9,`BRPDNNK7
M8C`CC"D0L_*=",DZ3>]['?%[$:$55?.\'SZ<BZS6/QF6)T1$XQUUDW$4$UR6
M0CK.0<I,JL<I)1DYOY$T))'][W->BHUWZAY^?LW765!_,G@[.2GNX2:^W^NM
M],ORR"%4E2>-F*F*N&M"+"Y984>E*J6L>LSU&9,X9L:L;,GH%]?YA3`Z_P"I
MD_[D395T--VW#V$<91^M/EH"5`U,:_C94Q',)L0+?VNDC65K7#^CQX_F?"G@
M:W^T5)M3_'1]5/M?FZ%*/3\QLM%R7=[:UY^>EC2D+K]S8T]Y8UK8O<R/_/\`
M-I*&%[OSXDFB9\4JK.WP/1#ROM&8UGURS/V7=++/E!>/U>[)MYK.S>!%?U5#
M+<Z!FF"%K9*&GCI[VM*F1KI&(GP/C>]/=[VAYS?JN,'TOZ#?R2?81N2M=5B(
M>=755G"2Y)K*;7%PZ2XZMMB[^P"'"_9?R[YX@S9`F!MC"FC?%`_WHBALG_@=
MT-EK?JCKS;3%$9*&FZR)-9N"+UCJ7237F3RY%G)648=!+-F:>SDIF%PN:]WO
M(7]8H'%O;&&@:OY%]OD_D;ZUS'ZA60];V2#O'V8+CK(;#/822$/3ZQVCO_R]
MU=SYZRK'A45.(D@IJ#?&0#ZCK[5>Z4-AW_T@O_Q0A<1:@+2'=$N)L\4&*<*3
M]LOA"EM;>D)JBB[">NV6BUE.IQ\,2I$,R!TID2SOFDG>V1`L=]4/XWOY,<IV
M3A?2>[ZZ1<]S[J64UMKF-?VW4:^[M,E6)JYK')I"'06R:6KU%-Z1R2%23J86
MR-D\K6+^@+W_`,4'97Y>#\,H[R>FR947V0/QUC);B6;AY`-%CKDXFZDL8,:B
MR35A50R8:(,8DAQ#(HXX_5'.4+W<A^LW-_MK_$GP?C>TJ[O]GZ']7,6\&TN*
M2:&3&[GFIHIS]IG[VIHC+.314&EQ@QQD2K')&TLB+W>Q[AU#4Y_%!WO0?7?[
M`]R^BGVWH6XC]YU-L/E<[;@!S2\_[=2!+7UN7JL^+7VU9_B'5:.L4BG.B'KV
MSV<HSIH9"#OD<'3]4[NCKOYI^H/U%GHQX]9UK['XW+Y6>":MOJ2=V$U^FK\_
M/F8:<@R2@CDA')!(*!A19WD?$UB,1'AZ76TM1HJ=7$UA*UM=0V<H=C89>>60
M8TFU6`JRA2[RM<S\)2I/QY&.;ZL>X=[D>U/;X"%$V[;1E#U,D5C$4:>Q%C$^
M=#(P8BI99G09OFD,#3[,-KI71,:_VCMC=[U7U8H2A;Q13NR6OVX<<4UK0#!4
MTY>0B3.60P@X-;%*P2RJI)A65+1HP[)OXCWFD>GN2-O_``@RPZ$,RU>A4-<X
MIB302-JS)1[B*2:*8"P#.D$Y[5Q``PPG?`^48@CX(6_$ULC'N>P)5AQ.3DK(
M_P#+XJ6"O2&1D3(L\,)=-RD-T9";7BUGXWQPGA#6"6<*/(]L,`;9FN<Z7V-#
MAH\=?8X6W-S8=-JLV"<J&#3@5K)&9:M$#)S>@JB(0DL)[>XKRF2G!_BS>JP-
M5)'2-;Z@V]$'$4`+)=8]#SI;.KB%(KKU;HL=XU#';D4=S37I%,(?/.DON_*=
M^1($T)\4<:M5?<#=-Q=[6T'Y;:/,5R3@?G>ZQCKUL)P&O'AE?&ZB9,ZM91EC
MNGCB<6V0D956-BJC6(&6/22GYEALJEZT`&YB'KK`04`HH$%Y48I<L8>@TBF"
MBZ6S2:(.>,9A)+8T;/%&QZN\!1CF/DO+2BI$J8"!K"DF&B@O/V\&(=0XB:ZP
M/@;;4!+XLW`L@:@D0K&R1[EC1',:B@@29]::4BO+I*&-ULHE>ME46.62$>^B
M(&EL;'TT&ZDAF<5&UL<+9O8%#$:OQR),LOH$BI650-O-4ZO2WE1FZ$6)I5CB
M=%6OL!TLH'#YS\K]@W%=2S5Q,(HI,B?).\<J5\?HUCF/4(NL8<'F6$5@X(UC
M>V!!_NN_\FH(`/VU2B!)Z6N2VZB61$XOUA?'9+#':12R2?"[VMC5`9A%D<0#
M.,!)^5\],PD\2>P>=+`HLB_B25$8N^H[`X8>KD5"VN]L<J,_(D1R(LG@.['V
MDE$,<3//GY"31&%):7=H)G0R:4D>>LL1EGL^N6=H79U]C-%%$=3QNEB>V1GR
MI"CO0'93W-"E:55$W=P13UE.+*3,@C2[B'030&QM]+5FT$&CSZA#A."A&6-S
MI"O[D=/,]W@,G,5=;G9HZF_TEL$-*8T^PN[,NA*E@!M6G7P7OAI]Y;^RR08B
M%K/C%A_'?'\;D;$Q&(&^/!Q/@Q.1A><MFZ+-TT?[BL\)3CD;7CHTMQ(SY1R'
M3M1'*]CG,<J^J*J?KX#L\`\`\`\`\`\#Q^?R-_9'><>^UGWXYG_@G*>M<WWV
MNXYJW8?J6>UCW?O=9]:>2@W$>'UV$M0-E4;9<F!8%5L0+'OG-;%%[V_,L<P>
M<++9;ZX]M[PWN_U.L*WZ^`Z2WN;WIOUVUNNQV;DKJ'<QD<RN]1]>_M7?VH`D
M6Z;I2)RZC/ZZ>LL$MBV5S"R8_AA<&SGL7U.;R+Z\!\=Z#85Z=#Q>K9W[#\X;
M5OSF/^QG`.CU^8K>Q=:X[CIBZ$VJT=)T`+-FW.<$CD+S%Q,ZX#AB_+(E4-/>
M,S]'?ZS'T7(P=7JNCQK28;&C]9_QF(?GL#ZF@R]-N+@VTLY:XTK`Y?.!.8>V
MOIZX<@=UO(SY8VBQAL0^TG'^H:?IW^;<)3';3@>?A&^M_*?M)W:[RN2XEVFE
MR.9$S-7CL)J-'%8P7O)Z:XBLR;JV#98VNUTDL\S7.D/#A##6WR31<VYQ:9V.
MKYGD?LY;R'AWVOWOV$IMT1R7+Y?C&D*"/_Q+F^;T-21N"<H,,1/42WUL8RYF
MA"'AK6N9`,\'5T+KN[[OV&KZ3T[7%Z+I.PZWWD2D)."H*]L6:)^I0H&8!AI\
MSG<IE*6DQX)$5>"##70,$BB^-SY4<CWA?7BGWF^R')(N3<XK]EC"^&:"K_PV
MXX?T.KI^B\G"_)IFIO8KBE.%#=E:VOT%B\]EQ5V$$31B(&#M5$;%,%/.@93Z
MS?9#=9H=N3S?T3^U&8U%ARBFS8`N\Z7]2>LZW"RGZW,_B:E8"^P8//UAROA%
MF.=IZ*[''6=\<$7XKI`V?\W^NFDM>>=N[+O.CT'(^=_8W#!<VQ'9Q[_"="QE
M7]D:_1IO^4_7#::RF)-PFUYV_;CI-@]L8LT;::YESMF^.0^0*`-'EPO+<K81
MFZW!V69L\YI8K:;FF8+S0^:O=;>6N7*,D(V0NC;JZG!V!-%1V`E&T<J4,:F2
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M_D?Y#];>B1#@VQ`=`_+#2UZK+'9-B>^7^]49%^CPM']LN^X#[):JJE^VO&L#
M0Z7I4(5SF?L3]:Z6LSO0JC75%2X34V?3,+=CD\9ZKHYXIBZ^86I*!M(ZRR#,
M&L$(_6,)X^J7UPZJ->8<KGE[E/LC#]8I`]2/E^;:(#+=7H.;55]<[S)ZCGF)
MV&@M-!S?O.-J="=!+1.?9,V5)+"(*1;B1$A>!5+[)XOG%'UA'\POI-MSBUIV
M]$XCW[FS6-%LN+E7M'I.<Y3?5FFKKTEUUSVZI:(0];0*2XISZB,(ADXSHV,"
M>?K+Q@SH7UWUN)P^7YL/U3I06:R'!_JK%M:H&)>.X7<S=8Z)]ANKW=D8'2LY
MM2:V;+6YEE=DCLO;0`6J]_X(J5$X,.WH4YU<8V[Z%T7/]]AJ9[3,TU)3Z:JL
M:`>NQ]V7H-)HNU;N^OYJXBKM;HMX@U'G9")*\(H>%A@)\3E0+^_5GM_6-=U+
MZ$XC86];B,U3_</D.GGXWS?'U?,L\#-L]JP7&D=#I*>62XUFP92B#32&7-EH
M/?#)`Y"/R(GKX'N=\`\#SOV^1K9MW?&6,^FBJR-E;DPBZGI_18J@<0W2DTYE
MB'40=;C1E36GD11,8L,<43_19&HUJL:%BDSA09I9_P"W?NE25FLE0,L8=EM4
M'`R7YX)L$M=)8]1FL9;.>OK6RSD,A=:CBF-8DC92D;*"$=488RNR>RD$O#R7
MA%U=IG1MMH)+F`$:9:N,+.CV_1PJM!+\=7QV)BQ36$#%:HTL/Q(Y@2-;[+)@
M8YG[)358`EQ1!BMJKV^UFO-K+<DR$25PI\N\LJ=!,J./[2&M(^1Z2M?&]SHR
M5:$0E8G),IS9`,]=0Z0?\*[T%U%O>F9BO#`N91`\^//$-UJ&SC'D/">0TJ!J
M#3/*8V"186/;X'3%N\YBAM0@XEP659358LK1]%8WU?\`O%K4EGF6ZWVDZ;9G
MPAR36;XOD@GA:P=8'1>R5(G^`U=948\T"H(&HOR(1X*@&Q=D]OUC0#YX*>PJ
MK*/_`"&PUG7&+^43'10>MD%))$Z%S_;+_P`R5)`YJE7<:J[/I;N`<C1VPBS+
M;]6W=B+5.C1]$.8F=DZ_*=8S(LKB&MAAE<BR(\AGI%&Z,$R^)H:D8@&NELZH
M6TCN7V-D5T+<YFRL"CB9ORG:`>MZXY\<I%B;\P45='!`GPLF8U98U>T$Z"MI
MS9`UI;K539HBV&]U@[3W4<YI*13.>7-9F]5;:6@<0LC&M?)"J%-14])9/=[`
MC_L_'>6]7P^WQ]L%I+/(W>6O,_I%M.H[C17-QF]142PR$!5EKW1M!665*.>U
M`T@"F@6*,54:^1R^X/)3M/XG_P"0SZA;T#:?6'?;OI`XM(;EJ#6\4Z9%DNAD
MTQ5S+;@0;S+#;FK+81^"4LI8M>3;016;6/23\=7#M!TO_D:_F(^JZ5LOV&(Z
MH3E+.)[-8;V3F6JLV4M>3<.U,E\SH&%+R`;O@B'G#22`MYLA;I87RRM8R!H;
MK?XZ?Y/*K[8W%QQS?@A<UZ<*)57=8F9Z1T[7<][/>HK[0QV6TNUZ=#=4%_3U
MPT<L]25\D?[2R5T$WQN=`X-9_P#-50TM9]TN,]@KPKZYL@N=Y"ZKK>VL+S4G
MYWI%)TW1V=5`S,0:>SADG&N;1A`<+_DKXY;!&-$D5SE8$U$]>_GEVQ`EC?<P
M^T(G[F,\>LCKPN386IOVSTHX$+*.IA*K+7/:&C!$'(G<CT5K9XYE3YVLD4(0
MQ_T$_DQ^RNM*O_NYM^A<LLVSDTJ=4Z'KV;_05G.[YD)5E18[!4>H/CJY*SY6
M3!-+:/%/,Q9GE>Y[$@#T"[SDV+"^LW:N<5,NGR_,7?7G293-S.W6UB6GJ*'$
MDP5T$X57UPRZ'A?#6R.9$Z**`IS)62,<Y7*H>87Z2_Q[Y;[TPZC#E]!I>90X
M/F6+NXXZG%T_4G]8@O"-4LEY;Z6\T^1I\E3YSX*_Y8#RB&F/#E%0E\<#&J&P
MK`__`!/]QO.6(MS9_:"P9/0`9@6`H#G6&Q;$/_:#H?W`H30].T5L79$D6*OL
M2)$<%*.*.-$J-2)O@;+_`*D?QR<V^I5_K+VEV77.F$:6DEC=C3;&&LS`0Z+3
MFCWHI6`W,1\('Y`"25T=@5*`4/*4JI+.L:L#2I]ZL`1F?Y-!NQ[/15R92GWG
M%NA`1U$3(:DJL!DR^-VNFLS:_217>N2.+,$P&R02,FA22%7$N12&-#T\4A<@
M-"\1M+=2!.H[/(#QV-W?0"G4UM(*QF>(>)NC[X!MPH@D[#()V'011/C%GBB1
M\:@P#JC*B1B3!Y$FJO+2@$_)B"L]G8BUM1:UTC/P'6>KZG*<(6@)WP+.GL;-
M%)Z1^DRN5`H5QG[U!=,[C=?7;.<RL@@IC^F9&]V\&RTLQLN6R]09):0Q9TX'
M0UM6'>0%B/>]A$!\<1/NBF_Y2^H:T/Y!N<P4/\B?(K]PL&:%BJN3&45!(,?7
M2VYE;KIB#;"RN-$5)<V&>?4Y^/V5SS45',9.R/W*WT#:M_*+1$;OZC=`,N<K
M7)<UQN>`#L)[*VHK%:8;5_(40+14-B+/7S#AGO4.RB9%+$1^.V665?7U"&N,
M\@,^R'\7MCQHS$`BF6>(ZQD>19:GQ<.QO<U:8+9D:^ED<TJJBN%(31D1RQO/
M9`5[S%D29Z1M<H:]N2=H`TG\8'VNX0)6`3:[,5.6QM92EA23$9.A[VE`&1EL
M9FJZO@)M)Q=')?,A'-&$,="C9D'CB>U)`OU]4.1U.7_A^Z9"[(+F[#=Y_N'3
M-8,N>`6Y+++A)RS7V;TR=*74!U0.=@(&@B*:D0TT7M:,C$@B!V_PS3LK.5]*
MI'93"S"0:SG<SZ@>AU%N39'?L5WGX0XP-'3$7^;O,K[G&(2Z&6N<5%%&D7I)
M*]@:S^-%R5/\\6WEKY$%*@^QOV)JY,<335LY!Q>\Y]I7TL&C_+I6W]R+[(G&
M/8^N8!6NCA5C(T?&WP/5N/'/<3:J[9-HSZ[#@1V:53J>C,(F2P`!&N'$?!RV
M1L%-";[:]2_9/)(.Q/\`E(J(BA*1MSLK$6^L*42QJ+W.4D]%I<Y1<[ELI-"$
M;6QR4PU'H;#*"/@R;:51863L$F97HCI5;,CUA:&BS^=_FUWO_K5DJ[1\LM!Z
M:I[_`(#16-<(9!!:40?2LET(XQP6B=S>D_":7>U,+X49,TL>*98/<]\BR,"[
MG\0MUK;W^.7ZEQ#YV..NH\#89NOSNI&$L8-/-1]$U%5'-;V:4%\]XG[D(T17
MPSD->]OL1$^'^\-3_P#\46_2#<65O2_=K"<WK!-EF<UF<;]@[&@@C'`J/V*Y
MKKCD'1JS7G9.A+`"YX4##3VXT%@$I*0BSR(L(TC?`J']'>G7W6OY$^5?8XB_
MPU)H^V[6KCVU1F"<6:WH/20N,C!:(^&X)P=[9TI[;:OG5HU.R"5@<ZK.V198
MXU#U<R-T)ML&2\#1,L;D2."NN9<R!&L@\@UE+#3?)=\V06"B@(+1ZD/]OM:W
MY$A1SU9X#02IM9K.?_)X2(%D]H3V5^1S`8#GECI8AB&LJN=%F%U[GB>T:%K8
MHW_,Y72-5&M<$@GW1[JRFM8=%5TH[R#Q;&O_`.G]#*5'9S35T\$00]EDH'*?
M;4DS22I9((G>K)(O5?;\CPBHZQJ;/0BSV5?/=T4\8Y-E!75]16Q%3%-]ULT&
MDJ.<F35[Y'R_\H=)G#N?$O\`S_21?0+FY$"[GY[9W=+D<E3W8(])IR2[C+5B
MA#4XTL`)UA9VQ6;$L%M[&A@A(>&X>2(>&-(TG<CU]@-#I%O<-_:10`22;F*C
M$T9-?<D"E5Q=PRY9:23G40]';UUJKH3(GCRN54C#B3VO;)$UK@B\>*\FR]:N
M<&2C(K0KFSAFG%K*W1&/<YJD2T0[C190[(BP,*;&YWL;&$.O_-25WPO!JRG;
MT^>TJK2\N6+=3-;IZ`62IJ@1H8EKVA62Q4SCJA(JD)RM@(:3ZP-DD1B-;)[/
M`6J77:?*W<=S6D50(UL8(57DAE.G?15@AOXX5G8"%Z!\1PP4T,K',>+[G,]S
M6Q^QZ/4'3JJLVV-L+JPVDNNGT6JFG=&!(14%#-LZ^S>XIH5D;05=2,`=.YR/
M&-D21SHT8YT?J]H-[064XVC%:.X"*N6CBKQZ<<^EJQEE!%,B("L#0]_&*^*)
M'?FI,X<AZ.C229R2.7VAU7FEVDM5<8PF:YN99H;JD@)6LJZB$"48"+06\D9`
MVHJ99K&OK!508:5_X[8FND%<KVQJH1TZ_?2AUI<%H176%;*)85+:NWH)S80[
M$.:B`>8-/UJQG57,@*DF4D9[F*B2-:LSHWO#@;I+VGF'%-U-E:6Z03?*^PT,
MYD(T4M>V*<9]Y/TVLDD837O8GQQD.:OM>Q416^B@DB$UY8`&1K[KYP%NAX*Z
M#_-K1*^JNEED>;6#Z`WL=_<O"9^X/EEB27XFRRJ[V-8YK_`?UE5E#9RTO"]+
MJ3QM$!-1O<_H<O[5[83XS`1XPS>Q5SJY1"@9(W^W\>X2)HZ-]H\C5<$<5"50
MP]=GJ>T;$X\F65('Z/7V9]N37"S544B*!U&^M2W#AL552`A\<9,+7?'[V^[P
M-]W$PGUO'^85\CR)'!X3+C*\LDPTI_PTXC$<298'V9Q,[D1/>^8B>5SO57/<
MJJO@2AX!X!X!X!X!X'B(_ES".3^0'[`6%5#&":7JN855M8CE6L5G#3`?7[E-
MM7W;J^!Y$YPL+Y#A('UT!'QRK)(4.C8&S*&EK9YX?F_09@<?'@1AI^>Y?86?
M-J4;0V>;CR?8&C4.UQ6AYM30YLW48LF5SE*V"6]NP=&HP:*,V&!J!+W/^K]&
MH[W-8P&&KL<QCM)?6>'J="@/08L@;V3E5%05<.-JM`042="@>FKZTHRO<*VR
M&K)3E8(KOC8%?N&_96:STW?A<SF.-"W?*B9^>]LMKE];NL-T+HES_DW.\C><
M<RD0]8[-\KGN*DJ_LC-#-:_CV,M;7#NE9`.QP*U]?ZW7V-)KI;^+?%Q5Y6"P
MK;#.:#8A\:'SH+!A<QS/.8\`G19*V`J;*JDK)Z^FDJ:2O'6:S*KFD.FB!JYR
MD_=,+I=49%41VVUN%YK(8AN8TMI'SS"D`GT^:+M<)8WN$VL,VNMF$2*44XJ8
MMT4!,T;0U8H-1T`X=]RVR&C%C@_<M[82N:!!'8R6)/U4LC2!#:XQ*4`-S&S0
M120USSX!(&?',1(YKWR`_P#,P6I>'V,UC4TK;8(7(=#SZ16$%<%I$5M76GPU
MJ,O,\13NN*NQ'%/D(C@$(&!D'A+E6")JAT],SEC$#RFSS]A#065\=;8*$BMU
M#J2[NBLS7U-]FAD/LLW)T'H]J$-+.#!1#6->62VMBG^65J-G\!PTE7:YNNV.
M^PL$?.[C8@)9=DPP\I=-0]5T>!EH-B1;Z_#6UC<56.T=G^>V<L$T6Q$&M:UA
M,#"D,8/&#)O>J2[?[<4G(=-F,*%VOK%>SJV.ZBAO[/EN=<ET&7M]Q:\]V/%<
MP*\*TZAC\_DK%V095VE;^:EX')-`DD8T,02MO^DD=I-NCB'Y`3(Y0D7J>0YV
M#3.9BA=3J]MDXI+AW,Z=*+.W.;&I+&NGMZL2`RVT1<L%:KIS'O:H-?/$/M=U
MU;8;`D;6WF9Q@*5Q-A=$4Z16G5+D"K#V<>(MJTGM/U[+S]"6Z(.MLX1FVPK'
MJ/7230HU058`IJ7$Y*IJP[(C,76KL9+!\5A!!,:%5LJ(Z0@IKY+-UC`0!*1!
M71RR7UBXMTC9:D5TC40,;G&;,_ZEXJ[U=K4'Y2VYC+4W0)$T:5(95[]^^IT:
M?DUM)8&5X8XXWQ3Q)`0YSIT<U?D7WM:"CK::XL<OU:PV$<N>N:::JO,U=3%B
M%U%NM3JP<I8QHX&FT1E9B-+GM$Z&58:F$B#]O:U:N:-'3Q!B8.^L(;-EJV^8
M=JN640]ED=56ELS&MH,>^>I(BJP94MKIW4,^'?V?R5]M<?LM]62UY,(5#^$?
M.L0*'W9[R7SG!\HUVAS&4Z/GK7]\S@W(:4S_``TV39"D']$O^M5O0:3++J;#
MF-4:7+7[*LMXU$(#/A?&2.YK8A@L>7<7E_D\]R71]*HM-9Q5@U-O#\[CZC+`
M=)L;EY6S(JAXH:Q]==86P%T<<]-8%D6`\M?6PN5[&1QC1!&.!M[?1[_F%/9-
M$$K+$F6ER]3G([G$/N,KD5K[87F>6PMF5IZ/L6)L+2W9(?;Q$8ZT=%!(60$1
M[HF%AL$^F#;*U^S/UZOS::KBMA_L7]9(P9:@C]^I*B>Y[57KLQ`J^2"LBJ(Z
MZO`D$66*"-@YAK)6+.LSG^![Q?`/`\ZU]J=.+H]E62PU+K0397IS:@JVRY%@
MK(]':@6,(1,5];1@(J/2:1[F-16QK[4;(OO:$E9HW<7H@M#;&!8]8JZLDH"K
M(["S65EGSV&#V0],')KVBM@!?GXB2("('V$Q")\2HUS6H"[:VFUL)KQVAS%3
M3F9J$6E=8@&U$IMC:`CM=472BRZ@H:&FGFDD>TF"!H3(73.F>YD;96`\((]9
M<BZQ]PH=OBS"[=ZWB[3E1!PIT5E#5L/J0,K<5A$KM.U[1?@C8](7,<K_`&.E
M8J@V2;C5WX,SZX(8^NK*F(:N'_ZE\=B/IFU8=/L@A28FZ>0J,R2RI'!11F-G
MB@1)6*D:OA<@)%["/>V-?9YG(W=AG-/72&F5@>IPL167DGJZZ8BD)M-3?S!E
M6EGH"'^V06!XH#(E=*QK8GJH86O4RLSY;,_7DS.KOV@YKYNJ<C4D._MAH8["
MDLJ2/7405I%GBW_C1R+##6OF@=,]"(O:D01#7ZC84FD@NUS+LH2,7#<YN)+W
M`61A$;8S2U9")7:*0&80HUS6*1(6UKHC&^WTB:J>!(^5N["QFIM3J:N&2-NI
M)$EIK'1X2,R6#]O+4\Q\,6\(_<AY(8(!@X/R89&/(8]SG0N?[@;ESH3Q3#;`
MC/7A]UG2HQS:U=EB!:P@4ZTC1#+%4Z296LKW1^DX3@UAACEGB3^Z-'1/"JOW
M'^R?2."_7#J'::/EMOL".;NP]O'3-ZED!<4'2:.XS5,TS2F9326VCCEK0"T6
M1(P)(H6B.6=8V,=[`9/TL^TLWVEY#1=C.P-$0QE_LZ#95&7Z1BB:UEAG],VM
M/&JQKC7A6LP%UFK8&9/;(V1TI;4]?:O]@;#C;K4,K78T:0*[4O.F"PTC-+S]
MT=)@):V&R@$MXTV]Q3&@.T"-",:=\IXSY%:]\43V*H>3_8BYCZW_`,P]?E>2
M8[2U%9=]&^O'8W8*B+SR4X!Q\K1M]3BG45]39BHPIS+$DI8`U;75L=O",Y6M
M*)5H/W^9$[4/[=]==8U(,]EY,YJ&G0MUN?OGEZ^LU<DU*U:[,W-E2D3I+I&N
M<5*Y\H@R2.:GQQ>CP]0]++H--RS(7IILL=K/1Y9LTEW;X[\N:FO:T&^LP\[!
M7WI@[/?KFHUQLS7QK%\;H)&APS^@(%/L9%H["CT46@CIWV+<[71NVF0_,8Z$
MRBDBO;2ZCW3!1(,O1BD>P%J1/F<KD])W.;ZA'G1:>\FY=T@.>6*2VO>5Z`2K
MS!!^3JB+JI?3Z:.\S*WUI:'5#H*T,,8]+-)UCFBL6Q-^2:(ABAI1_AJ"I>1]
M7W+IKXQTM]]>\3>',(M<55YC-9O1;B(1K;%AUU1C"VE1:5QD023--E*'":^9
MS62,AD#='>_8'E5=;T6AT70N3X,J`JKIK+]U[%R+0V[QV1OG_=S*VNMS"1\S
M24I@K/C=Z%_$0Y(Y))_:Y`^9K[6?5O5:[,T(?8^5`3O1*R>P,[%B5&>`%3!P
MTTM?1C74.BO[&RN2'J4$'(IK$:^5L;(T]?`I5_+UQB]O^%47V"HZC/:+6<0@
MWW-=H4!?<T)F9SZS;8,J=L17W)A:CPX;0&,G+MPQXT%AF80Q'21*^0(\^J?\
M@^93CV4P?=;Y_+MEC\_7%":?;W5)'B-#EXX11`FU5@")9WD_2:85K8;*(Y6-
M?`D9L9#6D.;&&;]P/Y(^5X/'SY'CFTQ?9.CV]$10PRX'29O3Y/-W1)SPG:D[
M36<4-:96Y^HNQCR`VRD3*0++$R2+VN^((]_BNY?LKS-77V`T534X0@K)4W/.
M7QD5[@+O<A5QXLVDWEG9/!M1;%]N=55HS)[$F!"HQ)IID?$GRS!&/\H'+-O>
M?9G`6E4;GKFX3-T"S.%O2KFMM9*74ZLRR^&JSD`*6\,E<JO(=\DS@A'OD>QJ
MHQZAL@^_$-7%]3>A./@S(U;)59&RD%I2;HZ%XR;?(&ZQ)(ZOG5-'84]G72R1
M2(R:5)45KFJUGN:\&]_&5@PZ+B]Q7D[0</*']`L;FZL=%4UT5_DJ32CX4JFI
M[JK=EK4JQI*B\"=`%+,16SV21,G>UCW*C@TY?:/Z^@?7CO7>:8/:T]8*1H:_
MJ?-<[#<W-7!J,SHIA;C)T5(T')$V<VDSV]V,\U=)6C,E>X::!WR3JLK@]+.V
MXW4YOZ&7_-J"CKB+#,?5NRYW'613`6%6*%1YHIX0<$#.=V1=OL67E<V*4%9D
M0F=71.>Q6K,H:K/XEZ&*QQ&G.N<;T'D0!@F(?9?]28[JP)M)*8=\@EU7R7N=
MNH1OW*C/4H\:*:(*O(=$YD4:O=%&&N'[3<5[QD?NSVSK_P!5LCU;3[REV$NK
MSMSDN,U6DSN4)N<=6U5AHTM;/E]N-J?V2E--D8J0M_)*A1B#KZ0O0'E<V'\X
M'2J%M@))]F3!"#LP%L*NKP3.5_NM#54KR-,.*>G,L[EVAC4),+`V--#+CF'=
M(4Q8TD1H-W0_53^<9VFD7G=G]F;/!E5F/LF#Z7[.Q<\I\M?V;*90':2N9LJ&
M2ULUN(R@Z<=WNBD#L8F-22?V+X&YON_TZ^TO6/H-R?DE7*$7]IA*/ZSZ+=4.
MG6FO1C]]E`HGZAMML[".3/ZJ>@(>867_`//&7WOA5RK(KUC\"WGTSX)V#Z[_
M`%0X'PWJ-0@6BQYVRMK=[+9NHQ%>=H-W:VM6:!H<KB--GC6QSZEI-Q!\T+!9
M7*O]K?U0+1:/B"[2]WF0V964T&1W%5J,YTVO#JAK;+7-+>2AEWY5KH;'G39;
M,E\);&&PRJK!X'(0QRN8QO@:`OK5_!:WC?VO9V6L^P6?TV&P6KO[;`Y^TY;T
M`C7Y2C91WE0ZGGNG48.)HDKX%8BV$5:;*>7#\4GHL_RL#<(F.K'VR?A:H%*Q
MCUH4!M*4\*VF%(_(EEE=2P\E-FCKQH9GK/"TQK$F=(WT553W@X`Z$45MI5VD
M(WX9%<(:!#HJ+7P"QVL!K+1ILU;9\_>$\LZCCE$9"QK72->LGR-<YS$#.H5M
MS:`9PCAR[>6NOZX<DBEU`P@>?9(&-;G.+J><FF5I0T8HWM1')Z#C/=[G,540
M&ZZEA_=`[J\+RUD#)61V!S/\1T=D@L$TB@1BZ4FRHABA"+`D?UED0>:5C"&2
MM:JO5/`O%S_3Y_=<Y)S\LS8<@+G2Z:PJPC-)C2K62OJ)[L*NS]'14;:Q1_PQ
MWQG2QOBDG?Z^K'.1OO"*M8%F<]7UFANK66386F;:`V@-@OZZM3+T5/\`M&=!
MJ0@"5@B@S]K:,F;+\+"D.')B]J1/65P0"/2&S.K;"*\KGDK74*E77YW1A$:$
MR1OYL(TPM36R4I,GR,85^)/(R%)FO=[WN>J`Z[L@T+.IGA'C5!4-1I)V%(#8
M5PE_G(UA::"3IS+D32:2*]##=ZLL4DA3T1T2-7W-0&WG*".(`5M?>Z><V](1
M@,5?7V85S");BMA)KXHJO8@U!)+$E7X2/G;,+&QOZ,<OH@2/LJVZ,M+RKN=%
M.((+/7Y&2:3/JTV"&M?\%65&P?8R4DDH7Y<564^1(E6%_LB;/$BIX$:Z>H@Q
MQQ&6C,M+RQ$J&UCYPI=60QA]Q)`.Z`I:O?9\*W.:WY(YHI'O$D"GC_N]6N1`
MP)=0.X"SSO\`U)NGF27*S#WH*EP1E358L\!(D5B3U"TT4T7Y$[Q&SMC4J&"/
MXE1L;G(H->(I"E@;76FIHU<,DTYJ16)JER0&1(T,RPE[94,^:49O_F-3\=9$
M8J/1J>J!'AAOXEI.[\VY,M'C%M#:-:9^MG(/:R.,=Q<!_?+9204=[F3(R-TC
M41BMD;^J>!.]CI,E7X^QSD^AN[62,R($)\HR!``#RVL/SR:6UDZQ25Y#+(>&
M9\CA9D,<.L,+?5K)(4"-Y[JI:W2,HXS75%79R#C_`)>JK!FPSR`"@1J##5]J
MG@:5;2HY1YBX?SX`@HUE='*]JO#%"TEV?JA9:X31FDA3*W\&LN\[6N,]`)WO
M08_1]_J1`WQ@12>__DQ.]LOO:JO>CD#?3Q2P=:\AYI9*V5JFXK.$>P@H4Z>-
M)*P=4CE-!L;@,R2)OHU98BR8Y%3W-E>BHY0E#P#P#P#P#P#_`&_V_P#'P/#O
M_,*2`=_(5WRIOK$9M#GS>7:.0$2(!;D44WC7+&Z0ZLD(E$LW7I:U=9`)",]S
M2IG10-]99?;X&FN06_\`L%;ZS0,.QL5;4V%;M:^MZ-)95'"+K7W9\6#YI0T-
M;:Y)]KG]O6"$0SR9G(0R[&^*$C`EB6">=S`M^!]=*[@G+NU]ZU&]Y?\`9O-9
MG/76,^UW:5M[OE6*SO;^B5H&3RW"..XDBS%VG1N@"UEE_DAUF^:ES0/RP##)
M(S\IL8:]OK7T*J/[-4UV\Q5:X0K%[#`<2$U]G#EL)S2BNZVN#RN2@=5CO5^9
M80)4&OJY1C:($MDQ'X_RG_,T+8]$^E]7RO10LQ/6\//N.FMQ'-_L-],.Z.$J
M-M]5^\1L=:5$6?Z*82[FFTG$/M;1]8C[8(72T",K(U<<T::(*=L/TM;J;'A?
M0[*3.;.[-T]I60ZW.SY:4#6@5B4,`H=82+13"4/1)S`UICWFE/+E*'$A;.V1
M)&@A5E]4;0;C1$<3["OJ^J=3S6=.GH):J9U<SZWC#SC0"%.29L#76ZI+))((
M1+)&Q'0L=%.]@.NU94RY_'%/!KW[;IT]2X+0PW)Y=KI:C,$-H:X>FJ6R#N5\
MMI[F?G.GM2OD"=(U$25GQAU!VY_5^VB<LS-E7G$U89O&Z&^JC1[D*SFN4;;:
M73]7S5Q+>\\TV&NI0(1Z^TOS):A\C'S2E!S2)#&%^N-_6<GH4V%N"MIP/6[?
M,5-O99SZM<TU#0,%BN#8"TFO.I]YZS]@]+2B9T7`92((I?AS`=PRZNK09U5.
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M4.P/N`5CFC(])7S""N:.>Y9ECE!#R5[<@:.CT>98J+GN-W=[6WYTLD\-<=3_
M`'GWTX95B.Y;#3'B2R/<@TJM>R-55\:-^140,_IFFCIKRBYI5B:+3WW2S$T1
M%7F&;-E]GJK"6DVFR,F/TG,)=-H0M?:V:I;-B?$2TBJ;&YTDH\L;(@N%Q[Z[
M\WU]6?4]6Z_7U8E'TVFLI\#QS(4^A['WC[!Z4:07)\YWFIH6Y?!X2VK]-HU#
M%#)`+DH`ECLK^-A\LB>!#?VBZ-J>%=^J>(4.8Y13=KY5BLYSOL=_QR3I>CHJ
M4VG(O+N^Y/H^AWV*MK+89#*6]JRMM?V^J7/$V((H;7C.^=B!;KZU\(X[]I^.
M`TEZR;A'UN^O?-$$U_4N9Z*==)P3K;M.FBQY/1L=8E1'67'^C4]K85$QE.<&
M+76(<,MA&USY3I`B'H_&NFBQF=BP73*+K%H%M98^XZ'CV7MZJUY;J.=!@V-'
MT'O/+X\]'M*K_,U4EQK9["^QA".CL*LJ`8CY6A8;ZC:6*/[1?5'59:RJ$"W7
MVB^OE)K:>H-#;-%8D]XY^5;U)@OY[T;%0Z![)XF)$XAXI$4WS2MD5S@]_O@'
M@:,=]2`9W==#B+N+`H2LT]>58YQ]R86;93FF7+SUHCX-^XJ"J'JI8'%H]B>C
MYVM;Z.3V-!=QQ&;N+[,#V,=R?^+6S/%J!KVNA?>$Z$B`8BP.(76!FTY=1#))
M*L$#1$EA;\D37?(WW`]G>D-,<T]PXI@E;&#--4:ZKU_0(_R''#O"$KZ'H%E%
M*![JU"B&2C335\2F^^2*)8F1AP!%S&GJ0B'UY\.C(J0QYM4)NZ$-U585],LH
MI)V0!WSZADVL96SS2C/$:6Q&MDA1CG1O4$R6UJ:TNOIIM>;&RUS\C[\<>'+1
M`F36'X4%@:!?P7BPU51"+(KJ]C2'&H3'*LCWL>QJ@]:4_,7<OR76@5L)MKEY
MZX#Y;-E*\8,:$X*WD?BKJOMHQC*Z,E"XR)GN-E(26.)T0\BM")NB!9!+PV>H
MM](4D9K$>(!%6E-J;*02P2GAG:/:1'/2R=`4@,9TK9I730RD(YB2N\#A#J*C
M2V,_Q7TM=^W"?BV=1[1"SK$U3&.!L62"ZLL.K84=7PDH&$L7RL$D'9&B++'X
M":2%CLX,?7VECK'%#P!V@53)H*LJR-:R!I*GL@=N2YAZ!X,7Q#L9'"Z">*93
M%^!K50#,G06-M9@`:-]38&U%@;!:K`]<[``R)]K7H:'+L()TD.C8P))"(8P8
M'>UT2Q_VO\"OG5*+&]JXKL_K[;V53%FNG4!HUV1FKBVDV\;+D(RE<-4R6F\>
M.5"EB0XYWYDTHL1T+VPO:U4:H>7?G'1?N-_$!V=G$1LA31\[VNFSH=A8=&94
M2X+;@9AE75IU2BU^6/S^8Y1MK&-RP6=6?^?.62*R4N-&^Z=P7)W7\ZO4Y<E+
MGN3_`%NYE2ZTJYM`;2]7NUEV434YVAL:]@^A4*AL<^.%%HK$Z(<2&(Q\9)J(
MTB.>.)OR`^/XOOI/VK7]CTW\A/VBM)[>[L]3M-ME\'T@749WHO5[_3T8%E1V
M1F<"U]`108#"#>YU`-71BBE&Q1S^BP0_W!*'\J'UE[+]E-5Q^LXQS\S9#5@V
MZ.L\EGK*S.1`R'_+2V/SVNBWEW/4S3BQ#3QHUC90O=(_^YOR,#<CC&:`3!X?
M(6D.@F)J\IELSM\^7\D[<VE31`!O#SUQ7[0,^,O/U=JX:<23YUCF]SIX$:UB
ML!1"7)L6"RIH)+AUA3`6L]7+J[22@9:`PC#7)(\[-^'616$1DCOF1I+!VN21
M[U6)&N:"-H;8S99LJNG5HQP]+-6-'L#*>`X+&$4I+&JR$KHSZ*P$8;:SO0A(
M9RF"R-697QL:J!YYQ?XI>H:?&1AZ0[ZVO/R2SQ\_-AZ)M+BC1;)D)%58V^5I
MXL]')7:,&%23VGFDNB=`UL23)/%&@311?P^=-SI_[\7W#B=#FH`_9ER<;RBV
MFK(;8JC@99ZYALV[K;RHDKXCB(1T1P\0ZQM55D:Q'*#]Y?\`Q"0BZ6.VL/LC
M?ZISR!;52%Y'D`J<ZQJ=#770SWW-EU<K-Y!L2#O@D/;#`PL=(9#'O]9_F#=7
M<4O-3RHC);C2AA6&AAJKW'-NS&EYP$@T93V))^;+5:6G)%G]A#(6DO<GR/>]
M86>K0UF]2_CP^OVWDT@W-MAO.'4=JE@'LLQFIJ35X=RMK4K!,Y1YZQT!R0Y?
M1U+B!'UP\TX\R->]OHD3/`;G,/XZN&YF%EIU'H^^[ZZ.^@MFA;W+U.=QUQ8S
M3!7=@E@51'BDERE15HH0PY-JJCUX36L=[',2,-FE5-C1(8J:BO2JK)Q@VY<%
M4\1I0@HM,$=#6?MPU*1/HL\#FP*N#_E$3-'=%)"YK4CC>QP0[UOC/*>G:O,[
M"_QUGJ#,97_A1:#H)^DB#KDMHJGY'DBYV',T-C&RTA56N+A>]C98XI?D<BJH
M2Q<5N9T.'/SMQ_@6T9JZ=0=;E9JD;0CH*6P8J>NCI&1WXY`(`,#I3&OCE'0H
M:-D;HW.:U05N4U=1RL":IS&1S^8`DLR=56P87'S8^K86>"T.CNT%ASH%6XK2
MP%J1/#.PB9L+(W1O_5CFAUY[$X;9:V@OK7'@;O5#6Z7-4=39:C,-B.@LE-#'
MJ3+O&::VI!1K0E25CB(]&&/8QBHY4\"TQ^ZF=FBG4TUG0/AN+F&OK;BGE&+'
M-HM1810C5F:(Q89UM7V&:D_"EC;*R9IEC,WY7K$BN!CE.$T>LSXH46:D*@*G
M`FT`MU'49LA92M':P6*P'X:\G'MT'*0)OH2T66P@D_M16NB4&_11/J;:FTY]
MG/E0ZRX>B',A/+*JJ0G012SA4%FF7H8:I]JXPIS)Y(B_W"-?FC;$V1&M"?LD
M>L&5HW`;"\BK)K&]*B)M_AN2;JSC+O[2M"R+8\T)^ZI:F/($?\:1ODE9(Y%<
M[^Q0B52<CI:K55!T]KD'[%*UH1%]E9K=XI^@<P<2LS=,?FZ!OY=&YY(\KI72
M*R2229&)\:1J$B-K:Y-+6ZVYTQ)!=3EL\DD0N47#@U,(U:34H\4N7/WY!<UY
M\B#1,22!&O5?7^U%:H33HJJ]MJO/W!8VQJ$#S\<\U?`2VXU]O'?6`,A(D%=+
MFAV`WM?6D2LE>K7+!&C6.C7V^[P*VVNA#JY#JM^>HLU8#Q07M*'\5G7-NGSD
M1$NFT(:X5(J\BHJ6$0N^*4G\21(X51S9EDC!>NV`=0%GB)DTK`ZHZ1X4(HL#
M`D*L;Z%0QRK&?'6\U/:CUHD0OX:0S1SM;$[YF+"U'!"@-E1>T>GDOJC-65Y9
M6<.@&A>189V.J)A$CCM8/R,-7^SYI0HR6@/@6&6&%?\`U**[U:"*Z8B9C+_G
MU9">XEQ>;)`CJ&B5\\A27D(U@)"'S@M\E>8!\4C8WS,9#./[E7^_]0Q;5V/)
MKH+"IJ9H:VG".-$,N!82<T+9V(31H:6N$7&G?V%2+*YGH,YSTBCA5$CED=&'
M1GY,]9ZBJ;<@VTLA(1(U@?+_`,LBWSTU*L575D15^%#"K*RX%B>Z9$->X:!S
M6.C<L/L>%X.&V=JS'LHDA0'%*4:H6BJ;(N$R*JBF.7-UE58)75A5EHBYHE>4
M3(R!DL<C7->JO<C`B[4YW$&TI.LK*F%8L\]YDU35`5E>.C[`.Q,?!4RB"1V]
MO8%R"_#-(7"$^6,58Y%_N;[@@&:UC$SU:+8Z_(-SET7Z,H+>VT&BDMI8&L_<
M8%&("'&2NJQ[>1)AD]88)HW.9&]/[G@BV6]M7E3@6@"VA-9[`PA;8<6ZIH(:
MIB!TCE)(B<.\6$=I?R1JB.A(E5&,1"'.:"92@U1$-+K3RH8[`*P4V>ZOK8HE
MM?:NCC)6UBEFT)P4];)*',D8B122O_MC]GHKW>!*VKVE`:%`RE*GC&GV4M@*
M\NT(+QJ3OS[)QZS8U3;J2'3U0&CC>T20V$AB"R^WUB^56J")JF<]!=:0W`VG
MSOH$)+`6>ZA>N;DBFK_W>^%"K^@&QA(<:[VPCJZ&=L2QHZ+U^9L81J^^JKJ"
M"4HO1CUU:`;GJNV`CKP*E);"T/)(>T4?7TZ?N!3&Q2#.C:V=\9#73R,E?.U`
M:EW:G1W+@SF5MS?$LJ/>+/LJ(4\8=63UT=$!$1OK"$ABR21>YT<RK\T:*KO?
MZHT&H1>'$%"Q'V]NP6J9.,T5;(2F`/@28<@EA$P>]IY7,>BJV57I'+\357W?
MHWP%*MTD56\V**\JEE+*JK:82M-IKH;XIHY'T+S5,Z9J'1E11SK$SY',<L:N
M8K5D:K5"3*$LF:(X`,VVNH9R"ULH$N(*BCB566)%'>`?D]$S]G&0'-._]Q9)
M%^#,$L42M>YC&-",A#*X2Q<;&95T$`YD`]I<5N@A@D@FG^80E\8W_4:T+CM"
MAE3\<5O]D:>KD:V-B/:&^[CKD=ROGKT:0U),A12^A4<D4[?D`A?[9(Y"3'1J
MGN_1J2R-1/\`A<K?1?`DGP#P#P#P#P!?_D?KX'C7_E7H/KC2?:7[5[CK/&K+
MO/5NH=KXAQ#F>6T?0MIC.6Y6NSGUHY;U,#86]=@S\U9Z(X#;58[6#EVC19W2
M+&L:^GM>'FWZMVO_`*G]&GZ%T"JS%:^KI^IU_),-]=K,+`9KA@,F0J^=XU_/
M*B\L(,QDPLNZ*20J<`,<BP*M9K%CIGL57A+&TZ%#F/JMQ#E=\#*V$./-_8P7
M@E:0I')J[+="KZ7!?76JZ"=J+7]PZ%G:S&6]EJ]+7"0-T5V1HP?R9!:JO:YP
M5=-Z99"P&`W6KL]C3[VHS?\`ECQRJZON,IMB]"RA_P`NS6@-&6CK;.NOL;L;
M-]?!-7"6^68($^%:\F%PH69^Z6^"[EH:+IUT^_ZE@M;QUG,I.H4(Q^1U>SZC
MSC+9(G9\AUD!Q(;:(#';"UJB,G9%SG'4],5*)#^Z"`BDPA"'(^][C#8>VQ&\
MY;SG[.\@Y-:X[5TW+^L36=@5S,_5N8`79\MZ$->T6NKJ^BTTX:Q4U!>VM0MT
M,-92-<]\OM!XI6\6*Z'BIN`4._H^6G=9Z/H\0#OM(7TR;*:[8_3RHMKM';8N
MLS=AI\E+:V,@%8<=!"6;"R-\T2.D=)(%B^<\B^N>!C`WGV$[!U70[W$\:_R3
M?\(^O-?75XW*[S$09222MZ;]G:?6WV4R#"BM"ZP:^BHSK26,EXXA$:1Q,C"F
M.R['EM=@:?G>%YYD.+<3L*<73:SA_'+OILX&VELH'V4-1T'J.]M&;'JA`7/R
M@*ROFM;20.LL2Y?4&&*4E(@L#QWHG,,)Q+[==)?:;3FF(^R4%9]<LD3<LAV'
MV![?9]2R%9>V?+6EA$I@:7/\RX(R*AH:U?@HP+70P6EK.037C!QA5FDUML/7
M$@8>SRV'R]778VEI>5CYJ2UY3'@)JFPL#*;2Q35\96D*)YG0ZI-+=3K^<5I:
MZHL!CF'#L<@7:M^X8V[^JW+><9>38/R7UPVTFLU-`D]I-J?K#3=%T]-:X6^Q
MW1[F&QJ>C`8WLMHVHTX<D0D%Z#=B0V,89(L<TP0E]?>SC\HZQT/&\DQN>T/+
MOL'=;_+:[@G1#*K>\PV3K4VRNJ?0:C#G'VF1S]C8)6Q)5G_-F":\(MS8"7RO
M14"S^C+^G_1(,-T%W(^J_6O=V><$LHZ3E>MSW1/J'HK+'SX^BJI;3G>YH=3H
MN15,-;0!A-K`#CPXJU'M9*LDRLE")..9V./LM1A-JZ0(K=\T$P^D&P,%9//0
MTI'WYT,%Q;X^TO!2GK6+12-8*]KC!7Q(^66%CH6M\"5/LOW7EC3]]G/K%RC&
M?73%[KK.7XD[HF;;J[KN_;:CC+%!MJV^[1I]-4Z"A;&E)3?N,%6RBI[(**,.
M06P9$J(#/^DF[SM1U'$7%`/69'GG-.>6_6.XZRLAJ;O08W&XK0"G::EXY256
M2R5GDKS[`:2YJ\_9E..FLPK*P="*\<ET;W!#_3>SU&LZ)L]#37NBJ,_8W^KZ
M1I[.8<RRV/4]'?PMU]CTB^K)="Z'!T_3,P3/F\9C/R"W4,RJTIQ%B420@7C^
MJ_8KP<WH_/`>@LBZ?UJGBY10U6@K"[_D_3^UYL$1IH'7,V.RBNXV27Y=[DFQ
MRTI<%L.^O-C+%M&PD3A6._ZC89>]S7:L!;7_`#W75&*QM2#+2,?/J$L*:^*T
MH]A!+16V:LKRTI:`&"A!KI0K(VH'$9$ZN9(Z)C@W3_6C8XCM_3>,Y?J'%^3W
M'9^*_;+ZI[_E/=<=C*KF.LC#N/L+S4._TO11<5+4YG5:+35]W,ARECMLR"RV
M?/%[AW.0/;)X!X'GSZ%@HVZ#6G#SB1-O-#N+/\@CI&NJB*]H^A<*4.16.[GF
MT&61D#)8(V"+_P`N65\3/1RM\#NYT`PBJ;FZF<4FFOB!CAPDV%Y7WG[L2V*6
M.9V@/ZC77$,,R5KXED99I7JYJM1554:H3E29[)M&,A-<+HIVDVQ-0$FO:">I
M]=;_`.4'YUV@@Z@5(K778L8D;WEN5T4L:QJ@LB^X$FOJ<<:^HH39G6&<M!\Q
M>2.`VFBKR`[./+J34O'FCZS%J"K>FB;^-:0Q0.$9#*CY?65)'("76]45Z!9!
MUY4V<-D2-2N<*$..:1E<X?*^OC9(!N:P6O*=9E2*Z>)?FD%C>TA'*D2*#ILP
M,%6Y<.OIRKD.[)N9`(6`7^^L8JN.N"GT*0U5C;=$6>4P"PG:*0MB2GL%CGC>
MBHYR*$2:66ATL(T\-=IS"KBNE(M*]FPW>9KJRMIH1"!7S65MU\9LD=^8=-)*
M4]ZRQ(U(!7_%)&QP8XN-N_QK.41C:05MI54I9@_3-0M>R5S0YPR97G]W*AKP
M@9?9Z?MPDDTQ$RP.1WJY/`Q:0.AD/L5%U5M1-&(=G+$5==T.PMG5KO42`2K*
MO.J#9RB/*)_(69Q<L42*Y&>KD7T4&M1QR4\=A6PE>Y!;+\:Y`(ZWN+B[F8*/
M`A,)EM2==L;9U?&0]8AYHB%1WR-?[6-:BM!1TX6-G">?%>:6*,Z>`0^O'Z+J
MZ@T&RJ63D4]H987G8OW/-L(L?:Y\5>YL$[VIZM5TC44.DVJSFG;+FK$\_1%Z
M'+TQFD,,T6KO*B>WEE3_`-!<!WG66500K60O<^5X4;$8QKHIWQN_O!V\>PW-
M,I8,+IJ3F^%V6>GT(-Q-FZK(P2CY9\4Q@=@37Y330!W;H[YI3XX6-+=.I#9'
M>YOQR($H;UXEW1R6<?50*E:UE)H#,P3J%J](78%D?M-7>)/5[5]Q7E,);$23
M6BD.%^*/U_']CT5X,''G0IL,P,'H;^>[S5GKCJT:+7:9P]A"342``-+BO^KR
M-E',!'DE@KY19$2.9[5'AE1R($RGV)-;D;6LL]HL]#=VMMI!WTQEI8S4MI:*
MQI=-+I\OHX+Q]?(BL@1E<6\<.9T;$<Q/T\!I77/)-<=3WVE%OBK"+/7ETW/U
M.SOZ'/4L(YC5!6""FZ\/HM#(;!4$#ER2P$AB2$PLG=#))(SP&88#CZX_,-J)
M]1*Z4HLJO!M==O"JNUBNIR*;4B):4_58$-8D@T'L:YT@X,9#GQ_&5Z*@.6_+
M1YKZ`DLL^IN<W7UU;`(7)#:EC_GDQ22ABTG0)+R%`JZS?)),L<5VTE[X&2>^
M".*((+TN6J1(BGV\VD$;#;D14F1I]SU*W@6JBF<.7(ME:]N0:>)\H['.<^;^
MU\OQ1^CFR>@.`=M-7UP`4)UA04E?:EUX<=ST$P0B)CXI_P`T%HM/UKX+FR,K
MF2JPTA2@H'JD/O0CVM4&S8TZB23U\:W=P;>,ICXY`M#>Q(3`;^/<?AUL]UV1
M+"20P8N.2!L#$(C(8V.1JM56^!\AS]0`()(!57L!RB+7%K?]"W]L2(\^L]'L
MM*,?KR>VRF<;,^`IS&M9"]K?7WHKV`E15)5:9"71!V!T=2+6UUL5^ZZ2KJXZ
MD,H%HU9\,7395()#6)$>1,V8IS5<JO5'R+X"C:Y2N*,4&Q%.6$,02SJZD(CH
MLMD="0X&.XEL(W;4>6*<FJ#FE5I"QPO^#Y8W-C>]R@MU>0@*'N:XIFFH1$DB
M?6"(5;4\8?Q>\B*SGHB-W;7UK7U\<J.^:?WBL?Z?,V1%:G@)L^4Q1M23<C!O
M`LY?VT0::6TU=YFR@JP9&H]SRKA();LX98'?B0R?(Z.9)7M<G]0G#'`",S9N
M?B7%2D'?N].)FOQ`:;:U\5LR#]TE#K+$LNPA@JA*S\F))O\`GQ/@B=(R1LL/
MM!5QO/<0%<!R'4Y@50,`?^#!K@S5)H:R0LMNA'.*F&BAMB)'E1#M>KXW1.D<
MJHYK4C\"0]N-!6::2JEJ*ZF?>Q7,>0?#04C(QLR&P*>*\-+L<JY+%M&94(.V
M)CW-6"5LLB^]K50$"+)W[*DI7LS9-1+&4+H[+089#G9]U=:.DK]78R+4#ASV
MU&?9-D_#D2!DP,CW,>UTK96`D5+:X%E9'%7TYE0R'0QCMJZO-5LFKKX,Q8.!
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MY<W[@'SA`D)E+8U61S1^R9JM;_RUB1SPR:3_`",8<*Q2LHVRU];!?`,"P6-`
MJK$"96RBGW3(^>SG-$H#IX(W3QHLZP+%`D?HKI&`UM-77/Y(?SCT_P"&'1"V
M#+:UQM/8SK"6'&7(*8\SEPP4T(*,>L44C?=[WHUWL^15\"\_(8UL>;'T=[KZ
MRWS@]:(:/>T`574,H$&GC,KJ*>2MR5>RM^6>=T@<0XTWMFA9,BM>JM0&)T5;
M<:WT=]:.KZF\L*<<:2T(468\.1`"BA0;F`C)LJT-LF2CE-6,XE1R)7(K5<B.
M4*]9@S4DMJ[8*SK`Y@FV)H%=5X_%`U,X\7XM$L%DR6E]7_NREQQO2-C'/6%S
MG-1K%1P-^,,NS>4S]J<4*+<Q1RVLA#/Q+818B"B)!;C]FI+(*1\[U^>0H6..
M-D;6_P![45R`\LSH+TBWGQ84!L=1)+4W,HY=U1S-S.>S@)C;4UK4ELB',-^=
MYJ0L;_RB%:L"(Y?50;(N@M)#9E&(-KLXL_R!RV-D?84)9$L,M74F/`GL*:`]
M)G`J^9LD#V-?&KW/:](_<&)KNA6EC"7,S5W<5E8-*GLS*C1UE;7$F$W)$)<!
MS1]$4"HXS!)'Q$(A),JRN:JL1ST:&5!/:3UAU9;Z+6W0D#*NXS)%OMWCG0V1
MLP0]"X!B;JI%_$:'[_F'26%GI(U)&>Y/:@,XO6ZQ9BDBTUO5G5XJNE2ATX=,
M7#;?N9,MC-#"-L3C@8))U9&OP/2*&14]Z,16N<"02JV$K#[F[LHB`TAN)G6V
MIMEGM+9"17>^$\?J%,#:2#5XRR/6QA=#)(Z5KG.FD1D@.O*W(98YP8_0++V6
M]D:^MS>0W,P"?O1!$5L--86$O3K"2`)`W(U!R2(FCR3*YD;8/<Y@)RYD"KF6
MX3725]Q"!%>O&FZEI[,Y[Y%.GKQC(;WM@6?FF%C63Y1?CE$EBA1JQ22K$C@[
M!\Q!8@!%E:<L>.PK$FFGI^K7WI:I3Q-@66<2D[5:"!3L'<L36/\`B,D:SU_5
M9D]X;POKZ]TG$>6*\N4YS,30P_ESF6%A,0V`)D+'RGVUA:V9C_9&GK*03/-)
MZ>KGN5550F+P#P#P#P#P/G^R>G^OZ?\`O_\`'P/!9_-U8EP_>_[)GY\:SGL,
MIL.5R7(\,P\HLS[3Z[\E*SA:U95B_P#+2(H9[6,;!!`26R$>9Z22#RL#4C]<
M./9S[&_9GE,&DX5FJFG/U4.JZ->[%FDH^88[F-"+=:7J'2Z3+Z36$90S,UF6
MRUN.Z(B)(9K,H.(F"-)H7*%9.J=0YWM^X]$[[K]53]MWO1-[N+:/*4.9T[N8
M9OGBH15\TQ]!BM$<!2SP?].YAIV54T85$`#GS*YDLCYQ'(#HT^UT>ON:MG4:
M$:RQ)%5I\M,<9BZ&:Q&AM,B-6$RYVRIZ+!ORULH$#XA"A'F-2M9"UGI!-++(
M$D?6["2==PWVIX+4;?-[VD[7E;_LG$\/NIK+_)^<_9#A?PZ8"@J]"(`-0T\&
MSXF/<USK((UP]H2/7UTHZO62-`I];6!D]P:'+CF8X_6'4^?VIEK#/9?D5--&
M01E'YT>R(NK6#.7I$$1$$](*3:$2H+6#.@]\1*A;&GT%G9OXK4">\"8#6[/+
M6PL=KI#S0YE^NXS0:';17D\*S:P6JN`YU`;,6-!\#DC)EE8WT!AX[0Q6^>OL
MG0QN6WNN98>>NS1&2OZJ_P!#44K<'!M*D"L$L%GW.BJ:2#\\B&"$9I0E=,Q5
MFG9$R0&]3PY6ZI[3+LX]J-#9UM$VILMEG(]-2P'44!6AN:6PWX>#MA*.^LJT
M0APP23DBS?BH[WCR%-E<H3?]J\=09*/@G(;N2+*X_P"NO"\.;O>%X>E/H#LY
M]GNW+<=.W:;S?9FUNHA[V3*:''CC7`!EP8<-2/KXX1C(_>T(3F[=V$G/W/\`
MBU!GS><4D]BS0\VS?*:HG'W6>"GHI*$K77Y-41)J1KTRN#-(KR[&*5E:]\Q,
MORM8Q@6E^I6FYOC>]\=WNDU&)Y]R?4V63Q7VIY_N0-+L.=]4XETVRGI.FE`B
M@Q7E7:O`)NDNZ>KL1B(('9\::(V)8AV*#'VW.M=];.T[[C>OY.Z.YY9=Z?*9
MS>8\M]UB2HVG6C<*3FW7]P<%4VY&*DK_`-L5+2$7U^&21K8AAFH#2K[(#&XO
MG=/K/R0=I5=`FZD+GOQ-`^VMZC]B$5V;'$M3&5XE/JC*R<-XLJQG/*A=.HJ-
M6&?P)"Y;:_XSI,+7U4@RQ$\BZA8OLI:TU:T9I_W0VVFK:YY5G)6"FG9HJW1L
MSFQC/C:+_8]&*KO`:6HBZ4'T?2"6'/)]T.V[0\W#PTS*Z8FM_:KZFU^IR=ED
M;.*"($',6CZ\N8$L^"RK)828IFN6=BA,%[AW8CZT<_Q'^75/#Z3[B=(M.H:,
MC+C$V=__`/2[\"%K\7D'&[">S#0"TU/=KJ\N'5=Y;F5-C7T(,SW?\F.)P)6:
MZG>V4K,KR7)ZAF=`AT(=U>`B/AUA$5?8L,D!OK:#+&_YB<V:8AM6TIPD4MS)
M`L<3'-9!&$7FZ*BWFP'T.]L0>9=BRP!V;YYT[*4E_/74MX"VUFRN,T%32C51
MFN>^\F&M#[*-[=!$?6CJL<__`#V>!L1^U>&O'[#%=T"P/&^E8G[*\BH>LU^?
MK*$ZC/IME6,J\1]FSM;S&WN*`0A2NJ`V3X!X(+`\H>P%><0A,38HPD_Z`59.
M=[[Q'INX&N,D3OOLYP#,AC%BI2C7&TM/LAD+":.HK<H\6JDS4E.*()`RPCD@
M$(G_`+X(Y91I5#]"?P#P//UM887;#7RE'9R`$K4;"2:QMM&]Z03,*)!0F,^[
MZ.,9.^EC5TK(!ATA=\K&2-_\MK0^XW304Y$S*I^<ULHHSFUPY%C9798<9PB`
M&_A$U_0`*E@A1TQ$D2$(\866'UC1K_U\!^5]]8#9(6.XLJ8*:6_I8QKA;!L#
M'%OLB[:2Q`CQVO6ND<TE\T+X)'2_E0_\I[O=%"L(*]7GJ.NM:VYKT*I591B'
M6J:"W,I;VUT<MF.);C8HFYWLKK`+11$,D6,)A;OQXEC65%E8B@TS\[2F22)7
M/1)G`FO#O]YJ;%A];H`TK)%7XF=%RE1&)&"KIVP/`8]\,CGR.<UBN\!6'OJ<
MNBSU8TZD(M;J:P_;`TU6EIP-![FVAQ5Y9F6G1@J8YZLLOBB0.PA8K7>L[9O6
M-K`8Q@]0.!#$)<4M%>7V.E),@MM[I1C!*:R_"'I:^NA_ZI$BDPE%B120%/4I
M(G/2-SVM]/`;=>2^N.MIKNYSAM7*HD=K%:[P&A>E@B`E!S"$%]<9<1?B'_\`
M,]T8,<CT=[V+[?C=X#UU<YED-D1UU^;MJLF!L;R@]"A@Q@H9+@;(BQ?>=2`N
M)+>0[Y)'OG&E(>[T_&C5$;Z@T9;$B2OM_BT>6@%@,=76IP^ZB+T<ZVAK7Q?!
M5A='&1M95C@J_P"2)C',E3XWO19/C>"K/<5]*!):SW5)"'<E/F>)>7HE+8U-
M@/\`D"C,(D'Z3^7?$V@U9#/%,.^2O@]SF*ULJ2HT,20R^-*DTDT\==4E@%$5
M=Z[9XY`THCOR"4B6\-ZZ^(B(C\B:"*,V!QC$C2-C6M8R-H.D1E*8D`DE^>AA
MQ2-N*P;HE196XS9*4@BOEKK27H(<`L7SQ#R,KI9))/3Y/^6D*(B`:E:@Y2M'
M0;*DSIP[+-1*R?3T,ERX5'.%)@6(/5V"_N*2S+^*EDYDSH?1D2>^)RM!HYJT
M?+;Q74]U3QJ?H@CX2&ZVHJ"S)"BF.;7UUIH>L&"QQP3/]SB5']B(U6+(OO\`
M10G"]+)RKFOKM5#8165E=5N40"]#L(X*E5AAO[2;)UNVK2UJ330W/AE6)Q[)
MQF/A?\;Y/<#5N;V4%Q!<&LK1S2@C(_R+CH=<+6GAU8M3H=)'`/6])FF!L=4=
M5S.D#B^.*-T[XT':_P")%#[;6'[F/?%RZ6DB.FN%,IHJS;V5LHT1U:7835HE
M4+O0ZE89UDC%C?!$^&*47W$L<]9%\!FU]9='DR/N]4".RF4CXCQM755$#"YU
M,-BJ3[NHTY\5<AY(CG,(:1$LC?D<UWIZ>`O-N*[\>V,?;T%L";:_C6P!5[:W
M%5^,_P#;BK2MJ;TS5"Q6,@]DU86)7HLJ#N<0K%]S96@D4QU:$D<4VTKZNPIZ
M6W)HGQW=G9M%'((<..7^ST-C+7LB&*EB:Z0C\A/;`[U3WO\`<@9=K8'3''/L
MM-3FDVX:4G[P99U]3#7&.@K9X#QKB,\*&6Z#:)`V249D?L<OL1K7+Z>`B7AE
ME!<0VL)-4L8LPCFED66DOYYOPIF!SLM@I;@,`,T^&*21[G(QTK/5\"I[V^@+
M!Y)<]%.(EGEC*BT._-L;,.8VNEKA*O\`.2(2TFK#3&V((@L\L@T)$23N<.UT
MLDK9&KX#1F</8U0,5?94\AX_J$<2-+M+L*RBKX9H)$'?<_)\MM-%_<^!LC(D
M1J,C1556J#CO$8-'_D!Y8,5"?6A,%$G:71^P@.6G=?Y@>1:>Z/+G(DL(W$L]
M7I,QOOA;$C%5`?%G4;&O'H3'&8L0!IET^DII1[^XI,]$0<9ZN`O[2@%CCLR%
M)1(QR92'.0J)[/\`E.C]P3F#76M;:VD=WE*2LLK2OJ1\5)HJBQ)NUOP61?L-
M51T`N5JS2JFW-4^:2+Y")Y8I)F,>K(E5H,8MUME3!7TGY=K&3&.F0></>7A<
M`E=<$V<;6TP>`'D<XR:U*<R-9O5L3O8GN1GN:&6)<Q"7IE]I),3:AWS2&)3M
MK;'-YZLJA)P1K;1!_#EK>6+1R3VXS9PGD_(Z57^V5OQO10:4%.7++/)H"!;'
M'A2U=E+?1T%Q>5]7/+.\.JN/W4[%U=?!7$2?%'6S33O9/`SW(]41%4)#=?:$
M;\,2Q?5L*&_<:AMZ53/@M?V>R,+H&AGU@F"('J(;#06<EC(]")F01_A?\<;D
M<X$O34D=5DJ?)2UANJAKMT;IJRJMZ8PUU+G7S3-E?_=@C/W6CMQQXS_W:*`>
M.!TDK6,>QWO4%FNKRB=(]E=>:></.VEK>XFRJ:!<W5YVPC%DM9WCU@>(M%NJ
M7+&.B!EC=.SX1DE5SU<]&(#CR&.V6JL,AH<GK)Y826'HR1E.ZE$LJ$FQ>;H)
M`0B\.<6-(LT\@T@?Y#&N1\12RHJ_$@,?1YTD+\.E(O\`27M*;LP)2/W:BLKO
M5TPGXZ#5E.=6A8.(<.SB>88D(<\Z>@]@DJRI\OQ(#9ZJ@A]M59L6[GI::$I:
M%F=R.2=^&@HE6U^<@..3G]A-8EU$\?Q"^R.%D@,C7N=&B>WP/@-2574@A#:F
MKNA91+&V/AO,E>:=EM/8EBP4S2PK'F8`:V$=FKB)'.]KUA@6=/<K/;X$,EQ-
M"V0Y=[2$5P9=.]?0C/)1U%O./"E$CAHZ?FY]]*'!8`/8B*QZ)[9&M:U%3V@I
M5&7%K#K"+W:"0P$DNOGT\7/;>)F>;/Z*EE/:W>$KH)VP5GRK)$CW0.]WHBJJ
MJY0D8+'CC9NKLZ9Z6PA-!IM*IDV4:\F>MK600W.7T&8I<.>,V]:%9&RD1-?/
M$3')$OO>J^K`CH:"C&,O;2?,[*7.3$P5-K?$XD40E]$@\YC,ZR+1"B?(39,$
MB5[/5(T$AE_YJNBB:H7"XR^MM,P<)20:3+QQE@U-E8NSN?>,2`6TNV,L]+"&
MG[5`4,7-#`'.Q2IEF'C(?\<I,OM"(>H!ZEE0^CM:_1ZX`>ST==#?785/>A5E
ML$(%?WTY1FAMIC6OTMQ.DC4@A?`V=&-5S6HOL"+3W:[/O(O`Z.\N:RLGB*M&
MZ//9J^JXKMU9(V:V&@F(*'T53!^X^T5Y2)(A)39&QM7_`)B`VZVWF8&5'9X/
MH6=OIFQ30GWM!G'T1\9$MX7::'3,,WDK2J84<^9D\2#SR,18&(.]&I[`[^=M
MW=+9$6N;I=H<CJRU%(JR",G=0$B$50<QEK#"[9.I98525$"_)E0EJ>JOCC]W
MZ@E_GZB\D24G"7XI$LAA<)*U//RX@D!=HY)*B-VH[*-./.2:--^+![HPI/EB
M]4_Y<3F`WI;RU4.P`*I]D7)^')*P*&\R#*0H`>P!((/KFY[JS)X[%99T;^&0
MK5'C(2-/;[/[01Q-.T.6%S,7HJ@3]Q4E]Q=OYE,64='"Z`%T)>C[Z22E?^,^
M.26!PJI*]TBJQ%8Q&`I?Y?96,U<#IA=3#505L\C[/+ZC,N*OV6<9KVBE?%U:
M`LU(Y:J!DSGQN@D5WJLCGQO<T&>&21,QQSZRSB9"R=ZOW^JQE?*,"W]5C9-!
MW$QY4PL[U_Y+(_1[/5?7U]5\"2,JR<MA]G%J:0V2I@AM[2A&Z$<?(+7N>U66
MH8X71@ZDZ*!LD:-%9)-*YLJ^L+V-=[0P!R@;.S2KGAHR9;4BTM!W6>BJ*DF:
M[.&'AE<P@[K2DR('\SG1C^C8I)VHYC7-:[U#Z5941KH(9[8K]LCKW(6_/Z@!
MPRF`*0X$^1Q&\%#9//8CCP33)&Y7O^1ON8U6JT-\7%A_Q>3\^'_,"L/BR]8B
MG5L@\M>8Y8&N<0$\4VRA065SE5C4GE5J?VJY51?`E#P#P#P#P#P.B$>&!9W0
MQMB<3.I$ZIZ_\R98XXED=Z_HCEBA:G_A_O\``_/\_FT'*K_Y0OMA917E;GB+
M.A^O`5=8R1Q0V@J2<=SD,TZ.K8X[>RICI(/QYU)<0*,L;71P_*GO\#4YSK6P
M8O&_8SI&QIU)'T^)VOU4E*2R=::=&=8Q%=J>D;"G"@,0&V!_;Q*D&&,XE8)F
MR2),U(D>C0@BET-&2^JSG'LJ.REGI70Q[%E-7Z'H=<Z"<<T4FEMWB759S\2I
MDT4-6Q]<ED44J01R6'Z3,A!ZZ,/HU73@@%Z^_P!-H8PQ["P$&)O=1EK5U37L
MA2RM!=5/>U]9S9`"(P(#WP(QM36LEED5L<S&APX3O<WE?L!E>JT8UO4WN"Z1
M5]9OH1K7.OJ=05D1*Z\N\Y7D&)D8*3.7E)(#&:%`ZTEIX#Y!'P#(CXW@P]6,
M#A;G<@<T9I9<.ILF[GB'DTS:>HQ'18Q]=4#U!,<S;VIFS]=>&"C.C^:.!@R%
M0D.]'C^`[\:YHUKSRGIR0+D2/[#5XY3*_P#."'JWE_7(>8BCB6>`>.]GNFQ/
MLGE1_P#+=\KY(U14^-00969&6BYU54E]<UE_F!ZZQ)IS`H:<K&UP4K;L*X,N
M'EF%4E::9`E?'9-E%D44M$]D4Y$SW`X^3FLW_49S^JZ*TM<!R6A.^PVLHM+8
M:2W,BPO)9H;*.M-K[.*70VQ9VT;*R&`63XPCIOGC=Z^WWA'?;.U<HON@=$[T
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M`$KY5O-(3IHBK'\FFFT>=#M=M=:1YDF?@$&D)-AP]8`L5="K5,F_<X1"H)!D
M9"Q(YP=^9MM+91!SV)<PS]#Q'N;+;\\EU714[ZG[8;EKRC@[Z0RPF`KI+!?8
M3,]CW2*R:56,]ST!)Z'3'1ZN+GUC>_MH$F^H.>4F;QERT2&NL[`J1Q/0/\BM
M+N6('/5!5FK46(F5DXC6M:UD7H^8'[VC2\>VUADOEH+6Z!X?@LU]?,[FLS-6
MZ!UR+EVZ%:^QT)E.*ZX%JK5FG<;:C_#4#/<KG/?-.Z5&!D6XN]U@.#N#0KM*
M"J@M",R+6H3B,LIS:EL%))E:VEES],ZNSM.4VQ>>D+B771X+7SNF$*;&"CL=
MW>A74`/2*?0M`*/SM=)-O[L>HTM0GXW[.%K*B.(<2&M/L8?F,,:D]B)-(1:/
M)%?*&[P-B.#%Y3V_^/F^SP<BOZ-]6M>SO^'U<P9LFHMJGLVXR^)UN7'N`*6O
M(R&0R^>L99X`B!X:F6R>TLP=9Y(G1AA_5D48K['?4X`K6/()&^X/UE06:V*C
MOK2XO*[OF$BBJ8R!II*Z$0#.2JI=BU%D:YT<9/ZRC>\/T5?`/`\_>]#N*C<:
MJNGGA>'_`)KJC`F%G3(3%9P6!HSQA'#[JPLBX"7N8,]\;8QOGC_5C)/8C05*
MB(PNS4((S33DFT4S8ZG/5VG?9F5]8:37(E&NDU\J&1FV8+FE?$V6<4ETKIEC
MBC>Q`D.5*\8+(8RU($"*O2"+.,.BAZ79E%VK[0Z7-B5,,NVFH=":9$+8.0.N
M9,Z5S5<L2K%_:&&/3655L:BYUT5I/\<@O^/SW&J.JAP1:-1B9@PQB^E>ZEF,
MJZ]42698G3M]JJCOZN!PDY/+S#I:_'M2=K8"_NR9FS9LI16%'_E_LLDL%GM"
ME,IM`'%)`5)%,Z:N'=$KGP-5[E!.M0]$7-5U%I3'R59UO+2TL55%H]3G0D"@
M'CKXJ"WSN[DC,D%@<QY,([R'2JG_`#&JLC%4$C2))69&9VASNDKU70AYFC%A
MO1XCJYP`+A8P=9&/T$.TI-),YXC65!1`L?XT+Y6"I(OS>!#T\]WS_6#4F@CJ
M(=;>YW46@&0VTQ#]19UV;)J:>ZNYQ:OIEG<5E=7SW8,(L\KX(7D/5D;GKZ-\
M"0":T.>SGL;0ZGM"J<6L2NO`K$Z`=H=17_A@GL+`Z/-3E'6-Z+\,4D\#4(D^
M5GM?(C5\!5)K3=&=G3[<RBD-+.O:[6XZBM07V&8)C%%N[@A_[ETH4&NJ`:AT
M+@Y8FS/<:_V1JJJK%!4M#0OS"LZ,VNC#B+BMI7"V1A2$U=)6D0#$8JOBW,FP
M9++)&THH2PD52963O^-!62(T&:;77@-6*Z_T%*<?*%"8R@#N`!@X3+,G\I2+
M*Q?TJT&5)Q3WD)&/.R0.%6NC;&C'*@%5,?9"&UMT;\K"[RG-I_@NP-;"^S#)
ME:1GC+E.A22S6Q@TTKQVK+\:L&:R1KFIZ/#*>=)"^J"$)H\_^SRU-2(/67`[
MBKJ5#2HK.VTXPO0E<46^(IC1/QIO8R:%RL_Y3W*H(HOH)J[F`:<<JR!"-&CM
M"9ZZJ"M8/RZ^<:!`S.BRC4SP(9(HB"OA%1'.?\SD]5]04+"TW:6E`(3)4_Y!
M6MDN*B.I>3)9,**)86M*-#<=70.<\(N=6PBDPR)&YZ#M9[9$C4&^0I)%H`^S
M:8$V,DN`NHAL;",\E&L>+#&./0[6:N9+$4.GK(SWD/655217L]S`(;V>L(+E
MO0R_Q:SX&O#$=$KJ^56O9$9:NN.C'6,41!389/>.K(I6LD_1&R.]0<T0]I)!
M;-T*%_F%457*.7-O8PZ.9M=*36)&;3YG6""DVLN>@D_$"C?&?,7"Q6.<Y\BR
M`Q'U0Y3XD];&4!)S0G/B:1:#UT0%*:0=<6C6;F[DA#C"%>USFPQR2#QK['K[
M7/\``<=:N:.%5"["S@`CJK2$0)VAD0H2:6">QM1S$?H*L2Y5WQOB#7V>V"":
M-%1TC5<H)IC+T:G'/#:8LLPD=:)7163ADCA(D@"C.#927%G.VP>X=PTS97R2
M2/F;(U4]8U0.<=%%:CF2,MAG@/J#2;/.V1=E!9DGUI4,8DXLNKWDY!1<C"G1
M1^T>2%(&RN?&UZ(K0+92*&IL88--:G"FL_"G5C2:6NDM61BN)`EDJ'J[\R"&
M1LC%;.CQX_6%R>JN5`:T]U9!0H-##7&ULC@K.T*AJ9+H069H+5EE)5VC-(DB
M0&Q^$MD"L2*1/8C4>B/4);GGT;+NML*.6XMA*2,)T*,I$_>A0JR&2>>W?504
MR#P@_A5\C5F]D8_P#JDKI5;*O@.&]JV]`H:"]J_V]L[2H<_6Y<!]9=&ZBOGO
MC+"SOWTL2/G!M'#B/'629GPFN*7\>*)S&L8#XLY"!3<[<6>MKJRFN)A\ZN/S
MZQ6-G1Y46VCEJ9TT,]5<`5=S*')&/[)`F?-/&YB.]1Y&R`[M!BQ[2.P(M+&I
M'%KH)X*&<2")T4\-E^)47!4=M)5'UM?`Z`R644A826HZ5\RL6-OL\#NJ<8'8
M;2OJ8SJ_-AN>RR%CC'#RMP#'`^-G[S4J=EG.1:.)LC#!'/F=[(FN<]JRL]@*
M"U='#L=3KLU1Y6['OH)#X#6T\AT,\$3&5M6500?@2.V'[Y53ROD$AE&205LK
MV2-^='0AB6X1.NL;BY:T!E/F:VG,CK!6/O!A2[?126%9,(0S-UB$4^8O*>*:
M9%]ZPU\4@;E22/\`)4.WDD0'X4,&1R<=U^/L@K<<&(]*^KAL9@[2']V?8NPI
MZ6`VHE!]95C9&I,PK&>^/^BA+5/6S<^PESI,[71U`"V05WH83:]HXA4=8`V-
M]'6-;0!KL8=#'%(&0Y\8"P61#9D1_L^!X9I5H'\-/%FM`VF`2,:I*BS,2)IG
MB0$'6A].+(W/R-JC1-!.HX:(YZ,?`YJ_T_4(UCOX[*]O8]CES0)M+;O=27^O
MJ/R0:@:SIS*DD6R#DSS8K(D,J.65X[YX&DK&_P!9(T1$4(YT%4R:\.@LZBK&
MD<I#+NSK<^"T^Q4ZN/`S[6E2X:ODDMRWR+\,*3.:*`]L2/F2%%D!"R>7?$12
MW1`>%MK9](UZ9(\)\-KL5_;VOSTJFLYK:RM%JWC.&LAG1_I/72+\CO7VM",-
M$*1+JM*58VP`]B&2)^$+;3S5\3K(@^5#0:L6#E_P%R+9E?FB(I#?R(XW$.6-
M[_:T$L$B8._KKQM9!I;*J,FCB:[!_DCJM?'(YV?L@#N=D#SA#23R*V9#8_B9
M`C48YBHO@*4HXAE-9QCWM71#1U\0Y*W,Q*5%U&5<1235V:J`>=2C45?&JJZ5
MK/[5'@]ZM=_P^`VB:,]TXS!*2I*O&7PL+++]M4E+(86H2U!$(BL.001_CV\D
MJD1'K(KV/;\/HQ$]?`M=C(X[:DOAI*:LN00)J<FWI*.K2N$^?650<UU5::"7
M*5[`XZFHF.08EBEE,%C8Y8HU<D;0B2\H]>?)<S64%8@]0+--6EW+5E1*#1W0
MT%9%\G^!SQ0NAMZH<,%R/>V)JO1WQL8Q[@4=$%J+^'.(/I!U`HJ(*%T><9)2
M9P6I.&_:JX*)!PP`(G'CA^QL;VL@>BQ(OI[?[0;0H):40Y-U;F!TSUT8H3X3
M8[8.0A2Y'U5?I**R>$>E/9'@/G>]JS(KR9E1CV^CW!+'+Y<Y/1Z0ZHKJ6?/5
M^7D*@+)N9KRMJM%<R7%>1EW6$SSKB6.Q)!9(JH(@X#XD:Q?;(O@,V,++X\*V
M60VLK+6>9[;@0P"JEEOYZT]`ZPG-C$`&T%=H99K&9DZC310(\%'1S(KD>H1:
M^AJ8Y*RSK[L<N?1'W5N6;8(W1.DH:JUBJD*F'60][2WAOG)EB^/V+`Q?E5%:
MUO@9!?[5+3:%:_\`&F$$ME"K+6L=1@2WU?*XL9MC7P6.HSUI"SY1XHU>B0+&
MWUD:BO>JN!J:K-L#B;&#MY-8:,\FLE@#MC)"D4<)MI^'6#F:V=TT5?++\1$K
MWP@-,;[HII&+[D!)KJ19VRSRZ-U"-8/J!:5EW;60HX3KJ5XP9,4Q70`()JVN
M_`F69Y4K7.65%:LB,?[0[J*PO3K>2HK]2.RTD0Q&3$:<0H*0=K'0#C,5FVMH
M1YK96^C8B&Q0PQNC<LCV/]Z`L?OY[#X::QA%'MCU%KAJZ,Z`6>>R,%'EHB?W
M*'K5?9U,MC9/C/?Z.@]8WOBC3V(^-H26^CL+^31FG7^>T`\<I;RI33@P0HY<
MI;1%S&>W-[,'.PC/CD28B"&5"2W.:C8YE]C?`VT<1K6U')>?U[#JZS:/FP5:
M?4..=5E),UT_R5_[D48:@G_-](T?+)[6HB(JM1/`E/P#P#P#P#P.@DJ`.)9R
M96PQ(^*/WN151))Y600M_M15]7RR-:G_`&KX'A,_FHQF<G_D:^T&OO+'21-_
MQ+Z_M4:HRM":T!,AS.ONQKT2:RF4C6&"N,E'_"D8L8;2W/'>,1(DSPTK;"$7
M$=/VG/KA@NE6I%,:?/D+(HD.JL(S8*H;8491V2CNJ:N,%O7-G)]\0-:):&)"
MZ(4"69@1!G+323-T&*YYSH>RKD++J[K!8^,\"_TY-JEA?Y46OWL/Y)M3430%
MD:W1N+L(QDR$H]<HDL]V6D8.YO/.]5=A:W]9C>AZH(=_P7NHEI0*L_H]^.T&
M&3[.]BQQ1C!\[-B#+)U9!B#)F17^;<^&3YXE*E.!JS[AE^3^\;.D_P`ET6=T
MY.=-OLD%5\O76=$KODB9A:+'!Y>BDT-)`"<MLNB)#<7-1MD(M(4L*Z$*<$*]
MR%MK.A='U=K>[S-5><YG16Y&?M+"FL:I]6&558RMR!%<3(&")70#8:9Q]S"`
MZ>88QKU%C=-&<\%CDUG50Z;&@9":JU<=M]A<FVSL/VVJKC3=Y;\,%+L'@5XO
MJ\APPLOQ-CB]SY71OE(<DJ2^@99V.Q4E$8&FJH1;NWRN<TU?3B\ZK*@@6S($
M'R%Q%(ZI5LQK;ZW8](=!:/MM!&7-'-`0"Z2%?`;9F2NL'=Y6_KMG5VU9MZ(B
MDI'19FBR9DV7BNZ'*[`$6B+4FDH[:UE1@-+(KVS'Q),[UBB"-F@!%M)\QF;R
MH*YUG*K-'W`I-!C]7T82/4DRSNCL+:8FLBM@R):2]IL_9OL'M5@O[@(;2P*\
M9EHQ@H215<^ZQ>'MMW8WJ-<1<"C2'S[2H:=M\5GPIA/BX(''=1S6V]_Z[2M_
M+VVMC62&E)-:R:7TA,A,!K6$-N2M+E]/E;"G*J[1-DC;:0Z@K^#9:K-8/7-U
MO1"HOW?>ZO/Z'6NI=!-)8E@DAEA7#D?-/9QM"4*[%A]VUG/>9Z$>VI<>(%6E
M8"[.K8[\YNOW4%Q+J]ET?*FEC?O^GHJ#+,F`$&<0VA=$@POY*HV4L(QS4V"K
M!*^NTFBM:BYI*S%FG2$8/'W1%G390<6MI0OV4LF?+6-;;DRQV1PUK'%&#,[\
MH"."61\T(2;E690]^+IP)KZM$N?KW]FZ"Z'ES+M>7^/;_:76+IRJ\71&244]
MO%`]QP586,^+W2^LDCI$D20%ZZPF1CS70M$1O4C&R),U@K==7@GZ&&JO4MP'
MZE+DJIM`1M,U]'%#--9&3.EDD1ZJL`48R@S@]/7YJ"X.DY]<5MS8XZM*M;FU
M*H[>WA%U,0E6_58_D[!UI!=-J8+D6A@8L=DTW6W9`Y4\$8%G[`=$N5^P.J/2
MRM:""\M8W1@&V`F@JJW+:*Z?2!PD]>=6FP#F<^W/`,FC0\+#*#7S6=T&5>O;
M')/+&8#JI:?N/&#B;5^%UMB!4VU<E?GN@T%7=C]FO]#5CP5_9/LM>UX!U'C<
MOJZHF2GU--8ES/J[6*OL1WH(ES8&!,^>Z<9;8+8UW-@\M25NKK#0==<5C":K
M*[T3'LI_W6LA`LR+&YK<>FQT+@HWA/(MB=333Q,2*08>$X+5_7[E6'P?V*^K
ML5Q<Z$T_!_:OZTCA#!V=!/D+_1Z'I/%?VO59L>.N8L&<&DCED@F#<RQA_(<Q
ML\8LY@TP?H;^`>!H0V-^)3[GI\-06&Z0#3:BH*K%.+MWMFGN;`DT.:"]ZD)6
MQQHJ/G_]`D!,#88?1&^Z1'!!79.>7FFS]8#$902RR!A1TV/M.@W(=:7I8[$Z
M=]^'G%GVU9=4P)1WYY,3G#31E5KW`S0V,8SI05>I\SH=;H>;WFV@YGLJP>DQ
M&/ZM;/U5YG"FQYO>W]V["5><N[VXN3<Y++8H3--:G!$634>,_P":.9S&@D\=
MY%JN>=(J=1M]-F;-DPRX>XFBT@>U,K*\3+\NH`<%9'E$C%EYC)D9JT-HS3[B
M0.&<YZ_BPRSF(X&T_EFGBBM:B+:Y@>0Z@R@YY&4W&FO".D456;JC>A=,,GLA
M,V5F]GT&SIZ%\Z-8:/\`M-,8XBTE:\1BAV3<&M#\:X]-_P`K&ZQH2Q0[S5C[
M:]D)NZHSEW+ZW8`02DV=H$!B+7K5%;EDA/&GD96SH1,'*JLA>$A97BR9TK86
M-IHLIA]-KN>6N%I]O^[TEP)D:)QG7-DV'/UPY_.2:X<EO0*QE<M=GJHA[:UR
M-A&C@$5H,#$<L!Q'7\WT66BXID;&KY#H\]C*K*RVF]?7LW-=R."^?DKB_)Q]
M>L6JT7.S;>[G5PX`EK<HUKRY?S#7!;;(&8PN$"`D@BHT!$]U4&P`;%2<_(%8
M2E22V[JV/IL.:!F&);)+*/$JQ`S*KH4B]6O\!Q#ZW'/%M#9]53G/GDLUD<:9
M0Y<UPP0LU1*77.R6]FU)9%Q.UB#1+Z-;$KI7M8K8GH#0/"KFS1E8PF>T(A8-
M>7E:(6<;(!\TED&84#<E]5FO!ZS-CFRPSRS1N&EG1TC_`'C.]_@)L5Y%'93L
MJC:8HP,^UTL)1!=EK()A(1'L8//73="7,HV<B-(!6M1@K9?2)JM@7V*#IGN?
MF;?O9.5*$.?769\!)`5"0`0(,0VOBCK<EN9+*KM#GD/(A]K8Q95B='(KF-7U
M"*]/:5=_GH`ZU:ZKMJVK`*L2P;,C,V1=DULT9@T%I!U9UO-$$*1(5')[$BA:
MBS*]RP1,\!=#;$&0\<1S15O0J@#0$:(J^T]1%'8+5E#,6XL^FHL"DDLC(?*$
M]9R6*C7I*BOC4%ENH,$M&SV=R'>%4,S18":?44(-HV,0JPJQT:&O0E;86@L%
MBD_R'-59_>OO>Z<>%L8-_:&4]'>6:6K8FR@0PUZOJB1;4^<DV-C(W-+MNQN&
M,$":4X>><*'U1T;7^[WK)(X&G2Z,&6P,KAK&JTQ$$I4:?NNJNOP#Y'*Y;>.4
M7_J,):$B2"0_^D5BN8/&LBHC5:US`D6$2UJZP;5R:*LEK;&U&IZ0BHK01@ZD
M[Y"6I63K>]`(GGKL[1PM2.REA5XKYODEF^1DWL!ACW@YU4R.KOZ&M*J#D;>`
M'GK=V)!+_DK!?G67I$`4@4`/N8[W/?),CI)I?DB>Q4!PX[1>E8.5'^`L5%=-
M_)HWR5=..2Q@UG8K9(-7[\NY+KAXZM/RD@D3Y/3T;^KOU#L=M919R)<Z73.N
M+,ZND9*(&`CJ^Y.2S%N!4(U_0XV^TUD\#GR-@2"%8_9$K7.]4#I`(_*_=@+&
M6FGC)E>RSKR"62FVS0+2$)1**&OW$M::?!?R*]\`'_F#Q>]KDB;([P,2>Y+-
MJ;*P_P#25Q2+-:^B"X^M&>V-K1Y;:`,S?&6UD#!\:1>\=73.2.9\BO8Q5:#<
M*O!B()'&6*RSQS1R-BKY*%D(1)D<9]B^U&_/'?*Q@CTD;\*O8OJUC&KZ>C0D
M5]A<!5]6/70RLSPU6=<E2.K,G#*-`R0JPKO<3'?'2ER,#L@IOA@14EBDG']$
MG]WL"5B]'8WFGNL57;B@!K=(-"%#8`KG)^>!DMKVWQL#[`A$=9*0@C8X5AL&
M1NG<QBKZH_W@F@ZD:IM:R,&RIKJ#\4X8^NJ\UD?VWX1@B`ZRRJYW`V5@7=B!
M6R3QQQD2HTGY'/C6/UC0)U"'#L\GIQ+.Z(OIZ6PJKXB^.?FJ\,IU,/#'5"#2
MP9-U<%8R5Y!/O]T)**\5S_C1CO:T,JT9D,=FJ?+U4^0HJ@S3Y"9*T6PQ5P?3
M'&N3]P'LPJW->R\$U31'M(DAC"423XY%D1B>QP1H*-94YS]4ZXYT!9ZK/:2*
MF#6WJ8C,N`/^17)9LD=EC7RK:Q1.B(KW,:\A%D6.5$16^`CU1P4E]74YQ]=5
M1P2W$>1TM([(U#B@#ZX=HHA)TV!LP+!"0T8LHT:"2$#N]ZN:U$]P.W/TMO<6
M)U;BKFB#@HM9:W$,1D]0EO>7M&BD1VU-538RM_R+\<J8D5A0S6QQQ/8Y5555
M7!/E64'I,Y+1CZK(T[;DTC34^<'DK9CY`*]J@T]R78_M$8D4E0X*1LDRB*HL
M=:.O]WQ.:\.[25.2AK=49;VV2+M`PJY0KR4ZA$/%(H6@2R,-&FRI\M8]R_!8
M2.<LZO+8U&-C]S5:$499[QZJ2UAM[J6S,ND*SX+!ZFURUO7M>>")Z!B8:L(J
M:D,H".05[Y"GO)C2/W>L*ND!';?;306$=E-TKX3C4TM11U=Z1703E#Q$_"[*
M6TT^`*)-L2YU%C45R1^X`MLW]RIZ.!QTU/T7-6MG./?Q#_"^>.I"HX@C0=C6
MP5+KDT8(P3%T:,40HZ2&9&-(BB$C&9[5DB>YX5`FM;NKL*^VL+BP*)'K!?FJ
MI,=1#I326*M@J*@HL/E5T=#&^-DI#)XT>BOC8Y[&(J(@8%Q82P(X8NIM*R"Z
M@:<6^XH:<RG@LGRP.MYRJVSY2!&=$6Z5/5'11_COF5JJ]R(Y048[<UU*+6P3
M'W'RVLBV[J2J"=8J$#5Q0#(P&NX1$%6,&G%;*-[9Y58BMC1ZM5/0&'63C4FG
MK[,2=U,VO&EC'AFB@<YX`\)37U!\!W/HP9KTA\SVOE<.B.5S/T:Y$5`M9EM)
M?)S2T4W75&NLK^XDL73-&1E)7QHV&JGM;=H/,J>-IHC7**68HY$L8Q$+/25O
M]J`GZ2GKL@-HJZ_[%8W1"MI!DLY6LLYKM]WDX!J`A3;.G65U2`SXV65<Q$%A
MKXT3T(4AX\8-0LDP:LEJZ[2_NPRXROFCKJ[2Z^?$7]I#,(3$++3U?-JNO)T!
MK(WP0+(.K/?"^#U:PB22,(TM;")C[:VBOXFD-/\`8TZN,MJ\FAAAC>7/DQY6
MY2RO)P+*NGD_Y4?QBQQ_(K4D216J#HY>(,T<R\"U=C2U%A86=*=4WL^ODADK
M+JH:)#;S59E'5P!0Q$6BRP21+/'!,+\\:MGBC5P(2NI6Z"$&LT=[,!1YDLZN
MI;3J>^L*NO@C`/+G:CX:B\L="6ZO<Z"92PQ_R3U9(Z:616N0&7G<O3E7,%V7
MH.ERL?56MJ7'9;?;UL426,4\4E/5`./KX9A7/2>(@<IL4<PJM;)'\,LBL!./
MS]4%&\7,&[(>B:6T:\MZG=ZF,R2]G)D0RI#.&-OK4&`Z<12&012C#HQ(V^V-
M6^Q`Q%HEM1`J8H_70J'52V5J9:]5V^?=-2PADQS%69/^<!OC-2H;$R<2"*5I
M$KG/>WWRN5`Z]$4);4`(C=#<TU(";)#6YS(]AVMG<@"%B#3O`)D;H&V)]+[W
M*YC9IWQC3OD2/VI*OO#E1"YFI^"WG/Z&+)6G#2LDN]SK#83)E4848\N&RZE\
M$KP0)UCE5XTRSL2&'V.C:]&`\#-0VNO8;BFF,O!Z>:N)26KV6GL&-L1?2*)F
MO,FVP,EO^$4LT:0ES3!^U6HQ4C9'[`F*5^:BG')U>MD%FFK\\]TK;6W?6C3W
M#R6WU!&&NS%S[K,T2:=('%>C6,;&L,SWQ1O8&U/@1`Q?'\*0%9I;AR54WX9S
M5E5KPV6)L8@[4G?*]B`CL;![/<YK/C]&JK415"8/`/`/`/`/`%_7^J>O^W_N
M\#PS_P`PV(U^J_DK^S]S6MN*?'9S!<2FN]W?D55!SW/6==R!]NRG73'5U@ZN
MCT;/QA["7WC3>Z8>.#Y6NG?`&D+=8?)499.VNL?4]=W]<''3Z6T!FW?[]78$
M84;/@Q[#'G9=U[N\C44KT`.AKA7-_8*Z9)Y'0R.@\!@4K-QV?F`K"[&EYSS6
MQOSP+`L\BXYW1$YF_/M+O.OP.>IDLM1U"[UH!<M34SP"%)!82J7.L!@!)$(9
M^/RV7<RK&3[(7T-L6-26L-IJ,)H\%16>4;7UU^^1-976^H*&T^LI.D`'P618
M$$()O0BIYI(7Q1M%!)-WNXRFEO\`%=EYY!U;78APVUS!@LT>EN`:PVP@A`'X
MGVS&S66AU@0FYO*;/?BUSIG!R_N,CHFM]SF@W+3C]8["Q9QDO.N56%[<X.2_
MXYN^N7UM>&40'[-G*B*ST='GB,7A)J^H+F%;1$65:6&R!'3"/,8K6`HX6GL,
MEILS!HP;L8VI^RD$0XIT%#\H>8`Y$VYM[P*U955X9X<3_F)A)@$9*C"?@?)\
M38VR`J!<HIJ>+.6E3EL[HLQ-0UW0J/7?F/WG2+>D6IS--<"[:XU.?TU$'HXV
MU=K&31-DKV/'BCG$GD2:&;P$[7\VS)5)!C+6G%N;K_.=&5DL(-T>HKNA9K*6
MYA<D[V"W1\-.6`5#*LI51$^:9I(L@3H(897.>#5$WG7]!LSL/A.<29B>9AMM
MM2*\5E/K&2'G)?6MQMNHZHBN=EXP_=8_N"-@AB9;ULI(PTL31HD!?;D<I!)0
M#.[^.VGDN5J'"\_QFT)YS="BI!FKC.LT5C/C-?55@?2^J#^LU13S$UM)T69L
M4Y2Q#D0@M]#+ZC044E)N=+GNG8+85-AGJ?1'-$[%Q>RU58>>)3:#91)"F^R5
MCLM[IB@&A$TM6?'5T+JZ-K88BW/"5>2U85JVBVN=K,EQ0W8+9V5)9]/(Z(87
MK:.X(GS>TM>><[$R9^ZB%LL=/7A1VED#75@H\7PC3)&UC_`2=O@KK,G`OM5Y
MG<8)V0IM$%82"!])P5KB9:6DMA[>'3"ATE;G`:6[;+*8E@4ALRPRRPJSVM^8
M$L*4273"$4;#I&OXUWFDQF.H"1_W^P(H>WV(,M_45^CJ8JJP@,F(2.=IL:3M
M*)8V6$Q[GM4)-L\$/F4K*7H^YR=.!;UIU=)D[VQO]!9FSLU]U?17NS#XYCVQ
M`TP+J^.(`PZ()(OPVH0D+G?)$$-";K8\V(Q6&Q'+C,].-1U%W0W%".+K=/<Y
M*KFL%TI>1Z(3?GUHF=QM9M"#IWU,J%5UP$2R5TT)UE(\'0%SJH_?)Z;H?6D3
M;V3;9;[+87,?YEGG6=O<`X`'-[77F:?+5EVQVFVC*R[%#/M`QZ':6(K"O8`Y
MD`+==%J\QBZ[9\EZO)UFCK1Z*ODKOP'\[ZK<8R09ZR74^`TLFF$Z9+I@XM1I
M[YM9=EF_NKIS)16QC1*P+)Y6Y9J#:_1NYAS;'!5,5!:Q;Z])U6&9L8XX2NDQ
M9C,XFGK!K#>R#B0B2%B"4@M<1<UC#[2PE+:_X0N9P?!?+UC@O3`>DU/4A[G[
M7\@$OZD8\FILLL4O:N8S1$;&N/)"8</90*:6TP.>Y.'23X5EBD8L+P]\O@'@
M:.NL\^T!G0^@V#:79%@G[/1?@EJR[@BC'=*0^Q0=JZ1)S)HVO]\$P8<0[VM^
M-J.\!>S^6U9ED-!)3ZJD"E6D`*L#%U-^-0!WSGL_,RXI%TA$2U],`^4E"/RU
M::8US(V^DK5!5GP>[$&+L1\8XX2&:`RX]]MIFF?X>WX*R$NJ@K=#["+R&P'F
M5D<S"I6M>KW1^URO\#C6Y#3K;+</I;Q+6PL+RY&CF#MZ^C#HJF&!)1CP&7A9
M=L8(/`.HC7N5)I6N<Z%Z.>BA@`X;8@Z99K+"ZNYBIQ2@F!"'6(T+I#Z1+*5D
M-J?NQP):N&M]T1*?"D,BRR1P^V96(@=^^Y_>EU].<'EM6%7$C4T,@]3):FPT
M4EB.Z*U;('6ZBHM#96C@",:1\Y3?D=(Z1'>KG("4)R_1:%*_\VFTL=Z?67<S
M&K)J*AY%M3!2@TTUV-_EOXI$<TL`[&.@*@C^-SU147U=X#.9G.EQV0UM8T^I
MC-&''"IB&UAS:8)C?RQK``L2QU]L9/&[Y'M&E0>.-LB?.KGJU'H&;BL7IB+(
M5Y(6@NEDD^6#-34F\2J-C52YS:.ST%UN_P!M@A8X"&3\MCATG4AK5D>B2,0,
M&[P^NK[0RRS8=U8%2$/?!!'7Z8A#X"(*];&02LBTV?IZ]*QCB(6L>^&21O\`
M?"KW^Q5!6)JM37@W%C307U2;86-@VJB-AZ56VLU)9@P1V-9;K6:LH`^O)("=
M^*U$B="A$GRM1WHY`28::R-*)&;CMW7@E/KVNL91-U!75Z)7Q0W!(!2;\BU8
M*39S2S#0.C^6.)K?1'3HQW@+SZ#;UX:I"%HK.QJ1(K<9:8?>DE(V3Y[=E=>*
M?LZL35_$AKX/R'3$DM9ZI$YO]S4#N)QEZZGNS9PM!0`S.JI:404;6!6;CWDP
M0'5$959HK&['J'4A$T[/SGM>V=K(UD=&Y\;@:H^9U\1<$,=)N9?W4^MB_+.9
MH8((:]DT<33`ELNA$)$EC-')&YQ$#2A?ACDB2-419`<]?7:ZYWY%F!5VK!#8
M)%%,LZ?8DI1MH!61U[)`ZJ^J:>QDM!*]JO5XLTSO<]TLBD/5S@2K+`7E[:WN
M@HJ#74M=\[RZVH.+U$3/>,,4\D4()FE,L1HV5L?Y+5.2..<J)6O:]\C8_`R,
M7FNAUD]E`?77:O&SIU4/72Y_;Z&0^>5UG-)[K4^TCI&RCM+<UKU^)[X9/BB<
MLB1K&&`1AM[4$53#:/3W-7"1<7=C4R`=(H:POY88`8Z5&4FCEE_;/G>LBRPO
M6=['?JYR*]7!@$\RV9<=>7GL3JVG3FEOA((H]C:I`RE<DPCW%7]V)+&)8?D-
M?'!(R1R/B^/Y'(J)X&0)R_<,%29]%LI#&(0.A<[.E1?@+(HCXCOVP*R>EBHD
MTDB(*[V)\7L]9'>QZJ&=5\TZ"/$LLE!JGBK:+*D0^2V=,635D1,CN&-(=9FD
MQJR%CYXW*S\A"59(B_&QS'!W0\U-E*D0>@Z-"$08XII`E%UZT.$K!9V$04;/
MW,>1ON/]GJXB*1GZHUKF^BN3P'?=8;71"@55,'LPS2;F5%C9E]T,"M/,96E5
M]4,R2L,+JJP*:*8R9)9$,(FD6-9HXU=&X&U6<XWE=8BZ#]@V!%K,",7;20XG
MJ)P0DR1GH%'7PEY@M\\X\Y+22WR2-8W_`((HHE;ZJ#C#XYK2:6O#*&Z),>/=
M158PW['OJD*<.<6,^=Q1*9LU87PS?'%$6]B#_P!S72-?\<C)`?)7"]1`\6.:
MI-I&G"U[!1,C@.@:0W-7H;CPJX^71VX]C5GI&6/,I)#`A8WK-$0K(QW-8X%R
M;F5_:1%Z72XG9:`VMT8[9*V232UPEF%(//1+7?L]!S7\QU;"!4RD_,UY#F^L
M$?RL=,R9P+0',N@1"60E,(='2.KQH<O2,Y]L:+]Y")+-DAEU\]_6W3:BXI[>
M%4F8L<OY@$4;D:.A+58"B9@]WB)A3JC$P2DDB1A0+29C3W(-7JQJV*239,IJ
M_(D&1G,N0D%;/(8R"41R$-:B>D#@^X7D/1K4J,`VDK0*:PFL;+3LUV2L+&0R
M>:]>0::R>SR^;>38'310%3P,5OYSH(E8L+&.^0!_%4J],WYL!M+6MM$MXK%!
MSC/Q4,K2K"Q%<?`#R9@EG5W,00C6-6<;X/TA:Z=41[P=N,YV;^\D"3Y?50U&
MZKZDYF@GH+#.W.44`_Y;QLX4V1+A%OCK,6'\1Q),;F`0#^C5^+W/"50<'GR*
MC/B.J-Z'2U5B/:N'?1RPW!A3Z]E1.%:PK2MD.$LI`WE&2^P?^Z1/5J-D]4!^
M34-42-954E/HHA;IHF.*&94RO%$KQZB=T4H93J]J1UDHQ31Y3/8YC'1-A1JJ
MBN\"(C,4)>"&@@YV]"AFM84A,L^;%#O!&*FB%AA2G)"E'MD99Q+-,;\T7XX:
MHJL<GZJ#)/Q!P4E"1/SJV*'J[BVM+,RLSEB8>9(%%>,E:S/PXZ*$FN).>U10
M_P`MJ%0RL<DS5C8DH(-YSZ:8RJN8^96MB>9-^Y2"R<]+&K!;P2Y:W/ZJP%3.
M&.9>#T`BB%Q.1BN1Z2_+Z2*UH5LO^)]*/N]+8!Y'>1K:1ES3S668NSIB8(+*
MP-'`C2MYT/&J3UUB](6I/,HI#7-3WK,][0Z9.$[4EUG8_P#3S8_'<S1RDBDX
M0T^QIGM^)([&K/O,&89,3#-`GK"V%B.AE<J*U6^UP84O$.I._`63F=E7'CQR
M0P@UN)T)5*,IL@2S(Y8L/!6H,^%(XG1(Q8H8X5:BN:GH@8H_">D1'*^NY5JA
M@HROA&%LN;U#H8%BD<41^+/_`(N4:H!Q`ZH]\CXWS1RK^K?7V^`^I>7]+`=9
MEB\OT]K;6.F`6%S\O<2`5SP9RB921F&9NI8-4O+/>Z*2)JM;Z^]/1S&^H9-K
MRCJ;H""6\AT5I(/(VJBEFD+%MI:!2#+6,<(J/.G6$8XSG#Q/8LL;22X5G<QC
MWN=X"E?8?KT]UGFU7-^D(V@KP:NN(AIVQ4\+JN\EL!BCQY[RN@NEKS[-A8LA
M@TGR-AE_MC<QC7@@@\@ZL?\`Y!#;<JW@EG[+:)+\&BR59,4!40?MDM2`96$"
M61%)L*PA8`15E1C8AD_(C'3XV*#OK.?:2KTS0I_KCT+5U0%''206%[%6UH]F
MEE*(R3\VS!V19SZZN!@'>YBC^X8B.9H\;F*BN!AQ<3Z?2:'1V`_#]LRC_P`8
M5N9J:AN?,B&O7'"_A1>Z36U9\04'OE4EWO\`ED%9\?M^.22)0[,%P7=GS/>=
MQ3HM2A<(ET7#JP<=6AV%E8"$YBX`FEJ][?6-,36_,IXT@R>LPKF_+)\C4B0%
MX7Z]=065@=GD^J%UUZ(%H+!6F9L<C-/2SCKC*"B&!Z`/4NMI?G4K\<F507C1
MNGDF_(;$Q0:>@^N?81[FJ#S_`!O=OJIC7R6I%,5S."N&GHWI6_D*1H>N@Z`D
M+2R5\9D;5;,C(9U]S(I$]O@-D_@'>&NLI0>`]*AD>4I=:&1J</;-2!30BIJD
MQT?>0*]U?)%\C$2.7W/5B?)^B)X"M5_77[$6]M9BW_']F+#9/6,G2-,Y#7M@
M<03&X\VK)'[[;Z-(XV-3\1CQXWQL1WJWW*UO@.K*_7'['CU>A'CS6AIR6T_J
M$FBTP-V/?HLUP\JL)`@[(ZO2WE'ABBB?,V,3UF9[WHQTRL!=(^N';U%!J*S$
MW+![]\1^BMQ]91",J%(FE'8*.V;K=B0\BG"B=)&L3"6LE-<L<G_+8V,-D/&\
M_;Y7FF4SM]`4/;TX1`9L9I41L[GQV!GQD*5%9W/S1E0JV1BO)DE1CT23VO\`
M<UH2=X!X!X!X!X'%S$=[57U]6.][?1SD_N]KF?JB*B.3VO7]%_3P/"/_`#>X
M#G6W_D#^R4FHO-7C-!5U7URDI;N@LK*RI+4QO.:]E36:3%07V>@+;.4:^-I<
M!49(LB02RQ%"ME&E#2QE>;8[.5TS:$O5VJUQ$\F?*ST.GS](97U:PI4GR]&M
M(Z?>%.@KEE6X'!@HB980G_JD;_>@9%S#AM9;:"_V`FJQ%\&%6IH;F\/V&UYI
M7T;3YB[VQS3#;(O?<N%$SND#I$EJT.KX-/T&0IK`IQ?D>#(K\(105OYMMUC`
MUQI"%QPWT>U?M1JXPMY]^30,H:`^TLKVGRVOOJR9("8F)/G0;"*26)OP.8#?
MK2H:VE,RO/0NJ]`RV@I['3;G0Q[C;!ZN[=H0S"C\I3UE$VOJ</OLCH+/345F
M.'0W/[U=)^6<3/&5'*H1P1]7<N)HO35[3>UHE'$!?ATMM^_X*_HK&SC%KS0:
MJK9)+D0QJ(DL45]TPU\7R$.<M>Z"0B+P)(R^:P65=G<YGP=!%5`_8T"2(&T-
M-NK5-%9\$"M]"5.PYT)$4!81:-KU`1U=)`YRL8Y'^U`^`8G"@PQ45IU'M>$T
M-[5<Y+T..S&JCCON;;8+&TMI+1E#%2VV<T=37@:F8PH&:2LJPV,)BG66=5>@
M8EG];\=::?3VMCU'0[3,:`5E1IH`F=&CN+DLH"]S`!<^4ODH\V$%Z1B6,MK8
M$%QRM3X$B;&Y44'=*!&.VHJIY^K@UV?L9JO`V0>FONBV.D@H*/09)J;REMBE
MJ=1>RC6-734UE+)#-26&F?`.%*&V""4&S_T4BH8*70F=!Y)KH77N<9#<E].M
M@Z.VV.0&KZ\:\*HM`53&5:ITW3PH\.`.L8S'C!L9!\L`[I`7A[VAS&C5>:7Q
M.XU5M-4TVDTF/OM'DZ!]312/LP*JRB%)RML;KBN87UO2FW5R37#CZJA,?"+,
M3+*5("!9\ZJ^DYL_I>EW/0<K9;JPTXU]0Z-M@=0&W+2["*PBSNU""4W;5T"C
MJM./="1RN"D>3*:H[Q"8PZ['FOU?J;&:OCTM]5Z#6EY@9^M)WF@O75]8!2#1
M9@;$A.I+4"2N^&)'-I")_P![<WU@'1[%C]`E%F2BS%E5Y70TIM2<1QC[38R_
M5]Y^/9G5K>]6!C@_S)5KWI%H:2:*9"Y4B^-\OY$L;'R*K03-1]>N/RZJ$'+;
M_ITMQ87<]8;CM-D2=O>T>E`*;7Z0BE5#('7U4@U:.<.K#*=10F+ZQFQQ23*&
M;`)/F,]84MCR[9MY5N(=+;ZG&W&CZ+E=[N-4>>73X<2F)H?P(JRFO="4&)'6
MBU1(!-5!:/(<=[?BB!WF\_P^J];'+]UK9X2I&1E6/6@!\)9VPEI0UF6%?;&Y
M>NN<#817F2U&BO620/#>%!J08Y!(%!A2(%6\=B:FSAO_`,\?M:N/#MZK.XRM
M+R^7@:?:349LU_I6'C:N_LZSD<3JV8(8BOKR[[G=HQTL\ML8)*$NYKFVAZ17
MGV^I(T>3O05`&L>ET%-;7^$Z%85LI$%K5W]*595YE(:-;3D:)L^=MG`N#$?%
M^.]OHQX6>^NF<XCE=C]<@\R0/;VP/V+X`V>RVEP#2WDZVWV1Y40)79G)"P(F
MA",8R&:(E")/6-[REDEF;)[@_0N\`\`\`\`\`\`\`\`\#4K]A/OIW?D_V$[=
MSS)<?Q.@Y9PO!\EVFIW%Z7OJ]R1]&(-2T;:ZH;/KSG(MSU<!*5%$>>DAD4:K
MZQ^OZ`CE?RD!U^>^T]R8'QJ!_#WTECS9G_5,%@O5,:;WWKG)+?8"2E?B/6AJ
ML[S:&T<8*V8))"I&K-\,:2J$RTOW.W]UV/[#X4#(<VN>:<2XU;]XI>QY_<I<
M9/?8G15Y3.65H!-9)8Q@WPVCPNO%TSW^X8<>O"G$=*I4D<`4@HOY?^N5LW!:
M_J/&<+CW]6J-[?6M\?-TO+AQYRUP5--]<]539C3YQFEIJ'I/:BC\M/+>_@1E
MAUZ6M9(3"1%"@2[]2?Y0]/V?>:FHZK1\7I,E0\TZQTJZ=S;9W=OMN1TW&8<!
M-;6G9J+0CB045!T0?:SSYXACX?<VJG8[YD_YS`K?C?YO-]I>>XG:'<=YW7DF
MQ]`;TD$?1;=[L"TW?<>#^ONBDK+K.4&@(QN[Q'800[D^86"*OU".8.Z>OCD(
M:%@^<?R;]-V_UW^UW5ZO.\'Z#K^+<DH^LX$+G>RNEPK;7:V6WK<OPWKU^01=
M$9CJE9+DQG6:C)Z1PV<4CA!_:UDH1JS^7_?W6BNG5.)Y=DJG'ZN_RI/-^COV
M51VSK%[#W;7<.-R'(:1"PPRM-Q`S*26&T<^`^&2%?^6T`=?S6A(_/OY8+LCE
M/;=9UWF@N/VW(^1\RO2JG,Y[HVGQ`?5MYS>RV%=4W.R%J)FR<_Z%8$T:XPV.
M"&PO(+9!(QY+&)\"!"U=_+[VFX)Q[A\APJJ-MOK/I-'?XFWLM*/?5/V6QN-Z
M=9;/.:)IU_5;?F/.,SL^7'`M)O<L@)0?HXB[KS'1AO!M5/\`+?\`8Z]V[,W7
M0_7B$6E^O6[Z443I`(,E4[?=9:W[C2Q5-7>D_8.XD&H()N<UKYB\H+T"K?\`
M(2Y;2$56E0`_\=_+!TV"ZX!9=#?R^7G=_E>G%]3L<EE9R]#>W&)T'1@$M,A7
M577]8,#B@JC&"/70YZ;H&9G+((:38UT"C2J#,S_\NGV!N-#]8*^TR6%HK/7V
MI=-W/GA/+NB4>U^>SZYDL[FC>>YG<;+.='(&?R'HU'H70@9_1DMEEEE*:)71
MO(8$T4/\E>XZ%T[Z)460Z-PT3)=BS;X^_N%$I[<L?JP>DQ5+:<PRQVAZIC3*
M*W!@O2G**-7:.U]WQN45&(JO#/T?\A/V4H?LKU[DE!@L7T]F6[1B<1D\!D&U
MXUVN5M=P+E3&:+;V>WA3$ZNXI+&.RC334E/62R,=^V&6`GK,@0EH_P"5+[0D
M9\^#)<W'32E_77D95/8/Y/LRLTGVHN])SR_Z9SRGT]C;TV&U*U_)NG@J!7?N
MHCH;02:0@I!U58PXR?R'?=,#9:+*ZBQY?B;[%\8ZW<)E]=S8NJ(U/2L7JOL7
ME@`[=<UMNB&P/H0>:TY]LW*KI:IDRROC+D!G9(T)]U7W9[V']./KQUQ-;5X8
MC=[OI69Z;W>[XR5LJ:B$P=;TPC!-K^>X;3WM1<B=GU./K*82_KK&2G*8?\X+
M62FA0L!?X3]DOOWM.:_<3L^YY>@!7/\`'VO_`$*Y`F2!&A+W-5@:34DU,GQ6
M:=,T!H%M8O%(@(%&A*>B0B2.E8]4"+7_`'.^S(R<W?D>O,Z[1&G-=C-)#]0M
MUB7_`&@W4FKQU+=\&BC-,(&PG^(5%N<4NH$A'$?[%<]'LJ;'Y@C"B^^O\A+O
M?<V.&N#:7$3<B345+?KEKQKK=QB=,VFG[$S,2CNG^-UUPFRRU<!\`\CJ^Z89
M*B3O1\$89U1]R_Y""\TC+1UW6]3=SV^(S>)A^KFAL:;7`I4]>?>]@L;4451*
M.SYAK\_25L&;;91OLA_:LD$\UH.\<)ZZ%]DONZWZK=<UI--=<G[!B?LMDN9*
MR'EU_H(3\+7<AYF?J-#SXNLYYT.+_$=ST<^R)IM%:4)P<(A;:TO\(E%($!%V
M/9_N?GH-7I+SH/9LUS&ZT/!H=!>UOUMSNFWWU_Q/2N-[3>Z>^S.+S>7TY&^M
MZSK8.?R1L3VW/["#:3331221*1$'3/W_`.^!M+>31$;RE[M'SC&VN5Y"9]?"
M8N16X10/%BZ[;;#ID5-<3\_TFQV%YHZ>VIXB;6:L$BG5H8ZUR&3!8.;M'<=9
M]-=E4<\N.G$_<',5V#39":;GH&$U.?TV[ZN30WM/0CV.*OL(VJJ0J6X$JK*(
M.[#AJQQ3YWD-E2:0*^Z[IW\EU<O1\(RGWDMC!P[*X[(;_*8C"FY5>_9?3XJ[
MV6@K-J71SWIKM7C=W/22%F8F#.M+SA)H$:O<\1H31<;'[O"?7KB9E<FXGZQ;
M]1Z9P#IC1,?0WMCD:V^WNFR.%[[H)9,UGQK_`#_*ZK,"'$68%4`'>AV3C4KF
M,?'!&$9<I^QGWHS_`%"C*[WRKO$?)]#WO7Z2J6AX]2:\X'A?3>?WC.8X^]&Y
M>S37E:-RKH5-&IAUE'7W?XMF.MC`Q&.]P1+U;L_W_,H.?C52?8[/LS^IS7/.
MSWV9X3<M*=J\W0]8L]-I,U!G^8]!TFDP.A,;GH$LZRL?5D2+"D9<'OF10F[[
M/=(^ZN;^P>E&YC!]B+/B,_"^>D/)Y[R//6DF.+EV=.[HVHH%NLS<%]!ZD5DR
M)XZZK@('-KBH7I+4%CO85"$==6ZM_)9:VF#ARN0[#1LAX+DZW9Q9'FE!&(=O
MX*#?3_8[3)/?0V+(]K0+%E$Y^*,4P&TL2S6PQGLAF;$$[\3M_O491]@DWTW3
M2`[#Z:4=SQD348['9W4478HC>LU$`-R931(18]2O:"MS5I;#&11P5YQ7Q1Q,
M17QL"GG'=I_)\-B?J%#7X3[%ZS1XS=D[C[46_3GCY@304.AI\5@",(15]-JZ
M72;2LHIKV_TT0V<C!08RI$6&=\;Y(90<[B?Y.)N3-&Y.3]AF=2_;>IKUFP^R
MF:Q,]%-T,7DQ"3A_7L3GUIF[,',$;Y(O\6(L99J3\J1'0I+`R9BA9G[5:C[*
M=#XARJ\XS4_9VOA%#ZOF]K6\>@R^1[=-V[+`MR/)+FS77S"U4_&"-[56A5M.
MQ'AG"35Q4D;P%E:H2_\`3'#?:T'<=RW_`-F=99$QW.F3.X7%RVUY-45@%:#3
M$6^AI*K]\,R4-!;WKR8ZR44$$O\`$C5)FK[D\#81X'ST\#[Z?_*_[/`/`/`X
M/]Z-7X_9[_\`X/O15;_V^OM5'+^B>!S\#'*F484DAD,I#H!YIFCP)ZS3NBC<
M]L,+?Z++*K?:W_M5/`A#Z]]K@[MC+;4)4UM";2:^]R%M1U]Y8:!]584OXJO&
MLSK#+Y1(K5T!;))8(89XH4>UOSO=[FL"=_`9'1=A!SG`[#<RUS[,?'YRVT4]
M;!*@\QL%2)*;.,/(D!'M(EBB<C$2-WN>J(B?KX"-Q?I;>P\RRG2X\W<9(?6B
M%V(E!?Q3CW(84=D:&%)8#$B!3BSG"BMG6)\;5C25&^KO3W*$H>`>`>`>`>!\
M7_;_`&_7P/"[_-2&TW^1?[%A1P9I3+#-_5^H<66#GYM)!4:')*(9,%;V0UG8
M48=5/6H:WVL$B>\=94E5T#D4-*_1Y;VPZ)?Z/E5A:DH`;N1L``'=VA-S/GLM
M?2Y\#3V$4@-M7BXU@0BW=>EC+,U][&-"LDP9]F*T(SONKW%R`?0]0QD&PE,!
M?49RYHLWJL#V7KFN`J3)+@3G&6&D@SA_Y52LFHKI[\%I-\=[PIX[&_K8VJ">
M!M>-E5LH3>9;3735.@99R_M&]R;7:P'5`F?&?F;"/)9@_;X3%TA5B#J)@65[
M\Y6_/$2A,_M+%#KR&YW>@"TF8X]<KG,R+JJ#=UV^S3;NP,Z]@BJVI;JX;/47
M"D]2K[HS-2QW,M8<6U@X08`4T<]D>,0H=-!H9%@U,XNN_P#GHLF8T;8]Y/8:
M&_T&=KZJQ9HK6A'O!W`F:,^2%Q%@/^,2--.8CY1!P7BM\"1R;9Y&PX)J(\]S
MZOB@[*+9T06-&IJ6H?6;/A!<@TA^3JX:R*HT%D?)[2@91991X%:K&I#(R900
M[W.]"@H<!;GW>4RE2+%06`6'TY'Q3.M`<J)I30X=50:!+2WS<D2R.GAE.L15
MG61\WI)\D?@1GTW0G5E)RR&M-MJ#0[CG$&BW+ZW4&U!-KK+OHE]0Y9IK)&6%
M24M%F4=<UU>U4"-$LGJ8Y/S`7Q@OS=-Z4Z&P!ZC6@:6KDKV::V=J'7^-ON88
MW/G"?A3'=#CGEUS*S&W_`,!J5-_&82E;:0%K%+8598\`*%/JN37L=#1B9Z\R
M4]_=:T.YR^PT&'<'26U56*7JJS5Z6PKRR^;YR3"6)T6;NC$LH[NJG#@"?'/Z
M3!!UVG5OW,YE)R.F,Q!>B$O\OH=-I1;'7=XY=8DLKC0I-9GG5C*\*:ED`9K#
MYJ82*Q%M+"`6)X5S8&(X.SD]UI@MV74=CMGUU!MQK!O8S.@WM]&'3:[48FVK
ML'<"6A]),/3N)WP04E7.PA\%9.48QC&"(-[@D,>WV;+0>A&M\7D"RHI*XC=B
MBY:MZ(<?^/E:VI/O["&G`LBF#YB%T4)<I:P*CY(G3>Y%>@<+ZSLZV^J3)Y,W
M&,)RG[3@FQE%5EX:]M%TVY(M=JS7Q+<`:,/2Z"`PJQCDF)9'(K9I'-^!WN!>
MZE89&OS'20P-34HM[J<77X-F="#GKC,PP"VTFB/#-J/PJJO#=85%)&>!'(HA
M01\T;G.881+&$09.\^S>#H!"A`M$W/DD)5YW):P*YON:V1-G-+:R:_5I8PG&
M8/&9RM/+HY#I3*^_FH616`9,24]DI0.JRZMS-XIER_C6AMQ[;2')#%AKV7.5
MUSO`(;?_`*E\NYS@;<6Z0S5\[)T,A&@8IX`QN>C&MP'Q03BAR`MVG=`JZWSD
MG*<CSU;@4F2PY?>A6-AO\YTUS+C,UO23>1FE5N7K*W>5EQ&+6"QVM?`61O["
MPM1)!9&RNL07O@V57K:W>]3N]*1<WP]N'S7?["YNS[13H(,[L">=%`(;72#1
M48\%G2`ER0#?NN>?.X*2!+0PD(+Z\@T<-EW3AM=3:O'19X[[+\+FP-;"M77Z
MK0H1VC!V,M.'EY"C?VA;&@L)7J#+9M)+^";T?)&*LC@_1,\`\#H))&#A>061
M`*/'Z?).3+'!"SW.1K??+*YK&^YSD1/5?U5?`;).^P@:*IFUR0J)ZJJDZ.G@
M1/3^OK\IC?3T\`'WV%*9)*+M,D3'"](YI!]'3S,BD5C9$CD?&8YK'K&Y'>B^
MB^U47^G@5Q3[<UK+,VO,Y%TJL@$G.@AM;._X@%6V+!"E'B*!67KZ%N%/8U)8
M7211K\;D]Z,<OM\#M)^VM/"'(=!S75'#QO6'W#;_`.O*+(5['.C!C_)[3`Q3
MIU;[8XE5'O>J(B>`BA_<NOG>Y#N.;VBB]&*R>[Z']9@62>OI\WL;_P!>I)D4
M5OJLGJU%3T7T]5\#O*^Y%!#%[@N<WMT0Z?\`'BKZCK/U<*.E>D3IG.8._OD3
MD1D;'.<BJCVM:JJWT_7P&59_:['E/O8+GZYGR#:D2.FU,MWU3Z510Z*IA')%
MA!OA[+[&H3<UT8IDT38"(Y&-CF>U&^CE10;IG2/K.>-7K#]6^7:']BS$./I!
M8='](R/VS)JPR*/'53C.R1C5]`R"8A$!C=&)['2(UJ^KD\#-S7VCYEFH(<Y6
M_76FP.;?7)020#=<^D%32CT[7FRP4[JFB^PDB/K7$6$_M&;"L:/(D7V_WO\`
M4%TK[+<KM*TR.+CF3T`-@.!3F`LZQ]0BAK"OS11#L[7F,([1^$0)6F,<H4#W
M.:),J^UL:HY4!H5OVKX_3?Y+(G`L/DIKT<,#4-D[/](@)-``QJ@C#7[ZWNTJ
M'B#B2.9'$4KFI'ZL:GZ^G@.N+[5\ILRY[*LYM@;8TL-:I]B/VOZF3DG@@0P2
MMK'%0]<(GF$'^&-J0O7V1JQJJC6HUW@-A_W'P]`-:T0_#<74!E%/)LZN7["_
M3.H`L#R6H4Z<\&/L[DE*)AA257S0^]S6^[]?3U\#Y7_=#GUQ;54ECS+D8]E&
MZQ,H9W_9CZFVEO%8W4*I=/K6P=&?/%+9!3N_*E@>YT['^CT<URKX';=_=:DJ
ME2)O(N;R#3+7-CGL/M%]4:H4A:1S":]C6S]$FD>ZA)9_RD]B_CR,]T?I^B^`
MFUWWIYQ(<^PN,?P:FL?99A2')]K_`*NV-@T4TAI!,,LPNO87\%F0KWD1HKO6
M1J*Y'JY50'?/]J,X$ROEKN<\/<P`)[:EZ_9'@X/X0;X97N@`2(LAPP\D4J^J
M1)[/;(O^BKX$>)]Y1Q$"&&Y/]>8(:^%PU9$W[>\15H09SOB^((>HI[)11S5:
MC?8Q&I(OHU45?T\"3OM7]SJ#ZO\`TBT?W@M><U?0H<IFN>:!F3S&ZS;0C9.C
M;#'X:#]MZB?6I1,HZZ;5QD36CH&#O#'<_P!&M_H%?>"_RR?6GH-!32=3SD''
MMP9W[3<$>#D9V_8#E4&THR\""/JP>^\HS9?/8L)?6O2J:L@N+-]0UMW+,!(U
MLPTJH#]Y#_*A]3^@Z+D>#TEY_@_:>SB8@@3(A9S;Z_.5A71+S<YOEP=UUH'"
MU>-$FW5IS^R"J?SI0WSV$+A&-67VHX&[]B/OYW7A/V)TW#Z[Z;T>ZS%#P[I?
MV6K^B1?8VBSA%IR3D(6:AV5G-B3>8&/JM.NGTL=<``ME,A$<;BGS0L_Y?@8&
M5_F?^C5KQ++=HVFOT>`?:PYC_(L9=<ZZ%)I\DNAYC1]9M-'*"3D*RSM>5Y_&
M7S#)M="*VEF$;\K9/[FL4'[M?Y9/I=S^AVVDM-%T@_'\YZK9\;T^KS7$>HWV
M-$U.98?/L#*[3UV6DS]QDL0%7?/9VH9$X4+)H6QODEE;'X"?=?S`?1[.673*
MV_VVZI$YF;M:1UO=\EZ'1YOH6KYYT3-\IU^*Y'IKJA`H>DZRGWFSI09!*TB5
M4_=AY?=\7RR1`[LS_*-]1=J#`3DM5K+\V;_I*&ZEK\'I2+4/3=IZ]K^#8O%'
M10A20#ZZ/K&%M*BR$21RUTHZ/E<D4D3WA`7*_P"8#GNSYY7=3V'(^JY</6<X
M^N^IPG&,Q@]KT#[`Z#7]YG[;*'D*[)5=`%57[1L[Q&TN1Y@R?E_:A"9RHAO;
M$R4+;\?^_'!^Y]SO/K]S]F_)VV<R%)L;R:ZQ%EFZ^F@O\AB]V!3WM?=O"UN;
MN79K?5TGI958@TA*D"Q32%"D0Q`Q?L7]^J?ZS_8JLY+M<)H=%DKCC6-VM*7S
MZM.UG2-#T?HGV)R'U\Q^#I,?'^"'.$=>;,*20IQ?O8Z7]6-C8Y_@8/)_Y/>%
M]NUW,L?S;G7V+TI&]K,\5KKFOX_9F47U_N-9I-SC<_D_L`8#8%DX"^-U7-KD
M*1T<)P`;Q6RDDPCS0S/"Z/6]9=XK&$WN?_!_<HSZP2);'-:W6"M8:6P>1\E-
MB89[^7T1_P#YC$2*)/[I%1J*O@4W,^R/=(QC)@X,2XEA38H?7Z[?:,MJCR^W
M\-\[8!(I_F<QZ^]C$<R-?_A_U\!+;]INX@VCZ^U$IYG?GJ"C:GZF?:^=H\OM
M:OL+-2<D1GM;*Q[I/[8_8O\`X^`]X>_]J,CD02MC^;TG9$]?JO\`9*6#YH?:
MUKG>^U#<Z&1SO5BHJ?(U%5O]%\!KF=[^ST1T<,(U&D$D1)+8T^F'VH-(6$%&
MM*;\T&Z@';.LDK/B8J>Z7]?:B_U0.Z'[(]Z&G:%99W0$D).D4A%3]&_LY^W^
MW_EL]6$$;Y\:L21KW?(CE;['-_3]%5P+MQVG[$1#J351Q-;'*GRQ$_3#[%6!
M#H/A:]4@&%Z@%,^?Y%7^[^YOI^GI[O7P(_([Y]J1VO<1#82I+%/%`VD^@_V&
MD=$1%,R/Y9&G=GE58?1'>Q'>U)&K[D7T3]07!.]_9:[9*/746@J2HYAT:5?_
M`$L[*('(*]R,F](YNRP2/,_17>Y')$S]/5B_ZABE]-^X#)'*RVE^-T<OL8%]
M+>BRN:YKFN:Y7E=T3U<D:HB-5$]SO54_IZ>`WJONOVOB>^8^JZE<P^KF-@$^
ME%[12(KI6^CFNM>XJ[VQQN_^$B(J-7_7]/`75[1]F3(S(OQ.BYLB'^Z$ZX^K
MU7&%-'#+"V9S(9>Y?/["8Y'.B618_8C%]_Z^B*#3M.I?<&%SI`-9K[*%)O@<
MVA^J./-=&]$<LB2O,^P\36?CJU&R>Y$5CG-143U\!)A[Y]H1H7.M#.R>YTR-
M]_\`]+QP:E6%&(U)$6.X^QJ>C$<CO57+ZHJ*G^G@++/L9VXE"!%N>BU,J,FA
M'L[7#_5$,1Q<<+W1)^,3]E&D.D)D8C6L5K/[GI[E:U'*@=K>I?8@\)MD)V33
MH/##_P"I8!A/IT0W\B*%&D0?//\`8R6)I,<Z+ZL1ZHU?T]53]5#)S/:NZUMV
M`RTUW2>@^S0U429F"L^BV:*T8[G_`/.JP)X?L6AS(+"1J0K)&U2V/D3XFJO]
M`MI_UIZN^8:.+ZD]J^*:6)A!,VQ^N<#`X7L]TA#XU[<\B9(7_P!JLC8Y[E3U
M:BI^O@+T_3^FLB<\?ZW=)(D]JJV%^QXE`JN]JN1JN=U![6^JIZ>OZ_JO^[U]
M`ERB+LSZD`VXJY*.Q+'80533$!ED54DJ>_\`;RBJ\LZO)*%1?9))!-)"YZ*K
M'*WT7P/MZ2T.DN3'M8]@E58$O;(,\R-S8!)I7->)'_S"F*C?UC;^KT_M3]5\
M"C_\=6=(SO"+-LL,H$%[T74ZL"D'K-%G<WGP=-'6W$%3DLEHL#SR3)U*?EJ0
M0$.',.VS(*>V=RO<Q@7U\"'/L-'6S<,ZW#;U=W<ULV`T\1=9FPR;#0&1R59#
M/CI`PZ^V,GM6O<CH$A%(E^5$5D;W(C5!I_4=L[/KQS:$BY(OW#`W`K+(U+E;
M-\`NCN!X![F?00!VYMV#%&D)A$PXOY!,;Y&P0L<V)H6/\`\`\`\`\`\#P@_S
M@XUMO_(=]E=+*:K#(L5]<J"@%D4=HL;J_'#WU[.D\OYL:E_M<[W?BD#*(0UB
M.(C);'#^.&L/"<_+*XYKK:I247H6;Z/+/TNFN[BN:#:\:-SCJW+;/8:T'1VP
MXH$.U#]AK('BK\MZ(C8T>]K8PK!+J[/+YP5NKL!9-P/55I&<LKMUM!:%V&3F
MMWR5V:[)F)+72UE]1XTAMI*356#QVI5&R>UIUNJR!B_NW(Z."6Y(R=:<3A3M
M);YFB?IKL"GS%B00>?H,_P`]3-/H;>"FV]VZ8C3ME<V#2NC_`+8A!2HQE!L?
MA]`ZF'5V^"QP<M3H+JS`K*V#.YO.-T@NDN`B-#<8>M>;F*'068N__#@,&HB+
M6&57I(_VCH+%&'+M@(#/L?N<3B3Z.&7GJBF6L-M=2`06.E`QN+"Z&706<(EA
M,;$?IXK=Y?[J*I8A;V0O,<UPZQ@]:O&TN2V6#JXK"@+()^TF9LI#$GKYFC6-
MUQ"8^>NJ9ZH2!1+1C?:I1#T)=,YS19")"7RS>!&^&R5F?C*#6E4A%.4_FW$+
M6MDMX1P;>SJ\=BLE`9<5ES09NH@M*NXO#(U4L\=UA"M=,@A@\,P;7!,OUZY"
M+TOJVYQY!&0#U%KR#J1O$="PC/V&>BZE75%<PRFK[.8RE/+M[:ANK@,5W[?%
M($7&*P8N*2*)JA#>3(N:(V?/ZJFJJ.E2YIR:NNT\3-KFWW<]V\._"'`J++95
M=/<_O5E-$1'*952-]3!_CD^1[G!QGEYF'<&V^@J_\GS.BJZ@+4U<IU@XW4T%
M5<DCX.DM3+^LL)2X,++1.DH\^@E:^M>($R2=X+106`ZY==G-B"0'Q",^&NS=
MK3`!W\-;,"28/87BW%W;W_1-+/1V4UG;_ES&S*=<BA&R!Q,A5S(1X6@]^F9B
MTS7+N/U>SH+C_,-81HK/2DVZTU/.%S0HNAIZ%D)]O9$FV45S..78PL@,.48`
M]T\J,5SI7!B&Y.KU.7(KZ._JBB]#S4^D($=#6GYF.PS%HS0X6"*F(%.S#_P2
MD?&DEE7&5-8Z!5AKH9%,E<"K%;(;;0S-A("NK7B?WFIVUI5X/%>4\[-5?BOC
M#(HHZ"O,JZB(R-I\()`*P3NCAA;$V-KT#"T='D\'J,#-H+NA/P0^TS-;T:NN
M76&-AT%<VPJ$T\=$(\/WO6JJCW$"647XTK0FR21#QER)[PG7K.7V>>Z_-8(/
M:VV-D*M=&\*@T]3;6NJYEJZ=3N-[`:CM,[G]-H<?I:@-)P2JAK[&6!T2&QO@
MED&<%>:ZVYU?U^?M=E0U&3UP1@A5;(/J-/27].C9K`)@E=_A7Q9WFUD^OK2P
M"#:P&"\M'D>V:/U-C8*$ETUX"5H[#GW!,-'SMEM9_OVE%S8E9!HRJ:TH?V'/
M59->&2VIYXS."M,2*>O0,1"7GQ%N?-,R1`N=R'$7N.^I_P!A]%KI1!DZ"?SW
MG?*-T1L,OILK?=`P6XK-/M:Q]VP*#_(;/.8\!:VU&KF&RQI<SB2%PAK/X"!]
M;LI2U/4N$Z.:RLCK9/LW];C:(`"<^L!&#(Z[C:ZX)24>T!0T']MHYW6$$8[(
M9'0CO)_*7X6Q!^DIX!X"+HLWGM=4%Y_545/I:&P2)IU)?U@=Q4FI!-&1"TNN
ML("!"&Q$1,D;[V+[7M14_5$\"*)/K'];IF,CF^OW$YHV-E8UDO+,/(QK9Y'2
MS-:U]$K6MEE<KG?_`%RKZK^J^`H`_7G@58US*[A_(J]CW->]@/-\<(Q[VM1B
M.<V"F8CG(UJ(BKZ_HB)X$$Z'Z:5.@-G)DTF+@']Y;`1)/KKP.Q_;02C&$?MT
M!5EB2IWCLCB:Q?<JJ]6H]WJY$\!M`_1E`"I)8.I5+07$(3%4Q?7'ZVCA0RM<
MCHW-2#FT<SI8T;Z(]SO<B?Z^O]`=!WTZ%L?QORM[5.2`DB54;PC@CD4<R&6`
MP.))\`0@\94+T8]S?[W,3VJJHJ^`V:WZ-25ACRX.RD-<\AQ",@X-];`_8KI&
M.5$F$Y7%.Y5B:L:N5RO5CW?KZKZH#FL/IW':A-%/ZD87+"(Z`4POCW`BYQBU
M5RML6,)YG+`LS?5/[?:D:^B>J>`FT'TO+H2/EB[CH9XFOC>@;>0_7<`9J1O1
MZ,1*[E(LGM<GJU?[O7VN7T5/7U\!0MOIR%;#.0'JMG532/5SC0.5<`(<Z1L[
M)/?[3N7%Q+(Q[7IZ^GJBO5?ZHG@?:WZ>&5\\<CN[[HJ"/X5:$_GG`(!D?&Y7
MR2-03DD#V.G]51WHY/1J^B>B_KX&38?4`28.=!NP:VE-E>Z0JU!P/!6R2QM>
MLD;9HR^3D0.;`B_HYR*O^O\`7P,83ZER4HDTMC]CNH**[V(XJ7-_7ZJC'65C
MQH_AE'X[!#$Z2:=KF^ON]96L_JGJUP.L3ZQUTHR.;V7IMF^1'>MG*!Q@@B>5
MC'CI-)/#R9L4LT+55B?I^C4]OIZ>J>`EP?4J2&>*9/L-W5B0KZI`(/PP,=_I
M(]Z-D;'Q-9/;['(S^US?[6I_KX"^SZ^USBTJW]NZD4>,QU@\(AW(9#F"EI*.
MDZPMY6R6,62=JJCVM1%D1455_5/`3K3ZOB3RLE_Z^]PI&S3PQQ0UYW(PXI)W
M>[TAC^?DLTDDA*K^K4<JN5/T]/U\##%^JL,OODC^R7V-/:TA\;U36\Y6.*80
MGVD#?^BYA"D:QS0NBE9^BI_<U?1?7P'0/]:P1XGQMZ]VQ[I'*]9GZ;,_.Q?[
M?:D<D>,C1C&>GJU$3T1?U]/7P$/[+?5+FWVS^LVQ^I?1-'HR,3I1L+7Z>Q`/
MIRM9)#B]CE]W716;C*TJLE6Y+R\,1;)@UC(%ED;[/1R>@5W^P7\9'U\[WO.+
M6%9J;WB]=P.I&_QKDG'0.<T&'''CZEE.K4]V)D3,C:1XNPEV6';"38TC:TNR
MKYR@Y)UCD>G@(6!_BH^N_*+BBMAN@](F*AV/U7T-7%>WF:C0_2_5+;]-Z+S\
M.'VT0LL\=]9=*LFV0D:^LHT$?PI$]CWN"U?7?J)S7M/1[;IFMLM5%;W7UEZY
M]5#:^J/`&JEYWVBRS]EK+!D,]841_DL$F<@8),Z1T$3'/]T+U7U0*-;[^(WZ
M8=&K*Q2NC;FO,RB\TP;=*%K><7Q0E=R#DM+]?S,.2+M,7J\V(?H\?3B1VLJ!
MLMQ+2-DX<P<BN:\)#Z__`!*?5_K&!%PNCTO7,UF*?HGV3ZE$N<V-(#&&?]G'
M6!/10VQ7N8O*@(&D<7[J,R.".TI$8Y1RV?+.L@5WY9_$Y]<^X9WL%YU;NVA^
MQE'JNN=VMN2+A>J56DYUPL?<]FH.KA:#"@049M/6=O;8X^DET)!2V-805#.Q
M@;1C"8IPLQ5?Q._7*HUO(ML'M_L##=<J)P-E8Q"=/94TG8;OEW8;+NW/[KLN
M=I<]6TNH)RO1+HT@2`."M"C@)^#X%CA&2$$$S^*_ZD8;GXU!+T7NN(_8DYF+
MS_I0W<K+-]%YD_CQO9;'`0<YV0XPA-9/2Y3MFHHE9(PMY.>(2"5)'0MF0'=I
M_P",/B]GIKGI&.Z!W/+=).Y\/@,GKI>Q;N\*P`DU;B*&YTV4M2KJ+9QZ.]SN
M&&B(^:XE`DGF)(49)C"WS!._1/JS]?OL5T7/]GT:66@U>$GRF7K;*@U9@=:#
M8<3[UF^RUE>6$`]!93Z/KO.A/S6/_5[!7BR)['/:H0'D/X^/I34],")P=[M*
MO;X-EO;Z;+8SO&RIXKVSL]MT;89[3]5S.;T`4>JNN>:_IE[+G)K1DB5$I+48
MQ5@'6,+BS\ZYFW#8CA&AN[^\KP*"H%ST>@Z+K)-]I`\'!6P1W%ELX+T+8:6U
MB58)3RYBY)2I95?.KU>[U")I^+?4K*.L:`V5*MU")1G656=UWI3_`-O"VUN9
M7Y^>>`O;RHV+1W0D\0_Z+\\T;D3U5%\!QZ3@OUF$S=M<::F"BS=57FW5Q9E[
MO9?C!5E#(L]B>09'J%E8)72C*DZH[VM5JM?_`*HH-47ZC?34L,>]@P^9-K[4
M`>W%LY=WK#`S:P^6+\4^&<C62P2@%3S1I&]%^-SW-1/U5$\!;TO(?J/D<W8:
M?64^'K,Q25E]9GVUOI+"8$.LRT,[=&4CR+HASF44<4C2O8CGP*U6N]%_3P$=
M_P!:_I7=VLF>(YWSLBYM/VDQE0:0</8V'Y%9/95RUXI=C#.3[ZL>29\8Z+Z1
ML<Z5OZ+X"B#];OI?GI#:L3G'&:Z>"XJ:VQ!D6G^>'06*.=1UYPY)KI67!_QJ
MHD4B)/+[56-%]/7P.\GDWTL'9;1F9;@D48(0\%U&7+D6LKP;*W?GPTL&3E>T
M*(Z^1P,3GHSY"T6%JK(GM\!.7ZW_`$6>-IKQ_)/K=*'C7FA[.WEH,)*+E7A1
MJ?9"Z<^1CHJ5XD4BRSL+=$L;%]SD1/U\#%L.=?0OG=/+H"<'];,[1AV&/HS;
M83,X..OJB.B'A"XR*U+"#=#4@Z<RU@<+,0Z(>9)DD1RM=[O`==GP[Z;3@6=G
M=<K^N4U55B37US8V>2YU)7UU>*LP!%Q9%EA*.&".^ODA?/*YL;'0N:KO5KO0
M(CH,G_'%;T?/M3EN;_5`BAZIIG8S&VH_,N>*/I+E:ZXLG5`LK:-BQ3E"4DKH
MEG]L<WK&UON=/"CPE@GF_P!+,]'2J9A?K'20:(VV7.NGS?+JZ*[L*-977KZA
MSPX66)50X9_Y:P^]P[F+\BM5/`C6Y-_CH!Z)6\MNJ#ZM-WEH8M:)3&8OG;U_
M=YX$4>EEL9:=U:/>V<"R(,&^9"2?BE:QCEC>B!F^G\>375<H6=^J=DM\3>R0
MSTV7Y7:*R/+,M_\`(;JP<$!-*)54A5-.,0;(B0PE>V)SD>]J*"B3M/H)D\=;
M;*(OZQ"Y"FI`=.?8T5;SDP+]HNAY#:T\:*G#F4_]U&8LD*0MD?*Q4<B>U450
M<NHZ#]0>2JRRT;^28XX:LS&K;&S*TX]\-7:K1U=#FKE`*ZHDMHD-T=R+&UZ,
M1\<LJ/=[6^KD!=C^WOUC?1Q:-_<.>"U$\><>P@^_&KY$76T9.EST+PS?@-C*
ML*$*8I(G1I)'#"]9&L]CO0%T'[,_7ZQ6I:)V#!2+>TH>AJ/DT`0Z'U-@ZQ:&
M1`XE\2++.ZI)](5])T^!_JQ/3P)FKK`&WKP;6L+@/K;,,6PKSA9&RC&`FP,)
M$+'E:JME@('E:]CD_1S51?`X6GZ5EBOX[S/_`$!?_I(UB;(5_P"GD_\`3L=.
MYD#7S_\`"BO<C45?U5$\#7I_'%6#4^-[,`VIM`S4Z[,4996,IS'6;2<AF5%'
MFK3ZF@_!NJ>.-1[)PXC@R#$>^$F=OJV(-C7@19W`H$/C?5";1M4^OBY]K5+;
M>Q$34KXG49K'1V\0=7=E/K'^[TG^,0E_Q*OMC>OZ>!!?T#&_;?J7R6A<&=63
MY@32Y@JG/8'&M*10["_K7T]:P!%%9GZQ($BK$:^1S:YL"/>Y_N7P+C^`>`>`
M>`>`+_MZ^!X<?YL*#.-^]W>KRZC847;$_7ZLI0Q=)<YH<<RLX^W\JXU\M8\9
ML]8S]S&;%,I8L$#H&M-1P[FR1!K7^J?0.:Y?MEQP78\VV.<QGW$R^A^L.FU^
M4N-D7@VXWL%2!'R'77.=T[1Y:Z/!:T:&V98/N7O(K%*=^*2WXHW!1S5";G'U
MVEASAM;U;.8RREJNBRWF8%DD`Z)DD9E"]7I^?VU(W0T=;I]$V2B'M6#CB33H
M][#!?B8YH1#6;#&8N=M2%Q^FO-+/7LL:@:QL]'TZHJY&4-U*LM9FK:WL<W:R
M4QM:E:().'=1EFUXCO:^.=/D"^GT*_Q#)_9ZNZW]L^NC:@OZ<\AO/M!;\ZQ)
M5:'4V>OPU?FL9S:CJ[=K1<94:]-]I:`*RJ(K8&8EBKZPMB3X6!3CI!W)KOHM
MMJ/\0TB2:RT,TYNOW^LN7[LYM]=%W)%V56Y^3.XN2Z*,JYI$$KWO+LGUWL''
M?\T<K`?0E974NVXA^]'E7-:-]B<@-B(]/)66%C3U]GS$]2ZLW2T]1&8;^&X0
MR1YI*CDR-<CGN:]61H#=(IJ4S5$9W2&:G]HLZ/\`SO<U%`!;6!@U7F<BE:*-
MAK&(S65&GL?2,(,6:=))J=))24CFD:.B@W,QOL_S'7Y_J?.\?T+.ZC$V#M3S
M75XVWR-\ZMNJB^"N.?65@?M$)&DSVB9%+8ME@@J;$L\F=&N$;\3FA9_[49G/
M&=QW7:_K+IJS45OV!Q=5]R,IQ<R:UR&GLZKMD:9_=9P[,621CWD=5U8/6U<.
M9')=92-KORTJ7,5A"!3>HM>8GTL%R[E6LLFP,;:16>9[1>9C/:FXKH5L2[4[
M,U!%R)FTNJUHHY0D9`;IIG$QPQ"-&1J!,&*S^P^RFVYMP0^ZQ?&<EUGJ='RC
MF.>RHQM:W7[[5VE;3UMQGH8(T)O<I6E:.S'EN=!,0(L#8X2+"1LBL0+&_>/<
M\CVW9M=)QFAZIT7E7(@L3]=L=?;K0$TV$@R?!*X+#/NB(:IH*R![@/+F'$G6
M-B%*`8YY$*M@=,C0@&LI<7!F3^@TMK<YPD2\M<_N*,"TGN,X`R`@6[BM<\3J
M0(=D,&]M;/%95?Y1X,:MKY83GL](_`=`P"Z?46V8`#O#Y"^<_;(86GL#;-C%
M*L-5:P:&%1'%$%35I%E91&Q2(DI<JI%\<#7R>U`D^_!YHNM-R-%D9M#.'1W!
M1";N[(M]MHL__D@N>U89EAGI!*:GM2C!Y(!":VO'&%:2()-&DT3D\";N^!<_
M[+P_ZS?8+:R]&S&VX])/]%^I'=?KKZUI;W/#`WG6>%66@Z!7,1*S&4M41;T1
MEQ)'`*)-7QCM!F:ULZA16SU!M#+7R=BPN?Z.5`"I8^WO)H8;"+-5PPMM@CXN
MGXNVJY]9'?4+(]`*CHRH&K)"-(X?X4C8#YFN);:&ZTK:G(?63@`3"-'JC&UI
M<NHL=19C%@4=1I+!LK+3JV[LXV1G!QP$2I7W,JK[!%1I:AMP[FG.@_KK]7_J
M7ROC&TZ9%@\%3_9'KNFL]'L,W4'])[]G*_HS#-=S.C*#,L-]F\8^G/EE*E'4
M-\+A7./<6Z1P5^^N67YK>]/P<UGDZ_%:;+]TX];A6^2GO<D,>+6=OY78769U
M6,-=:33,I@'->DD<0LHHT2*5.D$DB/#]&SP#P&+T\?2F<UZ")C/;_EQ6*U(^
M8]SY8O\`Y_S4AT=0B2P/CFB>I[H_:YKD<UWHJ+X&K87D'WQH\WAB.&[>RH<S
MI-F_6:3*;^[K+:RQE1)I[Z3.U.?"N@:HZNS1E$>,;I:PLLXUI+5C$^16OB>"
MO=\2_D*GMK4:#K,UP(/4`V6=O+6UP_\`\[M7/C;F-Y-9`W-1M%LJ7<W)?JZ2
MN:*^G<"QKY)!WH@,SH?UK_D#Z%?%8:UZQIHN3P0R15U]5](SM;IC$R^[&O.?
M6UD<'F`;6+5S4/S07$L4""S20C2(DCO>V,)3^M?.OOI7]5H0OL#TDB#`9A[[
M8FKS]Y5W0VSAKJ,RCSHD]F_-?N`=*,PD);(9Y8YMG;!S%JQ('N=.$8Z'G_WS
MT6S$S(V^BT&>9J-C1]*&EZ_F#!WF7F=L[/X$R=7A:,S+9XVC-IS:*JE*++KF
MI))+-'\[/F!H]$XE]]LEB^GU.A[-F0^/V5'FLI6T\^_I\/&*#H\\5EZZLI=:
M9D[\RHO`.FVXL]FDP\B7P4WX8KW2?%$@./M?,NKB=])V7-OL"!F='G.>8R,.
M*7HMA89S#;*K`H,(L&KQL59:U86*T-F%,ZP$G1DMP4R)K6_)&JM"=J_ZZ=FT
M?U+O,E]DNAV-]U[.ZG7[3GFV%T=^AF4NE!GK\F?,5AX@[.[&'M3#"8*]6FOB
M$,B'1/?!''&$'_\`2SNF,PV4M^4Q<G^I&3T/R`TV0P/8;,3'A:V;-U]9=:.X
MI#.?-JMA>:^@H3VUH0(=9+3FQLN;!"C6E,:#:P6?^[^EJ]OI,)V\BSR&>ZMN
M\O00Z_K_`/D)]E-G=EIH.?\`3B[2GYW.0_$5F7*J6V..:Y[-)#)&9(:*]CXI
MP0>B?7[[J6;K']U[8)NL?@J''&:.H=VZ^)O"]G2X86YTZV60K,62\Z1[]E9F
M24Y#H1CZ=H#70R^Z%\`2IDOKM]M+RFK)^M]TAU&)=)FH=OE_^I1UKF.F0EZ;
M%3=-NI:5V3H9J#+]%XY#9C5.-_(43-EN=+'-(XA)X@DO3_7'9'<4Z%SKBUS'
MQD;(?9*BW7&*5=M88<&@PN?HLOF&(ZRSZ:$V"AU.SK[F_K82H)8K*2>)TS4^
M558%9\#QK[L[WJO4P:C[915F8YG<5\`6-)ZONKB]AV,64E'YN3M34R[8Y:*P
MG(A(."%,*!LS!'R2P3->D;@R1?JM]QV[@.ULOLMG*+=LOQ<R%HH.Q;JYM='F
M:Z[N-9'@K4PW-1!"VU7=W8EQ+5CUPD5D&V(21'PL=X#7MN`?97J-^_\`%^TO
M-MYGN<ZC(6&I"LOLCU7+%V6YY+I<]K]R\4FEHM&W!*`7HBU=8U!43QJZS!KB
M(((XW,:%B^/\E[CR3J%AN[O[/9W>Y:[JND4U+A,3IAYXK+?:*YN=5<VLN2N'
M`92:QIBKINEN;60K\L9JRQ2,43T>\&7C,]T3E6;SOVEZ7]P1[;C6"UPI!@.,
MT?9NOXH&LK#[+(=8'==_'86N\&VVD%*/4BP`(!S1+U%K7L#'AE4(#IOKBZ_"
MZZ9R'[C97G16QZ=JV[0:OV'8J.?_`!L*^7H%9D^H#ZK12G\MT2U]D0V<F4:&
M:*%6A"OD$56*%I^X_7O7EZGGVG!^UN"P>FKOJQ59'9;JVZ5I<CN=K0XA+:6\
MOD@J+\"DML'L;#6P-LM`5#+94$GQD`3-)F:Y@0'T3G-?DWNFWOWGP]%;X!V+
MWQB!]!Z!T#44-5F*X>*IP!V6M=.=+396L5I=4'?(R+6W<>BG9,3&9)`]X3I0
M\XW!/UXU7.COM9R>7;WW8G='IZVTWG0JAL-#KL\18UF(UAR[0#JU6;%:S+I:
M\$51U6:L@&E0F%Y<T@-UWUGY-UGZWX"OR?V$XKT&NPNTZ/WO;;DN_N(JO3X7
MM]WHMB9H+LZEWHMQD3]/0&L8ZU*G>.O_`#R8FHYK50(8J\S;\^H?L9MM/]X>
M0E4-U]?+.EZ)F=-OG7+LGE)YZ>HRVN2H-V5S2V&:;D&.ASQCE'+M0+6-KG22
ME([P%@G)4N_T_-<EJ/N)PKFO0.BX//V-+@^<XG0\T`K\U<8BA$RMC23#[BE*
MGU_6LK!$+9-N)YC?V-_[?5I"H;"/`4:CZY`&U-AT9OVMY3AL`?VCH5!SP7.W
MNETV<=%/M]3<X/79^\;U.`:V^P6:QBCUU4Z!7@!53I1B`R'1M>T&=7?7WZW;
M=L.SROW8XX#S+14&2T^)JBZI?RLC8\1QEH!HMI,9>]"0RMU-35W=H6XPUL)H
MD<B^KGL;,LH3#Q/@/&*?JV+T\7W*R&GT5=T#*PX?-9UZPEV%O4%UEM=F3L/V
M%N8[;]HH)T&UQ<36#6),T;61QO22&0&_O,)R#$]IL]=_],UR*MJZ_P"PW2>@
M==J:TZOP]D%SVKTFDZCT/G&V81IK!N[WM_TN>@J&EL95RC4E4^#XI46=/`P-
M_P`#^GW7][T'IN>^UN*YMM>TW59JJ:^QV?SE/OL@-I.:OMM!2W>C'(B*C9LZ
M2Y'GL5/:.A`CQAIFRROA<X)%LL9]3[SEW!<M??:[.-7CW-S9L_I`J48._B_Z
MC;[%D1Z?%J<A-MB3TBH9*6O!&1\XU78(BL2!K?>$"#<0^IM^&MDS[FY$"(=]
MZR_J*_E@E#7U`/-=@S-Z&WX_GYB76&'VJZ>B_P#G?;!_G%&$DV)8<4[2G)$$
MT</QGU*Y707F1L.PO%L_L?\`5DR\HM5?86'+5T/+=!8[RWL"J6>68R.ON[4>
M1Y]E322P+8E!O+;"Z5\R,".1^._00'I3M<W[3"6V4#JP3HN/"UHB9N&631"]
M4S^:S]7,+'EZ>H"":.R.D4))A+$B">1\)4L+'!W\D^I7U,TE;B:FN^TY.MDW
M9-]'%2Z/%U@V@NICL3>6%74`U6H%*.QQ,&0R!I.D'1B1Z+\=_P"2QC)F,D";
MNAZWZ&[7J.;^RMS]AAJ@^@EP#:*),LU6T,_+>I5%G,P=UGCY]#FY]*_'$U9[
M&.'DFHGES1I\#'3-"!NB\Q^O)?=.JTO:_L,1C;=NZU/<:,;%9JK#S\_.=7!;
M[UY&FT.:K66^JMX\Q9+\%I<31R5"_P#IPE(AF8YP,$WGOU'Q6VEUFR^PP]#S
MW38ZE$Y;HO\`#,497[&\J:;/UVM!T.$FP\3K"[J<KNQ3QVR#,>.2?+9+++)7
ML48)HR=9]8:;$_8GG?$]]IJ?G^#KN$775NUZ'%":.GD8'T?H.^YO:X:JFR[A
M.Y2Z35.E#MK$V,FB)KHVHDT[OF:@(M]:?3C"?7;IW.L9]A>LWUW-L^>=;=JJ
M'G=1J;[6:_G]%SB_!3-`Z#G)F`TV*JA>>C36@SHYJN@ALI8GR"HZ#XP<F=LO
MKK]?P/L%]>-[K;TO77&PYN%;P\VR%[J)^589N(;N<1:G#V.?.KK2)^BH[+6:
M2&"(VJA,TLZ-8X*.58PBN?F_U>T&OI.0<TZ9T[H&HN+_`%N*RTUY3T-3SOG/
M7;CEMO4V/2-!'75&<TKV75!716=1^V_^C'-`C?!\+5E\!?LB/I/]@L7]3N8:
MSI'>^($8MZ\UQG+2:@G/V=[90ZL'&A=$O"S*"[%.IM+JJ91X[Z`N>N+DL)&.
MD]ZN>T&P-_\`2I\_U6FJNJ]$[L562[;MG![:IV>9(%MM?J+/9[^HTG0*K_%,
M*W/7F.81CS(ZV\C+B;11-0'\=Y,KW^!WC/\`K?:U?0=`P_[:9"&'F5-TC=]2
MKQ:8:.FI@_S.%FY+F=Q4X`FFTEO@:ZSBK39JT><0DJO599OR4GG0,LWEOTC9
M#4[W-Z_[(ZJQZ_'68K1;;*5U"!IL=EJ/A*_Y=L(Z\3GC:AU--RR.MJ+2(,9\
M``LKBA&LG@DD4)$DUOTL[3TZDZ4'J?L-<=#;@\=S?/8KF@A&FK;FJ1E3KX*S
M*/GQZV9]EFJ++@W]U&V8:"&&%9UCDE=(C@[J4CZGT--RW6W'.OLM>5W5>6[/
M08FOM'5MW=942&RFR&MSH])4?MQ(5OLQ;LW0DRRR2P,A"FEC?`J)`\$O[9Y+
MZ>YW2Z*\HJO67/2^N<LRF^649@Y&=LL#9=AS>IM;JJNBXH[;(;><*P>X&257
M!QAM5K!)IO='(&[K+'0VF9SMD,#%6#V-%4'#UL'M6"OA+KQR(@8%9`,U81(Y
M$C;Z1QI[6I_:W^B!'6C['@Q-2_F<5I%9[$PHBA+J!Q%.BJ+$G$6^X#$NVOF$
MA=(?FJJ4E@L<JDRC^K_:V-'2-"JW\=^"S^"PG3@@=)1ZK3']))*U=I4:37Z%
MS?CIZ^'.@HFXPV'NZNG#I&QMKXF-L`Y(?6:$I_R/:P-A?@1YUN*.?EW1();4
M:CBGQ>E@EMS*PN[#KHY:@N-Y)=/7DA'V@T;'K\@\$T4TS/5K'M<J*@0]]-*:
MJS?UXQ&;I-,+J*C/%ZNE!+$H#<Q'615^LNH),W)2V)1AP<^<(:\-R2RO<JQ?
MU<GHJA:3P#P#P#P#P.$C5<Q6HYS%7^CV^BN;_P!J>Y%3_P"-X'CH_F/XYONA
M=Y^RO1<7R^VZ/3\9ZS]=3NB@TU,7HI&8;6?7?\*V-DIQJ$IHA@90(K(["64A
MC/F;[/QGP^]0\Q-IH+\_HVRI@;?4V._(TN_A!NTMY!7?_P"N:22\;H:NYUDP
M9@L]9F*>*`@UI!(S*UDT7S01/?!X#Z[/1Z7=7^$^[&6GSG/-WU)VJS76,]C`
MB\[T5_VGJ<)!0]/UC^="$K0['%[*ON:WH<9,8?XL@]P<H[G`"N5H,V#L.VTM
M@^AY_18LRAO)V04MYC.8YS/G:U]A&"36"W%N#5BFDG;RCK_W`J2=H`8SY'S#
M2HX?X(0=U;BR.`\1EXMS,K*7?7/M5>U/6/L#O<;./>5K>*\O>'6\EKP]19U]
M!FJ:TW_9!;^]@&":##H:NM:@<A0!<)+@KIB0+[0U-B#5);:FCW8=6;%G:\:Q
MV]T=OK;70O@O\35&%;/H$=B/6N/4(6KD4T1D#%4=C(IY9@M]WCB&I^OG4..\
M_P"K5%IG]GG-_P`0W=O0ZG35MU95TVER.N&NZ`N"FK!7N44D?V.ICH8;`5L4
MDDB2H]KU#MYY]8OL=JN;4&WYCGS^W\_T'$RJHG6\JI23+<?0BYV@4ZMWO-AJ
M`C;46!$V%*UT,4-84"DDZ/<J(V8A`I_8ZTP<;(Y*/:&9TF3#75E?AV)D(QW^
M7&Z^TGT[734R5]IKZ[]IJJ1(F.M;"2!B_C1!K/`-,T)S,#ZQWOAR<GT=-=-Z
MU]6KG0:WENMW[@L/87WU=ZB)8LUH<VA>69F`KWC72[JC,'*D9+94_P#D4J2/
M%CBGG>"6WJ;QZU2]=A^-#;C-1FQW%ST/F2D='S=1G;Z4ZMK=,.2UD&EUM;A*
M.^T1YY:J<TZEDEF6/\HE9`D/Z[Y/>\E.+^^%O?T4_5L#&M)]6W;0V'3V3^Y]
MS%-S?.]D=P6B;:PT7/,)S@"XUXC"8%&D2`<M1F"3(2H5_P`!H=EE>ET`FKZK
M95FR&UK1CB],9#!D[[.]#F+T0S%RW[>?SZ4':YDMTM>.#3,KIHXAT(2!C)HI
M`N+R;ZD==N>-_P#4#2EX[A.`Z5M[6JRES]A+?(82;:9#*49P&.%YYB-"6-U'
M>6UIM"[4>OO*\-E>CEC!'_'&6(A@1!+#28_<4SZ6*TA&KL!]Q8Z<7:I+2:.(
MRQM@K*\-W]>-:%C!6(]R40QS")I8@(?:QLZ.B610F_[7Y;I'UJU_1\!ML[=Y
M>\O>B\Z/3=?ASU46XYGLK$BP$>I;_P#(!;G.RW^EJ7A),7>#UI\\22*)`]ZN
M!J\H((N,YMN.[(TRY^O?VOSAN'LQ-G/7=,R7/]IC;2,7CG9"\./86EIEL]SS
MJ$=/6Z/05SHZX@:XL2;%SGLB^($VL-Z/]=2[?F^FNL@6$=I-B.32V-"S>\[E
MV69AMG]<L,W5:SWZ^DWW,*W.05Q$$K&?CW#E;/')\\)$H.7EF+B^RVIRVH^S
M/4:#4\,Q)Q.EW-AN,,8!F-]2<9KZ$SNF&Y[C\R$P&KJ*&SQ<$50TIHX93[ZM
MBG?)9/6%`<W9NE=+Z)K]=U_LMW=5.BU]UJSJ#&W]\RRV/)Q*//@`Y;!@4F9M
M#8LQ1\\H;0>F_:TJ"C&D#QEOA:KWRH&RGZN<.UHV5T_V0ZF/;5-,#=?6G)8S
M0=)*?G`^J='O^]<8J]0S"N.,^3I%A0PU1+(I@_<".XA8T8L[T]H>[/P#P&;T
M;/DZSG^XRX=NM`9HLEHJ02]]\\24Q-I4%A#VCI!2!"6,`EF25RQS12(C5]KV
M+Z.0-(5ISLS1:+7W&U^R'U]A;D^8<XUFHVU7KMK:XW4T71>K="I`>2V%@/KY
MHJ[B/1+*""KL)W/;<GV0D:!^D<+F($TX+ZZY&QP>XR>/^S.0V>B^T7.-=F:Z
MS#VNC(.TMA2$"V,)WXO_`%`(T<E;@\]!)3$($CB@X9VM)1R.ECD!B5_UQKC:
M*IH=_P#<SZ^7..S%3?5ZCUVMM*OW=$I^=19;2?DDP=5&BJJ?G%_+6GP5HWP*
M)[D=,R!SXVH&<?\`4#F]';:9FO\`M#B0JBT#U6BYW8MLB:X'!E$6%E18_8V]
MO_G8E6+=<QL-"E)EC)9/E5HR11/CFB1D85NU'T[P,.Q$,L_MEQS!9R\AUT6G
MR)/X>"CSU?I<>5SX;;7`^AZ;7;HV][.7EY?WPM9?AM9'M^%)&L25@;`^R<$X
MST'H*]2/[AQRIYAS$OC-785=G/3E!X<_F6QH='1<^/OF:X&BI<I?%AAFQ5A8
MR%,O!Q"8GN;'\3@I%UKGOU1!Z/?]L;]CL'SJV[%]B-[2XW:)@K&KLW2X?5:/
M.]THQ[Y-17Q7%%'I^@L?87`K(!2!:R.9[GHB3-"?;GA'-\7]=+.DN/LWSB_I
M>.:?7]6U!-7GBMK_`(YE^JYN"JQVCKL_0;:;5R]9S<94=GD[U27D26):2)%/
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MGQ).6#QIW9,ET?%"P9:NZ<3;7D4.M!I%&L79FDA=&[$*.`^:67U8K@=7'<+]
M;,=VS'ZP+['\R7"8;3:CH/0)+30YK*'7;^8"325PYH01)4^M?5]4T++RQNSC
M%EG-JO=&XJ`AJP`JTOU?^FVQ-Z"?_P#3HXV_3I.\W0>=MJVPSL5GF-*1>5&_
M/M`+:2WD#_SRB@%F$_?UCBD=`4L#7H_UB<#'Q_(/JC;V=K!9?9;F6LCV.@L6
M!A\]XIG*4.]9+R6RLTK*J*4PZFS>0NL+96)NJ!,_]-H[D&$ETT4T2B^`B8OZ
MC?53JWV.*P@'V0CFDAN=_9<XS>6EK:*EN9+8V>_NZRCSM+=H:1+1'4ZQD3W3
MYQ+.MAF%K1!P%:YP7UR>H^L`W!MA]:;O[7\\+K=RG3L5)+E,K0<WBRFDL;BZ
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M.:`UPM)WS*9;18S$5-F'0W-W5Z(PC1ZZIH!WW\T>JD:Z$<X\P:M#D?&@TD<<
M),(//ZQ\;^I>H)[)SGC7V,GUFB[9R@@M_P#CL,%F739"Z-K8X]E#<S5S16-T
MPM;7RQT[G#L"C^>&-KO:KX@B>]XY]-L7@O\`I+EOL7=D]6Y;TW38C)Q+@\^9
MH_\`JCI<'08-^<;0FXY]?;T[L?C"J\8@A)ZZ"628CY549CF@L3`?2CL"6P/7
M-EUG&76;Q<7U7T>=/S9(RGA<IU:XRTZ&)>T>2L(P@R++F]C$MBLH;(:T&<UP
MPL+XU0%3(0?1?I'#K;E6`Z[T[657)9[3[*FEYKE1-/K;_-97*UN-5,"59X*H
M2VLVXN*O:,53SNLRX"8YE?*(4D3@BK4YK^/PO5XZ<[>]=S94C:H:ZRIE1,3D
MJS.9;$Y/EIUF7K)L!<Y3,P!9&TJ&WC1C@IGSW4,9$S9%;!X$PY+*?0G+7/.O
ML%A=+U2Z!Z?UK:=<RUGC<4->V+]7@-952%\NLR*O*D]*6QO-]LVP!US993;B
M*>0&1[A?1%!O_8^O^F\>U!*'O^I4.KWV)3M6<ZE6X"/H-7-'UKIG3MWGI<K5
M.SI^DM=Y3:/2W$5=2M09@L!0SBXR6C+%X'W#4_\`'#U3HO+N<9_<]+@Z#H;^
M\L<V%H<?+4[(R31T&5U:E:DS68F8FC'W]AB`])3V8L%?*5/\L39D'D8,@8>,
MSO\`'/S#<Q7^3M?L1N-H/9F9"]'S>*O=/-^^YLNO%)T5O#G,3"R@JR19!:^`
M8-X=&/!`C8`AY6R/4,VA*_C?,OK'68OH7?"9ZJ^)63>9ZKNR1,='4ZRUO:CH
MD.F(Q4MC7X[";'1'Q@S2OE#2<R1DXI+$A5@/AW4?H_T2I;POI%7VA+&@QW_3
M6MRFLI;JUV>DSV<SEJN1MK^K&I%^/8;H'H-@55131*RP0=LBHC?9&\,L/D'T
MXI^'\'Z%M^<=;H`-KHCSZ:H$5MUJ(]`N5A320Z,*CI:EV9C"QO(%OK22L$JF
MB_ML\;'>K_QI@3*#1<PY<G#^T3<C[1MXNF<OZ7E*L0LX?3[N&BUG6\CFKG57
M^O)L*-]II[_+GTZ4E:$",T2I@(8TU&^CG@T1L1]%-=Q[K55RBEZCOB<AO.44
M`0^FV)F+"LMCL-@;R#)BT^QN:JPJ*#.!:+9V53;$H!(2'$L\\$3Y%&F>"MTL
M?ZP677+#1]LYUV2'JN8CR&).R?#=]9;'FZ]%"+-Y?@*7*WP-EEBK#:RY>9MF
MR`T6KE#!:^*TC65'C.",R`OXYS<;+86^'^U-'4Y/*5]Z=G+&YNV'<KKB1LBF
M6Z!#F`]66'7WO<_CK:N*8)I,\_SO')B`A61R!TC]/^G68Q72\4[F/<:BDUUU
MG'=G.M^@:BJ"XSF^1;)N@Q8>';7:G8G4%;77=]8,AIJ%\S6V220D,6%Z.:$P
M<VS/T4ZA><W^O=9QK[&9`IC(V!Z*ZVFDHC,^;L<O=]&K<+IMM1=0-TUI+UOE
M^-(L"H17G"D5*,'L)H"')"@)9&V^L6FZ_%]C=7P/IMSO=O3SX<J2FW];+BF-
M+YF^WL\YGL]==&S,@NFK/KY?!6>@F9505)BM_&$()LXXH9@@C-=?_CUY1N\!
MMN3\6Z34WNDMP-QBRMAH-EK;.[JZFPT-)F;/#49W6;/)Y.F)RE;I7Q5]O^W$
MCP!P(\!9)8VJ%G<D3]$*VOVG2\?Q'II>DX;W.BLJ&LL^IV<U_?Z+<V5G99J2
MHGT_8YJBNY,9=AG6==G[HD*BC/%^08!"E8Q0;VH[9],$X[3?9GOO`[FHQ.R^
MPW6!\)HLG8WSKK_Z#>G;K5B&[/\`#W-2=$3MH['6:BVHX_EJG5PIHY4$K((8
MY0A$+[._6?)75W1S?4PG)'=GM]#SFSJB>@!L%VO-:/KQN$PUEG]!>=<"R_$I
MUOJLLR^EE;73K;0_E,DD(DAE<#^S.F^C9/-.X:/4_43/9RUX8_+$9_*U6Y%%
M%VN$K>O[7AG)+*C)&V;Q:8V_(QSQ+H>9/9?(_P!DSK*&5C5!R\OZG]-M1O><
M<7D^LFFTDG69J&ICZ9KS\C(9>A9*R#BH-8P'.7BPPO9KI7UQ\8+0C%JA4?/%
M.!\<7@/_`/Z]?5#H%KA>6F_4\,W*":)N7KIC;+'-$P&,ZCV?-8X0@JC`LYKJ
MCM;;IIPD]AE49&73B-9),D:/;`H0ITS[/<R@Z3MM/VSZ@<LUT_.-MTCDN0*J
MHDCMERW-^S6W+^8QV-G8-DI*H$^.CM#)FRA)"/(X0:#W)-&J!OER1X-IE<S9
MU=?-45ECGZ8^NJ288AR*P$RM&($KYQX))H()@AY&QO8Q[F-<U4151/7P*>=`
MSJ`?;_D&J"X-2USM">7E[W[#%:;'QDZ*O;RCJ!T6`AQCGDZ@ZY')KAW-/</"
MK`(I8FDK#[X)`:?\=U#<T&0[.-?Y:RREFO9]&Q@5OF(L<6M0-"./2QAYZ6G!
MNAZ*`%B?ASGE'3EM>Z9BP0OC'C#8?X$5]R84_C/5&@_/^9_T_P!8HWX\[!9$
MF;2&/9ZD213LAA14]9'+'(B1^O\`8[_A4("^@%DEM]8LB;&3&<(_3=(BKSQ:
MNCI*L\(7H&D%A-HZG.(E0%1$K"YP?Q(U98%;*]K'R.8T+H^`>`>`>`>`>!XP
M_P"5'7[7+_R2?9Z;F/4.C<9U=CR[Z]9UG0>=;JYQ!]3>E8B\-RR%W($3@81#
MRW(`0,:CF?@G$S!^XATR1AI2LM+F^T7"]/[+43TW5\C7U>P![;R/&61>UZL1
MAWCT5_0]#^N!<7->>_8"BPF2AF#O"5%H+\[/UA/QO,*D&^8+A!<Y^M%AP*EY
MMQ'>P_8K*=JKX.P?6WJW#GD_YG]9?L)R$$FVO>+=<B:'G-N#S+2\_P!-9S9O
M3MJ*_P"`Z"80SY/F19@U%8;'[+K.XGYK3X,?F4=JS45G7M2)5#:6Z9RP:^M*
MN[JA,M77-U%3'6XUU")&/458T=R?)[$1P<DZ-"_'W#R/UT[%IJ;4#]"+YMSZ
M]KL'4_5#Z6YG.U&L^U&.YY0YZGY*W[`]'S9ES>\ZQNBTN3RD!E5!H[\5^5H&
MQSOKQ_B%K"`I_AKGI'-.JVG+>37`WU^Y15::6]T?2\EI=-@.O=,HJ?2TM)AM
MI>]B%,=:7*'MHS*N6@HC:\&)]PW\2I/F']J`U1:LAO0TG($SZ,7[98RTL:>C
MKK4"KEL=5B#=%//).79&V5NVM/-_$1Q,OL*9\4K?[_:]P.3&:J[YQ6<#[YSC
M0V>$U639F,3-L.?S:"HT\"35+I<Z5)?Y><XK$QW(X)D-A)*4'\S1X7/:Z16Q
MR!(O9N]U/7-%><B^X-/0=9=;WL-WSS["<[DS7#OL.N5VMBZ.O*T&AXQD]GDM
MY@\6`%#"93[2JE(2*J.E0M958Z,+Z_5GDW",C3]BW6W[,']B,=C,!>YK["_7
M8-@N<^V)&*LLE8\BN.TY+C!]_4E%[7DW/]$K]K!1SF9_99X9)JN8F0OX(`TY
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M`#(E:#_^J.>^GQ>YY^_==;T?U);K*N;;<@U_50G=:Y=RKL!!"TW0^1Y;4@['
M963^?7U%+-6:2AV((L%4XZ"V!L'13-#G#C]P@Y-'9;OMUEPC-X3FO2-\>^XY
M=K'1ZS(Y?NW+:2QQ/1K?G&KSE<@A'+]H^D`LJ.W`>'*;%8P#6<4WP_\`-"Q7
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ML0<KW(OM=^J?JBI^BAJKQH'U=J>/=[IJ7I>YV`0_)L;N]WN:;DM=!&M/3]*Z
M(=0R9#,AY`*D(N:'3TQPI='&*YX[X62R1I,1)*\&)SC+?2<[[%?7#K>9Z=I:
M;7P7\N(H\!>A)DX5U-+@8L-G)CJ:*G#&BBN9B)8(#87.K[>R.8/"0^1C87!#
MO3L?];?KW1D#[#6;[JG<,QIL]A38.(<QQ\"X:.F+-Z/0R5-9?YH+-ZRERDV>
M_#OIR"#I92;)B6/_`#88?@"3+?E/T(+I;"M(Z=I^;:+7:+'USY3:H:Y_8;,8
M+,$ORF<T+<S+03@X_65%AH+(JK->E%H;TTB6>!'QPL!'[CPCZU\[[+SOEQG0
M.M:6SM-K19T3)UE75VEL%MN[AU7)])=S:F?F95)(R3#6U25;#36+7TH#(S`A
M8IS&R/!RU.!^I?)!NI?7&UZ1W/)U^<U`FE3>[*@`=FLGI.79L<I\E'\6.FQ\
M[=#E]K,LI]B,D%R4BI$BG0(]X9W4\YRW-<V^FL/&Z/;].X[8]EMY<A:5'1L+
ME;V"_P!SO['<65/JQNBY@HHG-9^XSLZD,':,>(^N061R^_P(]RU=]$\`7T0/
M.]*Z1>XOL>/IQ-<19YG33ZG,5.I"-WM'T#)1"8<*X`!'ML</;R'%PS5-?##%
M[8XV*GN#YIB_I!I.S4^FZ3UGO'8--F*K=CZ_KEWFR2<L3I,;=NSE;GZ\&MPL
M&?#(`J-A<O%#H!!P?VD8XLA7>DTKP[_L'R/Z-YK@VF[TEKUG?Y6][/F.="G4
M>GJ,BIUX!O3:<:TSA6IJLYG]+DN8--,LY"5GDAL*JBG:.\N56Q3AW:[`?QYO
MW-['UG[&=2O=CJ+T?-&&:H<:I"TLT5+?9.[TN>)&P=;6W?/)[.U/BDGJ)'TP
M%@2D<*1^K/4%:X%^I^UJ^.<7K6?8*\&H#[`.\UEEF68J>X&[1LK;H;:+8C:7
M.4!<(FHWV9K;$=*J(`R*$JO<R22`B5JA8?['9KZ4T'0$QO9];T.#6D_72UQ`
MF:JW:`[]YYK.`W)G`U#**@+)*V-O"YK6M%=^1*]B.:Q%1$4*NXC*?5C6:?80
MY?<_8W<47,.23=JT8-29"ZEU(/$9HZOGN*KF7^&IK2SV/+\]?$4KH:R42!I!
M,P]FA!S/G8#`X`/].2\)67G;K+OM%O&;73\RT'^0YDBGJKO`/[!?QYX%T><R
M24H_(Z?H88YRS(4195UY*VO-L"U18GA+5QD/IESW[`_9.HOZK[+LUA6EI,Y9
MT.9!M-50]<AL^;T^AO<YCDJLPA-K_BN:Z7(;9@*8^>FJAFSQSPB,B'B"-^8]
M7^I7'.Y'=1O6=.-`N;*P-$Z$:;;ZJOGTO)[`CG7*<:%=#4H`>BU%OR34@%,I
MY&0%@53QOR))9V3/>$LP\=^E>9YAKM[C^3_8+K>#W_7J/#Z&.2"[CLMB0!=4
M^TEUF'K3A:$W4T>;ON?`#F%O6%"65<ROFGDC?)*'VJ[S]`P:S-T`C_L-T%W&
M.E;G:9V](_R2^L-QK;3H64U!>K/MIK(""S!T'8E`J:AA[0&LL8$A9#"$YLL@
M)7+S?J,/8Q\C^OW$N[29W['WV9S>CN26&4E52Y>LQ^HZ5I]?A[.0PBZ.T.9Z
M)GXJ^ZC(1\Z7LSW1^\2/U<";4%?6GB/V<[F#U/FG41>=2<GY+BA]%M<Q5W^5
MH+ZY32]9V&DUNKM--8WD?7R[+H/Y)Q\`;(*\((9L1'_+CC8#B[1C_HIB)</D
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M-:/A.5E@`.&R)S`G+):[ZO<YX?S'H%!]:>EUQ&\S>^Y=<XJ:]I!]WS[!XP<'
M!]0(O23>EMH":[/CY*LA1N>.L+$F%()0(Y?:]R!!&_Z/AN=9_P"JE'9?2RET
M5]W3FQ.YT%0_J\)7[!/)U7ZZYW18,,G6:,BJU%G;BFU9\AI5BT)%H_;)Z_.O
MJ$[\DZ!]2>O5(_)&\@N1L7S/GFX[#CKF+6W`Q\%4FGD,M(J*Q'WLNZ*UM=$)
M7E2'L,<@QS8GP/':T9Z@UK#[+<"LM)A8[/ZB7<O2\?B\A2<_S@O1>=$!5D-S
M>I)R[-"7%7NUQ8ZV%3/*>XDQ[2:V;U$<U\LK/D"O.6^PO+,/V3+]<MOJ=S/$
MV-4+392H.S6X)L+N#IMSS]1LIC[W5+K*W`BYG/YNJ@A=H+&K)AKHR)'1PC*T
MB9X.Y?L)]8.<[701X7ZJ48<XI!9NTFAZS1G26WK679-95YR8&TTM-/60]"`D
M#,@`>H0E0Q341&#N#8%O9*[ZKX#@%=V7)_7_``Y,72"LG6-Q=YH:?/5]/9=&
M/HK<NGUNNOK&US6/SK9X(;&94BB%(>D3FP.E);[@K3GNJ?5%I)Y&3^F=$6`R
MBT5KJ+(7I&<)/&Y_MKZLH[@VUC;8&CE=$_>)$1]408TFIKVQ/'.C9,D*`G5_
MV/\`KQJLO6\-IOI_6ZZG-OLAJZKG]MTT)<AF^B5E[2\TJA:RR/III*NAHJ"K
M1UI.%#*]29B0I@I_S)9)@DWA'V:YQVKL').8;;A7+ZBFL#NQQ\1EJ]$W5%Y]
ME*<I;`1\\N:&ESEF=EZ1I]FDDD`<;W#SAOG:YWXX/7ZY=8X_TX?H?/=/];.0
MYJOUF#N[[IM?D[VGVV?T<F!%H''"Z+(SYD`BJS3Q-)`E8<3[OS;<6R9\+)AG
M33A7G._;#@)9=%L\I]..625-"-#S-NUK=P!&S(Z0S2Z+<9Z(9DG,/2OS@<^3
M=H[W3D_C'5;VK*V`UT:.D#(K.@_7;A/U,^H.LOOK#Q;5VFP(V=6!39V*GM"6
M1&6"Y'56V$OB\B4!NK/1B%`^X@Z:LBLAO1[58GQQL"-J#[6<9S%;>&"_1SAN
MWNLIN,\NJW.>U5#I77&VNZBVZ#4V)-])QBO)(T@@XTM7+,<^.4?5S,#<]WOD
M*\"?^&?<#EZ[SEN1RGU"QG(*;3=F-Q=88:*)2:W*6Y\ES6C0SYBIPT]F+T-M
MEJ;)]DR*1]8`!82_)9-81(_P$(8CF=E]@:SZ^VWUHX99#.[LG.'7(X4=_P!)
ML^?X37Z;K.'>4'J\(:MW@N<QY`9;L9+2."D=;U*AN5OL;($3X'NW.\VRBX3H
MOJ)R#I%9IN_Z8+7:`.G6TKR#;#M98"TNO9?XU(7]NJHX0[Z:L*(G#DJPXGMG
M1$B<T)]ZCWL/F/5OLIQ0O@GURU&-TG0,]//&?DBJJN`JV\YY[K!KK[(`UV`M
M*VW$Z!LCS*3&VS/W%Y&@DA'(2%D+W,#YIOO9>'CU55EOJIEM!44%3K]KT7G]
MO4Z`K2YC34-V)E])SFNJ:["FT4?4#!]M&Z625W_D33M=%*DRHT(QZOT+=[WC
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M.?XVQU,L@#JI\FC.SM<5=O?5O@%?6N6REE_].Z.-T/\`P*U%3T\"B/3=QS,K
M[]<LP0W*.AV_6:QE58G]0N=)MEY3C<Q=\YZPT4[-XN/?!Y";7V-8!;5BVK*,
MAPCI7?D.5$C?&#H_CVV&[T>)Z%3[PG2D3Y;8K7Y2;671M]='X;U/"S]T:;-I
MM-7-*M)*LCY8@I?QX9(EC]\CVN]H;"/`CGKXY9?*>EC`5\5L=-@]9&'63/EC
MCL"741WPAO="U\JH1(B-]J)_?Z^U?T550*^_05#T^J_-G%#V0X,JZ>?/+>8^
MOY[?DYJ;4W$M.5>8:I"#KLO8RP/_`%&B23UB1DKWNDD=X%R/`/`/`/`/`/`\
M87\SHCY?N=U]DX1'H4[C$(4TH@L==959'(CG6HH]C'$RPGLA;VMKFR02/G';
M&1&OQ>BR>X-'7;ZTJAW-?3_F7;-73XGFNFW%UE_P:O25>PK98BL^=J]!S4+9
M[[.V29)1)JY69^>@49(GEVH4CI8(@8%67/G/L.ZWR=^R@T5*_*OVM2';V&-S
M\>TO7!QZS8:NSQ-E/74=Q56AUH](*J=ZTWOE;#/*Z6-KPCGE?9NTYW?65E\N
M@H<HM-IPOK#L`PX.?]"^Q>&)#L,@9=]>UE!-+JMCL\/RC103UE/,E;;V0-O^
MY$0%,8]7!CUNEKKH71W1`MKGW,K!,K>36FAP(U]7XW3DQEQ6^?O'YC>TU'F]
MM:U9D-I.;03-M3:Z"O\`8B2-:X)!P%,(3S;26)]!5U4Q?2'YK1RCT=E3E"X[
M.9`^2GBDIM)8Z4[%0AO8:3#95GLI9I/CE%%KYF+"@+!:Q6M[]=@["2ML5B[U
MRF)2:TX:.NN9I,YKR;IYX#/VV`BQ#/L4BA9#`22V:*9[E2-/<P,#+AGC8/0A
M"%1E6&SXO7W][=Q-C(/!U5`.'(!H;U!+0&3\>M8`,!62_P#)D;))^1!Z0_D^
MH))\9NGY+CVV.>GKYLUU@Z`@V#!R]!`LL!?T48I\A^6S]AEW:7)5MU`/^7,0
M)**&1)*]];(Y\DO@-03.,O!\?T6BTE>;O\>9=9G&=&6RK-4FFQ59G6"QU)&F
MRE5FL[KYJ0D6`:(.4084(:TE&GB)1D:0!][YW3LE[T/.6H=Z+I*ZRIL,-U[I
MFS!/W=[](H[RO"P(A!70HQ(QJ4RZQ`\=DM#<+<_XJ:#%<R/B0AS&`^-YT34]
M![8'3[*2VV5]5T5K89.KVI[=?9VEUE,XVHSX%+!DZBSK]33PUN>AMJ0``5M.
M>X$97(^"22)0CODIUR1HCMD5H)+2VFR?2MOJ=57$2RS7]Y6BV`GXNAML),%S
M3>77^/E^@`Y0JZ,!J1RQO5D7HT%S+A4^?YE>1-*S=R<3J\CCB:BOK6:..@&T
M=/=Z&MKX7R35E!8VEX8.D)#'CD-$*A9,D[F1QR1AD9F71S;CBK[>8XZQ*PWV
M_@AK2+)+_5_,N"HX,B05\M19)%-7G%>Q4D624=L#61OF]J1J$]ZZ!+"S[@->
M,/"RP6(W]G:#;4;/BAEC4]V?38U+$RY`-K*NOK+:NI5:28^"!I<0\1/QP2>J
M!!5)1:1^(UU-K3K2OS,]1G-+H)+\Y!JF/>-HF1<LOXYZ@"TQKR+'31Q`C_XW
M;WR'!&G0$R,&@D6,'MM]#U,'FF`*X*3)O>I0ZT@C%Y3=G1W?)K?.6U"`WK(G
M7@=;-'R$_.@PRY:"AG_<H[G]VG%%K54;VCQ`\1.D6]CSK#T.PUO3=%G=*/8V
M&^U72&VX.BSO7&WY1G7ZEV#7.34//R\SJQK>FK:,26.L;5M@/B(FC;\40=MK
M97.@WK8->ZC&SP>FY_57HIR41V!RF-A*D(SMW0MUI`6?P$5H`*!+6OREAN)#
M1%]T=>-*Y\:!<GE,^G'Z@)^8?#<WEYU,5Y(Z!11201F=OYI;:26>U<DEDC(<
MLT]HOX7PND9![2YT>YTB!^AEX!X#*Z210"<ZWQ>KCLILN+BM21I(J92DN):"
M&B/DN(ZI098#4LGUS9$@6%[)?E5OL<CO1?`U*\U[!]3\=F;O"Y/G/V2,'N,'
M'GMU775_623YL'1$:[HC:4VS,Z")2C:X+.LMK]J5$LKAA'_C->A*QB-!CZ?M
M/TL"VG.NH5//^F3R\Y;DJFOVQ1!D0-%<Y:1T@]=T:6TU(P3<_P`YTMB*MQZ2
M?D0WS5AD9*L3V(#JC[)]1-AH_P#,+KE'6+[3]1;;V\AF?T<<>2'J\^1:YOLN
MSQ-3:[^GLLIGX-1"7^Z"/""N+Z:&,P<(ECDF4)ST%;Q#M_)]_LZ3GT]7T3.=
M)Z;N:7FG6KFSI":+J>6SI/\`ERW%?B+BTN<C0;*I`0RQ&9+$V8LEDLL;"94]
MP0C:_9W/2]$J#MQPG97NGVA'UHV$0^"N3[S)[W?YW$9#J9Y7/<:3JJNU9NL*
M_0TX8A<H@HUZ&QHQ$L_X_P`30F;5=Y^M(&"T_:+[EO4"!>X<BZ7L.OUHE@-8
M7>2Y]SI0,-O%L:1FW4."SJK,`<4@?/(46.^)\\S8T9(]0@7LOV>RKZGA6;A^
MNO7!JSGLX&CA.Z#L\GFJ^MO\KGV6-5G[".BV<]WL"-926J3K;1HVIE81`4^4
MF%9V,!JW_6>$<SY?;=5W/U_W&9MND<;J,ELTJ.B4)F5OLX4(W/$8G+Y[4]==
M9ZIE9D:%L_[Y&)(.XH:-[G^][X5!T\(T7U4U/0+'D=;Q'H><V&X9OCB-O#TZ
M>[:X"@!V(64GGMJS;2763L=MS[$6DCZX!KF4$13J^69K2HE<$T9C[%\#VG`^
MN4!'$R;W&<6'S$AG-XS\=:5O02^GV$H+9,Z!I-7*E<$W86Q4$$]J2(X:9BR1
MO8^/V,"L'$:SZD6W4<TTWDW8=)7=FZ=%C^4+T34T%72<P'I*K47>JQ&:J:SH
M:W3\)4Z:"00OW,)%T-G&U\+"?QG3O"8^U=5^N+.EX7'7/*NJ9GH%[OJ#`&5^
M?V&9J=.[;_X^S'\_KD^78'MFMJ&/1YVQ!L!)8)0%L:TEY'N;)`H=%3K^4]TZ
M]F=AU;Z\(MIB^%[[I%9I;S=VPNMU;.,V]?6@/I.>T_0+$,ND#34&A/N;V)R'
MVL$C(7+'"U?`9N;^POUCYO<]*W=7P.WN.3[$>_Y25N\AH<AH,Y9#RR10[/`Y
M_,UVY+M3+2R'$@.MR(18/E<T9LCY2'OE\!PMZ?\`7C"\H#-$^GNIJ,1DN9YW
MLBA)U.KC!0"\ZF;H\"-=EKMIC]-7Z?8ZXZW)8;&6BV+9(I127PQJT.GMO>/K
MK+MK9NZXK6=))O:#D_6::^N-G2\PEH]+V2NQF9RYK;IUG#;28>*ER(JZO<A^
MRGH@Q8A)H)$EG]X5GZ-UCZNZ;H?.MCC/K31%!A@[@KJ&/_RBDR5UEL=GH;S7
M'6<L0-X,376M]^VC6U"4(/`06P,5D1J5SG)&%B^2?R#<[W%(#S,;ZQU2FY\N
MNNY:.GWU$+DH-7>YJ;>Z^XI9K@,>://"5.C*8(<ON_<+*(X9(H4@^5X1CG?M
MQ]<%S]M>Q_53EB9_H58+9&4<VQJ,Z4^STTXM,5BL%:V-%)!TO2)L<W#8'-K8
MJ1M,*Z.P8V>7UED!;O/LKPW-V^QY^SZ7Y_`[IV!IH;G6!:^.BRN;.%L[3FXQ
M4_2!<C56M+@J>K+="9HA((2)IR5%E']SDG\!1^PG:.-6NAYS6;KZS9#9]B^S
M7ULYW8[C<U6@$Y^;9+JP)+D#G-X5HL;JW#<WO8L237'V/Y!-B*!(D#!W?)[V
M@XK/[-<L[CKNC[_>?5KG%Q:<9^K76-B7FM26RZZI8$8K]D&=3-'FR44N<YQI
M)M1:BT5M**5-:1-GGA&@5)(%")A_L#PNFAZ-5V?T?Y5EK#`Z!'7.AU5^!74$
M-QAASLWGZ',6A/-9"I]Z2!,A&3$G#$BT>?:A1!,,[EB0&89VSE>*YU+14GT:
MX=K*'D4%WF+5^CS,M_?VEE;08BSI=;/90\Y?7!"M/D.O-1!--.8)5`-<C4;&
MUT@2%3?:NCS%9R2GN?H54:&N@I-JN0T%X+3W5_GJO-41<5H3;Q!<NK1*R&I?
M?&/-@JX2XX<^2D\3I)GO@4)-+[O85>:^IM)2\$^OW2<Y>WO<_P##\'0Y&P"Q
M<N_PW98LG@B^(71F`,2BMP\Y:$6<A=B!5?GA-(*BF7_F/8$D]0[?TC<<T^J?
M1N0\:X[6C]"TM^'C:_JO/M'I#\Y6OW&/&Q?[#+29][,)#L<8"<=9/?'%(./#
M$X?Y)843P.7$NTZ[KQGV9H:;Z\5OUKV.`Y."[+]*R>&I3-$9/)6K=0A#0W>6
M:'?T.EL%>;4AK`]OXGN;.S\E5]@0;'WK=?7&CP*6GUFQ_0D#;A*L7?R\?;D]
M[:2='SV8ZWK(&4^%YU3Y?+C9G3ZYD#1Z]IA1$U---/`I+998@<=WVON+FOY$
M_P"MG+Z?2:>ACU-[+F>,:[49JTNC-+B`=15I3WE5`#3!Z'E>B.HORS4.81>/
MF][XHT49X/;DG?=]TC)]-U%I]2<=C$S_`!^QL<^%5\S(DV&WZ'?%G9#(8W/0
MVH/[&YF6I&R5-U"1+,UTW]W_`*:O<]$"*B?MWUK$89O,[[Z^XJSZ^_*1A=8Y
MML^=^FAW.]Y^(5G+[K@N6QMP1SFVYO3T&"K#1003Y'G!RP_@E1L&=[0M3S3K
M?V$T'6N65NEX]B>;\_Z!H];8Z]H'+M:79S#QX^Z&KQ+O52D0U5??:+24(1S#
MY1?QGUT#0WNDF=%,@1IF/LW]C[:?4V.:^I5'6P<SO9J"$,WE>LH=%HLSH-;F
MZZLK,DY]FP*G,SA]F5;7".D)&*;7JC(A97?(P.WH>F^UVDYGRW4\EIH+'>WN
MR^T`UYH)^9$\J#(P&>"WDW,%>+I<!T[79JJF6HJ):VN*@;-H)Q8(Y38TD:YP
M-(G[O?8#"8K::[8\4I>=Z</JF"YOBZ>[Y=K&VO4XM-:0U,E`)=4-PE11Z4B6
MS9>B3DJ2%[[!X;H$?"^9X.!O>/MJ9K\%39##T]6+<:_39/>8>Q^NW1F@9L0S
M>\UHVW]]?6-IGXKTBHYU;7>@:^J='62R3H(YTD<<:N"=.%=9ZCU75R9#HV#!
M#YO61ZFKCNTY!T+#'ZJTLCZUN*M:B@U-B2;@LN+F)+$,OYV3M(+&16D1-?\`
M"\'KSJ@K_KKT/2\GK<50@\?U+\WKL6ZMGF?^R7A=I79[13::;026!)DIA/XI
M,1+CGO:\3XV0QH^)?`N;^(,TIK_V\7^U\AC3/B'21ATJ(/(]K49\J$3#JJ.E
M1?56_P!J_I^G@(<%#.W2S6Q"PRAPLGGJWK.Y38"K2$4:U#?$T2.+]M]M=#+$
MKII9%FDD1?:QL:('R\#%M0=%4/$)&]`7D(<#%%^3(28&3$A`:,:LKK"%L7I_
M3W.]$3^B^B@Q.?:*ZUS!([BOL:2YRUC8Y_7!R@5<P=XX,`66J/>4LLL\(I*E
MI/"D/]S"&2QO1J(GJ$I_G1,-G`A%E_(C4*:5ZQ-'@F:<Z=CI(")5CC,F&C$5
MTS6>KVM]OZ?W)X#+W[]-`N>FH81):8*P>9J!YIP1G$5;%A'9$,MA&X-L@KRG
M&HYSH_[Q&M1W]_M<#ISV5S62K9:?+T-3GJN>QMK>>OIP!ZX6:VOK$FWN[.:$
M6.)DMA;6IDI)$SO62::1SW*KE5?`P\V,;2J70G%.*&@(EFSQ11!$YQ%1(C)7
MB%DV%G8V-B94DRNC=._V(^%\7Z*[W.4'7_[?_9_LGKX'WP#P-/72Z$$W^6/E
M-A&7TN>YK\IE;22CSFEFEY-!11X/N]3-IND4PL$IE+M(;2Q'%I&2,6OLAUE6
M26.6)C?`DS^-W"'X:3[/!%8/0\_A7M$@3!-)S\'G$^L,#KI#+'H%'G:YKP`\
MIJIK9JB1C33#+/`1,U?DGE5P;.?`9/2JVQN.=[NJJ+%]1:V6/TH-;:QI*Z2N
M.*IC(136)!%/.KAIWM?_`&,>_P#3]&N7T10KI]%K(`_ZZYH>LJPJP2CO-70)
M^URA34UB95WI<5K:TSA:3,SMKS;9TZHTJN"*;(CT?'Z>US@N#X!X!X!X!X`O
M^W^W_=X'A\_FUTU)2??[[!&;JYUU;EJ3E_U\.&'JV#OI[)SZ&V%@IHH6P/NF
M6FAT=H*',2![R88)&/3T2!5:&IU3`\3HEL^[V>RYOK]1FZ/6\P4'-XS2=US_
M`%W16X0.=;G<_>CY"SR7'J/.PDL%O='$&`/%-#/'^3%'"+($RB4W">+?4#3?
M8W@.ZVN>$YQ;&\D*UW3#*WH???LOW#J599TJ7[=A^#57_)?KEE\K'H&RQ4-`
MW07ERUJ3R.8CX&A0KD_7]C]<=:5O;Z.V'@TIUQ%U+9%R8?5W%>%L,L=FFJ=G
M&2@TP*TU"?8CQ.LXQK0MM>17F.BF':V,+<_:+!?5OZ_]:"K=<9T+E?VNH.3U
MQ^[ZKR4YFW^K'VZX;;3.?>=5J^).DCU6:<ZE<R?24\%\VQS-FZ<^J`/6M0><
M*A5-=J,3TNTV0U=8;[ZZ7=@+47/7<+;&](I90ACSR>:VFZV&4J[#9&]#,%LX
MIY!+B>D62N$*ABCE@8QDH)E/U'/7M_D%J#<_J1T^V'/LY6VE3:4TLF',@SFH
MNK:NK"11&I%"+=$3AI!#\<A0L4<ZO>WTD>#D`V0%7A,,#7%DEW^FM`A(H+4P
M2S`TE;8YFLLK"JCRT"5%E=5B65?^?&,RJBGDGB-#EF-56O:#$U-M=;3HY>!Q
M0KK[$<KLQVZS<6%S7"T^(U-W:_M>SV%1UE='1!\WL:)M674O0LV2W*8([V3N
M;(+^.%UOKIQ+BO6MKE>7TW9M/V7J.IJKD[C<%M7763^H/&>.Y6V"O-5WSMHL
MS1NT]XN[@5;62I-);01;2X<&3$S\9X,SPH[O.C]4[?U:'NO->>WEW09^^8-4
M5$..(S_,-*ZOJX,_=,'R53=Y^HI6&Y2JBKB:P&ME@_`%A&E>Z:)7R!L8Z'C?
MK#VWB.,^V_;K<_G@?2+,'-\+Z[];X,+04G&>Y\_$"K=9Q?['Y/49],2?E>E$
MMJ[:@TE+.%,Z4TZ`UH\(LYK@UVZ@+=F6UIT7ZXF/^P]GBLM(?I*?FN>$H-CB
M="+ISLWT"KTGU_,NK?5<TJM-E;/\NQDI@KBJE*@G(&*FKIF3-#%QFMQ\'2XL
M[F)H!<9T#F2:QDVBB*M;B72$V+3,Y+N(BR*:VAFS-L':5PI*QND6OAF)']D?
ML?X#GAMI,;683,-,L7,H<7]O1W7\]5#50A6!7/,Z;[M#;`1YT.OM(+J=HHT#
M:]72SS*Z.57>^20)6Z.>FJ+?A^<8VZM#HRV]'ZGMAJ^?\'EV""U!LM=;]`V5
M[#HLUE,=9V6((,LFVT@1]4V6)R/5ACV0!ET&C^GP;<54]0P.Q[W:RZFN=BN`
M<@N9.8<BZ'V_4-L+O1:RTVH^=MM=K<.)4,%CM[%J4-;#601"!*YI!]C$'/[G
M7>ZJB=']3<+M<_IZ#AQ&,GZ%TRJ`!R_*,WT#8UU=T6XX]S?-4YP='S?#XXTG
M]N&._--O+H>CDL"?D9&26H73^KUY+T?.ZS,=9I*_IV:^OO.])MC?JCKM#/S^
MLZUSW=F@4US4<MZ6+;GW7/\`H^$OA*J[I[0-UK5:&%EF`1#&\EJ1!"%J)Q[0
MD9S&<QW>>Q]7^792\;"^P@E!'90<@UL=Z^?&9/O=31'4@K**YD(E@K]F.$54
M%#3"L.LA[`0E`?:";[GT_*">R\\Z;S&VB[OQ3GR66DSA63SG5=33]$QL6>LL
M]LQZY];N#&5I4#;EP#THRSX8FB/D4F1\`?I$^`>`CZ*C!T^?O,U9_D?MNAI[
M.CL?Q")!"OP;8*<`O\8J)4E&(_'(=[)&K[F.]%3]4\"*Z+ZW<$SN,H^?`<>Y
MJ_)9X2A%KJ<S$9DP;W9HN>RICBHYZMT9=F);F$&H0]JRJ:3-/Z_)*]S@<=UQ
MKD&C^/\`R#E?.;SX;0R\B_=\3F['V7-C:$7=C;-_+K9?2QL+DN4N>;_S)B97
MRO5SW*Y0U5]N[?F>1][U_'LEPSF='H/\IQ<RZ/.U552SZ0SI.6S-'PBFUL;L
MU91&4NQGR6\KK)L:PM%$S0J1JCB9%8#I3N=[S:ORV_K.._7Z_'UFMYN+<`8.
M1\'1QN3=YI]3T[:V=M6332G1VE)#E[$X8<V)1],YKVP+#+'(KP@#-]FI-1S0
MSHU/6X`XW2!\MV&`4C;Y;95\D?0@L2'9#V#M9L\R0.7%D=-`)08Y\&;(6N%&
MC=9K^:,U`>W`NVYO9Z#(9*UH,=H:'%\CV70>55(TLJEDWM=BZC1;?/Q3/#`E
MS%<<FH)JR*>SH:N.6H9#-&?<,GE1@0QEON7R&F&PYO9>&:V`C2#22\RR^/UO
M.MERN+,1/OL:UA+QJ6CK\7I,$+73UU-[H0WELD:@RQ0.1&A;?L_>^*?7/H('
M.NQ<1YYOZ&U$J\ODM>:7@-5TTW+.I!]D5'T.BO*&M+&FFZ+8Q#B5L:RK)&B6
M;G/D=\:!'])]F>2G]MS<N:Y#E\YU-0:NV#_Q_K/(Y\7=PZ2BT+;O(U>XS8HX
MD>>E)HZ]I\Y#VQ$V;VQ/%>^%'^`BZ7[9\[FK=]H_^CEEBIBJVA(Z%RC*:?(D
M:764((%VM=>4-+FZX2*[M@SJ&,0XXI9'T(+(2&KZ.;$@2F;]R>(\6Y7]=N@3
M\/O;P7J6-TES6L(,QU_M\PSF*75M39:CF>(R[VI?^233LJI(D@AA'D<4LK97
M?#("#:_:SGND[-A<<-SW)WVMWFHY%=RVC=WD>BT&.L>A[K&<^VX>1)J:"NL!
M[ZMSMN#8?N4$\BR'`,A(CCC&<UP23D.YV&U^PE;Q7#XJNJH'WG;LWT'>6FGJ
M#.CC9;G=3:TV9H(&5F>$9B#K/;L:='2&-,2*EFA.:USB)8X@JKR[[SUV2P7_
M`%2TGUPQM:7J-OD\?BL[S3<5P]5%7Y[G6<W>EDL*BQQ4510BU-EH"JT:UA8D
MMS?%CUCE#<OS-"Z?5/L-G>;;+H&7,P/,G`T'/N<'8?D]EGT@Z-U*AT4.QUVS
M;1"!B'5[,_ESZ6%A"?BS5]41"68=-&UPZ/"N&U^].?O+K*:>?A]8?#"3I<Y,
M;D^QUEU_U=$S8]`[9\OY=0V/*YQ^W4VZ$O!"L<#%+41ZM(VSM>`K4]X*U[_)
M;7TX5Q=?_2U4$]$&W)@7.JJ^@&3U]O8:,:Q2#/9:WJ^1R_O5QD<K0G`VOSR`
MPUM\$^I9)(B-(4(ZYS_(;T//2]#GOOKE361@)=7)1UE!;V-29HV2U/L9F>9/
M,Q-Z?KKO..(_=-",0@$515,,*'_,E1\4@2]V;NF)S\'U1Z9T#@E81N$Z?T?$
M0NI]#H5I^4$XO;18K2Z7(3'8$<:^!*L(X2@TLP0E@!:^46-LGK.P)%Y;]L>E
M;GK_`#WE&NX[E\*;?7-@/JYK&ZV&K(T-#?<OT/6*UW.CK#FN<!L,ME3B*RMO
MI3Y0OV^R>@L$)".8_P`"#9/Y`^^8S!F[7?\``LCO%,T\^2H2<$NR!#R]A3T?
M-YK\+1K>XUI@V9)T&LFK0+"-SGNMO0>6%L<;I?`?/6_MKUKAO6[JA=R;3[+#
MZ\GAC,W74H^G*WM4_<5]P5LJR+2+FBZ(N>EN7`P"5[RUAA@C(=(B),]\`1/I
M_MOJ>MDT'^0?5W)]#+S=;5]>SA6<S_2=@#_F='J&TKJ:=NGYK5)2S4U9+'6G
M$QPD,DM`IW"2S?!&Q@9G7/MM]M`H<G8R\1O;&5E[I9[[.<6KMP4'JLM5V<>>
M<%;SZ7)U5K0W]B;G#9H#62_&/5$M_P"7,Y%<X)*,^Q_;A^9?6_<5G-MY'H^Y
ME[T?2TH9VPUO^%K5QMR.>LZ"C90VJMI=!!$R_1ATTB",>YTB2,]Y$(1KSG[Q
M=QLZ_1Y&OXC5;[(\Y`J)^HU$$O3>J=`SX>ZT+<L[FE]:QU\^?U._S`IT]I:E
M5\Q5074#2QB1L3U=&$@\G^Z'>X,4VQO^##T%3^R09CG6'RO*^F@1#7M-8:RE
MH$B8`/=#!Y7<5=(&4#!_RV4XW]LY#_EC]`ZM5]O?MU76AM=;_68"RLLD9S,Z
M"XH,OTT@66+;5M<9824(\%H&9<_+):$5"1$S5\8IE9-(2V5)8!T":>O=3^S4
MOV*RW,>=9+]JPXW1>23Z75IC=9?6T',";;*G:ZZ72&F?X!"-K)[FUSZCBQ_O
M%+'3$&3/D'+';""`+]@OMAGOL#+AS><V.BY;?]V;CJVP*YMJW76?P9.FT-?+
MHA=.$97Y:VHDKP5.<80L4E:!%$UHYOO63P&#L_L%]QX.P=HJ*KF>GML@^JN^
M=8>H!YSMZNOS6U#VEB)D+X;;CDE+I9-QSN=;B6U#9#4USHQQY?BF]R2@OYKN
M/>CN<?8K;IQW)WW9?KJ+1<<RFRI\PNVU.]TALM5?W4A/[;8BW(@5#D]-3/T5
M/#(V0'11V3$9*P:-CP:70.\_??HHU?4\ZYW><M(!J;^/4%)R;0G$G:309.VM
M.;B4UKIC@X(J^J+"BDMI(8G>PA[`II('2IZ`]B>M_>K7SW62_P"GT>5E(:56
MEVH?-==7OI:*F`M49L<]IG[20&?2=2LPI1J^N1I#LJU@Y)2&LG:UP)55]C?O
M0%=_C!\!NM?F?RMQ55@%QBM!C-A52T>;JP,A)K+JS/M:"^$O="-:6J&AO&81
M6,$@<^,^=X[0DS,]$^P#N,\_O-CS[IVUVMGV7>V<GIQREJ]#!FZG;W4.-K)<
M7J-8._EK+[*DHE=?$E$,KHQ6R$)ZE,B4*I<G*_D(Y7-I:K0`=KZK7ZFW.GR5
MYT>H$UUK71UM?4,PN`M0\]KL:%E`=5_ZO][U?SPQ5Y,'OD8WYXT0)`=VG^1Y
M)BI:WF4L^;J8<,'52F<JG&U^M-MMILPM9!80SZB<;//S%92`#I(\=X)`IC37
M&1MF2:`-LH#P]/4`V1E(=7.+BBG2OO`HP[FODAF62.,F..:=1289F>YJLE=Z
M+Z.:Y?Z^!QI*.@S`[:2JCA"A)*-LA:UY'N2-/GCDE96B2/5!J^O66-D<4#6P
MCM5J(B>OZ@O-C:QTBI[U69Z/>CI'N1')&R/T8USE;&WVL15:WT15]5]/557P
M"#XUAC6&3Y8O8WXY$D^7WM]/T=\ON=\GK_O]?U\!)L*$&Q*%->\H8H-9'QS@
MDO$D>]X\PK7$K'Z?E?CP$2)&DGN:Q9%<B>[T5`3`L;5`+62#RFREUTH\JV-B
M2ZVL#/QX[1COF*L?R'12D/N)G2RPI%(_W^WU]G]O@*L&?JA23S!A4B)M#'G6
M$J22R/)(D"@KWKZS/D_'C<*-&BMB]C?5B+Z>JJJ@9^@JLM35^?I()AJJKA_'
M!@G./LIHH?>^3V/.LR3#R%1\B^BR2O5$_3U]$1/`R+"K#M(VQEL<Y&*QT:MD
M>Q8WQD0%,>C47V*YDXK')ZHOI[?^U?4%'P#P#P-/W6;"7_\`NO\`$"++_!C*
MFCP-32U;C[JOFVV:OMA3=2]DM)F2-/4&0#:48!XY1[*VU](XHF,6!5E>@2]_
M'2RX2I[A-+E[BLS9?3;,BHU%YI:?5%Z2X2ZTXVEKQ+6NO;DU]5GIQQ_A88P6
M6)QCV)'^B^@;(_`QRQ!3Q203AAS0C1YA#`RX8R!2A2(W0D#$CS-?#.//$]6O
M8Y%:]JJBHJ>`S.;\QP/(,H)A>99:KQ6,KBK$NKR]''(-1U#[4V:Q.@IZU97B
MU`$AQ,DC11FQ#1.>OQQM153P'WX!X!X!X!X`O@>/'^7O[%;?C7V:^SF8Y%95
M^!['U'7?5S&UW6:S*#6^^S?*Q^-W!>KJ,K=3U1QE0?H-!=00>X$FN)09)7+/
M[&JZ,/+EVSM!AO0^A[W;&WY_2=E9]7$V-1VF"&RM-3FS1Q.>5F(/QEA>5!IE
M8.XR!*5\7Y,R_M:JV9PZ/>T)FZ)TAGUVYMR'BVYB-M_L`%4`=?VSK^4>ZU^8
M[CUZDSM:%R')8`,A])EM;P?Z\QAT]7*H_P`U'</M&!B?,7\K`JC)G>EY++.N
MB>7=+HAC\I?5(ME.TFQI9JF>MCHK\O6YS52)6U>4.Y[E82YC#!PX8RM@;,[V
M2#,DC"8MSV6UZQSGFWVCAI62B<HS6,X_ON>Z2XLM8F!CS^%I'<B[(2:+=4&H
MKY]9'%99HYQ391K`BOIP[!TLD_S($7\*W6HYEH>HVW'ND=EY1K1L!B-++7TV
MAMLIHV:WG]O39JGH;L:M/J?GL-%+IC9XS";6V%-B!G%CC@8@\:!*'2M?L.A]
M0X_N;:GYR39W/8>5V>T=Q?G^5Q6>Z%H1LEH9;,S0U>:K*/+'=$*N()AK:V:&
MV>>(>(652BX99W`^>1ZGZN8MG+9.AX6#[5ZS`<X9LY!C-QI.<_7$7.CYN[Z)
M&*7D*M6Z#H]H296,@@&@NZVML#R_BEG1)T!\"O7V=^S6GZT_EDVLUN<I:-X^
MOUU?SW'\\P7->;X'4;\TBA%U.>R^<%R^<IR<U7U`S3"TB&-B+LWQDN*=.BH$
ML<:[=EQ.<=^^T%V!K:3G5R+3_5VIR?/=36YD6^ZQMLGIJ?9]'!U^U997A.5Y
M=QIC'@"L4=H-EJ&.%$'-@'?X$8CK8[DBW)HZXC"9L%U#7QSXC/6V;Q6%SF6(
MLL(VKRY0\5NV(;$"4I-\1/\`,*5!'''.CYR2U>X)<H.TG]"Y9TWC6?I(K;3Z
M>)W<KL6D@J8H.BLIJ$/::#E&@Y&*M=?!:;1\CI@7R(,.&IVOI`I(IH3#96^!
M2;/;NO`Z_GNM5-N3@'K:9+-C:#!.LZ>SQHGY/_3]5ETP5G9G6<@M/!8);I5V
M,190[I'#(4SWI$&RN[^USNL\?4K[!\HY=]C8.<Z358=G>M"%<4OV"D`EI[BW
MY<7A>D8@BCN;^AIZV5PTK=(VSJXP_P`09D#YXI&H$1CYG'VZY"2MU*]`HWT?
MV8W<MC?AO'K].RJQN+M-35VU$-15\@NCJY2WUYD#(W30O?*]LDL?K[@E;[M_
M:_J'6K_J5=DV?!QSG_0:')\_X;S4(OE7%<5D2#6D9DD[!9G]LI:P+1Z*A@&G
MDM9"K$@XA/R"8VH^+P*G?7S:PZK4VQNTHIG\)^O&8WG8NF:^*N$SUWI^89"T
M,U4G&K[72B#D'U78^L:C-9L=&3ARR&'D"SQR1/\`5`Z_\LZ!]G_W`]O%[#29
M:OTVSOWTE+8V%SC2--H;HR;>:+5;G576=NKC5ZF8@$65;@R`D2GMH!F-AK16
MCH$L<J[$=];M_'@-1B)?\0T#=1S>L,M;HVFJ,1@K^:B&[!T'EV]K+02K+SHL
MVQB'`(/G=70E90`ELXQGSRJ'1TVDM<_HM+@.HV+1#L7H98)KFJ`>M[NJG?UP
M-LWK'YPY`T.XK.K5=*V^I["*90Y(SX8(H3"B4>H;,OK[U#=U&0LN/LT%N%C>
MDT_$;3:\UMSC#@<+=@[GEMDD.3HK*CIZ_,V:F..DG*$A#-,C-EF)_N]HZA^B
M;_\`+\`\#XJHU%<JHB(BJJJJ(B(B>JJJK^B(G@-W-[#);*OFMLAJ<YJZH8LF
MO(L\W=UEY7P'!.1I@4QM644-$6(Y?26-SD?&OZ.1/`6B"Q1!I32B1Q@X8EGF
M,(FBA&A@1ON6:6>1S(F1(GZJY51$3P,.:DI22I#YZ>K(-G0-LQLU>)*7*VO_
M`"OP$D(?"Z61H7YT_P`/JJ_%\S_;Z>]WJ'7%G<_"]DD-%31/B;7MC?%6!1OC
M;4Q3P5;6.;`BL;6PE2L'1/\`R6R.1GHCE]0;9'*^8%N->7SC!E.LJU]-8N(Q
M^>F=85$K!(Y*HUTE<YQ5;)'7P-=!)[HE;!&BM_L;Z`O"Y3+`6*7`.;H`K9*@
M;/I:"4]<-8I0AKZATB'0C,)2H%7_`,L;W?#'_P#!:G@<9<EE)Q(Z^;,YZ8"*
M8<F(*6EK9!(R!"V6`L\8SQEA9,,?&V>-Z-1S)FH]%1R(O@9!6=SYI<9YM%3%
MG0D(7"856!$%Q%)#&,A,9$L#YF$(/$V/WHJ.]C4;Z^B(G@8(F)Q@'L_!R.8#
M^,,6N9^)050_LKP9IB`06_"(SVAAD$R/BB3^R-\CG-1%<JJ"NM35+(LO[;7_
M`"K%)`LOX0WR+#,U630J_P"+W+%*U51S?Z.3]%\#K=1TK_V]'T]6Y*F.>&K1
MU>([]MB)'40F*O\`6%?PXR!56)[8_:CXU]J^J?IX'6-G<^&\:0.BIQ)`H(Q0
MWC5@4#Q!HG*^(<9\4#'#P1/<JM8ST:U5]43P,Z,$&&:4B$,6(B>9Q$\\8\,<
MTT[H8QW3RRM8CY)G00L8KE57*QB)Z^B(G@=;JNL?$D#JX%T+7MD2%P@ZQ)(R
M9A+'I&L?L1["(VR(OIZH]J._JB+X'9($',1$5,(-,5!%-#`3+!$^>&$CVH1%
M%,YBR1Q3HQOO:BHCO:GKZ^G@(Q.0RQ=S0:$F@J9KS*B6H&;M'@P*71AW:5J6
MXU9)[/\`T<5@E.*DJ,]/<D#$_P!/`6OPQ/C2'\4;X4=[TB^"+XT?\BS>]&>W
MV^[YG*_U]/7W+Z_U\#G^/![F/^&+WQN5[')&Q',>YJM<YCO;ZM<YJJBJG]47
MT\#FZ*-_M]\;'HU55J.8UWHJHJ*J>J+Z*J*O@<E:U51?1/<GJB.]/[D1?3U1
M%_JB+Z>!\5C53VJUJHOZJBM:J*JK[O545/3U]WZ_]_@??1%_T3_?X!Z(G]$1
M/T]/Z?Z?[O\`N\#[X!X#;SF.R./9:QY++9W+LO;@W17C,[25E(VYT%D])+*]
MM6U@HJ6-Q82(BSDS>^:54_N<O@.3P#T\`\`\`]/`P@:VNK&$1UH`5?&6:99%
M1A"P",)L;"=Q)YY#8(XTF--)>Z2:5WJ^5[E<Y55?7P,WP/GI_M_O_P"_P/O@
M'^W^_P``\#A[/[FN1SD1J.16(J>UWN]O]SD5%57-]OZ?K_JO@=!H\I090T!<
MP$Q`\T,1PS87D!R2QN8TF!I$4PZS0N7W-1[',]R?JBI^G@85>`]L5<1;,!,N
MP1)1/W*,=ORHR9T7Y"032,^>%I:#Q.F:U6L>]J+[?1&H@*_@?$1&HB-1$1/T
M1$3T1/\`N1/T3P.*>[W.55;[/1OM1$]'-7]?=[G>Y45%]4]/1$]/U_KX"66"
M2D[3*IX0A<Q`J64A`JS_`)P4#98VPN=')#*R4=LZNB7U]/<GHOZ*O@*K/=[6
MH]6N>C4]SFHK6J[T]'*UJN<J)[O]/5?3P.7@'@'@'@'@:ANTB<OL/Y3.!0%;
M+H<?6:O$TNAI<YFN19"SS@5#%#TNFM(=)UPPP705-;H!;5RSURPE(QHZ2#>V
M69[H@4/XP\__`(WK?NE63M"!LA>^&0FUK*$_+79@R%Z-U-JM3FR\AG0ZRUOJ
MM6)%(*04EB..TV9D$I/H\-M/@'@'@'@'@'@'@'@'@>&K^=6$77?=[N6-A/A@
MNJ'/\(T[`BM%9TU785U_SRRH81SFB1Q5B1B&ARFG3V$\,8@0S)X9'21JU@:A
M>#$A[GMO,*?MW7<S<<KQ<-SW_OYD=/;W=H1R7B%;+UO3T$FM&K*(0:>WI<L)
M^SHAA1!++)S!V/F_50J!<Z0_=ZSJ6ZP/++^+:=4M+KNO4=_<[B?6Z;$A7U^/
MI\KGS]/.&+!F,O6NMF@./_NFF8X08N;Y(D(4$&IKNON]A06\H[,"TJ;D?I$V
M1TRN%OLO:5#]7;9F>&L.NP[`DV-)R@@(8343WO%8Y$CC]H3U]1[7`:3O&OY[
M;4H'&=#]C\)9?7'=29RZ#&R&#Z'U>QJM5Q7IQ.7<P2R=-F.IY//H0)!<0@T2
M6;HD'CE;\$H5B`K-V<%9@GV^40\5=%0;)\%\)D(1-ED=+'7SYG=:>U@II;RV
MQQU,40(Z4J00EB/'0=SYHO<$TYR*N$/XJT&,68>J^T'/0WD4"A3U`IFBRFCL
M8&#@D_!9"5L2&J]&%,0A[9F3Q.6`AL<8-"IH\Y3Y?-9C87A&4S5AQX>@Q5>;
M9N_QJ@?^%229F+47PU>'HS\YH+N..MF,8),6#-8/E=(.%[V,".&9'85P%2SH
M-+@),CST>[T+A>H%92RQE(Z(N0D@F@;'!JXRZ&6WE'BL(X8YFQ#R3*Q'.B1L
M86*^P&9PN4J?KS]<M-(?K-/P?D`V_P"U<RJ#Q:CF<7>?L7<471*^D#SS)]&5
M008'F-?19JX&%;^#.8Z25"AHV2CN"#99^]F:(U=%8NSQV:KL["#D+"[9DVV=
M'F[E&5=/5T,&VQXXBU)?]I#!ZF.&&H(C6=L_XOL:#OK]^'0=;XMU[5#&8;3\
M\VXO3`^@Y('+OTAVAR6BCN]"=L8=&R#*HVZ,SDE<#=.+%-8*,_XE/EEE1H2W
M]HN>T_-OM_O+G@.OS1/).O%4'V6Y+*E9B<[M<)Q?OE<;8U&-E"@`OU9>8B=]
MO0G6$9#ECF&?+,T:2*)?`K[D=A?YH)22]-75W0;^YIM':@8=\*U^;QE:-HQ9
M&E:2<ZWQL9MY'9AV'X[)DMH*MWS&H^:2-7A*'[D;C;_GAJU5Y7FC9C[N:N,!
MK:&);>XM>/Y*]E,SS@YA5J&[`P-KQQTB::XI\7SHSW(O@<.F"Q6G7=`=SCK.
M2J*X^TE0^L-$<&[+PZ#04YE70Z6MT(5?$6!!.,%(3$@!5=+<PQ$B+$VP5)0?
M70[/F>4^L]/G-Z->]FUOW;[2/T:S_P`:)T8(F.^MWU;N[&F&RUQ%)%864V:W
MO<;HM]G^0K6#BY\8N!1?D1&!&4V*ZCJN?Y5FJ-P7.^?@P!#8#*W%I%C@$S8`
M`]<"#08@$?16%M;SBRDM=;2L0FST4$A7Y'N<[W!D6-?M(\_I1[G/9GJ'/,M8
M5:@V89,1(-&M,.9&,7C*^,ZVO<U+D_G@ANC6(JM(*8\@6QD@;&P-@6PRV=N>
M`?6[OF?W^[I@N+VDWTQ[`+I@R;O%*F8J2COK[H]59C4]58?YCON7ZEV;")CA
M@BC)S@[F0@P_JH,WD0Y-1!2[FUM*N8BSZOSR6J+E(GBN-':7G0L%G=*;J;TB
MM,B(.96VY;!J]SF33.4=GO&A8_T#].KP#P&\^`V_S1(EH&^C.MZHP(H1I<1S
MZ]YD$PRHTL3V13NC:]'(YGI_X>!JK9]#N_25>6'!Z!R/FZUYF/IM/1<J"W^9
MI=+E<)6RUM=H;DVO-JR])NM-765A7V49D""1@E(D<LCXU5X-LO\`CC[^9E]7
MD#N_`768T$].%6Y.]TG9Y\YFZ8;/PT@I%8RMV=7:3&<_$%:)3A%$$@V8\CY;
M#_U#6.0-NN0IYZ#-4],0P.*:N$0=\==/9DA,]LCU:T:>Z*-M)(T8J)ZS2O=_
MIZ^GHB`Y/`/`/`/`/`/`/`/`/`/`/`/`/`X.EC8YK'R,8]Z.5C7/:UST8B*]
M6M545R,1?5?3^G@<_`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`
M/`/`/`/`/`/`/`/`/`/`/`U"?8*DW;OY+?KU?!5.P;SR&JP@=]<Q8&N,IIKJ
M<OIZ5D5)TTW&'0YV`*2*.*\J_P!]KS3H#H?QAY_61'!,?\?&!T^0A^P^CU%!
M+G#.I]CL>@QB"8[0<_H"V&Q3U*68V4M,_34\-^;!41K8'5TI<5BQ!I97K(GR
M2AL8\`\`\`\`\`\`\`\`7_;^G_O\#P8_SM$9*+^1+[#QWPR'VDO.OKH-7`3?
MN`8,\-MA]+50REEQAD#V(HEA*GY8\+TE;#+&Z>-T7QN0-,>*W=)R[$]/B$(C
M+V>RDJ^:WAA@MJ1;6G,2J#1WNZBUEL5IFZ$VY+MYXJP^,<AC/_21C-A666.2
M4(;/"T.G?,0&`#6<NI+PZPL,R1GPL[DZ*JK9GXX:T@^><U]G4MW$K4B+L3K8
M\N,J-B>TB0:%P-Z`"PI;;2AUFKBV<U'#7YD(^:H*;(I\EQ/.-0T%=/)3!=!W
M]UL#Q7P*`LT$"P,%]SI$ABD"6\QN[?+:K,,T>9.IM6$F;VE%JH\[9U\#+3.6
M)VDP9B68<]&02;362A0$AK);_DF"22OAAF=[%!N]JM*JS[%O]A7*(<G0*;.=
M'T[](R0C6Y#;WTEGKM)+G:2B2KC9+I-!6#7,JQA.,::0@D<SQ)(Y'`H89;)U
MMRVB_9DKCH?N9Q^NM;(;W16.P&L\E;V;+XL0N8!E61,R5$4>="1??\+QVNA2
M!\05[V#\S<A<J?=P5!5YCJO%I;:66QK""9Y]'C\*7%-H-6,M?'4&`4LYC1*X
M0F21_K^0GP.G<Y05,.#F-'T?$`V6JUY>1+LYKU4HQ8;670TU-5:`Z@LZ<YID
M5[-)IOV8IE<4R=%GL)Y&3#R-3VO!Q]"^PE]N]5O>]4^<JKGK'1JNPM=)LYY;
M2]T<!5!80`$SPTA[*6/)^M$--`2;!*58F/(8P64=%C5`CAN5!4FAO+N#2GZ7
M16XS<O6!:4,VVOY<R03L":=L=M&3;'/*70JZT^8N>85H34*?"R:9G@*T)>D+
MPE?;75%F;H5NM6OH:7/D:0L/$W(\!!!&@R.FKC@4K;N6+3-LHR1)?PI98C!T
M#GDBECC"1>J;&POL%PN[M!AJ6IY=J;?EU9:'V!=$ZWQEF!<:S-6!J7E?4?--
M1:0(UC9XXV-(%-_&F6%KT20(UIZ^.N!KF-!I]-9`46QU%U=P/K=H)H[2B8'7
ME_MKX:?0:>VRQNB^*1H`]>?^$)\;'1AHSYY0FRG@F)BR0=3%614^@J_Y$QF6
ME<6RU^!*GB>$GG`!AAA_<6FB59DK6J,3&9`^'_UCY)/DC>&/UR3!/GIJS&5=
MFZ]@HZJ>`J8BV_(@K;>IEN+89YAT&=OZ.UH!Z8B".,R#YAB8(V.B62%CG`[.
ML]$T,EC55/-\_EIW<TSUW@>'65KCI],?1XR+0BU;R<E1CV__`-$@>FNS'WLT
M$]3)*,^5_HOO'?/&#9%IM`1@0==I-H;5;"N:#92YF<J]M^AN'U]A(ZJCML+3
M@BS;0>VCJI;"C"@;-8COAA:0Y81"WQ@M9ZLLJZ(L?%V@I]5FR276Q&="JS=1
M19?6"(1^TI>98:;';G2Z&'YS210&6:@QPFC*V2:!BRA:W!ZP>^XSO,3H*2#*
M9XC+:KISF9H<",.IZIE,^12Y76%9^!;D>U@KPQ(JED3@JV&O'MT2-K'R>[P&
M[B].+0F8:#75L^A6/LG.XWL#*L<_4_O>STP[3S"XPCSY7U]07[7-9$,V'Y6Q
MJ]8&HV=H?J->`>`>`>`>`>`>`>`>`>`>`>`>!URMD=%(V)Z12NC>V*1S/D;'
M(K51CW1^YOO1CO153U3U_IZ^`1->V.-LKTDE1C$DD:WV->]&I[WMC]SO8CG>
MJHGJOI_3U\#L\`\`\`\#`*JJPX@4PRN`++!85&"44&.02'&=$V$U@D\L;I1F
M&0L1DJ,5J2-1$=ZHG@9R(B(B)_1/T3^B>B?Z)Z)Z)^G@??`/`/`/`3[.VJZ4
M*6QN+`*JKX%C28VQ)A"%C=+(V*)KYR'QQH^65Z-:GKZN<J(GJJHG@4PV'\C7
MTYQ=Z_-']DJ;:Y8,XK\;*UMUJ(71M-BKU^.PIJ\NM>_\HL5&HDR^]AHTC?6.
M>)S@3:[^2?ZC'FN!EW]M4/2.W?%->XK6UD!2TEGO*H]@;IZE'E2L)YO9NC:Q
MJK+$D#F>J$1>X+.<S[EQ[L@;CN6=)Q^[&8USGNSEV&?*R-LY0Z2N&9(A+87R
M!R*QZL]KV(CVJK'-<H2K_M_M_P"SP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#
MP#P#P#P#P#P#P#_L\#41]B[/1O\`Y.?J;DV0%FUMEGDU%9$Z:XGR00N6CW<>
MPL=)2_D*//K8DM*QF?L!/AC!?).TUL[)8D:&W;_;_;]/`^^`>`>`>`>`>`>`
M>!\7_;_9?T7]?`\*7\[^:I;_`.\WV(DEYKFK_1"\]X?-!K;*JD-*&S]=@SS/
MVRYAJG03$54.DF%DKI#E^!2GD1+(Q/C:X-''3MUEL'UHVMQ.2A!SA&4J;K/F
M,,J=+$377>9RU[39`"K&`.LRIJVC!/$C!E68UMJ&&$Q?SBY'Q`QKJ+92QQ="
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MO^9).QZN?[`2[S0`YS#7G3,O3*;+=67_`$_K(HB9P=)_D4&<$T-/HK2S4L6S
MK0LL7:'O/81,3"Y&/FDC?`)*)('(.ZO[*"YI`8*T**$^//6]QC\W+0;0<>2L
M6>HZ$MD&XG+V50^:[&/'KYBTKSK:VIP)8X_:4]H8]5R@LB.2GM-[S,.785`V
M0VF,IMQ)=&W0>+T89N-Y8.?2!#/Y%997<60JZ*X:Y4T.B*F5)42=\I0.\C!=
M$QXSKJQ;5;>FGT$-QL]QRJ6CL\!C\@^DJ+>HRG',Q9S0@&QZ&D+`>"99S1"U
MVBA:^)6TMI.;.#'HZ=_9]IS!G^08^JQ$^KH,V9.%^*'84[-M>C3'ZUXAT0D9
M]_;XF@4^1S7),#,6^$:1B5[VR`^1:+#55Q;D2U]R?CZZYTHI`4A^]N<UJ<M2
MW%<VKJ76\8%E%H&XV9Q),10;X#X28'$+,/&]LCPXUMG<7%SSJH!R`M))MS?O
MY)#3U7Y[Z,."WXCC)(R"+JYL_P!Y(JKV8QWYCX9&CR2Q(L;U1K50'[>DX;/,
MTMM5TM`*,'B3KG"UM.T\FM)L\\_Y"Z9;"4=0FUH&?#OIEJD#DDAA_'5&(4K4
M8$.\UM.H:[`5-5S>77V4MKHI=/7U6>HY*8&I%G33U=IC=SM94C"S]-L&$?CT
M!:$0BC`274KU<$*&Q@+_`.P#B?L>,VW6&8G0I9D65.9E:I-4SGNZOP*D?J^W
MY]M7'4E/67K*642H(H#9G"8_+BPM8^0Y[S/`[LQQ>VT%OFB,1?\`.XZ0:G,$
MX[@K".[Y:SFPMG994J^A#$M;#6G+N=7?6@EJ`>=,0P+=20PC#231RA@A-0EW
MMAQ+_-[0K:&2V=F175PNXIKX34[NERF?M[6QW26%=8$RUHFSV1X(M,TTF8=S
M5)I6MF-`&DG"=9Z#*5,CLY[`*=^2T7`![Q-%G<^TS1[>@T6#O+JXH-!+-!76
M9UGHC2HA&!AD#C`^V*/V+ZOF#].SP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#
MP#P#P#P#P#P#P#P*9?:'[:"<5/SW,>>4$O3._P"_=$)D,#3C$W<E)"9)\?\`
MEFNJZHD4Q*JGJX;"];5N*K["_IL[<?M<DQ(,D:!5C3\HS`XU?U3^2#NM1_EI
M%#I-IGN"TFT(`S5&)BP"NCZ:GP><J"P-5UNPP30!IE*K*]AI<68J3WCPF(8I
M(4@W/\N_UO\`K9`(-Q#Z35M+D+GZV'=9YYJ-&[+\MN;2[7@VF[7RK&:_$UN8
MTFBQF7Z1@.0_C5UK;6,-BL@,+8*HD859HP7*C^:6MO\`H7.^-]%^KO-^@69O
M0)L_U+<<BZ&_J?&:?(6&SY?0YS3\KU!G,(1>A6><$ZE$9IP[#_'XJE]!911D
M3%(..\'BO6OXR.X4'&M+EGZOZB]9[/:\2BXP;C<L5C]&R]^Q.JM<Y]>)%`R\
M-CSPYG08_KZ%I!0))$>E'1ASF,C%^6)X6(YE]N.G_7@K#9/NY4/=N![AK1N4
M_;CFSY]'GR8);]E31YG96C)C5M;V$*T9'(8^1Z0U&2O])<V,$+X1HPVXUUB!
M<``VU2:'9U5F&-8UEG7DP&U]C7FP1DAG`F#/D'+#+&E;)%+&YS)&.1S55%\#
M-\`\`\`\`\`\`\`\`\`\`\`\#YZ_]G@??`/`/`/`/`/`/`/`I9]\M_>\YX?%
M>4?09.9_)K0H;/3"SE`V/X0&=T^B%JZRR&RNR:"19WE&''*V4%S31/F#8^*8
MF)Z!0;J%CK2/Y$_I'8V5@?7YO:<EYU+9:>WSY$.;N-;6MTUY'19+52\XT-C5
MW^B^5T9%=/?5CB8'^V1JH]'.#>9X!X!X!X!X!X!X!X!X'Q?`\.?\Z.FY9COY
M!NC3[[8Y_'''\2Y/):D-KK$J\T,4V9WU/F0@5(K2,952-N%E_&DM;>L]I"1S
MRI*..Q6AH-T'0>>&9AMCENC?XI5//DK<A86$\5]3W=\.1""P6MTV7SN7T/-B
MK!6EU\KV,E"<2]KW/6&9LKPC4'/%@V^G+Z[T3-&;3)6^9M-'G,4RODU5-%>6
M0&CCBO+[3Q6,&0(S]G1K=S,JQ"+"RI928/@@$*=[@;<DW#2A<_GZWC]Q4`N%
MI4(DP':;,'I0UD.?F7"PV7YE1IZ`^RSFTM:K#_MRB1Q'?LX)+$'#<SVAA4U5
MNLXNCL>,=&YUH,9"^>TNK?>S.R5Y'K1[VQJK;2=-KY[ZV@8#OM1=%7@Q<3K&
M*P%IJX-@C'K"QP8]MT_DT]7!1;/J@6TJ'QULU=)SJN"QM*";>'T$%N^NQSV3
M&V]13447QPVUJ_/2%%1M85!'%#''&#]HK#'$6N'DYO?4NBH(ON/P'*C'5M/+
M164]M63=)O01"ZEH]G755JZJ?$C/PS"89Q?:Y9IE3XO`;H>DCL2*RA_RC!4-
M)$-DX-GBI!\[G:R-]GFDTIDMG=2[7$6=O4&Z&[6.`HFPFL*-GQ#LCD:]4\!1
MUMOS@>]LZ'0[K,Z&.XI::$)P4[-_2-G:=2D-T\TM-K@]9*)^^L<)#9A0VK()
M621QHQDCY'`TS:CI.B&9E;X_GF"XM=RUPE7L\WK*G/\`+^@SDCH'D->#G<X.
M;>::&,T4%[P963V[)+L^:1T42M?&#=M*_BV-J[($RNZ#L?RFX.J@M*B^SW-]
M*>.F8NI:ZFFK!0]Q8J3'E]E%CB!99R9&'257Y4L2.?+X'5TO)5-,;7@\;[*=
MK6%27-#I,-N()<%>GYPNZ</_`)'2VE::S"]$KR-2(P@0,2($^:LHPHW!.B"]
MKP>P=TP4E#NV=#YRRV,B1@E4`_):'J5S,/4@*#I])T#]V&JQA"L[4B6CF006
M.@L5>J3B-25HSPS[.?G=O=4^GP'4H<U-!FLY"/8VLF%Q?0ZBHD)O!*PQEP1G
M-1+?A7`A<8G_`,[I:YRQ#O0]())X62`YN=V%5.7SN:BL:;;4=A2_>ISY0'MH
M66-4/]>\5.!/?"F*//%-+8W<QAGQ?)^&2BR0H0UK98P1M%O^994?.6&>ZE4;
M7425]%$#'5T]=E*1][I2JB&FLK&\;A[:,JX2C`,+'L&THPYL8JQR.>]ZO>!K
MTT.FRQ<&<[]E1\-EJ:39F5UAF/VD444NP;8UNQU1]9/#6W]3&N9HVP6T,GYQ
M+CB!'@0#)'&\,C#3\LKK+43LQP'3K.VL,AI[=F\.LJ0%+S2YNM&'S=!24,8E
MDX':$ZR.B*+L[$HLFP#26588G)&H..UN>3:^EN2L\+=<RN;TJO@?T0,MNXQ(
M9#[K<V&=T&N`U%:[0X^OFI;6XTA#J\LIXUEK5;&$277Q/0)M(V.VYRP&IU76
M[X2LBKJ?45_)<\1;.L"I]##44KRM7J$I2*C*<^##LZ,VC10CK.;\")TD0\Z>
MKP>-!T7B'2\M0UN>,N,[H2=Q@ZJ*M+/;N@HG2:*H(!J@ZZQ!K[*K",O`7NAM
M8B)*Z2-('Q01(Q$4/U#O`/`/`/`/`/`/`/`/`/`/`/`/`X.<J*Q$8KO<[T7T
M5J>Q/1R^YWJY/T]6^GZ>J^J^!S\`\`\`\`\`\`\`\`\"MWVI^PM3];>3V&UF
MB@M=;<6`61YIDG,G*,V>^NOD2JI`*FOE;?WOX@D!%B8)4PFW#ZP$EX099#&#
MR!I(LNA=`Y/VLSZXX?I57AOOKWO''Z:Q^TW<J$@_CN;^P$R4'4..?1[(VCLO
M%E=<=U#&TTL^MK:4O/MEKU*NZ8$2ZL'AQA5[3\FW6J*Y7]UOY&OL/KN7UN#C
M@JZ')=%XYGK3['W^TSVV/W?8/K[@>2Y.EKQ-!:<IW>$M#.=;FA#T+[;GVA<I
M%?.97B7*`[NE\^*N.09^J#^D_P!//ISB=EA!_JM@>E_R']'O]']C[?G-;A-_
M19,"IK^51W^FR>BQ=L:-^`:?<I8QXJZCF;.(L,L#`D&#?=ER%4?!!9_PG]KI
M_K1?Z'`Y7%:C,;S@5CF-AL;'M6;'R_/>L;NGT.2JK?H%Q1T^>.N0_E#,L`KO
M\B>6=K8U",2OKKP0_;YSZK9/*[?^-COUC9:VNY[S+J)=OUGDG;_W;"UW&AMO
M]2>X7^FMZZGZO@/K]@-.)@JT4SY,57Z!Y\U1"D\:J$]_7/[I1<?R])]:/Y#Y
M`Q<=V<7/\CSGU\LN`'YFQ^LYE=^=FM9C=O&?'9TVV^J8-<70U^5Z#8%V9NKL
M1K@I[9!(9'"ALBX5=7WU-[5#]3N@WUW=\SZ#+:77UKW^JL)#C"SW2S6=QRNT
MN;1K2;;50C_/8L?+97=Y=D):GO&J:H82!`V5)_K^O_RO`^^`>`>`>`>`>`>`
M>`FOM0F6T-*Z7_YX3@3644">BN40>>$:65415<QK92&IZJB(JKZ(JKZIX&2^
M9_Y"#)#.C7CRR_EHD:CQN:]C$A<KG_)\SD>KFI[5;Z-7U7_3P.FMDDDKPWRR
M$2RN'B5\I<$8Q,CO;^KYX($;#%(]?U5K4]J?]W@8S:R`P<7]P>09/!%-$A,C
MI`9WI.K4F5\8;AV,<](VI^B)Z>GZ>GJOJ"QX&"61,T*8BO4&>5L3WPJ64\8%
MRL1?59BH8"W11(J?W.1C_:GK^GZ>!EL?[F->JM]',1WN:[U9_1%54=^B*S_<
MO^J>!R]?_8O]/3]?^[_L_5/`^^`>`>`>!KW_`)*PZBS^OE757(S#X+/H],,'
M62Z`+-PV=M%E]B;4B3V%F$?5.@2P$CE<PF/V-2/Y&*DL<7@5([<;FU^_O\=-
MYHJS,@Z\'G51$7;TW[*_44ANNA-SM-3U_I<0BKSRWL+8P$V0>J]C220V#S-=
M)[6AN_\``/`/`/`/`/`/`/`/`%\#P]?SQW>6A^^O6,QJ,54="#L^!\.,DH[S
M*3.E!9<@=BH82\?T:KBCML_HS3ZN$22K4F.(V`A'.:L:R^X-"]U:4^=KS":B
MBRV=TFUB,"SD&@U7MW.4DO%47.%\UMS*VKKL$"Y`5DBD&#`(>-(]8)D$*4F,
M&EHKR@QPM;7='S+]]0'OS5/1Z(..>EV`,`6F9N=/6C[H(AKIZF?8"HVF4V*U
M'0'(H.&R-)Y99`;XIW()X)ZTR#JFT!(RT<5$3G=7105VB$E#VF7A*HM>-'-:
M0!VLAM[&"-,`"244-GG0M]TXQ<H9E:SI^OHCIN:KC^4X\XC9U<8$=S3#<MN-
MWJ^>+^[7E?H+R5PNEI-?BZZM/3]WBTDI2EDP0PQOB:(X&80'R&-V:N2<2'HZ
MZSO:&,4CF6JK(\7EK6>-[+`FKQ@0]@;05RYV".&6IJCXHK5JNC1L;6?'X#SB
M*+38<GOKQ[YZFD^T_P!9TE(QV43+Y\NFK!-S4%G5=*904M@TL4Z!1BRCI;4D
MHI_O0N5KD]H1J]M%2$'LU_%,G:V-EEZ.JO--I)_VNAFH&0I6`PZ35U-H$!4]
M'SHT+HF6$\'YLHHJK!`V54>X.C2<4X9+UFK7,\YL<_ER"P9M!5V-CD\_D=#:
M5^DK):<07;-K;4F5@T\H,,M5"($6\2Q8LY4A'K)&$A2EAUM:.DV$I)>54I".
MJ\53CUE8)2Y2N)SUG=OS?0C$,OJO5UF:B&KF)$0088;;L"*@,B1&H#2L@^/Y
ML2?0UVOO_:==50Y64AQ\>E)IX8M+<76J"I":XZD=)0Z'4Q"@N,B#A(;79"J)
MECB281L@(6GMQ18I,SS:KL1=632/K:_>WOMATG^%@4`)6CAP&DQ=E>G\ZJ#=
M%34UXLT+#R32S;%O[@R+\R%0Z];58.RLR[OJ7.,^SHF5N0K*TGQ4F4`+V%.@
M05HP:QQT(-W566JL\U<?@VMH&\4MH0/Y4WOF?#[`<#+S,QOQX9OU]RSZ\?+/
ML+L6KS(^BV5Y2VP4=?H:G0[RZ!I3B,?`E@P&JOJ0X66I/%?$<C_QT>X'"'6Y
MP.^YU39"I%">?#]VXVUPLM9<7F9D7Z]XZHDQ-4Z5X(3+V"P=ZG/$0B&R]D#X
MD;#(GM!\G#8/6.%5]4V>T-P$%]H-+SZTLN91@TT#&11W*!6M5209JWK;8<EI
MQH;![(FM@F8WX8%]7!V?#)JZ\8CB\V:LLUC++.7==F,=81B9>S7)W*@J=HQ"
M#Q-)8=`L1H1*PZX(:?$VL@L6VS'ND'CF!)J;CF>FR<J7N(LL?M:Z@-S%N?R4
M\_#GZP^FIMC7,I*G.ZZMGK:TV[$UEG>.+"DKP766MS,`P\3D8V,%BON7Z[5%
ME\KQ\]MTZ(@_,1ZBMTP&IL1]7^WY4^CL,"'F<]%EA[D4K(9\H:>,0N8:6KLH
MQ5'6>:=`DZMT5)G+EF7ZENL-:,NA-:&+E[:V_P`@0#4:"UCVIL,.AS1-V3D;
M4BS)#FM5'N(H)AH)BIQ4#:-.T)HH=NL&"BAQW,@:(.IO<WE];-GV5FMT=---
MI,,5%0:36*;!H*."`:CC-).;`T,X9[6M8Z2)7('Z:O@'@'@'@'@'@'@'@'@'
M@'@'@'@'@'@'@'@'@?%_I_\`+]/_`(_@1ISWM'(NLF["NY=T[!]%.Y_<0Y[<
M#8G5TFGDR=Y/`XF*IOOV8PQ*T]\4;U2*7VO]8WM]/<QR($F>`>`>!JKO]-F.
MV??6S?L=-3UW(?IU4YRNG&NKFHJJ2S[ETPT(3,U>B'EWHK;%_P";,+)3UFAR
MDOOO`*^RSUNV9"AWA6'*_<_-?;SG'V[!^^GUSY5)]5N$LUG3==4PD;DCN_$/
M^EFN=;\ZQW<?KAI,Y5]8!ZYH:&AAU&3U&)<?4W37)``K)(V2$A76PV6]N=%!
M]V^H/!$^U]W<X:OQ^%,X]=?9&E^@'UTWM-T#5<9KZ?)8Y<[!T7MG6+&G`)M+
M$($7=YK(;(M"1%$`?.\+.?5'^+[3VTN;ZS]A]"T7/[;8B=LV/UJM*,30J3HW
M46TBQ57NM\7'5:^W*S=5UFSJ]"'<27LU\^BII"C$A%?7H$D==_AFY1T7-["N
M"[)V1YCA=\SDE'IM)`_$<K&UT>U*K,77"8ZOR.FMN=45WT2ZD:"=8ES2C&H-
M+)+!#'$H4;[9C>XYJ7M/*OY`,YSOJ/#]-I\'I;,W]RT7.?K5]>_K-BL4+0T^
M@^MNSM)?WWG_`&RNZK=450%C&%V5UT:3/GRR(&.?#$@+_%*"LZ?VOBZ]TON>
M;CM?T\GI^N9O[7]-TG0JN@^V_P!$ALOJ&9;L3L3EZ[%<\ZAWC&@:G1,L!24*
MK^6DVD4LGYDQ\D#@N'TGO\/WQYKTS3?7_EW9\K4_7RKI>R\0^PVXI$YK2]IN
M*HT\BVH,/SJYZ'R3M&JY1<4U4A#3K:;+X_4EP#12F%UT1+9`V;_7SKE)WCBW
M..N9XF(NLV^8!M$E@)#/@0^/WA6\$%E6I^T6L0MN+/$A8+Y:\E&?(-++`Z.1
MP3'X!X!X!X!X!X!X!X'ST3U]WHGN]/3W>B>OIZ^OIZ_U]/7P/O@?/1$]$1/T
M3]/1$_1/^ST3_3P.+/=[41ZM5Z)_<K6JUJK^O]$57+Z?^*^!@#CRL/L#%/(G
M'*8'#$`]C/QP91$G:1*.Y&I*YQGRM]_JJM18T]OIZN]0Y6#E%KBGPCE3+%!(
MYHU:R'\M_P#JK!&3*R!9?U_1'?U_[_`S?1KF^U416.;Z*US?T5JHB*U[53_=
M_HO_`+/`PS#*\)U?&9...XPU@-<V54;\QSAB9HQX$]/19E&'D5$_3^UJ^!G^
M`>`>`>!07^2<S0UWUBM[+*3V`VA!U6>DK2A"["L"'<1'9`%S7EU7V5-^PU;`
M"YO8;,6/`.;^.YS_`'>UJA5W8=-Z5G_L/_'U24E)0&XV]Y;S"+K6RVF'S&GZ
M%0_Y1;"TN6KB-=;@IH,+_DNK2,=A7YLZ'6"L@''_`"9'%1AN;_\`D?[?Z>G^
MG@??`/`/`/`/`/`/`/`/`\*G\^0V8M/Y#.P9EEG=Q:2U^N?UEN+P:OJAR)5R
M8VEZT!85M"0PW]Q_?[,:-RPI\4:22,:R%TDB2,\#1AO++/=KVN]VT%[)A`]5
MI_\`*<_+^VC:-^*S<D`&/R-'HW!1EU_^39G*T\PY"!$RB?*437Q-^$HH8,(6
M$K-MC*Z3_%]'>.SU7>#5I#$GCNN1Y2KDSW[?3ZOK3K8<&IN'P-L0:S1@(17G
MEY!H5G8#_E#O'4.,GV"V)T#Y8ALAD%MZ^TCSVS)X5B4J(--0.=#MO\Z-G7]O
MS60S]?3!1<_L*EPS[B6"O:9[_P`61HH(XN%Z5NQA+GHNJT=#)%#G[#+9OH<M
MA_E6?-K)6QSDXUUF`0%I85#B_(+D""E_(T1*+"08M)&V0'6(#E:NPLJZW$3&
M%6B9O/8^_O:F80ZA_P"GDQ=\,_-"CH&_6TMQA4'!#&FC>1ZC5JS.DFE+?X$M
MX@_.ZJTYS-G;`ZXA?]E_J+3GUME215;<V\2+8/N*K.S*=,FFL0!V1D.1HD,0
MCII(OT_']&A!E/#7AEM$T716UNFH,L=82MS06S2GNZK*6,%`F[T!UI%0TVBN
M:U\S*=ME^/(R.Z^9(929?CC>&!T:^"_9,+GQ`MSJ-S!?=8V&UI:RA35Y^:\/
MKA<CCIY<W95T)9VNM@@YV1$*UXRMEBBD6,HD>:,$ZNYOT3FQ=VG/T%SU8*T4
MVW]+L?:X'-!CC#$8O(PK;:&*LL]-J0;M*DT@\(8P>W'JS&O@>RVG:";8;J6@
M&@FT_,N679[<,NP8&S,:+(7M/RI(ZR";LFLS5.:+3#7>17.@@7&'!G'D?*!`
ML,[8GC>\%%EYM-=/:39>B"Q6?#&&L-4+SJ@/*PNXY1*CI@IRR9&5^ICT>6$<
M^SGKBB!ZZ2Z)$`8P66`V$@.SF5#SKB_7LG87MK80#8G1Q6+XJ>9-E+>5)-X9
M"RN.M81;S-&F97*))6.@@4@`Z2TG1B2(:GX89)%#E%J2;>XVNHHX,\$[1"Q`
M4%@'F+=MG:V`6EMH&VAE1G:$2H5D,9,M@Q4]!%]C")&2P2!(T.1P-6_E1@AI
M%P#0.^Z#QB'@:<(R_MR^%X:]EV)%?:5T!S'71]LZ<7\Z4<,B"5[HG2,B3T#'
MO-MDTJ]J^DC*LV[;"X>I$)T$.3JZ&B/_`,B$UN[&M[68APUG;:NKP+JIM09&
M0R=)2)/;('/&]09&JP=V954D\I><$M+V1ME5UNB(CK[$,'1L<-<-=H(I1R+/
M87HY=:*]P<LSZB//"V+_`,D^N>Z0'5;=+WG'X_VN<O168S*M<]SUG6@Z76[K
M1W:VT1>?Z[T.?2#6EMSOC\6I$CI]B$*7!,%?!0E`EO\`=/-X#]@Z?I>B1E4(
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M7<`4-#6(>>+5@?G6MG.,$,XVS.A'A1[T66>9D;?5[FHH-GLG2">1\XTF^`YY
MT+K%A21!)7<[Y72C7^\U5A8V(E8+740!]A45;59(6DQ!!98PHHL<DLDC6,7P
M)+A>]\4;WQ.A>^-CY(7N8Y\4CFHKXG.C5T;G1N7T56JK55/T\#M\`\"EW,_N
M]S?K_P!IMS]8^?9?<7K,!SZQVEIVJ,&L9Q^XMZ39B8;18;(7:VCK737F8O27
M#V)(XG[9`8-.(TF0D8F*$+H^`GOMZJ(F,*2SKXS)GHR$1Y@S2I7JBJC(AW2)
M+(]43]$1%7P%#P.EQ$#72,=-$CX8TFF8LC$?%"[W>V61OK[F1K['>CE]$_1?
M]W@1)R/[`<5[TS8R\9Z7E.DP8#3RX[6E9.R9:!U.@B$@-_$_,B;^*>-,*0UT
M)0KYA)_1Z1RN=&]&A,/@'@5.[!]U?K]Q/LG(_K_K-24?U[LUM8AT&+RM;-H#
M\SGZ/-VNNT70>DE#/97<[Y[09VF(+(L[28=CXHWN@;,C)?8%-NM=C#^PW+-=
MWSJ&EUG+?X]\Q%/_`(GE<M/9T'7_`+QD2F24])&U1'`::EX]TZXE@K\CG*N0
M>^WJFQ3E2C5Q$(987)^HW%&<KY_/I+G'9W"=`ZBE-HM3B\G65U1FN:TE=5MK
M\!QK,5U6&#7"9_E>8>T%?AB9$7;2'G(UKC'-0+8^`>!PED9#')-*[VQQ,?)(
MY45?:QC5<]WHB*J^C4_T\#0;9;9*SZ!_8O=TMM]?[KL/VL^PFWJ^/9[M^UYM
MHL#M=?9;H',UM10YCH6]#YSJ]G55=79VH>;%;GY+&Q@;#.'"4^660*=?77CM
M]>\F^C?U"ZOCCN?S_9K[A;#K?2>4:NHO\"1!POZ0Q)M,SDL]PCMW5=[T;GG/
M+[IF?J3Q8<M=,#IY'1%!`M`+EB\#<G]V,QP;ZQY[JO\`(_I\)O=GI>#X]O3[
M7GV1U9U7E-UK\9GK+%X_<Z;-SNES46IQV8U!0"Z2>%75=&Z20A)H@AVQ!2K6
M_P`TV[Q'&N;="T'UW^OHUKTS[%KP7-[I?OMS1_U`O`B..W?8`^AY_P"U-=SJ
MUKIZ@;]DDSE@)89^M($T3F0-6:.6*1X2_O\`^7"'EQG\>E)I.3X[7VOW.N1R
M^F:+BG;`^K\E^O7*KC>9+E&8Z\SJ0.(IZGI.,O\`I_2,[4QD,@J6(\V9_JOP
M(V0)KS]Q@/Y()?LQR7JG/79B+Z8?=IG/\M9@7D%U875Q@\!B-B#N6,,I(PZ5
MNJS?4K"F)!1"9H0II9(B(B'0R0!'OWMYE@?KE9_3+[78"LQ_.1_K=VW*<@U?
MQUX%6-;<`^RVE!YWN<<38UW-NA[>PC)WEY47;*ZM_`?;74#)3B_8DBN"H'T=
M;@^/_P`H7V&PM/@KW'9387'2N`9/78+!&IRKK70<!`#VJXK^T=?ZIV;<=QZC
MW+`\]N7##SQ9ZEQU9!*:"!.2U(E4-FWT'A3+U/V&Y0ZWK;1_,/L5O:R-HNC@
MT5H'7W#A+2OCT,JZC<7`=J5$Y2/BM+<BR2*5ORP!M1@S`O[X!X$4=IZO4<9Y
MUH]_:H`3'GA!3I*XRY%I5($ELP03)VEDQS)&P$<MTSE]BHJ1^BJWU]R`@3?:
M/ZS#6L=$1]BN$P74I'XD-/-US`16DA2(U?Q8Z^30M+>0B/3^Q&*[]?Z?KX$Z
MHJ*B*B^J+^J*G]%3_>G^]%\#[Z^`?U\!&I;0JTBL)"Z2SHG!W-K5PPVB@.DL
M1:XR046[#6N-.C6LN8&-G'218R$C>B2QQO16("SX&,68&!`XDXH8,9KXHW$%
MS1#P-DGE9!`QTLSF1H^:>1K&(J_W/<C4_543P/OJLDD:Q$,]D3I&SQ-2.19'
M>GHUJO1?6)T3_P!?T3U7^B^!V/8KV*Q'/C]4]/>Q4:]OHJ?\*JCD]?T]/Z>!
MV>!%O<;V_P`OQ?K6DRC9'::@YMM[F@^%6-F9;UN;LC*^6%9?6-982H6O:B_H
MJM]/]?`@;ZIZ"[9:;GFI]O875!A<9PB_QEC:&36-H92]%YJ(7;$7-F9\UC;6
MIFVS=L:\@F:4AWYRM<OL;$C0MO=4M3HZFPHKZN#MZ6V$G`M*NQ'C*!/"(8L<
MXI8\S71S0RL545JIZ*G@*,;&1L9'&U&QQL:QC4_HUC41K6I_V(B>!S_]_@'@
M'@43_D6SVFT'UM/3)WV4RMI3[?$W+]-LN@5O,ZBCKX+10[$J+3W9]71LL"13
MG"PP&S-@F<1Z?K(C$\"H_P!B[4+)]C_C^P]!#86UQ6F<"8A0/%,1N[&LS=GU
M;$4UQ<'_`&9)U#Y.85=F%'-&4)5!G_Y!$]1X)6?DM>T-TG@'@'@'@'@'@'@'
M@'@'@>#K_P"*%#LC2?R);RY+LM4'J;#ZW<`QXH-=^)^(7!96W:[0(FE$L`YH
MS[)L]?-"<^'Y7L`5R21.:UGJ&HWD->;US)?8'AUV8=G+'-YQGVCQ(80\Q.AG
M#Y71:2XZ]S`DHS]K9HKZ[H/R;VO:HTHSAZ\E9Y&SMBBD"$<"*,!+):\HU-G>
MP*XVKI*>@,2/;#'./)TPK;FGBNK.B-SHN5:;=ODKI39'D?"V6`=4]&!`Y75]
M+5Z8ROR52R;9V5Q45.?N<R17/W.DA_>P/VVOLHJLC\J:OQ#9Y349)6SH`Q6B
M0PQN<Z7P%J7,::XZ)B\D;MK+/;#<6]%SFAS&:T<^DOZJ]TMNT*@K]$VJ/S=3
MRZ)A<LPU=!^18F(T<6(^(,J&3P'%V:ZGKNXZ7)/O,5$F.S=;PE<E`C;J:6#!
M4U?4V>@DT)*DL:;K)?G'")?$/--")&.^)6^QG@961T+$M.1V>=KK;/!O^W/U
M0FMIS"X'&Z2^>SI(\FIK]'$H-K;`QV]:D(I!4;YFQL=&U7P1M5`A.AL+^YDO
MA[ZQD%/L;FQJ0:[.U!XU"92MWMWH0!+8:QN)J/):^RLK42:.:M_:+X$=9)&^
MY7*[P)5Y_I`<WW3D9>ANR!<,)+L<,E_7U][73L3<9LVA>_/'ODL1?@I2=.CQ
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M2R")+&Q%C57`O8^VK"*(XG/V<SG9NXU45,YA*6+XP;7_`.AVUTH(QX`MCG[&
MRK9F0S+'8QWBMB:]LS(V-8H*&2MH*@W@N9+'+KE&.^V+D@SU<2`MM*']6^>5
M,MC$<7;W.F_<K6FA(D_YSR2!"UD@<CI%]W@-G6DUT$U8;E7'ZJ8>*&Z!#&DH
MOVF=$`B+J&6)P]4G[A?:<>7X+J0PUCXQ55Q$*R*K5">>I-J!N=XGKT6KAS-U
MV`Z\Z'BHGTH%OCLO'D+&3/=$QNC5;RFGSE\+N+I)8FUZ&?`#[5&#E<R1T(0J
M9DY\A116&HQY,N-#K'`LTET;-H.=7DZ51-LVR048X-U]`ZH_^=H;3E!>DH<$
M)$?I.;$\)(YM8[312,J(:@FASME!2C5HNE$>S,V,!5/0A0I2I310?DZ1V65R
M6$-37R.K2/>#-\<48WH%@^=U<--QG['_`&!FUAUX+<0T_P!10A]`4'CK*&IW
M5=%;[/0<U#HSR!_\:AIS:]SQS)KLD&<9\JC0O9*Y@(7-*K*Y;$V`V@IR82J0
M:AI\S^^1ZD&)E_G]EGWQ:VF'T`5:E>:@),L\LT4<2%R1PC,3X7I$H?J?,_5K
M5]RN56I_=Z>U7?HGZJW_`$]?]W^G@<_`/`/`T(_?C:<[^VGW?Y/]&]U:9QGU
MX^KX6<^Y_P!Q"M!;J#FQVX8AFJY=E-JU\X8*T;3XJ\^=A,Z1>VPAE^)[X8W,
M#?("8+9!B6(,S2`CQ1S1)V>Y&3BE0MG'F8CT:Y&RQ2(Y/5$7]?U\"`_L[VH[
MA7)[359ZG!T>^N2XLES7/W$YH.;/VUH%8&B';.Y!')DSG/\`)T]4;>:*R5$0
M&BK"YF^Z1K&."%?XV!>TR_4?!Z_[`=1U?7.E=4N]WUDK4ZRJ$S\H^6Z#L;F_
MP%'09H*-D67R=9A":Y*ZN<KIA8'HR5RR([T!O?R&_8!.9X+.<HHM?;XS6]J/
MEJK339(9UIO,CRRO)KQMO8\[I1DD/MNL;HNV`QN+&@8Z=VHT8I36K""2Y@/;
MZ1?7A_%\$5I])B:3GF[WX5`)'SF@)98TW$^3X\4H'DG!:>UA](+E,!2'SD7%
MDQ/6XU%I:&J][)HO:%:/MM]*\1+F/M9]J>Y;;:=_U&?S.KZ!QGGW1]3K0N`<
M1S^+Q,$U'E:;BF7U5!A-65+;U)!UC<W(Y=F?.7[4DACC8Q`MEQ#Z>_4#"AX;
MH_.?JWP;#;!*BLT53J:+E./"UE,;<@0GSR`::2IDT04S7%N:BM*][&JK?5$_
M3P(N^Y_VXO.8$6'(>-6%)5],K\*;U;K_`%K54Y%[SKZM<,KE,:7T/5UL)`(^
MMZEMB*\BLY_C5*'?H+:.4@F2*M!)=(&KWZC8+['[,+[;W7W)VNAR6`M]Q#M_
MMQW'8ZSG0.SW_!^<\_K8>0?7#-4'&;N6MY1EJS#,-LNF'M`H3R;>ULZFN#7\
M@BPC"_WTM[3]><Q)N;K<]!Y-Q'LWV`N*WI%3]<=7N>?8S>\GX-E\-79G@6(*
MY[%>0RYJ0+C&5'TQU<V".6M(NRTD:V.-OH&S]U]2-HW:9;BK3.-JEO5T"GB_
MLB4B!_N"W*VOR_@I5(!_S_R/D^+X?[_=[?U\#5+WK^5/C0OTQN?L3PG7Q"';
M3L[?J[R+1=#Q>I"JW=9M;*0)-9#DDKG:7;YRARHQFE`#KQY2=)`'$&*U2"F,
M0-9><YG@:WJMP9]E"-'SCD^<RV5Z%VW.;>8C6]ZZV5U:XEGY[QCK(M.Z\/VW
MV5^Y.APJZC:Y:D86^IQ=+18>O@;7S63I@W5<EY!M>[;K(?9/[*8Q<17X5ZF_
M5[ZO67[6</Q.)XI%:/UKIC:YQ-+8_86[HB70###235^'K)WA!R3'3&FR!?E$
M]/`^^`>`EWC97TMPR%6MF=5V#8G.:US4E<),D:N:\@1KFH]4]466)%_U>W^J
M!Y]`?H=H_P"0?Z8_7,BA^P0/'[WG:?:'(%W)W*,-]BZ34UO4.@Q"V90$&[ZK
MU+_%K>C7'0?MMC4ZDLRO:^2"&8>+U'8%L;&IZYC?OS_'50]BWS.IZK_Z6_[<
MT.HW^<QO0^>Y'3[F";E5PEPW"TLVNY?FI79X*2*..VO76'JCOPTD1\OL#8IW
M;EYW:>/]#Y76=&W'([/<9HVDK>E\W-"!VV+L)?9*#>T4MF'85A$@I4+?F%*@
ME%-&62"9JQRN3P/-;7_1_P"I(4MUE`?Y+L'0?9Q_VOZ3]@--IL;]7^$9?G86
MR^E'#[GCW9\K+];(,V3R:J)P6.Z$ZSU=@3\I5E8S#E_W)'`C`?YWT(^D'W]*
MJJ[HOW[VGV"[#M_K/FN3<$O^.P"\/H<%GLY`/]E<QV:FY-QMN>YQI09Q.DY&
MZ#9H12LS-+7`L@A_-4AK0O/]1?JH<#WSJ?VA^OO\ANNWG%NH][U&I[;Q2GY?
MR0[G>X[1B<13\)Z,W_J!+12[RL?!I.?P%2LK3VB1G#/C8LD3G*H3/_+.2^#Z
M&=@A%'LS;6QT/$ZNAKJ4_1U]M97UAW;FH]2$$[(;3GVG)?(4YJO'"M899XFO
M8L<[%=!*%EN<_77(XGIW4^NG#9O1;+H^V@V=7<2<]QU'?XB-W-\9SJQIQ-+4
M5T-[H)[4''L<396,TUG,.^,.69XPHS&!!/U&,F*^P?WUC=;)9#B]LS$`\*:6
M>\=4JW(*A%=)7D==Z!_CCF3(LB"LHLC$K'M<@A*JI'@7_P#`/`I-][N`<8Z]
MP'K%[T?CG->E:+,<PT\M!:[+!YS57=4%7,;HB*ZGL[2DM[2N$+)K&OEC&]/D
M<GK[57T\!C9GI?*0/LE1?7_G_,>#<BIFYS.;&T)U^?J<=I^NUVES$]M0U_UY
MS-54U59L8<R<L4=Y9S%O?6RPR#,KY%<A,0;$O`HK]@_M1L^,]%RV$H<A1;@R
MXPNQ-D'::14/L.H7=_GJ#@O/`2/R+&8(C9&%GN/>HQ4C1Q5GBC1&_&X.C'_;
MG3:>_P`99S8S/UG)_P![S')^J:N2XN?W3+]YUL,@XF?H(9JB&JL\?1Z1@=.:
M61-`4XV\#]D3?BG:H31DN^U>J^S'8_KL..S]PY-SKDVZ+L863JV67I)NX@FJ
M")Y'?C.-JQ,T$0Z*)%?'#81.E]$EB]0L3X#3W6$QO3L=I>>]#S%)M,/LJ<V@
MU.4TE<-:T=]36,*P&5UE7EQR0$CSQN_5')ZHOHJ*BHBH'GK;]:N9_6?I'?/K
M]RKZ"U_V-QXG2<IT&JZ1HX_\D.XS1;GF><DILA)'FZV^[1LJRFN\C9.JHQA8
M8A!Y6PR6<L[G(T)+X[V7D/UHV%1N]7V#;T][9976RU_T_P"?<O[5RFJM,]7S
MU4-WO=)DOM'T#565T[G[R(!AC:`BBB)/L6B-%,+(@&0-GV[^X?.Z3A>>[CR^
MKN^[B[+4XW%XC"X!00-SI=/J[<0,K-I3Z\C/R9_4Y6G_`#;"SJK7\*P%CK9X
M)(F$(D:A-//^B\S[[S8+:8>[K=GS_959HKYV-FA18I&S5]W07M87&-8TEU63
M?*)8UYD4!@1#)(9XXY&.:@4!_CSZ)E;O5]OH#-C46VI@MLWC^:6#92X&]EX)
MQNC_`,+RO9\/)8PBC:;-&Z$BUK#9JA2@!#P'.^18BAY9P<?U_P#LW-L%Z1]?
M+W1W6"Z,?I_L,SZR=2VI8FEJNQ8/(=,VN6$T>:M#8(`+C3\NM0$'MLX1_P"O
M;40B'-208E[X`GKZ<?9BN^T/",WT-`YZW=5PRY_IN.F&=76-'N:B/X+!XH9S
MH/=F=<R-EOGS?=^+8TIXI$<BL>JH"/\`4C[6S_92KZ4W18RJYWK.7::"FU.<
MK]D[6IGF6@A%B#1["2PSF-N<ET6B&%?'>4Y=>D0KEA(%*-#)@(<&9C?N+@ND
M]4R>%YS276NPVM*VU+4]N%(J@^<WVIPM5^[W-)A)#"X[CH5>&-%,PBYJQY:2
M,AB11E3O^1(@MWX%$/Y(P)Y_J;N+FO%M";S&W&0V&<?2A;*SM`+VET(3@;(*
MLP>3VFA/F#2=S_C:$T9J?WD3C0L?.P-5_P!C,_7L^Y?\3-H-K<9D1:'F/*_W
M//W&ZKXC+P&3I6`AJ!,ICZC.5,.T-AORFLE)@N6"!LE27]KF1&RQAZ/_`/Y?
M_P`G_N\`\`\`\`\`\`\`\`\`\#Q!?S\B7-1]W=SH\],QNGON7_7C*U:0_F37
M?[-&-VN6S@JH61&HRN4VR809"(T<RR8/^*KI6.;&H:5>/;[6_4S><]Z,;T;,
M=%EYI?UG1=1@]$ZQ,Y03G=&L-7TW,F7)'[2RDM_\%/.K[(6:U$2O<Z4<N"6`
M@F-`A/LN.QO,_LOL>34\<O-Y,GH(Y>:)9[2;7UO1<7IOAU',K#_(8*^B"T5I
MM\W8"E+"R6;)5(4,CH#!9Y0X)@2]'1?8`RDO:F>NT<=+'"S-&&ZPZPIL_,&>
M.36HV_VD]I%%?LLRX?SUGAL#8W2!!-_&<LLSV@X?I)O\5B.\;3L%_CQ;ZA^H
MO%Q>[?YLE76Y/GY'5Y*.LPW#ZB45#XB!$N>M="'MB9SS`]$$P(B.,1L;27>!
M$UH9H[0VS$S%GE"`*&K6\NG8R59OSK$NT(VQKKUT=93NLH@'UQ5B<DZNA:6Q
MA#7._(=[PP*^N6<WC-[5BU%78Z#[/?6P/2/H'UY*&7%47K@?WV6%*RO%_=C(
M1X(R)(((8;`B-Y3DA=*Z#P(JSM@7J=^*1JB#[W`BUK-"KQU"S0.XK*"$O4V=
M$!=590UYGYM*+5/I#6%$-DA=^3\<?Y$ZHP'S=7-]<+?WU;SWD=MEZS/7^%L,
M/I\5SX7'"6=R%K),V+6EEKEYZS55WMGD!_!(*6:6R1Y[VD?'&@2_]HL_2=)!
M^MO=[^UL\1T_L>0#Y%I0T_`M<N'T3ZWV>9QJUVUCJGYZ]AW>_P`F7E#R80Q2
MY'1CE3$LD:U\_@,Z\LNA9^[I-!K,:S0T&AG]<;=Z7!Y_HL&D"RQ<-5I;KG]U
M^RZVZ)J3[V68R4>&2QD@)*=*QB,;+$.#0+P5M:V>)Q&T(UUMTW2:VCY3S_B=
M.VMEZ70#WPU)1AR/K2!F5F(#K=+JXXZBFCCA+E%K72CPC.D69`M_]M=AE9_L
MGJL/P[GN,IJ[BS,C]4^:F:"[S\.RNJCBT4='96-)1;,.LT5"3N]P99:!'C3D
M(0582_.<4U89G!7^K"KCFZX[89ZE;O\`/FAN&/=05]7<&RZ'1P9W88X-:UL,
M-K1AEVL3G)<P$DANJVCS),QS)G@YN4U8D?0N=Q5F<=\4W0/NF(16""Y]CZ0B
M?ZZ<[,L?6T)D4$&Q2:>)'2ARQR/)>D3U8CG>@9^B3;0Z'75H>B&H.;97"CNL
MILZ`9FZZK@J*Z-E0?5U(`59EVWUF43`R5@U2PJTL"G3S-0>.!6A*W.+)O5?I
M9W?,:>'$=(U'!-Z3]G>96E6=89W:U>7WTG_1[["36F0'H(;JTHL7+^!<R@5M
M`0R1M:=+9$MC;\J!!7-X-0?D+F^X[:WVCK):L:FV&,YS9(%H`K`K\FY%K]BZ
MVO$8?FQ+:Q2R>'5,=`UI/QI%#,CF.!:Z30Z'$UPNJ[!=]`OJ^L%)J,ISO.JW
M2=`O8+^&KENS+G/"EVN@Y;7UPY?[R;)8!Q/,;-*&/"^66*2,+J=+W>NQO-OJ
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MV6LL\YTCN-3G-GC\+DZ*ST$T>3ZWUP;!<5KS"H_4=-'<5-^`0<WWMCBB"LS/
M[!`Y7L#4]]V_Y6\;T*#HV<K^2[W0_3/CW;0^0]I[%7:'.T>4^P'49*R>XXYP
M#F6D++$#,YIU7;UB#[G4CF.K*W-)"*^5?W4A@X,RB_E][GVSD?USY(77A\V[
M[TSKVZ3K9OU@QNVZ)H\WQ3B>OD!%YMS3(V]*='D_L5]E+BB)I,U6:,H7]NR`
MQ^J,8$.R&.(-A?TXY3K?L3]L>Z_?7[1YS*5O0>=W;_JU]9N4U=V[6T_`,+E`
MJ[1]'L+&XDCAIKCNVMZ%J2ZB^LJZ)1`8*%H==/,,^4DH-Q/@:R/M_P#8+"=-
MX/\`;7Z[5G[G3=@DOJ?ZNUF!T$-8)IMCIN[4M+'A-+B*E+22;0XR_HM"89"<
MBQ-CBHK594B2O(<P-DU16CTM55TXBN_%JJX*L&]ZJZ11P1HQ8?>YRJYSOCB3
MU557U\#0#L.,_:O3\M^Z.TW6&MN=QU'0OL%WK3R6B4VBUGV&Z'A1K6K^JN?P
M[*,XF0+ZZ\$YSF<S:B..<RTO-8"CHQ!(8B_S0F?CW,.&_9.KYIQKZMT?/P/I
MMRIV'UW?.K<[J:=:3[+]FPE>);8'E3KT`1@76:/*Z\AFHWUD;(?$=;##4\[Y
M9)[F*(*Y=;_@(JM1P:RY?DN\LT'0=MT33]=[-VCL^$KM7O.P:`<B;0X#EQ=R
M%,TG"\>L=L6^SV3@&D:#0RQ1N<8U6Q_"%GKC^+SM%O<WW5W_`'DZ*O<=13BY
M):^YS15Y]8^:\XO\1K<#TKE7(_KB'M<WG:3&V]1?U9E7+8E6-D+;Y>O++(-^
M8V*<(!P/\5/V)^IFA^F70.9]-K_N?:_5^7I>/K.3]<O:WZU<<S59TK/$!"]V
MH\UB</U`2S[K5Z0RP+T>A/B.NKD:[)C!>$R-@[PL#_'3]8;*XZ7]F/MG]H2O
M\]^T=M]K.R9Z*N]]LG(./A<]_;>3Y:SX;AM#*670&:WEV8JY'7YSY[LNK);%
M'-`)-)#*&Y3P#P#P#P#P-,_.;'O]=PW[S_6_ZSZ.@&^S/&.I;!O+5V,Y^M`4
M#HL$-OBH=58Z?O/4-95L+85(7^Y6EE6&0"/C)&ST`K1Q)@Q?M:/V;E/US^DW
MW.[K78.U[9]+=_G.A?8S0!Y_-,K\ERG>9"WYK]E#\C?ZG8*!E*>AS%ZPXZXB
M2TM3*NLF8*+%,5Z1!N(SFAI=;GZ+5YNQ'N,[IZ:KT-!;!JYPEI2704%E56(S
MGM8Y1S0262L5415:Y/5$7]/`T3]Y_B\^O-1U3:[SJ'W'ON57GVHZ-UW/8FO0
M?$YBZ'L^^,V]ETW(\PL39)3I+RVQ1D+)C60R/&BS\1TS?_.50^?5K"_QL_7:
M2YOL_P#=7/=%K=1]6^B<<I+:XTU2F_`^OF4['T_>2"/W.=C%TI=EAINC$4M4
M](QC"0JT>42*1\;G^!>WZ$_7?/\``,/'#Q'O6A[/]7=V%9=$Y]+M[W_/]6S0
M;;03VLI8'09(!BRL979B((`,*9)"4(CGF(>LTC_`A/[^6T?>_M#]'?H53C06
M,5YU"M^X_>F%BY\ZO"X9]9K<2VHJ:PI=KA='G-0+O^RV%&#+#7V59H*IL#3Q
M_DA9*G@3WJ\%]PA?O-0]@"[10U?T?HN-7=9MN4R4%85LS>A-D_=1+>M-95D/
M_P`3$'JU_)D5_P"\_E$MB']1%E]@)/\`'"<1N.4]%[B79R6W_7#M&_V%67!?
MG6]%)GP[62FK74H<78>N9.I1I(A,9+*?_'87$1N0BG"+9,UP;#?`/`;FQSL.
MOR.IR9$C81]1G+S.SS/A:0R*&ZK"JV61P[U:R=K&$JJL541R)Z+_`%\"/1N+
MY#0<SY[S_K6:QG2WX2KR/P%6^7"GKX-5D@!!0M9G`K-;(C.6L!0OS"S03_DB
MJOHR7U3U\"9?`@SKGU^PO9+SCVATC3`K7BW9:#MV<)J/Q!G6FHSN6U.1"!T3
MI!I7V=-^WZJ27X55',*$%E:Y'0,]`[\]]?.5T6!WO,)LV/I,/TO9=(W&PH-2
MV*["MK3J6LM-CHQ9(R(D1*L6SM5BKXOZ@BP01Q.:D,:H#6R'UDQ?,MMB=?S(
M@O,QT-7L:/:"VA-QL[OI-9J(:.4%^CVNJNK+4$6F9M,T&\0@@@KVAM>*C6Q_
M$L065\`\"K'0.(=4L.L']+Y!V*HY<S98[-8KHX5CSF+<V-@-C[JZM*#09`LO
M4T]+1:48/1&@NDL:ZX&6"5JI"CHT]01;#Z+?7/5H+:=0REGUWH`A!14'7^@Z
M2\,ZU7N-4Q"0<ON:,VBM\!GI1S7P.J<\ZJJWPHU'CN<GN4'CA/I]]6N8ZBFV
MW/N`\JR&QH8R6UNIHL=4`Z!I1L!@IMR;;QC_`)UKICAK(F.>U+?/931DS-?.
MYLLB.`U'U$^N.QU%[L+WEM.^[UD\!>S6JL=#G:?=EC>B1E[_`#.=N*K-;PMT
M;6QOEN!#9)8FMC>KF-:U`=71_KSQ7K.=SF7W7.Z"RJ\6\:7"S5K"LM>\_G#'
MC#%)YYJLF31Z?`EP!1-@;+3F!2(.GQ>[XU5O@=K/KYP].89[BQ7*<);\IRH8
M8-!A-#G:[2YZNB`;(@TS`]!#9?-8HZ:1[RY5>5++*^1\CGO>Y0C?L'T_Y5UF
M6MN*ZTZ)Q#<TU-7YBKZ5]=]Q9\BV\.3JHB8:[(FE9]JTN@R]?$9*@@-F";``
MYZO%;!)_=X")1_03ZC55%35-KQ3([RVK%D)LN@](";N>I[>W+(0NTT'1>CWW
MY6MWEW<E>KBI;,HALC%^%&-@1L30EKH_'1-:G)#LL4#C+SB^^S^MQDXE5$^J
M&HX*T['Z['+5B2!1Q4^DYW>V%?"V-6L#*<,2UCU&;&X)J\"CO\ANUTG//K7:
M:_.VVFIH:;=\T(U1>5'M";!^*3957^3A%QY_38S4)1GUR+">ZKM`36"O>YLJ
M1I(BAK8[Y=EW?7?XJ](1>;NT3;4O*T*T)NYP-2RGEGUF.MZW8V&2$N[/H]YI
MM"*635.EKZTFB9#8+(><UX\39`]!/@'@'@'@'@'@'@'@'@<&(Y&M1[E>Y$1'
M.]&M]R_ZK[6_HG_=X'CG_F<RF5[)]R/M+P*]^Q.&X1L[WZT_53I',P>I6\N1
MY?NH,]>?8*IZ")I^E2AR5>(M`<HI!$$)Y"5IB"0MF%E^17*'G`[=SS6XGO\`
MG,9VBES7.S.SZ(/<8RU,2IZ'A[[#ZL97++@^F5$PN/Z%I]7I(C0HQ!RW`HL[
M9WB0$.;&X,<KD5'T7ZP9/L26UKD-#R+31<*HMI8F'UN0SG(5N>AD86K[EG"Q
M[2PK>A<QZE>6.5E%DL!'+32UYP'[BP96M"!-A56#[K492^L!L]49H*K$AJKF
MULB,#SO&4]06-D-),$/1$ULM;0T6-H;)5G)@2\BU9HXBR$'K)X'9T+!XW&_7
MKB?.`M!TC-\]ZWJZ[L^FO]M#56?1=66?'K*?Z[Y7`<[KDJIHJ>IJM";L;=D)
MB@58>@%BFL"YGR0,!N\NQF\[!/;RXBTR>>STN*T^,UO4^A]#S'./K_C*_:@F
M"71>FZ)?7"!9^SBRKCK4:HJE..$9,ULM?-\<:O"P=E1<PR-SPOFO)NFV';ZG
M"?8SZO8;3]%$S%AELO\`YW97?5[O3!Y$C3LK[D[%UMH:\4>V,A$2=SEBABBA
M2%/`;_U^YSRO2G9?/UO9^4_7W2%[2SSK,YWP#0Y;E.\5I6GEOKFGZ;`!856=
MO"]'72UQ(.IE"KE)ACD@G:D\;?`CKJO!NL\+9SO,=IYS>\[5='T$6/I^^HFC
M8_:Y'2+5$#GYB\EN:JKU(UEGJN:,$6G)*AE$*57PRN9#+X#XXCF*_?4>EX)!
MK+W2T^\K*K[%`PP6K;O0\SZ7GL?;;/GMVF8TE?617K>H8PPK(W-A`R8?]Z.I
MZPQS"!QX8@C;%VVGYCCLW%E>C6<R7PCBLQ_@]Q`^E(QK2H*/&W-.YYC):"SR
M]%G"K\H0J<^2*^;.DL;'LGF<$U\.`EXS;[3[*4-_HK'IF-PUAI^:\W"HY;0^
MDW?:\CJF<SO^F;.*8!O,-SSG(6-UL-`&J)#6@#UTI\T,OXT0P5.J,"-B.HYF
MFGEFZ+>;63)VV;+S-WHR4T[[>Y=4S5)H4M5?$1:FN?C))(W,BGAN1&#6,;#&
M?&]X7MMOKESO'6)-#]E>E6/&KSMVX$TM!Q3C%3E>T]7!XY2D'S99-N3GKFOS
MW`$Z%HB58Q+N[+.A+K%:^CC7TE8#`2ZSU9U#$,RF0KLA2"="^QM(3DR3Y3SK
MR>/ZGY*"SN[^&:2&,;2:4TJ&>X>Y39TLF/5$]$:_P']W#ZV[S<<^$ZQ]:NJ8
MO[$\VTW`,#9:+`8S3,HN_P"`T.!=GMQK;6\XIJFP=1.A"I:EHA)U"&55$*3(
MUD?K"V-@5AX_JEIJ?#:7*V0)UK7='HN:35+)CRLVN8T&;-KW@],NHKFGNLN7
MV3!:F^J$BGJA1()'R,*_%2;YW!8GN?$JW@^O,K\-4:+5YFF6OGCS.@L31.@!
M8/6@9;<Y_HUW.)F:JPAS]Q3U.=H+)3QUBK2?R6*0Z$H9/`5.`<-S%_WW.#:J
MLTFM@N<]TG:@X;-37E%I;3"<L`M]??:S:3S"B7\G/-%T.^EH:<">00>^++'F
M:7!6`>I0,.WT=>9L[O<;V^S>K[;T'I70=3:\USP];?UEKJS;<XT,_`7.:EV]
MMV>&N0Q^8/:'5?&00%!-&$8HC)I0NUA>;<[YIENQ:[JG4*S5](@X7BL74?7K
MFICNA;O";/H>D9'+=]DZ-:CT?,,",PZSMFF4X1%M?QUH,T*C!Q10M0/THQ$1
M!1D1S'(@\*(Z-WOC<B1M]'1O]5][%3^B_P"J>!D>`>!5_P"VG#M#]D>9U/%A
M;@"FYWM>@8^/O32)3H;32\0I#9=%L>?T#PF+[2>DF5(-#8.E?$QM#8V"M=\R
M1-<$=?R,5N^,^E'9,ER6CO+/0ZVOQ'./VG&4AMQ?CX?=]"R&'Z%/GJ2GAD*F
M*J.<W=G/$V-OLA;#[W>C&*J!,&^^I_UMZF+*%T7BV`V8LU)A,U(/H*."PC?0
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MF?&(`##`(,Q\TKGJC&-17.5?ZJO@*G@=<LC(8WRR.1D<;5>]R_\`"C4_557T
M15_I_N\#L_1?3_7_`%3_`.JG@<48QJO5K6M61R/>J-1%>]&M8CGJB?W.1C$3
MU7]?1$3_`$\#EX!X!X!X!X&M3OAI/UE^V/,?LC+-9S\P[/!6\#Z77P%Z*S2F
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M`%PX[]9\Y;:#N7;@<\+SKA/$,E6B7O6>G:'\@220N+$9U\1--@\8)??O%O*Q
MKG5.3KR2(T*41WO"5/HU]7MYQL+IG</L+=U.L^W/V>NZ7;=UN,]-))DL?%35
M+0,7Q'"3,@K![K!\<`*GJZNYGKQ+>W&1DQ_OD1J,#)^^_1+D#F=5PS!QH5TO
M['W0W+J#Y!Y9@:>ENGI'I[>SGGKY<\.]]*D\`(MM99R"W*<H0EL'82"N4+;<
MSP=7R_G^/YY2SV!57CL_6T(95M;WU_9E1`#LA4DZZU%O?Z.S(G>U7.F..,*?
MZ_\`,FD=ZN4'SX!X!X!X!X!X!X!X";9F2@Q031P_.QYP0TZ)\[I(X2YV#+-#
M'!!.LKXY)&JJ.]C&L]SG.1&_J"EX!_M_V_\`AX&`69(*"27^/ZR0)*L<$L\,
M*3*QZQQ>LZ?)'$V?]%153U1%_5$7]/`SD]?1/7]%_P!W]?3_`+/7_7T\#I(*
M@%;&XB5D399X!8U?Z_WSDR-A@B3T_P#ARRO1$_[5\#O\#';.JDRCK!,U(XHY
M&3JUOP3>]SVN9&]'*J2Q.;_<UR(OHJ*GJG@9"?T_W_[?^'@'@8A@\Y,4;!S9
M07L+#G?+#$/*Z6`<J&<D)S28I6-B/@C="]S421C'JK%:Y$5`R_`HC_)-*YGU
M$Z'"K7$!FV^#"M*@2Z=G+K1U,VWH?S\YG+YUI6`5>AN(6K"*\YAU<]RK&4&3
M`]\2A62\X#W3L-O_`!Z=CRSX+F'FF$YP?8Z&'JUUEZW*G36N2M=U:Z;+U438
MNH`ZKFX9E*,,*X5T5G,DDRM#<Y&!N(_V_P#C^!]\`\`\`\`\`\`\`\#JDE9$
ML2/]WK-*D3/:Q[T]ZL>]/<K6JD;?:Q?[G>B>OHGKZJG@>&C^>\2"@_DEU.ZN
M`R=!CE^LOU[Q=[EB@:BZS=U.1I^Z6+ZZY&MXB)0[*PJ7._%E@]9)70JJP$I$
MZ-0T)8>TN>35:<QTZ?YK];[Q;9LM7UMQ.SY95ZGHQ`^IQ'2>BP?E8L+/14`9
M(<1,65-KM:R:2>:"8=X@\/@70PG9>:],R.B^N)W.(/KMJNX55!@ON3G>C]'3
MJG".LT%K8L,Y?]A^7O&##UO-.D8G=@5MV.?`!<-T-*2^6S<DA#IW!K3P7"-U
ML]YFLOI.N4U+QG8:^//9[H6DTK9,.7`->V+Z>M&ZD6MM01:H,L,ILKD&:>(@
MQ2L2-6.^4+H]0[KS#LNF_>5Y<)T+N)EE5\=K;6_V6SYY]3OK3]<^64LN-IN=
M8GFH\$G2MI=V.<JRAK.^*M*@JQ)MI!A@VMGG(D"DI?-G=*ULDUL-J='GN6Z%
M=<+RH@@+.4&=P^C%AKJ+'Y_'1"19$>ITY-:Z$P&E.A.A$FD][B2'M1P2_!7$
MII>2:/4VX4L%Y]M_K;;%7$'RM>:;5ZSH3+//2#-`&`=)6R'NA>C@`AV31-9$
MGLC<G@0!ACJ#08K88C4$$G!T.K;M`*)\`4C5S>CM"JW=9LIDE+<55M91U;(]
M1Z3S5]BD))T<;&JK)8PDM_1MMSDS125^R+T/(^FV-`%T/EW6ZG/:[FEGJ*]9
MH%M/^G'02[O%`7]IFV3I0S4P]9,+6&%Q-GB;%_>%EN`="^J/&^Q\XZ/65_4>
M`[7"CWVL^LF^.JK?H/UCTUCHM"3&3Q7LF?2KIND\HP-[LSQQ;#-G0WG[0?8R
MF`G,#+%AC"LW9<EO.9=<-GY_DM%B^=]*L\EV"BH,3K<UUL#!W_8W2YYU?7$N
M!LAA]!F+JMM:V*>6O%LITKF@M8QL"E2A9P#*\/XY]8:'Z]_8"^VU!ANWWC_M
MCI]#@-4#L>_?:7>6==4UN&Y"-%H"!0^.Y:&E;/9Z&WM+".PM9[(*2"N*DCCE
MC"LG2!C<[I[+,<#P,G*MOLZ%,A94;=LTSLFQGU>6S29GG@_13:Y*4`G,TDKX
M2LGG2`1*<2%1RX"I6?-,#89E:^2SQ$&>0LG$<_I=/:F:>,\FFL-9<6-@03H(
M1J2H%M[.3.:C;&)&`/&+_P`B9PKPIWPHC%"1_P`.%VLY81=6<\QL_4NT6EI>
M9ZF6LCJ)[;B&*:11W8WYMO-7DUT=BL7O;,3-%/`H[&-]%8P$GH67T5^#GI:D
M4W-]:Y--G;R#5C:.(5:>IG!#U6AR$1@)%5>6-Q%+7AV=?`!$-93$&3/8B_(Z
M*()MP?>L@XMFBZER&A^P\<]4'4=VRDN]9ROM^EQ0Y<$^2Z]^^4!TLED)B3;(
M*0RZTU.?IL_:##&B'NB)*C\"5^]6E3V#GM!T#G9-;+I\Q=VWUS^O^5T8EQ3=
MOZ%RZES1FFY7G.OC4D\%9UK2\T&JK2BCLQXQ#[L$5OY(?Y)"M0#@][F_K9B.
MK[;5[*DLM3UB]I>']Z&R=^;I_L9><UW@N3W>^YAD[F[>)G^9ZG71`A9@JWT"
M.?4T3E8)6DFCS)X"'O>KYK0T`E)GN,9?C^8)$AEH.8<<O]MT+H6"XO6D.LQX
M]+THV^S_`$#7T/1KN2,^(*MKH!7LMC+*RA+E*8C`<SJM]9S6XS53!12GFU9=
MIIR(2X6U-N>READF?GB(XA[*(3#9])5(&*E0>*S?*3,D+R'#PA^FMGY4GH:2
M9J^YLU16RH[T]/<D@<+T7T]$]/5%\!7\`\`\`\`\`\`\`\`\`\`\`\`\`\#!
ML7%,%>\-/69JL54;$R:18U<C9/ACDEBC=*UBJJ(JJB^GIZ+Z^!F,55:U5]?5
M6HJ^Y/:OKZ)_5O\`\%?^S_3P.7@'@'@'@'@'@1OU[EN3[7S;7<MVX(]CF=C5
M/K#QR@@+.!DC98BZ\U]7;"G4UHM=8C1$(*<.2"0L21D0S0N?&X*-?6+NFQX]
MI1/J%]I+`F+?44[*CD74+$@HJDZUD$&DDRP<NCL'N?9[N.H!)@E>3^#97I='
M=6$5/6U0XSI@U^?:W[)?:_DGV#[%JNG\?W&\XG8Z=O(<G];]SFJ+0_6[JN5E
M=3Q\&T',=!39[:;K8?8+8:V>]V.J#J:JSESN-SKA9:N0\00@H$_FO%.'Y;C/
M7^_?7W[8_:;^,'FGU_A&#[-S\G;T76OK3S:Q9S?FFZ*=F\STD+7B+54V)UK9
MB&`/K9&7UZ2\H5M@.L$8+5PR_M32<'T?^>+J=^8IUHD^9X;QWCO/.B(.=<EX
MT2NBM\MF=-<"?L6P(KD4A(V2-1BI.YHYB/:%4)>W\9X6)G,U]`N3[FCT7V;Y
MG8Z6\^[_`'"#IW4OLGSJ,OH>RP.K(W(>HR.QT>!%^KFTWM8-I8+TL*>NS>D&
M=6#$1C)*P-R?U4[IU;AOU'K]#]U<)<<B-QZB9/(9R]V,?1NO;4QCRA(,\/5@
M6>KL=`>5=M;3Y64F_N=-L(8X#CHQ#SD!:#R^KG,MCU3HAOW-[G4I7;"]KSZ?
MB.+F/2VAY7S:R]PY$E2;,+&0R7>C0QE33CI4Q6]8E;)9TH-P',O@;$$\`\`\
M`\`\`\`\`\`\#XO_`&^G]4_K_P!Z>G_CZ_T_[?`^^!AE_F^HZAJ+[4)B4M"6
M2O<HBN1)OQECDC1D[6JJM5WN;_V>!CV@X=E6S"ER,8(8D4+GR,'<U5EFC;"G
MQF0RPN<^;VM:US%]55/T]?`YU\YDWYJ&PMB6$\J`96Q/B2<-KD<--Z/EF5WK
M&[VJ]%1KG-54:U/T\#BRP$?:SU/[A7..A!&L/VMA$:VL(DTTX[3B!5F=*@4\
M\#F1R?&C5>QZ>Y53]`Q8*QU,%;+5/(,(*G+LAAK:Q-G%B+E'C;&%!*L9DX-9
M\D"*D<4;_C5[U:U57T\#%M;"T'=FH(H?BDLK06&V(B9+.(&.P64@B!LCPW^B
MF$L8/&Z5L']KW.]S9$:QX.?P#P#P.#W^Q$7VN=ZN:WT:GJO]SD;Z_P#<WU]5
M_P"Q/`H5_)<%:6/U+U=?5,EDGL-QR*OG_$R(FXLXP;#I^4!,FI\Y,?7'%VL,
M!"NA=7O=9QN3W"L?+[6^!/\`]9H9Q/KMQ(9,W8Y24?G&,%ESMR*4#:5:05(D
M,S+`$\F<T,Z1K%EDAFEDFB>_VO5SD7U">?\`;^G@'@'@'@'@'@'@'@'@'@>(
M3^?'7TU3]X>K4LP<9]]9_7[ZYHX<FNM[&W'R26O>PS2L\#G[2%YM3^Z'(\M3
MHAQH2612.+9[&L4//CU^NB364%-8RVXUSF^.Y'FM<P*5D9\%ML+HO6P56<U%
M9775OC]<S+P/9:59M&97O=!_RCQ?C0F4$3FU45W[K0'-.6H1O`\368OG4>VR
M-W2TF/JR:DYTMC*9>ZV*$/+8R)L;R/RFDHZULJ]SF^P=T<$`('(\-H;K[87,
M],3E+73=IL+"HJN:Y4LHN#CFM+I@IJC<56NN["DS=[IM=+E6U6X/JXQ#XI=%
M[*\HHB?\=P1O3W>CK-]K.,=&K9LYT2SK8KC"9:ON:[\W8MO=/?V9E?4F:2GO
M<C?5VA%M_P`D"LN:NT&G,K'B*"AKH'>!)^'MX;JFVH&=EK:H^HTV)WM=!6W-
M[\=$@4EKGR]!$7?QVM.-9"J7"M@+12#U+5<Z:"M%5D:3`I&3C!V'/+T-1R2#
M_LI]9WB4T;ZZ8FH+-TG4QI97RPRF%"#DS2>RK=.:6KHA71MD^)7Q^`Q>9UY1
M^PF<RVK:RQ#'Z//J(-#'=5_[EA@N?:^PU8P`F?GK[M4KWZ2$>J:P4&O(.*5L
MK34<U_@*]I4V*\K*T!]F`+;:2VY]EZ&7*WUY7EMT.4-T;;&VT5[15=RE<A=#
M:/%5T%/+#,#`@4\2_,Y?`1Z*KQ]?2RDZ::$;FKM'!9<XHSGU$L>F'EDT%7<V
M!%;D]+I'754*9?O@9;Q,KG'P?"/(#!*Q8HP[][P7N=#G.>YS!0;7G>RH>=C[
M/8ZSHQT^$(V'+M1^:W-<>Q%LZ,BYT))AU):6%9+:QCQT+SD:#8,@,C8P.KH3
M-%R37<YO]"([B61EM,3TC`5.CQ>@R-<'R^P+?/D0QHS8KY<\5B!"A[*1CX3!
M3VC_`"Q1F+#.V8,_#LBQW;<9E[BFSE)4_O@L?[3+86F7BT<FBS;8\[L[A]<3
M>1:*VL]+9!G@Z5AF<:V)T1L%0@[OA4$F/12CC]?IKJLB'N)JC&NF&LV1--CS
M^5U]'8:\(*SI1[O+Z.R>T8B9A!_Y\`3(I&-#@>K',"1ZM6+><FN_S[\V1W;.
MKE^VU,_%V$=)7_7W/0T1UT>47IQA%</+"26^O(E9'(OQQ0#1L2%`6ZS,XZIL
MK76CV0>CHL7S+4]*IUK*Q)?W!8<L4"YHYL05U3@'6QR11@,%<3*XF9GY;QV?
M(QX0L%=9;B-,[96-@#-_T_KAJ8UMB`/SJYT.@TE-<D4U!EN4JA=='KJ^<MT,
MUQ57]U6_M[R'R0CI+\"A+/0."W-5];K6UTQH67S'4IJBHN+;9K66>OYW34D=
M9NX=OBL,%94^G-MGD25=%3.MDK1Z\TDJ=A)"33RL#)RO#^CXKZYAKDL_G[/.
MY[_(,T9K\\HS-ENPA:.XU?\`U"L>;L'N-@!8+2:S\FT@MF.$#LJ68II10JN&
M\#!#T<6[H*CH^*.$UM/KG1V.6I;:*^W#P>MX"8>ZTG/5R<*U%AE-=36Y$%B'
MH9M!!0O!?"0/G9/66-`N_::#.6,W8=K\\OQ]6Q$6D-!#8^>E@?="3B0Z*LE%
MJ_V.YMY+F:*LLY(W00P2!?)#\GK^(P/TI<Y[/\>H?CC2&/\`9JOV1-<KFQ,_
M!@]L:.5K%<C&_IZJU/7T_HG@+/@'@'@'@'@'@'@'@'@'@=/R/^?XO@?\7PI)
M^3[H_C]_O]OP^SW_`#>_V_W>OM]OI_KZ^!W>`>`>!BFA"6(TH9T$9(LR-26"
M5/5CT:YKV^OHJ+_:]J*G_:G@97@'@'@'@'@'@'@'@0?WCZ\<K^QN29DNH9>M
MOQ@R83:<XH9'G54\1U=8$BPE1N@+DH-`M5$)=UORM#O*ITP!K)1)Y8G!K/WW
M/?L3R'GU_P`?^Q/(P_Y$OK#)$L@1-B$/9]BJH@ZLD&K).@/25MAI&VM6(5^<
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MENA&L-JH6Q(40+#&^4R28&>5(B1OB_,'D3TDB;ZM]03'=^YBZGS`L71\D;?[
MW'V>_P`A%96;Z<*UR`;9[(F\_<9*%8@*0*NBD^`DH6)26CN5$<Y'JT'Q7=?Y
MW:E"A`Z,>:<T2@/"<R$F00T#4D6`V;,!L(H9*XX>ZDJYG0K!*]?C:DCD:QS7
M*$24'V6^L>DOXM=0=;Q%T;;Y![ZZ<1?_`%CL?36=D1:7<1;X(B)LQ";!,KR%
M_P#2MD&D]CU<CD\#@S[6</J,L.?8=FJK8FYO;2BI;/\`QF\2=;0HQKZ@`FCJ
MZ=Q4`8$%L%&A4S(H"(I(I5E])FN4,H+[9<`-*I*B/K6<*N[CFYW6QV`B6\]<
M5@,O)^-H]/&;^W2@CUH]G$\5R_(D[2/2)&+*B-4$NL^[_P!:[:R6G`WA)%G#
M=.S9P;,?MXIJG0P41NHL<_<PF9L0BIOZ+.`O-L02&1E`0?W3,:GJJ!U7_P!X
M/K3G0`R]+T`S+!7`M1-7&W^1V5&TB#2&78%$4/\`N%$/,Z&T_P`?+('D1OMD
M&A^5JJQ[%<'=HONY]7,;:VV3LNN5%AK,WHC\-99FE#NM#I'[.DFJPK3,#UU7
M7%$6&A$)N!4E'B]\K5G:Y4]/54"RU#HZC4T=3H\\6RUI;VI#NZ<\?U0<X"P@
M80'(QTB-6-\L;VK[7HUS%7T5$5%3P*;_`,CF=-TWTQ[2*#!FGV]>!E-'0$:_
M0T&5S='>9O:YF[K-#=W6MK;O*,%SIP*&K%8"R`E+`D$R(R17($L_50B2T^L?
M`YS'6%@1)R[$H45<A5=58S$0T8L$]BX.DS.-IAOR)HU?#^!5UXBQ/:X>&.)6
M)X%BFHC41J?Z)^GJOJJHGZ>JJJJJK_O7_7P.7KX'%5<CD_1OL]%]7>Y?=[O5
M/1$9[?14]/7]?7U_[/`&N]WN_M<WVN5O]R>GN]/_`(3?U7U:O^B^!R\`\`\`
M\`\#@Q[7M1S5545/7U<US5]/54_5'(BHOZ?[O`\7_P#-/QSMG5_Y.=Z1QCG]
M#H/\'^CG+]?JMKNSLUF.488D'5=]7-F=%Z1L-MD:'`QDG#M02;T(()<WXF-_
MO7T#SET^2S^-Z$:&`/B/LAOK>OM\Y;$8<S0ZWA-+0]0"FV&B*U!\0(/4.];.
M#G]%`7(E>/GJJV<4@<AMBXN6)X7`S7:ZW3?5?7!:3FU!=[O'&Y7D_P!'N7Y'
M(9['\T^N]SV@`@K=]!T&;HR<S'=]R'Y;B3[&PN+<64[)CERD$M#AE8/X&NGF
M^)TN?T^`LZ7H](5IZ`:5HY5N`Z'_`#>\0W6G_`/2BV:0SB'&Y\QP,-NR*"QG
M!C=[PTFAC0-COV$Z?G)>??7;"<>R.'W'UY[)S'/]<S_%.I8:OZ!??7;N%U=G
M1;<#!ZBP+AZ95<8CZHZS%6CALP),D5-\XL4+WA3D!KOK%P?0NNV%WD]Y0?7S
MO<FB$V)&4^Q)Y%M@+>'732YJYYU!TS$0VMOG,04:'^X78&EKAV/"(=_Z]JO]
MB@[>H87IW$[VOK>C<C(Q]':]Z^K1G+R\]L*C5<YZ5@'[SI/XG0\1HLR=++:8
MFSKK&!(9R9'H]_PO='`C7,C".+71SY#&QZ+<05VKK]GI=%F4(DK;-2A<[D^E
M79&HJK>I/2A$:RQM*L%A<LSFL/;3Q.AF(80GQ@Z>B\SZ14XZMZI<9M_!.;Y;
M/U%9A-7<T)M-H=:!NAI;B38\YYN$*'O^NYW3U8)$$%E="CU&6DK522V3]"&!
M:;ZS&<9Z)UR'.8S@U#A-#TN;.`;;NO8*<+7=;XURR^5]/5Z7@(]8>?SF@[1L
MJNW^7-U%0+9/KV3L/C)*/D(FA"FG6I1>I=@M]S)HA\OQ@_5'4_UCRNGN]/J>
MC0\[H=1>4M)IK0K]RN"P@]./CUB77F.DL3B0?>)$^*%)$#8CR#1+HOK+U#0;
M?C&;W72><C5O/;[D';P8.C<5Z;]=3Z^\V."W/&"-"!5W^2ZEC;>BM%S^FI"?
MFL!+F2*4&Q(A'`\#7UM1N2=59B<)B)#_`*^W.GJ?9SCHFZ#V&H^OJ9[9#M'Q
M^6TNKKGF=&XI9\^LI"XS(S`;>BK3_P`IS)@A98&L!R]0Q/?/KSJ>)=![;SJA
M'#)#-CT76LII\MTCA&B`B:?49"VTN]P5M_TWQ\FJS\KB/V626&REE&_(D]7F
M?&P/M=';5FCPD-:9)84@W>]G6V%VYR%64N2VGULPVAKCBI?CSD-L.$`H$,[$
M>1.XT-TTKT9\?L"<=A]=.D9GA/$-/W&]J>&<6U?/LEOK2'J\TD?<NMMJ<G40
M1::I^O>=OF;\_%MRM>3-6'Z://THNE9^0PY(W),H,'EO5+W",!ZOSCFV+YGG
M:6+6Y:D^QG0LMFM7J,[H\S$-<]"Z(+M+G(ZGFM<92"WX$-3GLU"1+:E2_DQE
MVLL#D4';]T`JD[IEC/6`WE3RSFW.\TFKZ%JJ]+/HWV)^T>\I8NN=QVFMM13K
M"-=?G77X<%R07)8-S8$453`QY*L7P)9^D6@$RG2ZI+-NCKK]U3=3<PT&5IG`
MZKB'V_YUD']3YA?W]VDLU7:Z&\C*.SS_`,R1*JZI")!RX)9YHXI09.[[W>]/
MSEKTWK/+,X]G8AA@=AM.4FY/D.YN=-CKP&ZK-_AK"#,5V5T\FS87);505Z`5
M'"3,2*D8X)$P@(6/KOKAK+'Z_P#;S_KOUOE'>JC(9>@ZF-S@J1V![WDN>ZC+
M5IV^(BSEN16<V/I1JG3@G11YBST$4ML,3-\4<A#$4/T:<,5";B<<:.Y'P%Y;
M/E0/:BHU\)%2)+&Y$7]41S'HO@.GP#P.B*=LKR&(V5JCRMB<Z2)\;'JZ&.9'
M0/<B-GC1LJ(KF^J(Y%3^J*B!W^`>`>`>`>`>`>`>`>`>`>`>!#?=>W9?Z_8.
M7H>QK[^PHX;FGI9F9T&`XL:6X)4>(XO\DL(82L%]JNFGDD:R-/3U_1?5`J"7
M_)QQH/)Q[23#],6AEEI(4G_&QL4S)='8E04L7X1&OA/G>;35Q5BKH8IHHAQU
M8][97QL>'7'_`">\5@`S^@O<=T'-Y#6)6RYO4VS\+&(>);'WM>(8561[1]Y5
M#1RYZ=Q#R!F,'8Z-7._O3P)Z^NOVXP_V5LM#4X_*;^@,RU0!<W;M;3!5X4(M
MO=7E!2H*<'9V$![[6QRMLV-(U56-KI'2>Q'P_(%K/`/`/`/`/`/`96EYMSK9
MRQ3[#`XO5SP+&Z";29:CO)H71$B&Q+#+9@E/B6,P""5OM5/26&-R?W,:J`RJ
MWZV_7JGE=/5\-Y(#*^8F=7#<]RD?I*8RUB)<QK:KVQI-#?',5&HC?89.WT]L
MLB."9(!X!8FP#00CPL]WLA@C9#$WW.5SO;'&C6M5SG*J^B?JJ^O@=W@'@'@'
M@'@'@'@'@'@'@'@0MT[@'&^M',O>D<USV]MJ^D2EKG78D1DT5=!=!:9*X%2Y
M6#"*9;UD*R/16?*Q%BD<L+GM4-&A.6S\.=<(G\<>LW5!%9R#0?X_:=;J(:TW
M1&U&KUE#'3Z-:/36%KBQ`#BY+.!KJ>>PJ5'&F0B<:%`R/R[7/[""]/\`XT-/
MK:+8Z^?9T6Q')ZM9:43]GV&?&'W^N;8EVUK'M-#G,T58$S3QUQQ9,0H<L$L!
MDI3@E4:SU^Q(ODZ9]$;[.3<TYYC2Z&RUUCU'I6)L!G]/H:[2XK28[-E+'TR/
MD%E?7-E2U\D9K9:E@\@;V1_-\02/R?![W"X'#]NRGTRP.-Z19;WHGOY@\/:V
M]W6YH.ALG8NZK3[C8R5^$U=W^Q(`0<77L=!$9##'!#&COE"N<&:O@.6Z_P#_
M`.>.7AU//>KY'"8;E#Z#KUE(1SZT!V^LC6LW#=:6$?7G;D:&"`@>*"GK9CWR
MDCJDK7(#\KB>S-NA2>6_0ZOL5GK2:4'HNNSO0<X#8NH+V387=*5CMET:?1TT
M4H>?'JZNXFEF:84#`T=WXDH848<8@^P"83&[3!?23-3=!UK>MXZ>L-X[N,D&
M=!H*_#MM:#99@[HD0.%S<Y)%X]UW:(=%=3Y^'\06"2Q9)(#EZ'C/M9S8P/FW
M'?J=R+7$:7$X&;>:.;%'28]^QZ#56&0[#HC.C&;,6YN[&06EK0389`BC(ZI%
M*D<2UR0/!!Q6=^RA[[BO,^J>=YU?L(U-!3FKPNKWF:,H,I!:R9\&Y.U6\JP:
MRM=1WYR59L3+>8B<QX;6-C518P:NWYQ]M=`/ID@^E_";06N4ZRL3-9QW"2WU
MMT)6:D.*SQE>)<63MX&&)8LL(KB4RI-F?;',F&,;"H2AO&Y='>MYW@%TM"-E
M;YF)S45WE@HP(0\_;MJ0T/J!H*CTJ88*XA'0L:,U(6-9Z,1&>B($:_:3G5QT
MOC&QSF9IX;[1DP4TM=4D64-<PYE9I::Y(8+^Y%#9V>Z&AKW$5T=G_P#.R6PA
MA89ZB.F:X%OZZY'0<_X9S?(:JM@J-#09N,.RK(SH2VBD?D%3LB)+$(-KFFK%
M*U26"22`PD*]@RK`V/P*_P#VIYWWW4]E^JNRX]GZ6XH.?[&]+Z3-8:DS,O`H
M;=**"57.K=1ESKP600<CT$?':ANE1LLH3I(X'M"ZMM<A5`ZE&%0P0,F;#++*
MCOBB<YJ*CIY&?_,\#'/:KY%16M14]?3U]?`X(7++76$M2QJ%1OG2!;-#%$D+
M>ULRRMDA2:4D!%E_18/5B^U6M5/3]`40G3N&8I+O?-[I4D5611_W-E>B(V.*
M69K6-1/1J*Y7(GI[O[O7P,OP#P#P#P#P.N62.)GOED9$SW,:KY'M8WU>Y&,;
M[G*B(Y[W(B?[U7T\#P^?_%$>HO*[[>]%P86BMX*3H?U\^J%_K:D,LN&C%%Y5
MT_N]R!&<)7@S$V%]?V%XQM9-,JL$<(]\7LF5)&!YZ>L-[+'4;?>1%'%Y$@>N
MM,02/>T`S(1W"A$0,$.2.IT%3T'!9F,<FWFF@*L4(HH8YDGC>C)0?^\/Z#CS
M,9]1^9]*K#2>0@VFS[WJ,M4UD6;_`.L/V%<%<]!@V=O:Q9F\"S'+:G19C/&-
M,%@8MN"^-@QDD[$4(/BY\NAJ0,E8=(YQ(+^XWD6A"L8]?3Y)DMK9T%)($-KR
M<_"24G^*26-6)-`9'\MGJ)/61T4:O8#US_\`E_5L]TG-6AMX!W'A-@;V[B4.
MITT-%?W.$S&7N;CI_/<GJ\@18W&9Z)<8T^KO@)9DG1D6<>.>0C5''C"MO-VY
M(2ZUVY-ILW49ZYSEJ1$.<_\`$'%W-\3)-CG9*YS#R19-1-M&`E+3*;*T<B%G
MY-9&DSYE"46V\R\TY19,N[$@>MZ3]><0.EK7V!%>6&WJ6RM&66"K"%%:+7A#
M6<0LI3I""'R"N^=7,A9&@6(Y1W>7#6H"XBGY_:VNKW^QALM?MLG0;CI^)7F'
M6[5NDDX_46=M;0XRW-)IG3NNS6US584^>-K9U1K@H1MK[I/6*V/I&J@N[1']
M$-TFJK+?.Z'HJBZ#1"#WE;7DNJ$+A(M;BNFLQH8'54H`MLV1D4,;&ROB"SG-
M]/K,MAM_UCH]8'#5\DH"N/<>P>OLSAI+;K'8HCAL]J[2IR-(FVSP.$YYF+PI
MI,ZQ3C"RA"_FC"(D<X,P:FU5Y2@WFJL\9SLDR$$7.:7:EEP5(5?G6Q092NS.
M=.JAY*B+#&FG1B"_@0225K!F(]XT@TBAPQNZ@R0.[XUUBLK>;<LVD=9BBK$=
M]GIK7!52JRTQ%W@MME'VK#-#@]#A*_6/HPT(%`/CFC6,=\Y,K@C3J='UJ@UF
MWQO6A;:QZ%SU:O'6Q]..,^2';27565!8CETJUU8?A[.XT,1[)1["H,N8HY)C
MG2SN1)PLSE.A]0X??]HCYCTO0X;.A;)NIK,U2E0W&,T1\=_)0;>LM,@47)A=
M7GK&C+>')-*Q;.2,,58G0_&Y7`VS367UAA[H#-1U6FVOVP#`TQ&>KS(*TG2G
M<&#LBKC/5EO/9R`Y^YIPA6$/_P"4.DL1#HO<.B0^`^MEH]KJ`:.?>=,H[3HF
MEXAC\#%%I=1$89KM%D:2*\TX\W0C63"-(OK$<L:O@FD6$25&Q1.B^1?4&7RC
M"-_ZE5HO>]%37G*N&T=U]B.J4(]F=:6VF9S4JJN1<E+FZRXLLC4&[+6B9G-K
M:DSBI7G74@T+I%G=*H=5A?=IZOJ[SNW8=5-7F:V:MM$T_4,X7<;:IRQBPV3Z
M3G535-2?-0`V[[.F;(16L$)#M9QO4PF-TT((;;O:<Y(H]CS#;"65]46VPHQ+
M"IBL_P#/\\`1)_E&HMMUE#`K$"_9KM(RFIQGAL-D<[*!MCC@:OO8$N[;G=>6
MZKV?/:D#5\EZCG).G<P;'NJRIDS.P+NK;!]PY17YT>VAJ5.S73`9YAXZDPF=
M<\2`RSE;[YE<#OYH[0\UR@5);!W8-B#Q32Y6Q'REI7$4[&=$I]E:!UA>I<S/
MPW-[44>D`!*D%CKA(7A.:]9I8'?&'Z@W(W*_E',7*YSE=SW%N5SXTB>Y5S=:
MJN=$GZ1N7U_5O^B_IX$A>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`BW^:SFJ!;5
MZB@I-)6,+%/977]4#<`M.!E2<(QHEC`0.TL.9$?%(C??&Y/5JHO@-.LX_P`D
MI"(RZ7EO.J@N&(D>(JLQ.9`(B@-?\AL,<XM9%(R$N3^Z5J*B2+^KD5?`4`.9
M\XJ@I*VLY_B:ZNF&.#F``RE"&%*)9R-ELA9!1P(X'C6$K$=.Q6JV5R(KT5?`
M<P514ULA$U=65X$Q?L_+E""&%D*^.2>6/\A\$4;IOCE*E<WW*OHZ1RI^KE]0
M4/`/`/`/`/`XO>V-JO=Z^B>GK[6N<OZJB)Z-:BN7]5\`<]K&J][D8QJ>KG.5
M$:U$_JJK_1$3P.7@'@'@'@<7+[6N=Z.=[6JOM:GJY?1/7T:G^KE_T\#ZU?5$
M7T5/5$7T7^J>OZ^B_P#:G@??`/`/`/`/`/`/`/`/`XO3W-<WU<WW-5ON9Z(Y
MOJBI[FJJ*B.3_3]/Z^!U1,7TC]7S_P#)1\7_`#%;ZS>WVL2:3VHB.<[V>J*G
MHG]W]/`[G*J(OM3W+Z*J)Z^GJOI^B>OIZ)ZKX''U<C/<K/[D;ZJQ'(J^OIZ^
MU'.]K57U_3U7T3P,*0A[I%'>(0Z.6*3WS1.]$B5&0JZ&1S71/9*])_\`ENC5
MZ?V.57-5$]0[)9_QE9$D,CHTA<J3*[UC:K%8R.*1[G.F]S_7U5WM<C415<O@
M-H*QL[.8ERUL==)%*;7P0G'&1/F4.=C_`,N&*&%(3`96K$YLT:^OI(K/Z-7W
M`EZF$RR4>.A(A#L%];L)MD*Y@%D:"L0T:SK$G[E!+6.^.17K#+'[5;ZM<B(B
M!'5;J-$?%KP@D,MK?-6H%5Z?N$5A[Q2JYUJ9*YP%14&!F_MQ7J+&1\3)%;$J
M2M<]W@9TVB>105T(M19WU96FDP2'0VMJ,:,32$,B_(,D)_;K"8&:QB>/ZJ^1
M)FH]/<YBHK@5[G8-JA1[:P$LZ\DRP2*$:D<))'?S/HBWMEG-)=[&15$0!4LD
M#7?(Q(6.<UR_V*">FPDFJKJ%KB["IIP(0Y+T,P:_L(CK.OFE@)/1U2E>.X&.
M3Y)IHUFAC]T<;V.3W^T.EFGNJH>-LDEGM3`Z6SL#6LB_!(BB&4&6&&\IH`Y8
M(+$B`]%E@B1KFQ(U\43O<U%"*=+MMG9ZAX2Y+0W=+?+3A6`P,9<P-"&0L\5J
MM>(351V`1(HH<1+[(Q@P[7(Y(H7ODB=X$49OH6AJK#=5$?+K8=*_."S9T:@T
MMC7J.+/4.$57_P"8%0PU5K7R,82,5[(YU$+D;)"Z29CWA9KZ\W'6+(#2#]1H
M*_/2AEUZ4(H37RR3U\@\C);$RP]/8>5:D0N*>J(U&++[43T_50L=X!X!X!X!
MX'7+&R6-\<B*K'M5KO1SFKZ+_JCV*U[%3_145%1?U1?`TG?R%_P\-^]G:X>R
MB?8<WDED'A<#C8J]G)Z7>3118.ZWEU"ZOMK36T21!W\FY>AL$L$KVS`BSPS1
M2QM>T*`C_P#Q-<%76M'I-!]HZ'=LI37WR8#1?5K,S5>@/(EC<9%H8*3L%//=
M"PS/8Y44GV>C41[I$]/`.P?_`!.)M^LZ[9[?3?R#RT5YN]$3TC;$YOZ@<WH4
MTFM60\>2ZT\-'NX!]'/&!81P1M);*^'\,::%630MD\"HAO\`\3&=6SHXM;BO
MO!3Q`R6QLDC>B_5PZ^(O7,4R2JM*@3.?8J:]"&2&>0B,.0>&")T'R2Q,5$3P
M$?:?PW=H_C?J<#W6#[(-^SFUS^USN0"PHGT<&O11:_JW[UAM8'7'G]>L[BFY
MC)36YPMU!7*Q9G6T#)7#M(84.&NC1?Q>\^H=UNH\V;]F,]08G2V\4N9RWU*J
M:+/#6<6WAI+@3F@EQWNP"L2<9<S5TO[>^2Q.@`5_Q*5Z+$\)+@_CDH-YE\QC
M6ZO[(XRH_P`CQVI/&7Z88&GOLGILEH[,^FICZ@/M8]O99Z&QL&L6&H8Z,4)C
M',2)\TSG`G5OT;Y[FY*Z[LMQH]+<UDOJ/FR_I<=95FK=>D&3V"53ZC[*5,UT
ME:;;&3/C!*KU,(+86KYY"&IX$93_`%`PTN;U&^INZ_8[(`5S7U80S/XZ>F4.
MCM!7UEB=6C9:F'^QE?(`\]H<;&I:/C4&_G4'T%F,=$\+U=A_B?*X7]8.'3ZC
M<T/2:>QZGH^QTVESGTFW^XZ6!N^J\MK:']DMJ*O^S<.'LVT.+S"155-(MC!7
MVL3XYI&J][5"G]5_'?FMEO0@2>N_9VFT'5=)DG#,O?HK26'[1:1:2BM7?Y#!
M5_8A^C@K[/0DJ=84Q#D?$@TT(K8T8Z-0<2?QK4;JVV$T6L^P>YJJRQTI/^#)
M]$VTM1NZNCL`,E>7R&U7V7`#J]$(83^<"6^<&ZM@QB)HI9AX%8H2AO/H[SGJ
M5MENKZJQ^SV.(V?+J+%V6?R?\?Y%@/J*SE8>!Y-F_P#*Y']UO+2AO+[,6]63
M.7*;".6RG,(F2*="?>"%R7^/3*SADK6Y+^0D*RGI[O+&.NOH]@*<;-V`=W0G
M5LQ8*=>6NAN;"U@6.C_(@-KX8&%11I#(UA'@/1O\;=198O"=+TA?W:E+#Z%I
MV9BII?J)RTB_SFGYU09O"AZ4J`/:D)I:/84]^0R")Y,8\D3W.=Z2>OM!BD_Q
MSYZ+*X=_[7_(30>W.Y[&R&0?2+EQ!C*NJ)R4YVBL:2CZ*(43=U]M:L$-(@:)
M',2I3QH'NE?)X#ZSOU"JJ/G'6^>8''_<)DO71^;8G9;LOZ)X'8=1'QX_2Q+R
MOR+*';=2FSE7EY]AEA++2U_[>X^4.`:1LTC9(6M"]-U_\2J,TZ2UNH_D!Z%;
MG23P71)47UOY_*TA21S@E=9SVFUL&VTM3*Y%`@DFDB!<QDL$#7(Y[@6J#_XF
MFM>865/28C^1/3F7XMO0N"?J?JEA]&2+&%7RP#F(]V]IZ+Y@P'ESH2Z*:1TT
MDCG-E>BM\"PY/_Q/_P!1L^5Y#E-O]TN=V6<QVITVFRUXSZ)\ZSO0:#_.XZY^
MESD-KD>I9VA=F;'0UL-V6V>LF+GMF.(=/^J-0&\=_P#$WNHM0MH^V^\L%MH-
M7C[W&A75E]8J$IN8$O1#`I+.H!7JS6K8UL)3%$;(]1HI!X7_`!*YC?0/3AC<
M^_)X_*9:0Q+%^:S=%GWV"#_B(<^FJQ:YQB"_,1^,A2C>_P"/Y'^SW>GN=Z>J
M@Y/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`/`%_7P.F%)_=/\WP^W
MYE_&^+W^[\?XX_3Y_?\`I\WS>_U]OZ>WT_U]?`[O`/`Z8HG1NF59I94FE65&
MRJU4A161L^&+VM:J1(K%<B+ZKZN7]?Z(@=R?[?[)X!X!X!X!X!X!X!X!X!X!
MX!X!X!X!X'3.1$,Q))G^QBRPPHOM<[UD(F9!"WT8USO[Y9$3U_HGKZKZ)^O@
M<U1R/]WO_M]GI[/:W^J+ZJ[W>GN_5/T]/Z>!S\`\!/E0J4M(GCM0!B#SQ%PF
MR,)4N.61\D4XJ1,:@C61L_N25ZR*]6JQ$17*'8J-1"'22N>Z-[_:Y($]XS'Q
ML]&0HR-7/5&JB^OHY55?1?\`<@-^R$L8(Z<,+]PLG-G;^87.?^.V2,461J)8
MK!"GO982*C'_`!Q^UJK\GM7V^BAQUIS:P"L(<&I"MNZJ&)L9$,"P322^R!6?
M+&_YFRS^V%6M8KT;*KT3^S]`0G1R&S%,,=&5-^%[#9(CR:^M:XMWRBS@AQO<
M%8H&YD_O)=-!+ZL1OM<JI[002B2Z0".LBO+?5V-,M?>$`211LLC09)E42$NW
M8!^.XVW.$DCB%B^-7?/\/I\#%=X&,F>N&V$H-7/H2*YC:V6.JTH]);!T\Y#R
MC$/K"C/CF:6$.6^$AA"F)*]6_$[U'<YP9F8I8ZTS2V("2#7>C'2.>0V.>&1&
M`"$."^&"(H6L1@#B_;[H((7.8C4=ZJGN4(?,K]_/!%34X5]3FLL(:L^QEM$^
M3]ULK..2DV_YS!ZZG/.&C8YY0\D)#7Q11Q1ROE>U$"N.CU^F+/N-/>:*_N+T
M#9#BG9W,+^W@DC9S\I!LE-5!L*T,$8PC_P`V6Q-,BJV,FG?/&SVN1H1!+I=F
M^\_<L[GM9IA<H5E-X^.4C/*(MUJKB]^","P@N"J[/U&.FB(+(+L8G"M@A]C9
MYX6JQ@7T^IVYT&THS3=">:=/8`!Z4!S!+`C/,K;\TZ6"*AU$QE@#=PCR0O:Y
MC)G/C3VRI&-#/'`P+?\`@'@'@'@'@'@'@<$BC1[I$8U)'HU'/1J(]R-]4:BN
M_JJ(B^!@DL+E:^0,WV,?"UL;60P2N;*DJ.^6.695C=[F(K7-<BI_JGHO@(\H
MXX1\)!AOY$TEB3*&R:*;YW2R"D?B"MF'5L3(0HB"&-5S'-6-[4=_>U'*#=W!
M43*.PC<'9&PDI#173JF`FS-#J;_X0Y"Y`AY1BI5%_-^1SH8BGQ01N7V+ZJG@
M1G%SNNBMV3!9!N;5SJ6'2%/RE58E:`RUI"LT!8A6U07(=`?1%B!3FE22?%"+
M`U?:LSW3QA'U3SS+5T&N1F+VYQ&VU&2JM#$<W1C5L5SG7%1NV63$5&R!0?CB
M/).-@5CR7K'![Y6>G@).>P@Q%[NK:IJNE#+8ES6NAKKO"V5&=$X9PE&:_GFM
ML)Y;8RY?+G8RP(IRYDAA.>^*9D;VM:$V5&7DAILUG3\_?`!-ALJH:FI?V.]J
M`P*VJ=81@ZJTM1Y/?(MP]\<+_5T<I\+'HJ1*BJ#MEQ$<%?4QUK2(C:R/Y/P@
M$!H*>09M;80#TUK5TT4`I=.K"7PH/%[VLE>DJ>BI[D!UB`S@5574CUCR@B(&
MP6*DFP1S5\,L:-<GP.A^&=($=[?CC]C4:Q?:G]$4.N%DH,,8A`DDDKYQ(:Z(
M=DUC"`,HL(3Y'$J(S\#W.;+\CE=-[$=[_5456('?90Z%AT;JW\$P">M.')'L
MI70QQ&-9&M?+Z10RNF83+)(A*^GZ1-3V-]W_`!`A!46D:+3$6_[#^ZU-/9C-
M7.ON:P,0@J6%(!J\0AYT)(J@0MC<^:-)&R1H^-C$=[6AV4@\\K8R4HB8VF$V
M3&QV\(P$H,0<TS%<?$Q2)B8[4R228=&(L:0_&_VQN]44..AK](:3#$"QLD09
M;+1WRE2Q0V*/?*)^W-8DGI$-$&2]2895]"4]&L=&BN5`<Q@7Y`C!9*Z%S?CC
MDC8-*Z.(<H2-7C(KV2`RK$U[&,9[%;^GZ+[6^`*79",&F.&CEB0.%3I0E7UB
M+<[_`)[HP50B=P\;4_3V2RO551/:J(KO`5&0.:]KY)/F5K'-]7L1'>JR*YKO
M[%;&GL8[V_HWU5/]?`[_`$_]W^G^[P/O@'@'@'@'@'@'@'@'@'@'@'@'@'@'
M@'@'@'@'@'@'@<&^_P!7>Y&HGN5&^BJJJWT;Z*[U1$1WKZ_T_3T]/`Y^`>`>
M!TSSL':Q\B2*CYH($^.*254>1*R&-7-C:Y6QH]Z>YR^C6-]5541%7P.[P#P#
MP#P#P#P#P$:'0TT]U-FFV0?^1"U0MV71H3"^R$J3BB0@SR!F/<^,4DL.6.-Z
M_P!KWQN1/7T7P%65CWQO8R5T+W-5&RL:QSHU7^CFMD:]BJG_`&HJ>!V)X!X!
MX!X!X!X!X!X'6Q9%63Y(VL1LBI&K9/?[X_:Q4>Y/:WV.5RN3V_K_`$]?7]?`
MZ'M):2V5LJO&6+XG")$Q'?,^9B_E_D.D:Y&Q1>J>Q$_7U]?ZIZ>!DHKE5R*U
M41JHB+ZHJ.16HJJB(OJB(J^GZ_K^G@8[YIE=)'#"KGQ?&JNE]8XI4>CE5(7M
M1ZN>Q6^CD5$1%7^O@=,DQZ1H^,-KGOE6-8G3,:H\2)-Z$O>CU9/[E:Q?C:K5
M1'+^OZ>`@_/J)ZV&$FLB'LEA:ATH)0KP4GBC%EE<`I4WSRCDR3/C8V5D3FI$
M]7.;ZQJ\$<>#8#.9$%!)%`3:GS2OL"ASFP5X;H'C1>DQSR!9+R)BQ_\`)2:,
M9_ND^-$>U&`CZJNZ`5.IE%*HLR?#"LJ?MTZ5L"DCQ'24L!44DI,Q84BN?\B0
MN]T'I&YJN15!F05W8/\`)AAIZ^1]`EK:#DGO/J/PX:%HS@*MHM*\R?WO:[X#
MI7S.G<8Y\\7L$^.-KP[QLGV!@SFQG9Z*QK;6P%"-()+JJ<FI+CB)>8)E\W&P
M98FDSS0PQFD*:BQMF>0OJL;P3*S!]=DM3*_360%CD1_V3\(D.ZECT5L:,M$6
M65=$E5CW$5D!$1X[88Y`Y7C3(Q$3U1S`<.DQO2S23+6GLA&OL#:22*C.T5HT
M&D$"*_",8"T.NAA(>34.4R;Y7.<M@UK8Y&QL:K@1M=R3HNAKA(!MX*"=^.,S
M03C!SC1Z=XI9\4:E^DDD@DW[,0Q$?&Y&(7ZRHQ/1$4(7W'UB[%8`DV>,Z0+4
M;2R$S-9^XRW>D'%HG"%O&O-.Z5!CIM=J)Z>9R).4T9TL2N#3XH7-D:#9R7T[
M[3D=7<;-W9L[I;.SO8K8&MMLQ9"45;^2K@[V4T"LM1&:8^\K"R$+D-]T<TSV
MR+%[XX71A.WUDX;TSB@^C!W?5?\`J(#;,K9:H*&NEK*RC-C>=+9_L]<1*7+5
M"$?/&CF(20A#V?)[8/1(U"UO@'@'@'@'@'@'@'@'@'HG@'@'I_M_\;P#P#P#
MP#P#T\`\#YZ?_'_[5\#[X!_M_LG@?/1/`^^`>`>`>`>`>`>`>`>`>`>`>`>`
M>`>`>`>`>!\541%551$3]555]$3_`+U_T\#[X!X!X!X!X!X!X!X!X!X!X!X&
M`^`UQ22LL/8,DL#U$06%WNB9`2R:%T[E5_I/-+'(CD1%;\7M3]'+X&<G_P`C
MP/O@=?RQ_+\/O3Y4C258_7^Y(U<K$>J?_6JY%3_O\#L\`\#A\<:/=(C&)(YK
M6.>C41[F-]RM:YWI[G-:KE]$7]$]5\#GX!X!X!X!X!X!X!X!X!X!X!X"<]]I
M^YP,C'KUIG!D.))>80VS98-F@02&`!`7"RAR0+(LDKB&/8]K6MC<CE<T%'P#
MT_\`C^`>`>`>`>`>`>`?[?[?^WP#P#_W>`>`>`>`>`>`>`>`>`>`>`>`>`>`
M>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>!BL_-_+G^11?P/A
M'_&1B2_E_/[IOROR%<OPK"K?C^/VI[O7W>O^G@97@'@'@'@=4X\!4,HQ,,1`
M\S'1S03QLEAEC<GHYDD;T<Q[')_5%3T\#M_^1_HG@'@'@'@'@'@'@'@'@'@'
M@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'
M@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@8DP
M0Q!`94L:NG`?,\1_R2M2-T\+H)55C'M9)[XG*G]Z.]/ZIZ+^O@92)Z>!]\`\
M`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\
M`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\`\
M`\#@Z1C%1'O8SU]RI[G(WU]J*YWIZ^GK[6HJK_N3P.O\H;^W_P!1!_<B*W_F
MQ_W(J(J>W^[]?5')_P"WP.IE@#))\49@LDJ0H2L;"(7O0=7^Q)U:UZJD2O\`
MT]W_``^O^O@=OY0R*B?D0>KO=[4^:/U56(QSD1/=ZJK6R-5?]R*G^]/`X_FA
M_P#+_P#5#?\`.3W0?\^+_G-_^NB_N_YC?7_=Z^!U)9UKI'0ML`73-8DCH4+'
M61L;D]4>YB2*YK%3_7T]/`Y_GA*OHA@JJD7S^B$1*OP)[?6;T1ZK\7]Z?W?T
M_5/]_@"'!*C'(6*J2*K6*A$7H]S6JY48ON_O]&M5?T_T3U_IX'/\H;T8OSP^
MV1C7QN^5GM>QWJK7-7U]%:Y$_14_1?`%+&1?19X47X7D>BR-1?@C5$?-Z*O_
M`)3%7]7?T3P.#3PGM<YI0[FL8LCU25GHUC6^Y7K^OZ-1OZ^O^[P.2&"NC69I
M$+HD9'(LB2-5B,E_\I_JB^GMD7^B_P"O@9"*BIZI^J+Z*BI_JBHBHO\`\?P,
M>0L:&)L\DS&0O<UC9%7U:YSU5&M16^[U553P.[WM]'JJ_P#E_P#'^BKZ>C&O
M7_3]?[7)_3P."$1*YC$<OND:Q[$]C_U:]'*U57V^C55&+^B^BIX'QQ$39FP*
MYWRO3U:U(Y%3^BK^KT:K&_HU?ZJG@<6%P2.5K'JKFRN@5/CD3_FL61KF^KF(
MBHBQ._7_`(?T_K^J>!WH]'*Y$]?5CD:[U1S?U5J.3T541'(J.3]4]4_T_JG@
M<O`/`/`PA36E/.8@Y<'X)BAJXJ!T+"5088G\D)RJJ$!JA2,^1/T^1CV__!7P
M,A9FI,R'VR>Y\;Y/<C'+&UK%:WT?)Z>QKW*[]$_JOZ_[O`[?`X>]/>K/:_\`
M1J.]_M7V+ZJJ>U'?T5R>GZI_N\`>_P!B(OL>[U54]&-]RIZ-<[U7^GZ+[?1/
M]ZJG@)UA8SAQB.'JS[)Q)M:-)$(D#'"#G&0C3V!"DS0,0>MBD6:9K5=+\;%]
MC7.]$4,T:9Y`\4T@\HKY(VO>//\`&LT+E3U6.3XGR1^]O^OHJI_V^!V-?[E>
MGM<WV.1OJY/1'>K4=ZL7^CD_7T_[T\#GX'!'^KG)[7-]KO;ZN]$1_JUKO<S]
M5]6_W>G_`'IX'/P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P.A&3?.YZS-6!8
MFM;!\2>YLR/<KI?F]Z^K7-5$1OM_14]?7]?3P._P#P#P#P#P#P#P#P#P#P#P
M#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P!?Z+_7_P`/Z_\`
MA_V^!@E?^:+_`/,7_P"7_P#FO_SO_(=_\S?]O_\`$_\`L/7P.K_\@O\`^K?_
M`"F_U_\`F;_RF_\`Z/\`_$]/`Z`/Z+_^IO\`R$__`%?_`/S/_A?_`./_`._P
M,QW_`)T7_P`P_P#!-_7_`,[^L?\`Y?\`^;_^O_[?;X'%G]!__F#_`($_X?\`
MA_XE_P#F;_['_P!_@=:?_-+_`/\`57_EM_I_\T__`&__`.;_`-W@93/Z_P#]
M)_Y/_P`#^O\`PI_^A_\`=X!_JS_YD_\`?_Y?_P`#_;_A\#L_^`W_`,K_`(4_
MK_P?_:__`&'^[_L\#M__`'OZ_P#?_P#@^!P;_3_X/^O_``_\/_"G_P![X'+_
M`$_^!_I_W?U7_;_O\`_W?_:__=?Z_P"W_M\`_P!$_P"]/_PD_I_V?[O`^I_K
M_7_Q_P"]?Z>!\_W?T_HG]/Z_U3_[WP.7^_\`[_\`W)_7_M\#XO\`3_;_`./_
M`-G^_P``7^G^O_A_7P/O@'@"_P!%_P#?_3_Q\#XO^G_>G_?_`.'^W]/`$_I_
MXK_\E?`^^!Q_U7_B_P!?^_\`\/\`W>!]_P#K?]D_I_I_V_\`N\`7_P#&3_Y'
M^O\`V_\`RO`^)_I_[O\`[;_[W_=X')/_`'K_`$_[_P#Y/@'@?$_JO_?_`.Y/
M`^^`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`
E>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>`>!__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
